var images_info;if (!images_info) images_info =[]; images_info["74"]={"74000":{"type":"graphic_picture","displayName":"Nailfold infarction in RV 2","title":"Isolated nailfold infarction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Isolated nailfold infarction</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/RHEUM/74000_Nailfold_infarction_in_RV_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This cutaneous manifestation of&nbsp;rheumatoid arthritis&nbsp;does not usually signal the presence of more severe underlying&nbsp;rheumatoid vasculitis&nbsp;and does not require an intensification of therapy.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 74000 Version 3.0</div></div></div>"},"74001":{"type":"graphic_figure","displayName":"Toxoplasma gondii life cycle","title":"The <EM>Toxoplasma gondii </EM>life cycle and pathways for infection","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">The <EM>Toxoplasma gondii </EM>life cycle and pathways for infection</div><div class=\"cntnt\"><img style=\"width:470px; height:567px;\" src=\"images/PEDS/74001_Toxoplasmagondiilifecycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The only source for the production of <EM>T. gondii </EM>oocysts (sporozoites) is the feline intestinal tract. Acquired disease in humans occurs by direct ingestion of oocysts from contaminated sources (soil, cat litter, garden vegetables) or by ingestion of tissue cysts (bradyzoites) present in undercooked tissues from infected animals. Fetal infection most commonly occurs after acute maternal infection in pregnancy, but it can also occur after reactivation of latent infection in immunocompromised women. Pathways leading to human disease are indicated by solid arrows, and pathways leading to feline infection are indicated by broken arrows.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics in Review, Vol. 18, Pages 75-83, Copyright © 1997 by the AAP.</div><div id=\"graphicVersion\">Graphic 74001 Version 15.0</div></div></div>"},"74003":{"type":"graphic_table","displayName":"Hip imaging indications in children","title":"Potential indications for pediatric hip imaging with various modalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications for pediatric hip imaging with various modalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Indications</td> </tr> <tr> <td>Plain film</td> <td>Initial evaluation of hip pain or limp</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Computed tomography</td> <td>Preoperative assessment and postoperative follow up of developmental dysplasia of the hip</td> </tr> <tr> <td>Pretreatment evaluation of LCP disease</td> </tr> <tr> <td>Pretreatment evaluation of slipped capital femoral epiphysis</td> </tr> <tr> <td>Evaluation of tumor matrix and cortical invasion</td> </tr> <tr> <td>Guidance for biopsy or ablation of certain tumors such as osteoid osteoma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">Magnetic resonance imaging</td> <td>Assessment and follow-up of complicated developmental dysplasia of the hip</td> </tr> <tr> <td>Diagnosis of proximal femoral focal deficiency</td> </tr> <tr> <td>Preoperative planning of developmental coxa vara</td> </tr> <tr> <td>Early diagnosis, staging, and evaluation of complications of LCP disease</td> </tr> <tr> <td>Early diagnosis of slipped capital femoral epiphysis</td> </tr> <tr> <td>Early diagnosis of osteomyelitis and exclusion of osteomyelitis in children with septic arthritis</td> </tr> <tr> <td>Diagnosis of occult traumatic injuries, including soft tissue injuries</td> </tr> <tr> <td>Early diagnosis of arthritis</td> </tr> <tr> <td>Tumor staging</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Radionuclide bone scan</td> <td>Early evaluation of osteomyelitis</td> </tr> <tr> <td>Detection of metastatic disease</td> </tr> <tr> <td>Early detection of LCP disease</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Ultrasonography</td> <td>Diagnosis and follow-up of developmental dysplasia of the hip</td> </tr> <tr> <td>Diagnosis of hip effusions due to transient synovitis and septic arthritis</td> </tr> <tr> <td>Detection of bursal or periarticular fluid collections, which may be seen in bursitis, arthritis, and infection</td> </tr> <tr> <td>Dynamic evaluation of the snapping iliopsoas syndrome</td> </tr> <tr> <td>Guidance of hip aspiration and injection</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Conventional arthrography</td> <td>Preoperatively and intraoperatively in the treatment of developmental dysplasia of the hip</td> </tr> <tr> <td>Preoperatively in LCP disease</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Magnetic resonance arthrography</td> <td>LCP disease</td> </tr> <tr> <td>Diagnosis of labral tears</td> </tr> <tr class=\"divider_top\"> <td>Computed tomography arthrography</td> <td>When magnetic resonance arthrography is contraindicated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LCP disease: Legg-Calvé-Perthes disease.</div><div id=\"graphicVersion\">Graphic 74003 Version 3.0</div></div></div>"},"74005":{"type":"graphic_table","displayName":"Fibrosis markers","title":"Markers of fibrogenesis and fibrinolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Markers of fibrogenesis and fibrinolysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Matrix deposition</td> </tr> <tr> <td class=\"indent1\">Procollagen I peptide</td> </tr> <tr> <td class=\"indent1\">Procollagen III peptide</td> </tr> <tr> <td class=\"indent1\">Type I collagen</td> </tr> <tr> <td class=\"indent1\">Type IV collagen</td> </tr> <tr> <td class=\"indent1\">YKL-40 (chondrex)</td> </tr> <tr> <td class=\"indent1\">Laminin</td> </tr> <tr> <td class=\"indent1\">Hyaluronic acid</td> </tr> <tr> <td class=\"subtitle1_single\">Matrix degradation</td> </tr> <tr> <td class=\"indent1\">MMP-2</td> </tr> <tr> <td class=\"indent1\">TIMP-1, -2</td> </tr> <tr> <td class=\"subtitle1_single\">Cytokines</td> </tr> <tr> <td class=\"indent1\">TGF-beta</td> </tr> <tr> <td class=\"indent1\">TGF-alpha</td> </tr> <tr> <td class=\"indent1\">PDGF</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMP: matrix metalloproteinase; PDGF: platelet derived growth factor; TGF: transforming growth factor; TIMP: tissue inhibitor of metalloproteinase.</div><div id=\"graphicVersion\">Graphic 74005 Version 3.0</div></div></div>"},"74006":{"type":"graphic_figure","displayName":"Aorta anatomy PI","title":"Anatomy of the aorta","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anatomy of the aorta</div><div class=\"cntnt\"><img style=\"width:535px; height:489px;\" src=\"images/PI/74006_Aorta_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aorta is the main artery that delivers blood from the heart to the body. The aorta travels through the chest (thoracic aorta) and the abdomen (abdominal aorta).</div><div id=\"graphicVersion\">Graphic 74006 Version 2.0</div></div></div>"},"74007":{"type":"graphic_figure","displayName":"Bianchi procedure","title":"Longitudinal intestinal lengthening and tailoring (Bianchi procedure) for short bowel syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal intestinal lengthening and tailoring (Bianchi procedure) for short bowel syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:497px;\" src=\"images/PEDS/74007_Bianchi_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bianchi, A. From the cradle to enteral autonomy: the role of autologous gastrointestinal reconstruction. Gastroenterology 2006; 130:S138. Copyright &#169;2006 The American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 74007 Version 2.0</div></div></div>"},"74008":{"type":"graphic_figure","displayName":"Normal anatomy umbilicus","title":"The normal umbilicus","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">The normal umbilicus</div><div class=\"cntnt\"><img style=\"width:593px; height:395px;\" src=\"images/PEDS/74008_Normal_anatomy_umbilicus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cilley R. Disorders of the umbilicus. In: Pediatric Surgery, Grosfeld J, O'Neill J, Coran A, Fonkalsrud E (Eds), Mosby Inc., Philadelphia 2006. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 74008 Version 2.0</div></div></div>"},"74009":{"type":"graphic_diagnosticimage","displayName":"Scheie brain MRI","title":"Brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)</div><div class=\"cntnt\"><img style=\"width:335px; height:309px;\" src=\"images/PEDS/74009_Scheie_brain_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal T1-weighted MRI of the brain in a patient with Hurler-Scheie syndrome. The ventricular system is prominent. Numerous white matter cysts (representing accumulation of GAG around vessels) are arrayed along the gray-white interface of the cortical white matter and within the corpus callosum and other white matter tracts.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; GAG: glycosaminoglycan.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 74009 Version 4.0</div></div></div>"},"74010":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:387px; height:263px;\" src=\"images/PC/74010_Necrobiosis_lipoidica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the thin, yellow, atrophic plaque with telangiectasia.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 74010 Version 1.0</div></div></div>"},"74011":{"type":"graphic_figure","displayName":"Serum T conc 3 preps","title":"Serum testosterone concentrations during the course of chronic administration of three different testosterone preparations to hypogonadal men","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum testosterone concentrations during the course of chronic administration of three different testosterone preparations to hypogonadal men</div><div class=\"cntnt\"><img style=\"width:346px; height:559px;\" src=\"images/ENDO/74011_Serum_T_conc_3_preps.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) During the 14 days following the injection of 200 mg of testosterone enanthate.<br />(B) During the 24 hours after application of one or two testosterone patches that deliver approximately 5 mg of testosterone each.<br />(C) During the 24 hours after application of a testosterone gel containing 50 or 100 mg of testosterone.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51:1335.</LI>&#xD;&#xA;<LI>Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.&nbsp;J Clin Endocrinol Metab 1999; 84:3469.</LI>&#xD;&#xA;<LI>Swerdloff RS, Wang C, Cunningham G, Dobs A. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85:4500.</LI></OL></div><div id=\"graphicVersion\">Graphic 74011 Version 2.0</div></div></div>"},"74012":{"type":"graphic_picture","displayName":"Peliosis hepatis low power","title":"Peliosis hepatis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peliosis hepatis</div><div class=\"cntnt\"><img style=\"width:440px; height:241px;\" src=\"images/GAST/74012_Peliosis_hepatis_low_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This low power (4x) view of a liver biopsy with H&amp;E stain shows patches of sinusoidal dilatation and small cyst formation between areas of grossly normal liver parenchyma.</div><div class=\"graphic_reference\">Courtesy of Tracy Challies, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 74012 Version 1.0</div></div></div>"},"74014":{"type":"graphic_picture","displayName":"Normal human myeloblast","title":"Normal human myeloblasts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human myeloblasts</div><div class=\"cntnt\"><img style=\"width:391px; height:261px;\" src=\"images/HEME/74014_Normal_human_myeloblast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear showing two normal human myeloblasts. The size is medium (15 to 20 microns in diameter), the nucleus is large and round with finely granular chromatin, nucleoli are present, granules are absent, and cytoplasm is scanty.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 74014 Version 1.0</div></div></div>"},"74017":{"type":"graphic_figure","displayName":"Breast MRI of invasive ductal cancer kinetic color map","title":"Breast MRI of invasive ductal cancer kinetic color map","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Breast MRI of invasive ductal cancer kinetic color map</div><div class=\"cntnt\"><img style=\"width:526px; height:544px;\" src=\"images/SURG/74017_Breast_MRI_duct_cx_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows a breast MRI of a patient with biopsy proven invasive ductal cancer in the left breast.<br> (A) The T1-weighted fat-suppressed contrast-enhanced axial image shows an irregular lobulated enhancing mass with central signal void corresponding to the percutaneous clip that was placed at time of core biopsy.<br> (B) The corresponding kinetic color map demonstrates predominantly washout kinetics highly suspicious for malignancy.<br> (C) Enhancement curves show mixed plateau and washout kinetics indicative of malignancy.</div><div id=\"graphicVersion\">Graphic 74017 Version 6.0</div></div></div>"},"74018":{"type":"graphic_diagnosticimage","displayName":"Traumatic spleen laceration","title":"Traumatic spleen laceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic spleen laceration</div><div class=\"cntnt\"><img style=\"width:404px; height:324px;\" src=\"images/EM/74018_Traumatic_spleen_laceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This enhanced computed tomography image shows a grade III laceration of the spleen (arrow).</div><div class=\"graphic_reference\">Courtesy of David Wesson, MD.</div><div id=\"graphicVersion\">Graphic 74018 Version 2.0</div></div></div>"},"74019":{"type":"graphic_figure","displayName":"Dermoscopic structures 3","title":"Dermoscopic structures mostly seen in nonmelanocytic neoplasms and their histopathologic correlation<sup>[1-4]</sup>","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures mostly seen in nonmelanocytic neoplasms and their histopathologic correlation<sup>[1-4]</sup></div><div class=\"cntnt\"><img style=\"width:596px; height:1383px;\" src=\"images/DERM/74019_Dermoscopicstruct3edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Shiny, white structures can also be seen in nonmelanocytic lesions. Structures are most common in melanoma. Both structures and shiny, white areas are common in dermatofibromas and basal cell carcinomas. Rosettes are more common in actinic keratoses and squamous cell carcinomas.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109.</li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556.</li>&#xD;&#xA;    <li>Scope A, Benvenuto-Andrade C, Agero AL, Marghoob AA. Nonmelanocytic lesions defying the two-step dermoscopy algorithm. Dermatol Surg 2006; 32:1398.</li>&#xD;&#xA;    <li>Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol 2012; 67:194e.1.</li>&#xD;&#xA;    <li>Cuellar F, Vilalta A, Puig S, et al. New dermoscopic pattern in actinic keratosis and related conditions. Arch Dermatol 2009; 145:732.</li>&#xD;&#xA;    <li>Navarrete-Dechent C, Bajaj S, Marchetti MA, et al. Association of shiny white blotches and strands with nonpigmented basal cell carcinoma: Evaluation of an additional dermoscopic diagnostic criterion. JAMA Dermatol 2016; 152:546.</li>&#xD;&#xA;    <li>Jaimes N, Zalaudek I, Braun RP, et al. Pearls of keratinizing tumors. Arch Dermatol 2012; 148:976.</li>&#xD;&#xA;    <li>Cameron A, Rosendahl C, Tschandi P, et al. Dermatoscopy of pigmented Bowen's disease. J Am Acad Dermatol 2010; 62:597.</li>&#xD;&#xA;    <li>Stricklin SM, Stoacker WV, Oliviero MC, et al. Cloudy and starry milia-like cysts: how well do they distinguish seborrheic keratoses from malignant melanomas? J Eur Acad Dermatol 2011; 25:1222.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 74019 Version 7.0</div></div></div>"},"74020":{"type":"graphic_picture","displayName":"Porokeratosis on finger","title":"Porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74020_Porokeratosis_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74020 Version 3.0</div></div></div>"},"74021":{"type":"graphic_table","displayName":"Classification DILI","title":"Classifications of drug-induced liver injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifications of drug-induced liver injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of classification</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td rowspan=\"3\">Clinical laboratory</td> <td>Hepatocellular</td> </tr> <tr> <td>Cholestatic</td> </tr> <tr> <td>Mixed hepatocellular/cholestatic</td> </tr> <tr> <td rowspan=\"4\">Mechanism of hepatotoxicity</td> <td>Direct hepatotoxicity</td> </tr> <tr> <td class=\"sublist1_start\">Idiosyncratic</td> </tr> <tr> <td class=\"sublist1\">Immune-mediated</td> </tr> <tr> <td class=\"sublist1\">Metabolic</td> </tr> <tr> <td rowspan=\"7\">Histologic findings</td> <td>Cellular necrosis or apoptosis</td> </tr> <tr> <td>Cholestasis</td> </tr> <tr> <td>Steatosis</td> </tr> <tr> <td>Fibrosis</td> </tr> <tr> <td>Phospholipidosis</td> </tr> <tr> <td>Granulomatous</td> </tr> <tr> <td>Sinusoidal obstruction syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74021 Version 2.0</div></div></div>"},"74022":{"type":"graphic_diagnosticimage","displayName":"Sonogram fetal abd circumferenc","title":"Image of abdominal circumference","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Image of abdominal circumference</div><div class=\"cntnt\"><img style=\"width:406px; height:252px;\" src=\"images/OBGYN/74022_Sonogram_fetal_abd_circumfe.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jacques Abramowicz, MD.</div><div id=\"graphicVersion\">Graphic 74022 Version 2.0</div></div></div>"},"74023":{"type":"graphic_diagnosticimage","displayName":"CXR of Eisenmenger syndrome ","title":"Chest x-ray in a patient with Eisenmenger syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest x-ray in a patient with Eisenmenger syndrome</div><div class=\"cntnt\"><img style=\"width:289px; height:298px;\" src=\"images/CARD/74023_Eisenmenger_syndrome_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chest x-ray of a patient with Eisenmenger syndrome secondary to an atrial septal defect demonstrates cardiomegaly due to right heart enlargement, prominence of the central pulmonary arteries, and peripheral &quot;pruning&quot; of the pulmonary vasculature (abrupt attenuation and/or termination of peripheral pulmonary artery branches).</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD.</div><div id=\"graphicVersion\">Graphic 74023 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"74024":{"type":"graphic_table","displayName":"NonAIDS cancer SIRs","title":"Incidence of cancer in immunosuppressed patients compared with the general population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of cancer in immunosuppressed patients compared with the general population</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cancer</td> <td class=\"subtitle1\">SIR in people with HIV/AIDS</td> <td class=\"subtitle1\">SIR in transplant recipients</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lymphoproliferative and hematologic malignancies</td> </tr> <tr> <td class=\"indent1\">Non-Hodgkin lymphoma</td> <td>22.6-353.5</td> <td>5.5-9.9</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma</td> <td>3.6-18.0</td> <td>2.2-8.0</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> <td>2.2-5.0</td> <td>2.7-3.8</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> <td>1.8-5.3</td> <td>2.3-2.5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cutaneous malignancies</td> </tr> <tr> <td class=\"indent1\">Kaposi sarcoma</td> <td>3640</td> <td>208</td> </tr> <tr> <td class=\"indent1\">Skin carcinoma</td> <td>1.5-19.6</td> <td>10.7-56.2</td> </tr> <tr> <td class=\"indent1\">Melanoma</td> <td>0.2-1.3</td> <td>1.4-2.5</td> </tr> <tr> <td class=\"indent1\">Eye cancer</td> <td>1.7-2.0</td> <td>2.0-7.6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Genitourinary malignancies</td> </tr> <tr> <td class=\"indent1\">Cervical cancer</td> <td>1.0-22.0</td> <td>1.5-2.5</td> </tr> <tr> <td class=\"indent1\">Vulvar/vaginal cancer</td> <td>4.4-6.8</td> <td>22.2-23.9</td> </tr> <tr> <td class=\"indent1\">Ovarian cancer</td> <td>0.3-4.4</td> <td>1.2-2.0</td> </tr> <tr> <td class=\"indent1\">Uterine cancer</td> <td>0.5-0.9</td> <td>0.9-1.7</td> </tr> <tr> <td class=\"indent1\">Breast cancer</td> <td>0.7-1.4</td> <td>1.0-1.5</td> </tr> <tr> <td class=\"indent1\">Penile cancer</td> <td>3.9-8.0</td> <td>15.8</td> </tr> <tr> <td class=\"indent1\">Testicular cancer</td> <td>0.7-1.8</td> <td>1.3-2.3</td> </tr> <tr> <td class=\"indent1\">Prostate cancer</td> <td>0.5-1.4</td> <td>0.9-1.1</td> </tr> <tr> <td class=\"indent1\">Renal cancer</td> <td>0.8-2.0</td> <td>4.1-8.0</td> </tr> <tr> <td class=\"indent1\">Bladder cancer</td> <td>0.4-4.2</td> <td>1.6-3.3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal malignancies</td> </tr> <tr> <td class=\"indent1\">Anal cancer</td> <td>19.6-50.0</td> <td>2.8-10.3</td> </tr> <tr> <td class=\"indent1\">Liver cancer</td> <td>1.9-22.2</td> <td>1.1-3.2</td> </tr> <tr> <td class=\"indent1\">Small intestine cancer</td> <td>1.3-3.4</td> <td>1.1-11.8</td> </tr> <tr> <td class=\"indent1\">Stomach cancer</td> <td>0.4-2.9</td> <td>1.8-2.3</td> </tr> <tr> <td class=\"indent1\">Pancreatic cancer</td> <td>0.7-2.9</td> <td>0.9-1.2</td> </tr> <tr> <td class=\"indent1\">Colorectal cancer</td> <td>0.9-1.4</td> <td>1.4-2.1</td> </tr> <tr> <td class=\"indent1\">Esophageal cancer</td> <td>0.5-2.1</td> <td>1.6-3.8</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Respiratory tract tumors</td> </tr> <tr> <td class=\"indent1\">Respiratory tract (lower) cancer</td> <td>1.4-4.5</td> <td>1.7-2.1</td> </tr> <tr> <td class=\"indent1\">Oropharyngeal cancer</td> <td>1.1-2.9</td> <td>2.8-5.3</td> </tr> <tr> <td class=\"indent1\">Laryngeal cancer</td> <td>0.6-2.8</td> <td>1.7-2.5</td> </tr> <tr> <td class=\"indent1\">Lip cancer</td> <td>2.3-3.1</td> <td>13.0-53.3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Thyroid cancer</td> <td>0.4-3.0</td> <td>0.9-8.1</td> </tr> <tr> <td class=\"indent1\">Brain cancer</td> <td>0.5-4.4</td> <td>0.6-1.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIR: standardized incidence ratio compared with general population.</div><div class=\"graphic_reference\">Modified from: Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.</div><div id=\"graphicVersion\">Graphic 74024 Version 6.0</div></div></div>"},"74027":{"type":"graphic_picture","displayName":"Uterosacral ligm plication2","title":"Uterosacral ligament plication during laparoscopic hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterosacral ligament plication during laparoscopic hysterectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/OBGYN/74027_Uterosacral_ligm_plication2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Thomas Lyons, MD.</div><div id=\"graphicVersion\">Graphic 74027 Version 3.0</div></div></div>"},"74028":{"type":"graphic_figure","displayName":"Blastocystis stages","title":"<EM>Blastocystis</EM> stages","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\"><EM>Blastocystis</EM> stages</div><div class=\"cntnt\"><img style=\"width:497px; height:618px;\" src=\"images/ID/74028_Blastocystis_stages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Knowledge of the life cycle and transmission is still under investigation, therefore this is a proposed life cycle for <EM>B. hominis</EM>. The classic form found in human stools is the cyst, which varies tremendously in size from 6 to 40 mcm <STRONG>(1)</STRONG>. The thick-walled cyst present in the stools <STRONG>(1)</STRONG> is believed to be responsible for external transmission, possibly by the fecal-oral route through ingestion of contaminated water or food <STRONG>(2)</STRONG>. The cysts infect epithelial cells of the digestive tract and multiply asexually <STRONG>(3,4)</STRONG>. Vacuolar forms of the parasite give origin to multi-vacuolar <STRONG>(5a)</STRONG> and ameboid <STRONG>(5b)</STRONG> forms. The multi-vacuolar develops into a pre-cyst <STRONG>(6a)</STRONG> that gives origin to a thin-walled cyst <STRONG>(7a)</STRONG>, thought to be responsible for autoinfection. The ameboid form gives origin to a pre-cyst <STRONG>(6b)</STRONG>, which develops into thick-walled cyst by schizogony <STRONG>(7b)</STRONG>. The thick-walled cyst is excreted in feces <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Originally published in: Singh M, Suresh K, Ho LC, et al. Elucidation of the life cycle of the intestinal protozoan Blastocystis hominis. Parasitol Res 1995; 81:449. Reproduced with kind permission from Springer Science + Business Media B.V. Reproduced from: Centers for Disease Control and Prevention. DPDx: Blastocystis hominis. Available at: <A href=\"http://www.cdc.gov/dpdx/blastocystis/index.html\">http://www.cdc.gov/dpdx/blastocystis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 74028 Version 9.0</div></div></div>"},"74029":{"type":"graphic_table","displayName":"Major causes of primary ovarian insufficiency","title":"Major causes of primary ovarian insufficiency (premature ovarian failure) in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of primary ovarian insufficiency (premature ovarian failure) in women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Accelerated follicular atresia</td> </tr> <tr> <td class=\"subtitle2_single\">Genetic defects</td> </tr> <tr> <td class=\"indent1\">Turner syndrome</td> </tr> <tr> <td class=\"indent1\">Fragile X premutations</td> </tr> <tr> <td class=\"indent1\">X chromosome deletions and translocations</td> </tr> <tr> <td class=\"indent1\">Galactosemia</td> </tr> <tr> <td class=\"subtitle2_single\">Ovarian toxins</td> </tr> <tr> <td class=\"indent1\">Chemotherapeutic drugs (especially alkylating agents)</td> </tr> <tr> <td class=\"indent1\">Radiation</td> </tr> <tr> <td class=\"indent1\">Mumps or cytomegalovirus infection</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune injury</td> </tr> <tr> <td class=\"indent1\">Isolated or part of polyglandular autoimmune syndromes</td> </tr> <tr> <td class=\"subtitle1_single\">Abnormal follicular stimulation</td> </tr> <tr> <td class=\"subtitle2_single\">Intraovarian modulators</td> </tr> <tr> <td class=\"indent1\">BMP15</td> </tr> <tr> <td class=\"subtitle2_single\">Steroidogenic enzyme defects</td> </tr> <tr> <td class=\"indent1\">CYP17 deficiency, StAR mutation</td> </tr> <tr> <td class=\"indent1\">Aromatase gene mutations</td> </tr> <tr> <td class=\"subtitle2_single\">Gonadotropin receptor function</td> </tr> <tr> <td class=\"indent1\">FSH receptor mutations</td> </tr> <tr> <td class=\"indent1\">Gs alpha subunit gene mutations</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 74029 Version 4.0</div></div></div>"},"74030":{"type":"graphic_picture","displayName":"Vespula sting anchoring","title":"Vespula sting anchoring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vespula sting anchoring</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/ALLRG/74030_Vespula_sting_anchoring.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 74030 Version 1.0</div></div></div>"},"74032":{"type":"graphic_picture","displayName":"Ulcer with clean base Endosc","title":"Ulcer with a clean base","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcer with a clean base</div><div class=\"cntnt\"><img style=\"width:320px; height:319px;\" src=\"images/GAST/74032_Ulcer_with_clean_base_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The opalescent ulcer in the center of this image taken during endoscopy has a &quot;clean&quot; base, which has a low risk of bleeding.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD</div><div id=\"graphicVersion\">Graphic 74032 Version 1.0</div></div></div>"},"74034":{"type":"graphic_picture","displayName":"Retinoblastoma strabismus","title":"Strabismus as presenting manifestation of retinoblastoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strabismus as presenting manifestation of retinoblastoma</div><div class=\"cntnt\"><img style=\"width:396px; height:126px;\" src=\"images/PEDS/74034_Retinoblastoma_strabismus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exotropia plus slightly enlarged corneal diameter and loss of red reflex in left eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74034 Version 1.0</div></div></div>"},"74038":{"type":"graphic_picture","displayName":"Coronal section through 8 week embryo","title":"Coronal section through eight-week embryo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronal section through eight-week embryo</div><div class=\"cntnt\"><img style=\"width:346px; height:432px;\" src=\"images/ALLRG/74038_Coron_sect_8_week_embryo.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">S: nasal septum; T: tongue; E: eyeball; h: hyoid; t: thyroid cartillage; i: laryngeal introitus.</div><div id=\"graphicVersion\">Graphic 74038 Version 2.0</div></div></div>"},"74039":{"type":"graphic_picture","displayName":"Inflamed seborrheic keratosis","title":"Inflamed seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Inflamed seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/74039_Inflam_seborrheic_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This erythematous, scaly papule is an inflamed seborrheic keratosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74039 Version 3.0</div></div></div>"},"74041":{"type":"graphic_figure","displayName":"Coronavirus replication","title":"Coronavirus replication","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Coronavirus replication</div><div class=\"cntnt\"><img style=\"width:598px; height:378px;\" src=\"images/ID/74041_Coronavirus_replication.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Steps in coronavirus replication that are potential targets for antiviral drugs and vaccines. The spike glycoprotein S is a good candidate for vaccines because neutralizing antibodies are directed against S. Blockade of the specific virus receptor on the surface of the host cell by monoclonal antibodies or other ligands can prevent virus entry. Receptor-induced conformational changes in the S protein can be blocked by peptides that inhibit membrane fusion and virus entry. The polyprotein of the replicase protein is cleaved into functional units by virus-encoded proteinases. Protease inhibitors may block replication. The polymerase functions in a unique membrane-bound complex in the cytoplasm, and the assembly and functions of this complex are potential drug targets. Viral mRNAs made by discontinuous transcription are shown in the cytoplasm with the protein that each encodes indicated at the right. The common 70 base long leader sequence on the 5' end of each mRNA is shown in red. Budding and exocytosis are processes essential to virus replication that may be targets for development of antiviral drugs.</div><div class=\"graphic_footnotes\">M: membrane protein required for virus budding; S: viral spike glycoprotein that has receptor binding and membrane fusion activities; E: small membrane protein that plays a role in coronavirus assembly; N: nucleocapsid phosphoprotein associated with viral RNA inside the virion.</div><div class=\"graphic_reference\">Reproduced with permission from: Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003; 111:1605. Copyright © 2003 American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 74041 Version 3.0</div></div></div>"},"74043":{"type":"graphic_table","displayName":"Post Lyme disease syndrome","title":"Proposed definition of post-Lyme disease syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed definition of post-Lyme disease syndrome</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Inclusion criteria\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; An adult or child with a documented episode of early or late Lyme disease fulfilling the case definition of the Centers for Disease Control and Prevention. If based on erythema migrans, the diagnosis must be made and documented by an experienced health care practitioner.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; After treatment of the episode of Lyme disease with a generally accepted treatment regimen, there is resolution or stabilization of the objective manifestation(s) of Lyme disease.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   &#8226; Onset of any of the following subjective symptoms within 6 months of the diagnosis of Lyme disease and persistence of continuous or relapsing symptoms for at least a 6 month period after completion of antibiotic therapy:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   - Fatigue\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   - Widespread musculoskeletal pain\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   - Complaints of cognitive difficulties\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Subjective symptoms are of such severity that, when present, they result in substantial reduction in previous levels of occupational, educational, social, or personal activities.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Exclusion criteria\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; An active, untreated, well-documented coinfection, such as babesiosis.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; The presence of objective abnormalities on physical examination or on neuropsychologic testing that may explain the patient's complaints. For example, a patient with antibiotic refractory Lyme arthritis would be excluded. A patient with late neuroborreliosis associated with encephalopathy, who has recurrent or refractory objective cognitive dysfunction, would be excluded.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; A diagnosis of fibromyalgia or chronic fatigue syndrome before the onset of Lyme disease.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; A prolonged history of undiagnosed or unexplained somatic complaints, such as musculoskeletal pains or fatigue, before the onset of Lyme disease.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; A diagnosis of an underlying disease or condition that might explain the patient's symptoms (eg, morbid obesity, with a body mass index [calculated as weight in kilograms divided by the square of height in meters] &#8805;45; sleep apnea and narcolepsy; side effects of medications; autoimmune diseases; uncontrolled cardiopulmonary or endocrine disorders; malignant conditions within 2 years, except for uncomplicated skin cancer; known current liver disease; any past or current diagnosis of a major depressive disorder with psychotic or melancholic features; bipolar affective disorders; schizophrenia of any subtype; delusional disorders of any subtype; dementias of any subtype; anorexia nervosa or bulimia nervosa; and active drug abuse or alcoholism at present or within 2 years).</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Laboratory or imaging abnormalities that might suggest an undiagnosed process distinct from post-Lyme disease syndrome, such as a highly elevated erythrocyte sedimentation rate (&#62;50 mm/hour); abnormal thyroid function; a hematologic abnormality; abnormal levels of serum albumin, total protein, globulin, calcium, phosphorus, glucose, urea nitrogen, electrolytes, or creatinine; significant abnormalities on urine analysis; elevated liver enzyme levels; or a test result suggestive of the presence of a collagen vascular disease.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8226; Although testing by either culture or PCR for evidence of <em>Borrelia burgdorferi</em> infection is not required, should such testing be done by reliable methods, a positive result would be an exclusion.</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Wormser, GP, et al. The clinical assessment, treatment and prevention of Lyme disease, Human Granulocytic Anaplasmosis, and babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089. Copyright &#169;2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 74043 Version 1.0</div></div></div>"},"74045":{"type":"graphic_table","displayName":"Clinical features of immunodeficiency disorders","title":"Clinical features of primary immunodeficiency disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of primary immunodeficiency disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Adaptive immunity</td> </tr> <tr> <td class=\"subtitle2_single\">B cell defects:</td> </tr> <tr> <td class=\"indent1\">Recurrent bacterial sinopulmonary infections or sepsis, particularly with polysaccharide encapsulated organisms (<em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em> type b)</td> </tr> <tr> <td class=\"indent1\">Unexplained bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Chronic or recurrent gastroenteritis (often with <em>Giardia</em> or enterovirus)</td> </tr> <tr> <td class=\"indent1\">Failure to thrive</td> </tr> <tr> <td class=\"indent1\">Chronic enteroviral meningoencephalitis</td> </tr> <tr> <td class=\"indent1\">Arthritis</td> </tr> <tr> <td class=\"subtitle2_single\">T cell defects:</td> </tr> <tr> <td class=\"indent1\">Recurrent, severe, or unusual viral infections (VZV, CMV, HSV)</td> </tr> <tr> <td class=\"indent1\">Failure to thrive</td> </tr> <tr> <td class=\"indent1\">Chronic candidiasis</td> </tr> <tr> <td class=\"indent1\">Chronic diarrhea</td> </tr> <tr> <td class=\"indent1\">Lymphopenia during the neonatal period or in infancy</td> </tr> <tr> <td class=\"indent1\">Pneumocystis pneumonia</td> </tr> <tr> <td class=\"indent1\">Graft-versus-host disease (maculopapular and/or desquamating skin, abnormal liver function tests, and/or chronic diarrhea)</td> </tr> <tr> <td class=\"indent1\">Severe/neonatal eczematoid or seborrheic rashes</td> </tr> <tr> <td class=\"subtitle1_single\">Innate immunity</td> </tr> <tr> <td class=\"subtitle2_single\">Phagocytic defects:</td> </tr> <tr> <td class=\"indent1\">Poor wound healing</td> </tr> <tr> <td class=\"indent1\">Delayed separation of the umbilical cord</td> </tr> <tr> <td class=\"indent1\">Lymphadenitis or soft tissue abscesses</td> </tr> <tr> <td class=\"indent1\">Hepatosplenomegaly</td> </tr> <tr> <td class=\"indent1\">Chronic gingivitis and periodontal disease, oral mucosal ulcerations</td> </tr> <tr> <td class=\"indent1\">Infection with catalase positive bacteria and fungi</td> </tr> <tr> <td class=\"indent1\">Recurrent gastrointestinal or genitourinary tract obstruction</td> </tr> <tr> <td class=\"subtitle2_single\">Complement defects:</td> </tr> <tr> <td class=\"indent1\">Angioedema of face, hands, feet, gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\">Autoimmune disease, lupus-like symptoms</td> </tr> <tr> <td class=\"indent1\">Pyogenic bacterial infections (eg, <em>Neisseria meningitidis</em>)</td> </tr> <tr> <td class=\"indent1\">History suggestive of autosomal dominant inheritance</td> </tr> <tr> <td class=\"subtitle2_single\">Other defects:</td> </tr> <tr> <td class=\"indent1\">Herpes simplex meningoencephalitis in infancy</td> </tr> <tr> <td class=\"indent1\">Papilloma virus infections of skin, including extensive warts</td> </tr> <tr> <td class=\"indent1\">Ectodermal dysplasia</td> </tr> <tr> <td class=\"indent1\">Pyogenic infections (eg, sepsis, meningitis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VZV: varicella-zoster virus; CMV: cytomegalovirus; HSV: herpes-simplex virus.</div><div id=\"graphicVersion\">Graphic 74045 Version 7.0</div></div></div>"},"74047":{"type":"graphic_picture","displayName":"Spider angiomas","title":"Spider angiomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spider angiomas</div><div class=\"cntnt\"><img style=\"width:410px; height:249px;\" src=\"images/OBGYN/74047_Spider_angiomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows two spider angiomas (spider telangiectasias) on the arm of a pregnant woman. A central feeding vessel, most easily seen in the lesion on the right, leads to other telangiectatic vessels, arranged in the shape of a spider, best appreciated in the lesion on the left. Pressure over the central vessel with the end of a paper clip or a glass slide causes the entire lesion to blanch. Similar lesions can be seen in patients with cirrhosis, and are most commonly seen on the upper chest, face, and back.</div><div id=\"graphicVersion\">Graphic 74047 Version 1.0</div></div></div>"},"74048":{"type":"graphic_figure","displayName":"Gene expr profile AML ALL","title":"Gene expression profiling in acute leukemia","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Gene expression profiling in acute leukemia</div><div class=\"cntnt\"><img style=\"width:500px; height:328px;\" src=\"images/HEME/74048_Gene_expr_profile_AML_ALL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the use of gene expression arrays (or profiles) for distinguishing between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Genes most highly expressed in ALL and AML are shown in the left-hand and right-hand panels, respectively (ie, &quot;ALL genes&quot; and &quot;AML genes&quot;, respectively). Expression levels of each of the individual genes greater than the mean are shown in red; those genes expressed below the mean are shown in blue. Each column (ie, top to bottom) corresponds to a specific gene, while each row (ie, left to right) corresponds to expression levels in a single sample. The top 11 samples were from patients with AML, while the remainder were from patients with ALL. Note that, while the genes as a group appear correlated with either AML or ALL, no single gene is uniformly expressed in either type of leukemia.</div><div class=\"graphic_reference\">From: Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286:531. Reprinted with permission from AAAS.</div><div class=\"contractual\"><br/><a href=\"http://www.sciencemag.org/\">http://www.sciencemag.org</a></div><div id=\"graphicVersion\">Graphic 74048 Version 9.0</div></div></div>"},"74050":{"type":"graphic_picture","displayName":"Inflamed gouty tophi","title":"Inflamed gouty tophi","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Inflamed gouty tophi</div><div class=\"cntnt\"><img style=\"width:548px; height:410px;\" src=\"images/SURG/74050_Inflamed_gouty_tophi_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gout is a disorder of urate metabolism that leads to high levels of uric acid and the formation of urate crystals. Urate crystals can be deposited under the skin, in joints, and within tendon sheaths as gouty tophi, which can cause an intense inflammatory process. Panel A demonstrates the clinical appearance of gouty tophi. Panel B illustrates the radiographic appearance of gouty tophi. Note the multiple juxta-articular, punched-out lytic erosions (red circles) and a lack of osteoporosis, which is characteristic of gout.</div><div id=\"graphicVersion\">Graphic 74050 Version 4.0</div></div></div>"},"74051":{"type":"graphic_table","displayName":"One-day rush with subsequent schedule","title":"One-day rush schedule for venom immunotherapy with subsequent build-up to full maintenance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">One-day rush schedule for venom immunotherapy with subsequent build-up to full maintenance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Volume, mL</td> <td class=\"subtitle1\">Concentration, micrograms/mL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Minutes</td> </tr> <tr> <td class=\"indent1\">0</td> <td>0.05</td> <td>1</td> </tr> <tr> <td class=\"indent1\">15</td> <td>0.1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">30</td> <td>0.2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">45</td> <td>0.4</td> <td>1</td> </tr> <tr> <td class=\"indent1\">60</td> <td>0.08</td> <td>10</td> </tr> <tr> <td class=\"indent1\">75</td> <td>0.2</td> <td>10</td> </tr> <tr> <td class=\"indent1\">90</td> <td>0.5</td> <td>10</td> </tr> <tr> <td class=\"indent1\">105</td> <td>0.1</td> <td>100</td> </tr> <tr> <td class=\"indent1\">120</td> <td>0.2</td> <td>100</td> </tr> <tr> <td class=\"indent1\">135</td> <td>0.2</td> <td>100</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Week</td> </tr> <tr> <td class=\"indent1\">2</td> <td>0.4</td> <td>100</td> </tr> <tr> <td class=\"indent1\">3</td> <td>0.6</td> <td>100</td> </tr> <tr> <td class=\"indent1\">4</td> <td>0.8</td> <td>100</td> </tr> <tr> <td class=\"indent1\">5</td> <td>1</td> <td>100</td> </tr> <tr> <td class=\"indent1\">6</td> <td>1</td> <td>100</td> </tr> <tr> <td class=\"indent1\">8</td> <td>1</td> <td>100</td> </tr> <tr> <td class=\"indent1\">11</td> <td>1</td> <td>100</td> </tr> <tr> <td><strong>Monthly</strong></td> <td>1</td> <td>100</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=95509&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The accelerated portion of the protocol is shown at the top, followed by subsequent weekly visits to reach full maintenance, as recommended by the manufacturer of the venom extract being administered. In this example, the subsequent build-up follows the schedule recommended by Hollister-Stier (Spokane, Washington).</div><div class=\"graphic_reference\">Accelerated initial protocol from: Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73:423. If ALK-Abello (Round Rock, Texas) extracts were used, the schedule in the package insert could be followed to complete the build-up phase.</div><div id=\"graphicVersion\">Graphic 74051 Version 6.0</div></div></div>"},"74052":{"type":"graphic_picture","displayName":"Overhead arm raise exercise","title":"Strength exercise: Overhead arm raise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Overhead arm raise</div><div class=\"cntnt\"><img style=\"width:374px; height:306px;\" src=\"images/PC/74052_Overhead_arm_raise_exer_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise will strengthen your shoulders and arms. It should make swimming and other activities such as lifting and carrying grandchildren easier.   <OL>  <LI>You can do this exercise while standing or sitting in a sturdy, armless chair. </LI>  <LI>Keep your feet flat on the floor, shoulder-width apart. </LI>  <LI>Hold weights* at your sides at shoulder height with palms facing forward. Breathe in slowly. </LI>  <LI>Slowly breathe out as you raise both arms up over your head keeping your elbows slightly bent. </LI>  <LI>Hold the position for one second. </LI>  <LI>Breathe in as you slowly lower your arms. </LI>  <LI>Repeat 10 to 15 times. </LI>  <LI>Rest; then repeat 10 to 15 more times. </LI></OL>As you progress, use a heavier weight and alternate arms until you can lift the weight comfortably with both arms.</div><div class=\"graphic_footnotes\">* Handheld weights or household items (soup cans, bottles of water).</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 74052 Version 4.0</div></div></div>"},"74055":{"type":"graphic_diagnosticimage","displayName":"Small bowel ischemia on plain abdominal film","title":"Small bowel ischemia on plain abdominal film","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel ischemia on plain abdominal film</div><div class=\"cntnt\"><img style=\"width:281px; height:288px;\" src=\"images/GAST/74055_Small_bowel_ischemia_KUB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain radiograph of the abdomen demonstrates distended featureless loops of small bowel with wall thickening (arrow) and separation of the bowel loops. These findings are consistent with hemorrhage into the bowel wall secondary to ischemia.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 74055 Version 3.0</div></div></div>"},"74056":{"type":"graphic_picture","displayName":"Infected eczema hand","title":"Staphylococcus aureus infection in atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staphylococcus aureus infection in atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/PC/74056_Infected_eczema_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules and honey-colored crusting are seen on the dorsal hand of this patient with infected atopic dermatitis.</div><div class=\"graphic_reference\">Courtesy of Joseph Morelli, MD.</div><div id=\"graphicVersion\">Graphic 74056 Version 1.0</div></div></div>"},"74057":{"type":"graphic_table","displayName":"Psychosocial factors associated with persistent low back pain","title":"Psychosocial factors associated with persistent low back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychosocial factors associated with persistent low back pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General or work-related beliefs</td> </tr> <tr> <td>Belief that pain and activity are harmful</td> </tr> <tr> <td>Fear-avoidance behavior (avoidance of activities because of fear of increased pain)</td> </tr> <tr> <td>Catastrophizing (excessive focus on pain and feeling of helplessness to control pain)</td> </tr> <tr> <td>Expectation that passive treatments/rehabilitation will be effective</td> </tr> <tr> <td>Expectation of increased pain with activity or return to work</td> </tr> <tr> <td class=\"subtitle1_single\">Work-related factors</td> </tr> <tr> <td>Poor control of one's job environment</td> </tr> <tr> <td>Low job satisfaction</td> </tr> <tr> <td>Short job attachment (recent hire)</td> </tr> <tr> <td>Limited work skills/experience</td> </tr> <tr> <td>Prior workers' compensation claim or time off work because of injury</td> </tr> <tr> <td>Litigation in progress</td> </tr> <tr> <td>Physically demanding work</td> </tr> <tr> <td class=\"subtitle1_single\">Other affective factors</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Anxiety</td> </tr> <tr> <td>Alcohol or substance use</td> </tr> <tr> <td>Socially withdrawn (lack of family/social support)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74057 Version 2.0</div></div></div>"},"74059":{"type":"graphic_diagnosticimage","displayName":"Cavitary Cryptococcus","title":"Cryptococcosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptococcosis</div><div class=\"cntnt\"><img style=\"width:364px; height:589px;\" src=\"images/PULM/74059_Cavitary_Cryptococcus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph and&nbsp;computed tomography (CT)&nbsp;show a cavitary lesion in the left lower lobe, which was demonstrated to represent cryptococcosis by bronchoscopy.</div><div class=\"graphic_reference\">Courtesy of Alan Fein, MD.</div><div id=\"graphicVersion\">Graphic 74059 Version 4.0</div></div></div>"},"74060":{"type":"graphic_figure","displayName":"Female perineum muscles","title":"Muscles of the female perineum","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Muscles of the female perineum</div><div class=\"cntnt\"><img style=\"width:530px; height:384px;\" src=\"images/SURG/74060_Female-perineum-muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the muscles of the female perineum. Note the location of the levator ani (iliococcygeus) muscles, the external anal sphincter, and the superficial transverse perineal muscle.</div><div id=\"graphicVersion\">Graphic 74060 Version 1.0</div></div></div>"},"74061":{"type":"graphic_diagnosticimage","displayName":"Left iliac artery aneurysm on 3D computed tomography","title":"Left iliac artery aneurysm on 3D computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left iliac artery aneurysm on 3D computed tomography</div><div class=\"cntnt\"><img style=\"width:290px; height:638px;\" src=\"images/SURG/74061_Iliac_aneurysm_CT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74061 Version 4.0</div></div></div>"},"74062":{"type":"graphic_table","displayName":"F-75 and F-100 Diets","title":"Preparation of F-75 and F-100 diets used in the treatment of malnutrition in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preparation of F-75 and F-100 diets used in the treatment of malnutrition in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Ingredient</td> <td class=\"subtitle1\" colspan=\"2\">Amount</td> </tr> <tr> <td class=\"subtitle2\">F-75*<sup>&#8226;</sup><sup>&#916;</sup></td> <td class=\"subtitle2\">F-100<sup>&#9674;</sup></td> </tr> <tr> <td>Dried skimmed milk</td> <td>25 g</td> <td>80 g</td> </tr> <tr> <td>Sugar</td> <td>70 g</td> <td>50 g</td> </tr> <tr> <td>Cereal flour</td> <td>35 g</td> <td>-</td> </tr> <tr> <td>Vegetable oil</td> <td>27 g</td> <td>60 g</td> </tr> <tr> <td>Mineral mix<sup>&#167;</sup></td> <td>20 mL</td> <td>20 mL</td> </tr> <tr> <td>Vitamin mix<sup>&#167;</sup></td> <td>140 mg</td> <td>140 mg</td> </tr> <tr> <td>Water to make</td> <td>1000 mL</td> <td>1000 mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* To prepare the F-75 diet, add the dried skimmed milk, sugar, cereal flour and oil to some water and mix. Boil for 5-7 minutes. Allow to cool, then add the mineral mix and vitamin mix and mix again. Make up the volume to 1000 mL with water. A comparable formula can be made from 35 g of whole dried milk, 70 g of sugar, 35 g of cereal flour, 17 g of oil, 20 ml of mineral mix, 140 mg of vitamin mix and water to make 1000 mL.<br />¶ If cereal flour is not available or there are no cooking facilities, a comparable formula can be made from 25 g of dried skimmed milk, 100 g of sugar, 27 g of oil, 20 mL of mineral mix, 140 mg of vitamin mix and water to make 1000 mL. However, this formula has a high osmolarity (415 mOsmol/L) and may not be well tolerated by all children, especially those with diarrhoea.<br />Δ Isotonic versions of F-75 (280 mOsmol/L), which contain maltodextrins instead of cereal flour and some of the sugar and which include all the necessary micronutrients, are available commercially.<br /><FONT class=lozenge>◊</FONT> To prepare the F-100 diet, add the dried skimmed milk, sugar and oil to some warm boiled water and mix. Add the mineral mix and vitamin mix and mix again. Make up the volume to 1000mL with water.<br />§ See related tables describing the WHO Vitamin mix and WHO Mineral mix. If only small amounts of feed are being prepared, it will not be feasible to prepare the vitamin mix because of the small amounts involved. In this case, give a proprietary multivitamin supplement. Alternatively, a combined mineral and vitamin mix for malnourished children is available commercially and can be used in the above diets.</div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy;1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 74062 Version 4.0</div></div></div>"},"74063":{"type":"graphic_figure","displayName":"Lower-extremity alignment","title":"Physiologic progression of lower-extremity alignment","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Physiologic progression of lower-extremity alignment</div><div class=\"cntnt\"><img style=\"width:505px; height:507px;\" src=\"images/PEDS/74063_Lower_extremity_alignment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower-extremity alignment goes through a predictable progression over the first seven years of life: from varus (bow-legs) between birth and approximately 18 months, to neutral alignment between approximately 18 and 24 months, to valgus (knock-knees), and, finally, back towards neutral. Adult lower extremity alignment is slight valgus. </div><div class=\"graphic_reference\">Modified from: Skaggs DL, Flynn JM. Knees bow out, feet turn in, who cares. In: Staying Out of Trouble in Pediatric Orthopaedics, Skaggs DL, Flynn JM, Lippincott Williams &amp; Wilkins, Philadelphia 2006.</div><div id=\"graphicVersion\">Graphic 74063 Version 14.0</div></div></div>"},"74065":{"type":"graphic_figure","displayName":"TM embryology","title":"Tympanic membrane embryology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane embryology</div><div class=\"cntnt\"><img style=\"width:439px; height:343px;\" src=\"images/PEDS/74065_TM_embryology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The external auditory canal is separated from the tympanic cavity by the tympanic membrane, which has an inner layer of endoderm, a middle layer of mesoderm, and an outer layer of ectoderm. The tympanic cavity has expanded around the ossicles. The membranous labyrinth is contained within the bony labyrinth. The perilympathic fluid that conducts sound to the cochlea communicates acoustic energy through the oval and round windows.</div><div class=\"graphic_footnotes\">OW: oval window.</div><div id=\"graphicVersion\">Graphic 74065 Version 6.0</div></div></div>"},"74066":{"type":"graphic_picture","displayName":"Chronic tinea pedis","title":"Chronic tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic tinea pedis</div><div class=\"cntnt\"><img style=\"width:342px; height:296px;\" src=\"images/PC/74066_Chronic_tinea_pedis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scales are visible between the toes and on the plantar surface of this patient with chronic tinea pedis infection.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 74066 Version 1.0</div></div></div>"},"74067":{"type":"graphic_table","displayName":"Egg alternatives","title":"Nutrients to be replaced on an egg avoidance diet and alternative dietary sources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutrients to be replaced on an egg avoidance diet and alternative dietary sources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nutrients in egg </td> <td class=\"subtitle1\">Alternative dietary sources </td> </tr> <tr> <td>Protein</td> <td>Cow's milk, soy, meat, fish, poultry, nuts, seeds, legumes</td> </tr> <tr> <td>Cyanocobalamin (vitamin B12)</td> <td>Meat, fish, poultry, cow's milk, enriched alternative \"milk\" beverages</td> </tr> <tr> <td>Selenium</td> <td>Brazil nut, beef, chicken, turkey, fish</td> </tr> <tr> <td>Riboflavin (vitamin B2)</td> <td>Cow's milk, meat, enriched grains and cereals, dark green leafy vegetables</td> </tr> <tr> <td>Biotin</td> <td>Liver, soy, whole grains, green leafy vegetables</td> </tr> <tr> <td>Pantothenic acid (vitamin B5)</td> <td>Cow's milk, vegetables, whole grains, meat, fish, legumes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74067 Version 2.0</div></div></div>"},"74068":{"type":"graphic_figure","displayName":"Localization VFD","title":"Anatomy of the visual pathways and visual field correlation (view of underside of brain)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Anatomy of the visual pathways and visual field correlation (view of underside of brain)</div><div class=\"cntnt\"><img style=\"width:576px; height:457px;\" src=\"images/NEURO/74068_Localization_VFD.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Liu, GT, Volpe, NJ, Galetta, SL. Visual loss: Overview, visual field testing and topical diagnosis. In: Neuro-ophthalmology. Diagnosis and Management, Liu, GT, Volpe, NJ, Galetta, SL (Eds), WB Saunders, Philadelphia 2001. p.55. Copyright &#169;2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 74068 Version 1.0</div></div></div>"},"74069":{"type":"graphic_diagnosticimage","displayName":"Meconium pseudocyst 2","title":"Meconium pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meconium pseudocyst</div><div class=\"cntnt\"><img style=\"width:396px; height:361px;\" src=\"images/OBGYN/74069_Meconium_pseudocyst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of the abdomen in a fetus at gestational age of 18 weeks with a meconium pseudocyst (arrow) and peritoneal calcifications (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 74069 Version 3.0</div></div></div>"},"74071":{"type":"graphic_figure","displayName":"Klisic test","title":"The Klisic test for hip dislocation","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">The Klisic test for hip dislocation</div><div class=\"cntnt\"><img style=\"width:471px; height:465px;\" src=\"images/PEDS/74071_Klisic_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Klisic test is performed by placing the index finger on the anterior superior iliac spine and the middle finger on the greater trochanter. An imaginary line between these two points should point toward or above the umbilicus. The line will pass below the umbilicus if the hip is dislocated.</div><div id=\"graphicVersion\">Graphic 74071 Version 2.0</div></div></div>"},"74073":{"type":"graphic_figure","displayName":"CF colonization by age","title":"Prevalence of bacteria identified in respiratory secretions from patients with cystic fibrosis, by age cohort","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Prevalence of bacteria identified in respiratory secretions from patients with cystic fibrosis, by age cohort</div><div class=\"cntnt\"><img style=\"width:748px; height:344px;\" src=\"images/PULM/74073_CF_colonization_by_age_2015.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><EM>P. aeruginosa</EM>: <EM>Pseudomonas aeruginosa</EM>; <EM>H. influenza</EM>: <EM>Haemophilus influenza</EM>; <EM>B. cepacia</EM> complex: <EM>Burkholderia cepacia </EM>complex; <EM>S. aureus</EM>: <EM>Staphylococcus aureus</EM>; MRSA: methicillin-resistant <EM>S. aureus</EM>;<EM> Achromobacter:</EM> <EM>Achromobacter xylosoxidans</EM>; <EM>S. maltophilia</EM>: <EM>Stenotrophomonas maltophilia</EM>; MDR-PA: multidrug-resistant <EM>P. aeruginosa</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry: 2015 Annual Data Report, Bethesda, MD. Copyright © 2016 Cystic Fibrosis Foundation.</div><div id=\"graphicVersion\">Graphic 74073 Version 11.0</div></div></div>"},"74075":{"type":"graphic_table","displayName":"Lung transplant donor criteria","title":"Ideal lung transplant donor criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ideal lung transplant donor criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age &#60;55 years</td> </tr> <tr> <td>ABO compatibility</td> </tr> <tr> <td>Clear chest radiograph</td> </tr> <tr> <td>PaO<sub>2</sub> &#62;300 on FiO<sub>2</sub> = 1.0, PEEP - 5 cm H<sub>2</sub>O</td> </tr> <tr> <td>Tobacco history &#60;20 pack years</td> </tr> <tr> <td>Absence of significant chest trauma</td> </tr> <tr> <td>No evidence of aspiration/sepsis</td> </tr> <tr> <td>No prior cardiopulmonary surgery</td> </tr> <tr> <td>Acceptable bronchoscopic inspection without evidence of aspirated stomach contents or purulent secretions</td> </tr> <tr> <td>Gram stain of sputum/BAL without organisms</td> </tr> <tr> <td>No history of significant chronic lung disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FiO<SUB>2</SUB>: fraction of inspired oxygen; PaO<SUB>2</SUB>: partial pressure of arterial oxygen; PEEP: positive end-expiratory pressure; BAL: bronchoalveolar lavage.<br />* These criteria describe \"ideal\" lung transplant donors, but most lung donors do not meet all of these criteria. Thus, all potential donors should be discussed with the organ procurement organization (OPO) and lung transplant team to determine acceptability.</div><div class=\"graphic_reference\">Adapted with permission from: Bhorade, SM, Vigneswaran, W, McCabe, MA, Garrity, ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19:1199. Copyright © 2000 Elsevier.<br />Updated from:<br /><OL>&#xD;&#xA;<LI>Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med 2015; 43:1291.</LI></OL></div><div id=\"graphicVersion\">Graphic 74075 Version 2.0</div></div></div>"},"74076":{"type":"graphic_table","displayName":"IBM versus polymyositis","title":"Differentiation between inclusion body myositis and polymyositis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiation between inclusion body myositis and polymyositis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">Inclusion body myositis </td> <td class=\"subtitle1\">Polymyositis </td> </tr> <tr> <td><strong>Sex</strong></td> <td>Male &#62; female</td> <td>Female &#62; male</td> </tr> <tr> <td><strong>Age</strong></td> <td>Uncommon&nbsp;before 50</td> <td>Common before 50</td> </tr> <tr> <td><strong>Onset</strong></td> <td>Insidious</td> <td>Acute or subacute</td> </tr> <tr> <td><strong>Course</strong></td> <td>Slowly progressive</td> <td>More rapid</td> </tr> <tr> <td><strong>Distribution of weakness</strong></td> <td>Usually asymmetric finger flexor and proximal leg weakness</td> <td>Proximal, symmetric</td> </tr> <tr> <td><strong>Creatine kinase</strong></td> <td>Normal or &#60;10x normal</td> <td>Often &#62;10x normal</td> </tr> <tr> <td><strong>EMG</strong></td> <td>Myopathic or mixed myopathic and neurogenic</td> <td>Myopathic</td> </tr> <tr> <td><strong>Muscle biopsy</strong></td> <td>Inflammation, rimmed vacuoles, inclusions</td> <td>Inflammation, fiber necrosis</td> </tr> <tr> <td><strong>Response to therapy</strong></td> <td>Generally poor</td> <td>Expected</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 74076 Version 5.0</div></div></div>"},"74078":{"type":"graphic_picture","displayName":"Moraxella catarrhalis Gram stain","title":"<em>Moraxella catarrhalis</em> on Gram stain of a sputum specimen","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><em>Moraxella catarrhalis</em> on Gram stain of a sputum specimen</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/74078_Moraxellacatarrgramstain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sputum sample shows several intact neutrophils and gram-negative diplococci with flattened internal edges resembling <EM>Moraxella</EM> species or <EM>Neisseria</EM> species. By culture, the organism was identified as <EM>Moraxella catarrhalis</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Marler LM, Siders JA, Allen SD. Direct Smear Atlas: A Monograph of Gram-Stained Preparations of Clinical Specimens. Lippincott Williams &amp; Wilkins, Baltimore 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74078 Version 8.0</div></div></div>"},"74079":{"type":"graphic_table","displayName":"Salicylate poisoning - Rapid overview","title":"Salicylate poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Salicylate poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td>Common: tachypnea, tinnitus, nausea, vomiting, acid-base abnormalities</td> </tr> <tr> <td>Severe cases: hyperthermia, altered mental status, pulmonary edema</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Plasma salicylate concentration, arterial blood gas (ABG), basic electrolytes, BUN and creatinine, chest radiograph</td> </tr> <tr> <td>Repeat salicylate concentration every two hours until it is declining</td> </tr> <tr> <td>Repeat ABG every two hours until acid-base status stable or improving</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td><strong>Avoid intubation if at all possible</strong></td> </tr> <tr> <td>Administer supplemental oxygen as needed</td> </tr> <tr> <td>Volume resuscitate unless cerebral or pulmonary edema is present</td> </tr> <tr> <td>Administer multiple doses of activated charcoal (first dose: 1 g/kg orally up to 50 g)</td> </tr> <tr> <td>Administer supplemental glucose in patients with altered mental status, even if serum glucose concentration is normal: IV dextrose 50 g as 100 mL of 50 percent dextrose</td> </tr> <tr> <td class=\"sublist1_start\">Alkalinize with sodium bicarbonate</td> </tr> <tr> <td class=\"sublist1\">Bolus therapy: sodium bicarbonate, 1 to 2 mEq/kg (maximum 100 mEq) IV push over 3 to 5 minutes</td> </tr> <tr> <td class=\"sublist1\">Maintenance therapy: 100 to 150 mEq sodium bicarbonate in 1 L of D5W, run at 250 mL/hour in adults OR run at 1.5 to 2 times maintenance in children</td> </tr> <tr> <td class=\"sublist1\">Correct hypokalemia, hypocalcemia and other electrolyte abnormalities. IV sodium bicarbonate is NOT compatible with calcium salts.</td> </tr> <tr> <td class=\"sublist1\">Alkalemia (arterial pH up to 7.55) is NOT a contraindication to sodium bicarbonate therapy</td> </tr> <tr> <td class=\"sublist1\">DO NOT USE ACETAZOLAMIDE TO ALKALINIZE THE URINE</td> </tr> <tr> <td class=\"sublist1_start\">Alert nephrology team early in the patient's clinical course; indications for hemodialysis include:</td> </tr> <tr> <td class=\"sublist1\">Profoundly altered mental status</td> </tr> <tr> <td class=\"sublist1\">Pulmonary or cerebral edema</td> </tr> <tr> <td class=\"sublist1\">Renal insufficiency that interferes with salicylate excretion</td> </tr> <tr> <td class=\"sublist1\">Fluid overload that prevents the administration of sodium bicarbonate</td> </tr> <tr> <td class=\"sublist1\">A plasma salicylate concentration &#62;100 mg/dL (7.2 mmol/L) in acute ingestion OR &#62;60 mg/dL (4.3 mmol/L) in chronic ingestion</td> </tr> <tr> <td class=\"sublist1\">Clinical deterioration despite aggressive and appropriate supportive care</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74079 Version 14.0</div></div></div>"},"74084":{"type":"graphic_diagnosticimage","displayName":"Three month axial CT","title":"Three month axial CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three month axial CT</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/ONC/74084_Three_month_axial_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 77-year-old woman with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk factors. Supine three-month axial CT post RFA shows that the area treated has increased in size (arrow). This should not be mistaken for tumor recurrence.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Schirmang, T, MD and Dupuy, D, MD.</div><div id=\"graphicVersion\">Graphic 74084 Version 3.0</div></div></div>"},"74085":{"type":"graphic_algorithm","displayName":"Chronic cough child","title":"Algorithm for evaluation of chronic cough in children","html":"<div class=\"graphic\"><div style=\"width: 870px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of chronic cough in children</div><div class=\"cntnt\"><img style=\"width:850px; height:880px;\" src=\"images/PEDS/74085_Chronic_cough_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PFT: pulmonary function test; CF: cystic fibrosis; HRCT: high-resolution computed tomography; BAL: bronchoalveolar lavage; PCR: polymerase chain reaction; TEF: tracheoesophageal fistula; CT: computed tomography.</div><div class=\"graphic_reference\">Modified from: Shields MD, Bush A, Everard ML, et al. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax 2008; 63 Suppl 3:iii1.</div><div id=\"graphicVersion\">Graphic 74085 Version 4.0</div></div></div>"},"74086":{"type":"graphic_picture","displayName":"Iris coloboma","title":"Iris coloboma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iris coloboma</div><div class=\"cntnt\"><img style=\"width:410px; height:504px;\" src=\"images/PEDS/74086_Iris_coloboma_ped.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Goldenhar-Gorlin syndrome. Note right-sided limbal dermoid, right-sided inferotemporal lipodermoid, left iris coloboma, bilateral grade III microtia, and facial asymmetry with mandibular deficiency and dental malocclusion.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74086 Version 2.0</div></div></div>"},"74088":{"type":"graphic_figure","displayName":"Chlorpyrifos structure","title":"Chlorpyrifos structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chlorpyrifos structure</div><div class=\"cntnt\"><img style=\"width:398px; height:162px;\" src=\"images/PULM/74088_Chlorpyrifos_structure.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74088 Version 1.0</div></div></div>"},"74089":{"type":"graphic_picture","displayName":"Lymphomatoid granuloma Low","title":"Lymphomatoid granulomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid granulomatosis</div><div class=\"cntnt\"><img style=\"width:392px; height:294px;\" src=\"images/PULM/74089_Lymphomatoid_granuloma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low magnification photomicrograph (original magnification 100x) illustrating zone of necrosis surrounded by a lymphocytic infiltrate with conspicuous vascular infiltration (right).</div><div id=\"graphicVersion\">Graphic 74089 Version 1.0</div></div></div>"},"74090":{"type":"graphic_figure","displayName":"Pulse pressure risk CHD","title":"Pulse pressure is an independent risk factor for coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Pulse pressure is an independent risk factor for coronary heart disease</div><div class=\"cntnt\"><img style=\"width:496px; height:338px;\" src=\"images/CARD/74090_Pulse_pressure_risk_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Framingham study of 1924 men and women followed for 20 years a higher pulse pressure (PP) at any level of systolic blood pressure (SBP) was an indepedent risk factor for coronary heart disease (CHD). Hazard ratios were determined from level of PP within SBP groups; hazard ratios were set to a reference value of 1.0 for SBP of 130 mmHg and PP of 50 mmHg. All estimates were adjusted for age, sex, body mass index, cigarettes smoked per day, glucose intolerance, and total cholesterol/HDL.</div><div class=\"graphic_reference\">Data from Franklin, SS, Khan, SA, Wong, ND, et al, Circulation 1999; 100:354.</div><div id=\"graphicVersion\">Graphic 74090 Version 1.0</div></div></div>"},"74091":{"type":"graphic_table","displayName":"Anticholinergic poisoning - Rapid overview","title":"Anticholinergic poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticholinergic poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td>Anticholinergic toxicity is almost always a clinical diagnosis</td> </tr> <tr> <td class=\"sublist1_start\">Manifestations of anticholinergic toxicity include:</td> </tr> <tr> <td class=\"sublist1\">Flushing due to cutaneous vasodilation (\"red as a beet\")</td> </tr> <tr> <td class=\"sublist1\">Anhydrosis (\"dry as a bone\")</td> </tr> <tr> <td class=\"sublist1\">Hyperthermia due to loss of sweating (\"hot as a hare\")</td> </tr> <tr> <td class=\"sublist1\">Blurry vision due to nonreactive mydriasis and paralysis of accommodation (\"blind as a bat\")</td> </tr> <tr> <td class=\"sublist1\">Agitated delirium (\"mad as a hatter\")</td> </tr> <tr> <td class=\"sublist1\">Urinary retention (\"full as a flask\")</td> </tr> <tr> <td class=\"sublist1\">Decreased bowel sounds</td> </tr> <tr> <td class=\"sublist1\">Tachycardia</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnosis</td> </tr> <tr> <td>Check fingerstick glucose, ECG, acetaminophen and salicylate levels, and a qualitative pregnancy test in poisoned patients</td> </tr> <tr> <td>A serum creatine kinase and renal function testing (BUN and creatinine) are appropriate in patients in whom rhabdomyolysis is suspected</td> </tr> <tr> <td>No laboratory findings or diagnostic laboratory tests can definitively determine anticholinergic toxicity</td> </tr> <tr> <td>A trial of physostigmine (see Treatment below) will help establish or rule out the diagnosis of anticholinergic toxicity</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Secure the airway, breathing, and circulation</td> </tr> <tr> <td>Patients who manifest <strong>both peripheral AND moderate central</strong> (moderate to severe agitation/delirium) anticholinergic toxicity, <strong>without contraindications</strong> to physostigmine, should be treated with this medication; dose: 0.5 to 2 mg (0.02 mg/kg IV, up to a maximum of 0.5 mg per dose in pediatric patients); physostigmine should be given by slow IV push, generally over five minutes</td> </tr> <tr> <td>Treat agitation and seizures with benzodiazepines (eg, lorazepam 1 to 2 mg IV push; may repeat as needed); <strong>DO NOT</strong> use phenothiazines or butyrophenones (eg, haloperidol)</td> </tr> <tr> <td>Give activated charcoal (1 g/kg; maximum 50 g) to patients with intact mental status or a secure airway and likely ingestion of an anticholinergic agent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74091 Version 8.0</div></div></div>"},"74092":{"type":"graphic_figure","displayName":"Secretin regulation","title":"Regulation of secretin release","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Regulation of secretin release</div><div class=\"cntnt\"><img style=\"width:570px; height:382px;\" src=\"images/GAST/74092_Secretin_regulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the regulation of secretin release.<br /><ol>&#xD;&#xA;    <li>Duodenal acidification causes release of secretin releasing factor (SRF) from the proximal small bowel.</li>&#xD;&#xA;    <li>Secretin releasing factor elaborates secretin from specialized enteroendocrine cells (S cells) of the small intestine.</li>&#xD;&#xA;    <li>Secretin is secreted into the blood and binds to specific secretin receptors on the pancreas to cause exocrine pancreatic secretion.</li>&#xD;&#xA;    <li>Pancreatic exocrine secretion includes pancreatic proteases, which terminate secretin release by degrading secretin-releasing factor.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 74092 Version 2.0</div></div></div>"},"74093":{"type":"graphic_figure","displayName":"Pregnant rate smoke vs nonsmoke","title":"Percent of couples achieving pregnancy within 3.5 months (red bars) and 9.5 months (blue bars)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percent of couples achieving pregnancy within 3.5 months (red bars) and 9.5 months (blue bars)</div><div class=\"cntnt\"><img style=\"width:383px; height:331px;\" src=\"images/OBGYN/74093_Pregnant_rate_smoke_vs_nons.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The x axis is the reported smoking status of the female partner. The y axis is the percent of couples achieving pregnancy by the time specified (3.5 months - red bars; 9.5 months - blue bars). Among women who reported smoking &gt;10 cigarettes daily, the percent of couples achieving pregnancy by 3.5 and 9.5 months was significantly decreased compared to couples where the female partner did not smoke. The subjects were women who were pregnant or recently delivered (sample size approximately 4035 women).</div><div class=\"graphic_reference\">Data adapted from: Table 4 in Bolumar, F, Olsen, J, Boldsen, J and the European Study Group on Infertility and Subfecundity. Smoking reduces fecundity: a European multicenter study on infertility and subfecundity. Am J Epidemiol 1996; 143:578-87.</div><div id=\"graphicVersion\">Graphic 74093 Version 1.0</div></div></div>"},"74094":{"type":"graphic_figure","displayName":"Hepatic metabolism","title":"Hepatic drug metabolism","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Hepatic drug metabolism</div><div class=\"cntnt\"><img style=\"width:549px; height:299px;\" src=\"images/GAST/74094_Hepatic_metabolism.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74094 Version 2.0</div></div></div>"},"74095":{"type":"graphic_picture","displayName":"Erythema multiforme","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:237px; height:360px;\" src=\"images/ID/74095_Erythema_multiforme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic target lesions of the palm in erythema multiforme begin with a central vesicle.</div><div class=\"graphic_reference\">Courtesy of Nesbitt LT Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 74095 Version 6.0</div></div></div>"},"74100":{"type":"graphic_picture","displayName":"Severe rejection graft","title":"Severe acute rejection of the ITx graft (high power view)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe acute rejection of the ITx graft (high power view)</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/GAST/74100_Severe_rejection_graft.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Farrukh Khan, MD.</div><div id=\"graphicVersion\">Graphic 74100 Version 1.0</div></div></div>"},"74101":{"type":"graphic_picture","displayName":"Radical vulvectomy completed","title":"Radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/74101_Radical_vulvectomy_complete.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wound has been closed.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 74101 Version 2.0</div></div></div>"},"74102":{"type":"graphic_figure","displayName":"Complex rearrangement in CML","title":"Complex rearrangement in chronic myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complex rearrangement in chronic myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:241px; height:403px;\" src=\"images/HEME/74102_Complex_rearrangement_in_CM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential g-band (top) and FISH (bottom) images of metaphase chromosomes from a complex variant Philadelphia rearrangement without the typical Philadelphia chromosome. The FISH probe is a dual-color combination of probes that span the ABL (green) and BCR (red) breakpoint regions. Juxtaposition of the ABL and BCR signals on the derivative chromosome 22 results in a yellow fusion signal. This complex rearrangement involves submicroscopic insertion of most of the ABL gene into chromosome 22.</div><div class=\"graphic_reference\">Photo courtesy of Athena Cherry, PhD.</div><div id=\"graphicVersion\">Graphic 74102 Version 2.0</div></div></div>"},"74103":{"type":"graphic_table","displayName":"Prognostic features CLL","title":"Prognostic features in chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic features in chronic lymphocytic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Markers of good prognosis</td> </tr> <tr> <td class=\"indent1\">Low Rai or Binet clinical stage</td> </tr> <tr> <td class=\"indent1\">Interstitial or nodular pattern of lymphocyte infiltration in marrow</td> </tr> <tr> <td class=\"indent1\">Lymphocyte doubling time &#62;12 months</td> </tr> <tr> <td class=\"indent1\">CD38 negativity</td> </tr> <tr> <td class=\"indent1\">Mutated immunoglobulin Vh genes</td> </tr> <tr> <td class=\"indent1\">ZAP-70 negativity (low levels)</td> </tr> <tr> <td class=\"indent1\">Del 13q14</td> </tr> <tr> <td class=\"subtitle1_single\">Markers of poor prognosis</td> </tr> <tr> <td class=\"indent1\">High Rai or Binet stages</td> </tr> <tr> <td class=\"indent1\">Diffuse pattern of lymphocyte marrow infiltration</td> </tr> <tr> <td class=\"indent1\">Lymphocyte doubling time &#60;12 months</td> </tr> <tr> <td class=\"indent1\">CD38 positivity</td> </tr> <tr> <td class=\"indent1\">Unmutated immunoglobulin Vh genes</td> </tr> <tr> <td class=\"indent1\">ZAP-70 positivity (high levels)</td> </tr> <tr> <td class=\"indent1\">Del 11q23</td> </tr> <tr> <td class=\"indent1\">17p-/p53 abnormalities</td> </tr> <tr> <td class=\"indent1\">TP53 dysfunction or increased expression</td> </tr> <tr> <td class=\"indent1\">Increased levels of TNF-alpha, beta-2 microglobulin, IL-6, IL-8, IL-10, LDH, VEGFR-2, CD20, and CD52</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74103 Version 5.0</div></div></div>"},"74105":{"type":"graphic_table","displayName":"Precaution requirements after treatments with 131-I hyperthyroid","title":"Examples of precaution requirements after treatments with 131-I: Hyperthyroidism*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of precaution requirements after treatments with 131-I: Hyperthyroidism*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">mCi (MBq) administered</td> </tr> <tr> <td class=\"subtitle2\">10<br /> (370)</td> <td class=\"subtitle2\">15<br /> (555)</td> <td class=\"subtitle2\">20<br /> (740)</td> <td class=\"subtitle2\">30<br /> (1110)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Restricted periods</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><em>Nighttime restrictions</em></td> </tr> <tr> <td class=\"indent2\">Sleep in a separate (6-feet separation) bed from adults for days<sup>&#182;</sup> shown.</td> <td>3</td> <td>6</td> <td>8</td> <td>11</td> </tr> <tr> <td class=\"indent2\">Sleep in a separate bed from pregnant partners, infant, or child for days shown.</td> <td>15</td> <td>18</td> <td>20</td> <td>23</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><em>Daytime restrictions</em></td> </tr> <tr> <td class=\"indent2\">You may return to work after days shown.</td> <td>1</td> <td>1</td> <td>2</td> <td>5</td> </tr> <tr> <td class=\"indent2\">Maximize your distance (6 feet) from children and pregnant women for days shown.</td> <td>1</td> <td>1</td> <td>2</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Avoid extended time in public places for days shown.</td> <td>1</td> <td>1</td> <td>1</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Duration of safe travel by public transportation (bus, air, etc)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><em>Travel time (hours) without exceeding regulatory dose limit</em></td> </tr> <tr> <td class=\"indent2\">Day<sup>&#182;</sup> 0 (beginning with treatment)</td> <td>5.9</td> <td>3.9</td> <td>2.9</td> <td>2</td> </tr> <tr> <td class=\"indent2\">Day 1</td> <td>9.2</td> <td>6.1</td> <td>4.6</td> <td>3.1</td> </tr> <tr> <td class=\"indent2\">Day 2</td> <td>13</td> <td>8.7</td> <td>6.5</td> <td>4.3</td> </tr> <tr> <td class=\"indent2\">Day 3</td> <td>-</td> <td>10.6</td> <td>8</td> <td>5.3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Examples should be modified to meet local and specific patient needs. These examples are based on dose rate of 0.17 mrem h<sup>-1</sup> mCi<sup>-1</sup> at 1 m, 500 mrem per year for family member and caregiver, 100 mrem for pregnant women, children, and the public, and occupancy factors for adults of 0.25 except for sleeping 0.33. Resumption of sleeping with a partner assumes a distance of 0.3 m.</div><div class=\"graphic_footnotes\">131-I: sodium iodide.<br />* Assumes 50 percent uptake by thyroid, with effective T<SUB>1/2</SUB> of approximately 5 days.<br />¶ Day = 24-hour cycle.<br />Δ Assumes 100 mrem limit and 0.3 m distance.</div><div class=\"graphic_reference\">Reproduced with permission from: The American Thyroid Association Taskforce on Radioiodine Safety. Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131-I: Practice Recommendations of the American Thyroid Association. Thyroid 2011; 21:335. Copyright &copy; 2011 Mary Ann Liebert Publishers.</div><div id=\"graphicVersion\">Graphic 74105 Version 5.0</div></div></div>"},"74106":{"type":"graphic_figure","displayName":"Strabismus PI","title":"Crossed eyes (strabismus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crossed eyes (strabismus)</div><div class=\"cntnt\"><img style=\"width:412px; height:575px;\" src=\"images/PI/74106_Strabismus-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crossed eyes, or &quot;strabismus,&quot; is when a person's eyes don't line up with each other. The eyes are looking in 2 different places at the same time.</div><div id=\"graphicVersion\">Graphic 74106 Version 3.0</div></div></div>"},"74107":{"type":"graphic_figure","displayName":"Boutonniere deformity","title":"Boutonniere deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Boutonniere deformity</div><div class=\"cntnt\"><img style=\"width:303px; height:363px;\" src=\"images/EM/74107_Boutonniere_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tendon avulsion injuries. The top figure shows the pointer finger being struck by a ball which led to avulsion at the proximal interphalangeal joint (boutonniere deformity), anatomically depicted in the lower figure.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74107 Version 2.0</div></div></div>"},"74108":{"type":"graphic_table","displayName":"Diseases causing ACh receptor upregulation and hyperkalemia","title":"Diseases causing acetylcholine receptor upregulation and potential hyperkalemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases&nbsp;causing acetylcholine&nbsp;receptor upregulation and potential hyperkalemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The diseases listed below are associated with a risk of severe hyperkalemia following succinylcholine administration:</td> </tr> <tr> <td>Denervating injuries (eg, stroke, spinal cord injury), after 72 hours</td> </tr> <tr> <td>Denervating diseases (eg, multiple sclerosis, amyotrophic lateral sclerosis)</td> </tr> <tr> <td>Inherited myopathies (eg, Duchenne muscular dystrophy)</td> </tr> <tr> <td>Burns, after 72 hours</td> </tr> <tr> <td>Crush injuries, after 72 hours</td> </tr> <tr> <td>Rhabdomyolysis</td> </tr> <tr> <td>Prolonged total body immobilization</td> </tr> <tr> <td>Severe, prolonged intraabdominal infections</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACh: acetylcholine.</div><div id=\"graphicVersion\">Graphic 74108 Version 5.0</div></div></div>"},"74110":{"type":"graphic_table","displayName":"Erosions and ulcers","title":"Differential diagnosis of erosions and ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of erosions and ulcers</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mouth</td> </tr> <tr> <td>Aphthae</td> </tr> <tr> <td>Avitaminosis</td> </tr> <tr> <td>Burn</td> </tr> <tr> <td>Candidiasis</td> </tr> <tr> <td>Epidermolysis bullosa</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Hand, foot, and mouth disease</td> </tr> <tr> <td>Herpangina</td> </tr> <tr> <td>Herpes simplex</td> </tr> <tr> <td>Lichen planus</td> </tr> <tr> <td>Lupus erythematosus</td> </tr> <tr> <td>Pemphigus vulgaris</td> </tr> <tr> <td>Perl&#232;che</td> </tr> <tr> <td>Toxic epidermal necrolysis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Genital</td> </tr> <tr> <td>Balanitis</td> </tr> <tr> <td>Candidiasis</td> </tr> <tr> <td>Chancroid</td> </tr> <tr> <td>Diaper dermatitis</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Fixed drug eruption</td> </tr> <tr> <td>Fungal infections (tinea cruris)</td> </tr> <tr> <td>Herpes simplex</td> </tr> <tr> <td>Intertrigo</td> </tr> <tr> <td>Lichen planus</td> </tr> <tr> <td>Lichen sclerosus</td> </tr> <tr> <td>Lymphogranuloma venereum</td> </tr> <tr> <td>Squamous cell carcinoma</td> </tr> <tr> <td>Syphilis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Basal cell carcinoma</td> </tr> <tr> <td>Bullous pemphigoid</td> </tr> <tr> <td>Echthyma</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Ischemia</td> </tr> <tr> <td>Necrobiosis lipoidica</td> </tr> <tr> <td>Pemphigus vulgaris</td> </tr> <tr> <td>Porphyria cutanea tarda</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td>Spider bite</td> </tr> <tr> <td>Squamous cell carcinoma</td> </tr> <tr> <td>Stasis ulcer</td> </tr> <tr> <td>Toxic epidermal necrosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74110 Version 2.0</div></div></div>"},"74111":{"type":"graphic_diagnosticimage","displayName":"Chylothorax PA","title":"Chylothorax post right pneumonectomy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chylothorax post right pneumonectomy</div><div class=\"cntnt\"><img style=\"width:324px; height:334px;\" src=\"images/PULM/74111_Chylothorax_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple gas-liquid levels in the postpneumonectomy space, with cardiomediastinal shift to the left.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74111 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"74112":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma IV MRI","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:321px; height:320px;\" src=\"images/PULM/74112_Malignant_mesothelioma_IV_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI scan, sagittal T2 weighted spin-echo sequence, shows large right sided pleural effusion layering dorsally in this recumbent patient. The diaphragm is intact. Above the lung apex, the right subclavian vein is seen in cross- section and forms a bright round signal. Behind it is the right subclavian artery forming a smaller circle. Above the vascular structures, the brachial plexus is seen in cross-section forming several less bright rounded structures.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74112 Version 4.0</div></div></div>"},"74113":{"type":"graphic_diagnosticimage","displayName":"Small airway OSA MRI","title":"Reduced airway size in obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Reduced airway size in obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:591px; height:236px;\" src=\"images/PULM/74113_Small_airway_OSA_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of an axial image at the minimum airway area (retropalatal region) of a normal subject (left) and a patient with sleep apnea (right). Note the smaller airway size and airway width in the patient with sleep apnea. In addition, the thickness of the lateral pharyngeal wall (distance between the airway and parapharyngeal fat pads) is larger in the patient with sleep apnea.</div><div class=\"graphic_reference\">Courtesy of Richard J Schwab, MD.</div><div id=\"graphicVersion\">Graphic 74113 Version 2.0</div></div></div>"},"74115":{"type":"graphic_figure","displayName":"Double opposing Z-plasty","title":"Double opposing Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Double opposing Z-plasty</div><div class=\"cntnt\"><img style=\"width:502px; height:523px;\" src=\"images/SURG/74115_double_opposing_z-plasty.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74115 Version 3.0</div></div></div>"},"74116":{"type":"graphic_figure","displayName":"HBV pre S-S ORF","title":"HBV pre-S/S open reading frame","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">HBV pre-S/S open reading frame</div><div class=\"cntnt\"><img style=\"width:469px; height:224px;\" src=\"images/GAST/74116_HBV_pre_S-S_ORF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the pre-S/surface open reading frame (ORF), RNA transcripts and translational products. The pre-S/S ORF consists of three in-phase start codons and a common stop codon that divides the gene into pre-S1, pre-S2 and S regions encoding the large (L), middle (M), and small (S) envelope proteins, respectively. The M and S envelope proteins are found in all forms of viral and subviral particles while the L envelope proteins are predominantly found in complete virions.</div><div id=\"graphicVersion\">Graphic 74116 Version 1.0</div></div></div>"},"74120":{"type":"graphic_picture","displayName":"Laparoscopic pyloromyotomy","title":"Laparoscopic pyloromyotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic pyloromyotomy</div><div class=\"cntnt\"><img style=\"width:360px; height:280px;\" src=\"images/PEDS/74120_Laparoscopic_pyloromyotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative photographs of a laparascopic pyloromyotomy for an infant with hypertrophic pyloric stenosis. The pyloric muscle is opened using an arthroscopy blade and then spread open with a grasping forcep.</div><div class=\"graphic_reference\">Courtesy of Mary L Brandt, MD.</div><div id=\"graphicVersion\">Graphic 74120 Version 2.0</div></div></div>"},"74121":{"type":"graphic_picture","displayName":"Staphylococcal adenitis","title":"<EM>Staphylococcus aureus </EM>adenitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Staphylococcus aureus </EM>adenitis</div><div class=\"cntnt\"><img style=\"width:291px; height:278px;\" src=\"images/PEDS/74121_Staphylococcal_adenitis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute unilateral cervical adenitis caused by <em>S. aureus</em>. Submandibular nodes are affected in more than 50 percent of cases. The lymph node is usually 3 to 6 cm in diameter, tender, warm, erythematous, nondiscrete, and poorly mobile.</div><div id=\"graphicVersion\">Graphic 74121 Version 4.0</div></div></div>"},"74122":{"type":"graphic_table","displayName":"Early complics female circumcis","title":"Short-term complications of female circumcision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-term complications of female circumcision</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Bleeding</td>\n</tr>\n<tr>\n<td>Hemorrhage</td>\n</tr>\n<tr>\n<td> Anemia</td>\n</tr>\n<tr>\n<td> Hypotension</td>\n</tr>\n<tr>\n<td> Oliguria</td>\n</tr>\n<tr>\n<td> Shock</td>\n</tr>\n<tr>\n<td> Death</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Infection</td>\n</tr>\n<tr>\n<td>Cellulitis</td>\n</tr>\n<tr>\n<td> Abscess</td>\n</tr>\n<tr>\n<td> Fever</td>\n</tr>\n<tr>\n<td> Pelvic inflammatory disease</td>\n</tr>\n<tr>\n<td> Tetanus</td>\n</tr>\n<tr>\n<td> Gangrene</td>\n</tr>\n<tr>\n<td> Septic shock</td>\n</tr>\n<tr>\n<td> Poor healing</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Urethral injury</td>\n</tr>\n<tr>\n<td>Urethral edema</td>\n</tr>\n<tr>\n<td>Urinary retention</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Fractures</td>\n</tr>\n<tr>\n<td>Clavicle</td>\n</tr>\n<tr>\n<td> Femur</td>\n</tr>\n<tr>\n<td> Humerus</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74122 Version 1.0</div></div></div>"},"74123":{"type":"graphic_picture","displayName":"Resectoscope","title":"Hysteroscopy: resectoscope","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Hysteroscopy: resectoscope</div><div class=\"cntnt\"><img style=\"width:483px; height:324px;\" src=\"images/OBGYN/74123_Resectoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Assembled hysteroscopic resectoscope with (B) roller bar and (C) roller ball.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 74123 Version 2.0</div></div></div>"},"74125":{"type":"graphic_table","displayName":"Radiation terms defined","title":"Terms employed for measurement of ionizing radiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terms employed for measurement of ionizing radiation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Curie (Ci)</td> </tr> <tr> <td>The amount of material whose atoms are undergoing a certain number of radioactive decays per unit time. One Curie, which was originally set as the number of atomic disintegrations per second in 1 gram of radium, is equal to the amount of radioactive material undergoing 3.7 x 10<sup>10</sup> disintegrations per second. This unit has been superseded by the <strong>Becquerel (Bq)</strong>. One Becquerel is equal to the amount of material&nbsp;that is undergoing 1 disintegration/second.</td> </tr> <tr> <td class=\"subtitle1_single\">Roentgen (R)</td> </tr> <tr> <td>The amount of x-ray or gamma ray radiation&nbsp;that produces a certain number of ionizations (ion pairs) in a fixed quantity of air. One Roentgen is the quantity of x- or gamma-radiation&nbsp;that produces, in 0.001293 grams of air, ions carrying one electrostatic unit of electrical charge.</td> </tr> <tr> <td class=\"subtitle1_single\">Roentgen equivalent in man (rem)</td> </tr> <tr> <td>One rem is the amount of ionizing radiation of any type that produces in man the same biologic effect as one Roentgen of x- or gamma-rays. It is equal to the absorbed dose, measured in rads, multiplied by the relative biologic effectiveness (rbe) of the radiation in question. As examples, the rbe of x- and gamma rays is 1; the rbe for alpha particles and neutrons is 20. This unit has been superseded by the <strong>Sievert (Sv)</strong>. One Sievert is equal to 100 rem.</td> </tr> <tr> <td class=\"subtitle1_single\">Radiation absorbed dose (rad)</td> </tr> <tr> <td>One rad is equal to the absorption of 100 ergs of ionizing radiation per gram of tissue. This unit has been superseded by the <strong>Gray (Gy)</strong>. One Gray is equal to 100 rad.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74125 Version 3.0</div></div></div>"},"74126":{"type":"graphic_figure","displayName":"Regulation contractile state","title":"Major mechanisms regulating the myocardial contractile state","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Major mechanisms regulating the myocardial contractile state</div><div class=\"cntnt\"><img style=\"width:467px; height:285px;\" src=\"images/CARD/74126_Regulation_contractile_stat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The contractile state of the myocardium is primarily modulated by three mechanisms involving calcium (Ca2+): the intracellular handling of free ionized Ca2+, the interaction of Ca2+ with the contractile elements (actin-myosin), and the interaction of Ca2+ with troponin C (TnC). The dashed line connecting TnC to actin depicts the inhibitory action of troponin-tropomyosin complex on the actin-myosin interaction. This inhibition is removed and cross-bridges are allowed to attach when Ca2+ binds to TnC.</div><div id=\"graphicVersion\">Graphic 74126 Version 1.0</div></div></div>"},"74127":{"type":"graphic_table","displayName":"Precaution requirements after treatments with 131-I carcinoma","title":"Examples of precaution requirements after treatments with 131-I: Thyroid carcinoma/remnant ablation*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of precaution requirements after treatments with 131-I: Thyroid carcinoma/remnant ablation*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">mCi (MBq) administered</td> </tr> <tr> <td class=\"subtitle2\">50<br /> (1850)</td> <td class=\"subtitle2\">100<br /> (3700)</td> <td class=\"subtitle2\">150<br /> (5550)</td> <td class=\"subtitle2\">200<br /> (7400)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Restricted periods</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><em>Nighttime restrictions</em></td> </tr> <tr> <td class=\"indent2\">Sleep in a separate (6-feet separation) bed from adults for days<sup>&#182;</sup> shown</td> <td>1</td> <td>1</td> <td>2</td> <td>4</td> </tr> <tr> <td class=\"indent2\">Sleep in a separate bed from pregnant partners, infant, or child for days shown</td> <td>6</td> <td>13</td> <td>18</td> <td>21</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><em>Daytime restrictions</em></td> </tr> <tr> <td class=\"indent2\">You may return to work after days shown</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent2\">Maximize your distance (6 feet) from children and pregnant women for days shown</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Avoid extended time in public places for days shown</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Duration of safe travel by public transportation (bus, air, etc)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><em>Travel time (hours) without exceeding regulatory dose limit</em></td> </tr> <tr> <td class=\"indent2\">Day<sup>&#182;</sup> 0 (beginning with treatment)</td> <td>1.2</td> <td>0.6</td> <td>0.4</td> <td>0.3</td> </tr> <tr> <td class=\"indent2\">Day 1</td> <td>3.0</td> <td>1.5</td> <td>1.0</td> <td>0.8</td> </tr> <tr> <td class=\"indent2\">Day 2</td> <td>7.2</td> <td>3.8</td> <td>2.5</td> <td>1.9</td> </tr> <tr> <td class=\"indent2\">Day 3</td> <td>15.0</td> <td>7.5</td> <td>5.0</td> <td>3.8</td> </tr> <tr> <td class=\"indent2\">Day 4</td> <td>-</td> <td>15.0</td> <td>10.0</td> <td>7.5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Examples should be modified to meet local and specific patient needs. These examples are based on dose rate of 0.17 mrem h<sup>-1</sup> mCi<sup>-1</sup> at 1 m, 500 mrem per year for family member and caregiver, 100 mrem for pregnant women, children, and the public, and occupancy factors for adults of 0.25 except for sleeping 0.33. Resumption of sleeping with a partner assumes a distance of 0.3 m.</div><div class=\"graphic_footnotes\">131-I: radioiodine.<br />* Assumes that disappearance of <SUP>131</SUP>I is biexponential with early effective T<SUB>1/2</SUB> of about 0.76 days, and 2 percent uptake in remnant with effective T<SUB>1/2</SUB> of about 7.3 days. Consider formal dosimetry for larger administered doses given to patients with functioning carcinoma. <SUP>131</SUP>I kinetics in euthyroid patients stimulated by recombinant human thyrotropin may differ from those used here.<br />¶ Day = 24-hour cycle.<br />Δ Assumes 100 mrem limit and 0.3 m distance.</div><div class=\"graphic_reference\">Reproduced with permission from: The American Thyroid Association Taskforce on Radioiodine Safety. Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131-I: Practice Recommendations of the American Thyroid Association. Thyroid 2011; 21:335. Copyright &copy; 2011 Mary Ann Liebert Publishers.</div><div id=\"graphicVersion\">Graphic 74127 Version 4.0</div></div></div>"},"74128":{"type":"graphic_table","displayName":"Urogynecologic reconstructive materials terminology","title":"International Urogynecological Association/International Continence Society terminology and classification of complications related to insertion of prostheses and grafts in female pelvic floor surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Urogynecological Association/International Continence Society terminology and classification of complications related to insertion of prostheses and grafts in female pelvic floor surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Terms used</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"sublist_other_start\"><strong>Prosthesis</strong></td> <td class=\"sublist_other_start\">A fabricated substitute to assist a damaged body part or to augment or stabilize a hypoplastic structure</td> </tr> <tr> <td class=\"indent1\">Mesh</td> <td>A (prosthetic) network fabric or structure</td> </tr> <tr> <td class=\"indent1\">Implant</td> <td>A surgically inserted or embedded prosthesis</td> </tr> <tr> <td class=\"indent1\">Tape (sling)</td> <td>A flat strip of synthetic material</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist_other_start\"><strong>Graft</strong></td> <td class=\"sublist_other_start\">Any tissue or organ for transplantation; refers to biological materials inserted</td> </tr> <tr> <td class=\"indent1\">Autologous grafts</td> <td>From the woman's own tissues (eg, dura mater, rectus sheath, or fascia lata)</td> </tr> <tr> <td class=\"indent1\">Allografts</td> <td>From postmortem tissue banks</td> </tr> <tr> <td class=\"indent1\">Xenografts</td> <td>From other species (eg, modified porcine dermis, porcine small intestine, bovine pericardium)</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist_other_start\"><strong>Complication</strong></td> <td class=\"sublist_other_start\">A morbid process or event that occurs during the course of a surgery that is not an essential part of that surgery</td> </tr> <tr> <td class=\"indent1\">Contraction</td> <td>Shrinkage or reduction in size</td> </tr> <tr> <td class=\"indent1\">Prominence</td> <td>Parts that protrude beyond the surface (eg, due to wrinkling or folding with no epithelial separation)</td> </tr> <tr> <td class=\"indent1\">Separation</td> <td>Physically disconnected (eg, vaginal epithelium)</td> </tr> <tr> <td class=\"indent1\">Exposure</td> <td>A condition of displaying, revealing, exhibiting, or making accessible (eg, vaginal mesh visualized through separated vaginal epithelium)</td> </tr> <tr> <td class=\"indent1\">Extrusion</td> <td>Passage gradually out of a body structure or tissue</td> </tr> <tr> <td class=\"indent1\">Compromise</td> <td>Bring into danger</td> </tr> <tr> <td class=\"indent1\">Perforation</td> <td>Abnormal opening in a hollow organ or viscus</td> </tr> <tr> <td class=\"indent1\">Dehiscence</td> <td>A bursting open or gaping along natural or sutured line</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Haylen BT, Freeman RM, Swift SE, et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Int Urogynecol J 2011; 22:3, with kind permission from Springer Science + Business Media B.V. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 74128 Version 9.0</div></div></div>"},"74129":{"type":"graphic_table","displayName":"Histopathology of cutaneous blisters","title":"Histopathologic sites of blister formation in blistering disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathologic sites of blister formation in blistering disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intracorneal/subcorneal</td> <td class=\"subtitle1\">Intraepidermal</td> <td class=\"subtitle1\">Suprabasilar</td> <td class=\"subtitle1\">Subepidermal</td> </tr> <tr> <td> <p>Staphylococcal scalded skin syndrome</p> <p>Miliaria crystallina</p> <p>Bullous impetigo</p> <p>IgG/IgA pemphigus foliaceus</p> <p>Subcorneal pustular dermatosis</p> <p>&nbsp;</p> </td> <td> <p>Varicella zoster virus infection*</p> <p>Herpes simplex virus infection*</p> <p>Epidermolysis bullosa simplex</p> <p>Acute palmoplantar (dyshidrotic) eczema</p> <p>Autoeczematization (id) reaction</p> <p>Friction blister</p> <p>Polymorphous light eruption</p> Contact dermatitis</td> <td> <p>Paraneoplastic pemphigus*</p> <p>Pemphigus vulgaris</p> <p>Transient acantholytic dermatosis (Grover's disease)</p> <p>Hailey-Hailey disease</p> Darier's disease</td> <td> <p>Stevens-Johnson syndrome</p> <p>Sweet's syndrome</p> <p>Bullous systemic lupus erythematosus</p> <p>Bullous pemphigoid</p> <p>Pemphigus gestationis</p> <p>Linear IgA bullous dermatosis</p> <p>Dermatitis herpetiformis</p> <p>Junctional epidermolysis bullosa</p> <p>Dystrophic epidermolysis bullosa</p> <p>Epidermolysis bullosa acquisita</p> <p>Coma blister</p> <p>Bullous disease of diabetes</p> <p>Bullous leukocytoclastic vasculitis</p> <p>Erythema multiforme</p> <p>Porphyria cutanea tarda</p> <p>Phototoxic reaction</p> <p>Arthropod bite<sup>&#182;</sup></p> <p>Fixed drug eruption</p> <p>Bullous pyoderma gangrenosum</p> Mucous membrane pemphigoid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgA: immunoglobulin A.<br />* May also be subepidermal.<br />¶ May also be intraepidermal.</div><div id=\"graphicVersion\">Graphic 74129 Version 4.0</div></div></div>"},"74130":{"type":"graphic_diagnosticimage","displayName":"Bimalleolar fracture","title":"Bimalleolar fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bimalleolar fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:471px;\" src=\"images/EM/74130_Bimalleolar_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fractures of the medial malleolus (white arrow) and lateral malleolus (blue arrow) are visible on both views. Although spacing in the mortise view appears normal, this is an unstable injury and requires orthopedic referral.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 74130 Version 3.0</div></div></div>"},"74131":{"type":"graphic_diagnosticimage","displayName":"Lateral malleolar fracture","title":"Lateral malleolar fracture","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Lateral malleolar fracture</div><div class=\"cntnt\"><img style=\"width:540px; height:390px;\" src=\"images/EM/74131_Stable_lat_malleolar_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This nondisplaced, oblique fracture of the lateral malleolus (white arrow) was stable and managed nonoperatively, once the absence of a medial injury was confirmed.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 74131 Version 4.0</div></div></div>"},"74132":{"type":"graphic_diagnosticimage","displayName":"Extrinsic compression CXR","title":"Large thymus leading to tracheal compression with tracheomalacia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large thymus leading to tracheal compression with tracheomalacia</div><div class=\"cntnt\"><img style=\"width:388px; height:532px;\" src=\"images/PULM/74132_Extrinsic_compression_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest&nbsp;frontal and oblique expiratory&nbsp;images show marked tracheal narrowing with expiratory collapse.</div><div id=\"graphicVersion\">Graphic 74132 Version 3.0</div></div></div>"},"74135":{"type":"graphic_picture","displayName":"Spacer devices","title":"Spacer devices","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spacer devices</div><div class=\"cntnt\"><img style=\"width:360px; height:223px;\" src=\"images/PULM/74135_Spacer_devices.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A variety of spacer devices are available to enhance the delivery of aerosolized medications to distal areas of the lung and limit systemic absorption.</div><div id=\"graphicVersion\">Graphic 74135 Version 2.0</div></div></div>"},"74136":{"type":"graphic_picture","displayName":"Applying upper arm brace","title":"Applying an upper arm functional brace","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Applying an upper arm functional brace</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/EM/74136_Applying_upper_arm_brace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a commercially available upper arm functional brace being applied to immobilize a healing fracture of the shaft of the humerus.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 74136 Version 5.0</div></div></div>"},"74139":{"type":"graphic_figure","displayName":"The association of cadmium with renal stone risk","title":"The association of cadmium exposure with renal stone risk","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">The&nbsp;association of cadmium exposure&nbsp;with renal stone risk</div><div class=\"cntnt\"><img style=\"width:486px; height:324px;\" src=\"images/NEPH/74139_Cadmium_and_renal_calculi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of renal stones in relation to the estimated cumulative inhaled exposure to cadmium among cadmium battery workers in Sweden. The risk for experiencing renal stones increased with the cumulative inhaled dose of cadmium.</div><div class=\"graphic_reference\">Data from Jarup L, Elinder CG. Incidence of renal stones among cadmium exposed battery workers.&nbsp;Br J Ind Med 1993; 50:598.</div><div id=\"graphicVersion\">Graphic 74139 Version 4.0</div></div></div>"},"74141":{"type":"graphic_diagnosticimage","displayName":"Cesarean scar preg A","title":"Cesarean scar pregnancy at 6 weeks - transabdominal ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cesarean scar pregnancy at 6 weeks - transabdominal ultrasonography</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/OBGYN/74141_Cesarean_scar_preg_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image shows a retroflexed uterus (U) with gestational sac (arrow) deforming the bladder (B).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 74141 Version 2.0</div></div></div>"},"74142":{"type":"graphic_picture","displayName":"Muscularis propria invasion","title":"Invasion of the muscularis propria","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Invasion of the muscularis propria</div><div class=\"cntnt\"><img style=\"width:567px; height:152px;\" src=\"images/ONC/74142_Muscularis_propria_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-C, Urothelial carcinoma invading muscularis propria (detrusor muscle)(pT2).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 74142 Version 1.0</div></div></div>"},"74144":{"type":"graphic_picture","displayName":"Postoperative subcutaneous abscess of the palm","title":"Postoperative subcutaneous abscess of the palm","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Postoperative subcutaneous abscess of the palm</div><div class=\"cntnt\"><img style=\"width:548px; height:371px;\" src=\"images/SURG/74144_Subcutaneous_abscess_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subcutaneous abscess of the fingers or hand is usually the result of minor penetrating trauma that was neglected. Abscesses of the palmar skin are typically localized because the fibrous septae anchoring palmar skin limit the spread of infection. This photograph demonstrates the postoperative appearance after surgical drainage of a subcutaneous abscess of the palm.</div><div id=\"graphicVersion\">Graphic 74144 Version 1.0</div></div></div>"},"74145":{"type":"graphic_figure","displayName":"CLL nomogram for time to first treatment","title":"Nomogram for time to first treatment in patients with chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Nomogram for time to first treatment in patients with chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:601px; height:446px;\" src=\"images/HEME/74145_CLL_nomogram_time_first_tr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nomogram used by totaling points identified at top scale for each of four independent variables. Point score for LDH identified based on IGHV mutation status. This summed point score then identified on total point scale to identify two- and four-year treatment-free probability and estimate treatment-free survival. FISH was categorized by Dohner hierarchic categorization.</div><div class=\"graphic_footnotes\">LN: lymph node; LDH: lactate dehydrogenase; IGHV: immunoglobulin heavy chain variable gene; FISH: fluorescent in situ hybridization; prob: probability.</div><div class=\"graphic_reference\">From: Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011; 29:4088. Reprinted with permission. Copyright © 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74145 Version 2.0</div></div></div>"},"74146":{"type":"graphic_table","displayName":"Hyphema rapid overview","title":"Overview of traumatic hyphema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of traumatic hyphema</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"indent1\">Typically caused by blunt trauma to the orbit</td> </tr> <tr> <td class=\"indent1\">Associated injuries: Head trauma, orbital fracture, posterior segment injury (vitreous, retina, choroid, and/or optic nerve), and open globe (rare)</td> </tr> <tr> <td class=\"indent1\">Risk factors for poor outcome: Sickle cell disease or trait, bleeding tendency (eg, hemophilia, von Willebrand disease, or anticoagulated)</td> </tr> <tr> <td class=\"indent1\">Causes of spontaneous hyphema (rare): Diabetes mellitus, clotting disorder, eye tumor, or, in children, child abuse</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Signs of open globe: <span class=\"red\">Emergency ophthalmology consultation indicated if present!*</span></strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Markedly decreased visual acuity or relative afferent pupillary defect by swinging penlight technique </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Eccentric or peaked pupil, uveal (iris or ciliary body) prolapse </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Markedly increased or decreased anterior chamber depth </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Extrusion of ocular contents or intraocular or protruding foreign body </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tenting of the sclera at site of globe puncture </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Large circumferential subconjunctival hemorrhage </li> </ul> </td> </tr> <tr> <td class=\"sublist2_start\"><strong>Clinical findings of hyphema: <span style=\"color: #ff0000;\">All patients with hyphema warrant prompt evaluation by an ophthalmologist</span></strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Decreased visual acuity </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Eye pain with pupillary constriction to bright light (direct and consensual) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Blood in the anterior chamber either grossly visible (hyphema) or visible with slit lamp exam (microhyphema) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Damage to adjacent structures or abnormal IOP </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li><span class=\"red\"><strong>Caution! Only measure IOP once an open globe is excluded and if skilled in the procedure.</strong></span> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\">Comprehensive eye examination by an ophthalmologist</td> </tr> <tr> <td class=\"indent1\">Solubility testing (eg, Sickledex) or hemoglobin electrophoresis in susceptible patients (eg, African or Mediterranean descent or positive family history) with uncertain sickle hemoglobin status</td> </tr> <tr> <td class=\"indent1\">CBC, PT, PTT, INR for patients with bleeding dyscrasia. Perform other blood and urine studies based on presence and degree of other injuries.</td> </tr> <tr> <td class=\"sublist2_start\">Orbital computed tomography (CT) without contrast with 1 to 2 mm axial and coronal cuts through the orbits if any one of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Concern for an open globe </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Concern for intraocular foreign body </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Trauma patients undergoing cranial CT for other indications </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Concern for orbital fracture (palpable step-off of inferior orbital ridge, limited extraocular movement, or significant periocular swelling) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Initial treatment</td> </tr> <tr> <td class=\"indent1\">Assess and treat life-threatening injuries</td> </tr> <tr> <td class=\"sublist2_start\"><strong>If rapid sequence intubation necessary:</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Rocuronium is preferred to succinylcholine for muscle relaxation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Succinylcholine may be used with dexmedetomidine premedication </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Avoid high-dose ketamine if an open globe is suspected </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>If bleeding tendency:</strong> Treat any underlying bleeding dyscrasia. For anticoagulated patients, consult with a specialist.</td> </tr> <tr> <td class=\"indent1\"><strong>Place an eye shield over the affected eye and maintain except during eye examination</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Elevate the patient's head to 30 degrees and maintain the patient at bed rest</strong></td> </tr> <tr> <td class=\"sublist2_start\"><strong>Cycloplegia:</strong> Dilate pupil for examination; also provides pain relief. <span style=\"color: #ff0000;\">Caution! Only perform if an open globe is excluded.</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Instill one drop cyclopentolate one percent ophthalmic solution (response approximately 25 minutes), <strong>or</strong> if unavailable, </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Instill one drop scopolamine hydrobromide (hyoscine) 0.25 percent ophthalmic solution </li> </ul> </td> </tr> <tr> <td class=\"sublist2_start\"><strong>Control nausea and vomiting:</strong> Prevent vomiting; treat nausea aggressively. Administer high-dose ondansetron (0.15 mg/kg, maximum 12 mg) IV or orally.<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2_start\"><strong>Pain:</strong> Topical pain control. <span style=\"color: #ff0000;\">Caution! Only perform if an open globe is excluded.</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Instill one drop of 0.5 percent proparacaine ophthalmic solution <strong>or</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Instill one drop of 0.5 percent tetracaine ophthalmic solution </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>May repeat topical anesthetic after 5 to 10 minutes if needed </li> </ul> </td> </tr> <tr> <td class=\"sublist2_start\"><strong>Additional pain control:</strong> If topical pain control is&nbsp;insufficient, give</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Oral oxycodone 0.15 mg/kg (maximum 5 mg), <strong>or</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>IV/SQ morphine 0.1 mg/kg (maximum 8 mg) <strong>or</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>IV fentanyl 1 to 2 mcg/kg (maximum 25 to 50 mcg) may repeat after 3 to 5 minutes if needed </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acetaminophen (paracetamol) 15 mg/kg orally (maximum 1 g) is also useful; do <strong>not</strong> give NSAIDs </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Ensure definitive management by an ophthalmologist</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IOP: intraocular pressure; CBC: complete blood count; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; NSAIDs: nonsteroidal antiinflammatory drugs (eg, ibuprofen, ketorolac).<br />* Refer to UpToDate topics on open globe injuries.<br />Δ Ondansetron should be AVOIDED in patients with congenital long QT syndrome. ECG monitoring should be performed for patients receiving ondansetron who also have the following conditions: electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), congestive heart failure, or bradyarrhythmias, or are taking medications that prolong the QT interval.</div><div id=\"graphicVersion\">Graphic 74146 Version 21.0</div></div></div>"},"74147":{"type":"graphic_table","displayName":"Localization diverticular bleed","title":"Procedures used for evaluation of lower gastrointestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedures used for evaluation of lower gastrointestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Radionuclide imaging</td> <td> <p>Noninvasive</p> <p>Sensitive to low rates of bleeding</p> Can be repeated for intermittent bleeding</td> <td> <p>Has to be performed during active bleeding</p> <p>Poor localization of bleeding site</p> <p>Not therapeutic</p> Not widely available</td> </tr> <tr> <td>CT angiography</td> <td> <p>Noninvasive</p> <p>Accurately localizes bleeding source</p> <p>Provides anatomic detail</p> Widely available</td> <td> <p>Has to be performed during active bleeding</p> <p>Not therapeutic</p> Radiation and IV contrast exposure</td> </tr> <tr> <td>Angiography</td> <td> <p>Accurately localizes bleeding source</p> <p>Therapy possible with super-selective embolization</p> Does not require bowel preparation</td> <td> <p>Has to be performed during active bleeding</p> Potential for serious complications</td> </tr> <tr> <td>Colonoscopy</td> <td> <p>Precise diagnosis and localization regardless of active bleeding or type of lesion</p> Endoscopic therapy is possible</td> <td> <p>Need colon preparation for optimal visualization</p> <p>Risk of sedation in acutely bleeding patient</p> Definite bleeding source (stigmata) infrequently identified</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: Computed tomographic; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 74147 Version 3.0</div></div></div>"},"74148":{"type":"graphic_table","displayName":"Causes of reactive thrombocytosis","title":"Major causes of reactive thrombocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of reactive thrombocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nonmalignant hematologic conditions</td> </tr> <tr> <td>Acute blood loss</td> </tr> <tr> <td>Acute hemolytic anemia</td> </tr> <tr> <td>Iron deficiency anemia</td> </tr> <tr> <td>Treatment of vitamin B12 deficiency</td> </tr> <tr> <td>Rebound effect after treatment of immune thrombocytopenia (ITP)</td> </tr> <tr> <td>Rebound effect after ethanol-induced thrombocytopenia</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant conditions</td> </tr> <tr> <td>Metastatic cancer</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Rebound effect following use of myelosuppressive agents</td> </tr> <tr> <td class=\"subtitle1_single\">Acute and chronic inflammatory conditions</td> </tr> <tr> <td>Rheumatologic disorders, vasculitides</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Celiac disease</td> </tr> <tr> <td>Kawasaki disease</td> </tr> <tr> <td>Nephrotic syndrome</td> </tr> <tr> <td>POEMS syndrome (osteosclerotic myeloma)</td> </tr> <tr> <td class=\"subtitle1_single\">Tissue damage</td> </tr> <tr> <td>Thermal burns</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Severe trauma</td> </tr> <tr> <td>Acute pancreatitis</td> </tr> <tr> <td>Post-surgical period, especially post-splenectomy</td> </tr> <tr> <td>Coronary artery bypass procedures</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Chronic infections</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Acute bacterial and viral infections</td> </tr> <tr> <td class=\"subtitle1_single\">Exercise</td> </tr> <tr> <td class=\"subtitle1_single\">Allergic reactions</td> </tr> <tr> <td class=\"subtitle1_single\">Functional and surgical asplenia</td> </tr> <tr> <td class=\"subtitle1_single\">Reaction to medications</td> </tr> <tr> <td>Vincristine</td> </tr> <tr> <td>Epinephrine, glucocorticoids</td> </tr> <tr> <td>Interleukin-1B</td> </tr> <tr> <td>All-trans retinoic acid</td> </tr> <tr> <td>Thrombopoietin, thrombopoietin receptor agonists</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This list is not comprehensive and does not include rare causes of thrombocytosis. Refer to UpToDate and package inserts of potentially implicated medications for further details.</div><div id=\"graphicVersion\">Graphic 74148 Version 8.0</div></div></div>"},"74154":{"type":"graphic_picture","displayName":"Lichen sclerosus - trunk","title":"Lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74154_Lichen_sclerosus_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oval porcelain-white plaques are present on the trunk of this patient with extragenital lichen sclerosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74154 Version 3.0</div></div></div>"},"74157":{"type":"graphic_table","displayName":"Etiology of macrocephaly by onset","title":"Common causes of macrocephaly in children according to time of clinical presentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of macrocephaly in children according to time of clinical presentation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td rowspan=\"10\"><strong>Early infantile (birth to 6 mo of age)</strong></td> <td class=\"sublist1_start\" colspan=\"2\">Hydrocephalus (progressive or \"arrested\")</td> </tr> <tr> <td class=\"sublist1\">Induction disorders</td> <td class=\"sublist_other\">Spina bifida cystica, cranium bifidum, Chiari malformations (types I, II, and III), aqueductal stenosis, holoprosencephaly</td> </tr> <tr> <td class=\"sublist1\">Mass lesions</td> <td class=\"sublist_other\">Neoplasms, atrioventricular malformations, congenital cysts</td> </tr> <tr> <td class=\"sublist1\">Intrauterine infections</td> <td class=\"sublist_other\">Toxoplasmosis, cytomegalic inclusion disease, syphilis, rubella</td> </tr> <tr> <td class=\"sublist1\">Perinatal or postnatal infections</td> <td class=\"sublist_other\">Bacterial, granulomatous, parasitic</td> </tr> <tr> <td class=\"sublist1\">Perinatal or postnatal hemorrhage</td> <td class=\"sublist_other\">Hypoxia, vascular malformation, trauma</td> </tr> <tr> <td class=\"sublist1\">Hydranencephaly</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Subdural effusion</td> </tr> <tr> <td class=\"sublist1\">Hemorrhagic, infectious, cystic hygroma</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td colspan=\"2\">Normal variant (often familial)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"16\"><strong>Late infantile (6 mo to 2 yr of age)</strong></td> <td class=\"sublist1_start\" colspan=\"2\">Hydrocephalus (progressive or \"arrested\")</td> </tr> <tr> <td class=\"sublist1\">Space-occupying lesions</td> <td class=\"sublist_other\">Tumors, cysts, abscess</td> </tr> <tr> <td class=\"sublist1\">Postbacterial or granulomatous meningitis</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Posthemorrhagic</td> <td class=\"sublist_other\">Trauma or vascular malformation</td> </tr> <tr> <td colspan=\"2\">Dandy-Walker syndrome</td> </tr> <tr> <td colspan=\"2\">Subdural effusion</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Increased intracranial pressure syndrome</td> </tr> <tr> <td class=\"sublist1\">Pseudotumor cerebri</td> <td class=\"sublist_other\">Lead, tetracycline, hypoparathyroidism, corticosteroids, excess or deficiency of vitamin A, cyanotic congenital heart disease</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Primary skeletal cranial dysplasias (thickened or enlarged skull)</td> </tr> <tr> <td class=\"sublist1\">Osteogenesis imperfecta, hyperphosphatemia, osteopetrosis, rickets</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Megalencephaly (increase in brain substance)</td> </tr> <tr> <td class=\"sublist1\">Metabolic central nervous system diseases</td> <td class=\"sublist_other\">Leukodystrophies (eg, Canavan, Alexander), lipidoses (Tay-Sachs), histiocytosis, mucopolysaccharidoses</td> </tr> <tr> <td class=\"sublist1\">Proliferative neurocutaneous syndromes</td> <td class=\"sublist_other\">von Recklinghausen tuberous sclerosis, hemangiomatosis, Sturge-Weber</td> </tr> <tr> <td class=\"sublist1\">Cerebral gigantism</td> <td class=\"sublist_other\">Sotos syndrome</td> </tr> <tr> <td colspan=\"2\">Achondroplasia</td> </tr> <tr> <td>Primary megalencephaly</td> <td>May be familial and unassociated with abnormalities of cellular architecture, or associated with abnormalities of cellular architecture</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"11\"><strong>Early to late childhood (older than 2 yr of age)</strong></td> <td class=\"sublist1_start\" colspan=\"2\">Hydrocephalus (progressive or \"arrested\")</td> </tr> <tr> <td class=\"sublist1\">Space-occupying lesions</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Preexisting induction disorder</td> <td class=\"sublist_other\">Aqueductal stenosis</td> </tr> <tr> <td class=\"sublist1\">Postinfectious</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hemorrhagic</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Chiari type I malformation</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Megalencephaly</td> </tr> <tr> <td class=\"sublist1\">Proliferative neurocutaneous syndromes</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Familial</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td colspan=\"2\">Pseudotumor cerebri</td> </tr> <tr> <td colspan=\"2\">Normal variant</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">10/28/2008--Requested permission (JD). 11/17/2008--Permission granted; figure to Terrence, mailed invoice back to Arnetta (JD). 2/4/2010--Renewal requested (JD). 3/26/2010--Renewal granted; agreement mailed back to Arnetta (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52213&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Child Neurology, 7th ed, Menkes JH, Sarnat HB, Maria BL (Eds), Lippincott Williams &amp; Wilkins, New York 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74157 Version 16.0</div></div></div>"},"74160":{"type":"graphic_figure","displayName":"HSD3B2 deficiency","title":"3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) deficiency","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) deficiency</div><div class=\"cntnt\"><img style=\"width:602px; height:382px;\" src=\"images/ENDO/74160_HSD3B2_deficiency.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74160 Version 1.0</div></div></div>"},"74162":{"type":"graphic_picture","displayName":"Los Angeles grade B esophagitis","title":"Los Angeles grade B esophagitis","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Los Angeles grade B esophagitis</div><div class=\"cntnt\"><img style=\"width:456px; height:218px;\" src=\"images/GAST/74162_LA_grade_B_esophagitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Los Angeles grade B esophagitis: One or more mucosal breaks longer than 5 mm, but not bridging the tops of mucosal folds.</div><div id=\"graphicVersion\">Graphic 74162 Version 3.0</div></div></div>"},"74163":{"type":"graphic_picture","displayName":"Hypopigmented sarcoidosis","title":"Hypopigmented sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypopigmented sarcoidosis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/74163_Hypopigmented_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented sarcoidosis. Discrete, hypopigmented macules and patches are present on the trunk. Some lesions demonstrate central papules, which resemble the configuration of a fried egg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74163 Version 3.0</div></div></div>"},"74164":{"type":"graphic_figure","displayName":"Fontan stage III repair for HLHS","title":"Fontan stage III repair for HLHS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fontan stage III repair for HLHS</div><div class=\"cntnt\"><img style=\"width:424px; height:572px;\" src=\"images/PEDS/74164_FontanstageIIIrepairHLHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In stage III repair, the extracardiac Fontan uses a tube graft to connect the inferior vena cava to the central pulmonary artery, which already is connected to the superior vena cava through the stage II repair (Glenn shunt). As a result, all caval return with the exception of the coronary sinus is directed to the pulmonary arteries, simulating as closely as possible the normal circulatory pattern.</div><div class=\"graphic_reference\">Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7<SUP>th</SUP> ed, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74164 Version 10.0</div></div></div>"},"74166":{"type":"graphic_table","displayName":"Classification of mast cell disorders","title":"Classification of mast cell disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of mast cell disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary mast cell disorders</td> </tr> <tr> <td class=\"indent1\">Mastocytosis (systemic and cutaneous)</td> </tr> <tr> <td class=\"indent1\">Monoclonal mast cell activation syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary mast cell disorders</td> </tr> <tr> <td class=\"indent1\">Allergic disorders</td> </tr> <tr> <td class=\"indent1\">Physical urticarias </td> </tr> <tr> <td class=\"indent1\">Mast cell activation associated with chronic inflammatory or neoplastic disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic mast cell disorders</td> </tr> <tr> <td class=\"indent1\">Idiopathic anaphylaxis</td> </tr> <tr> <td class=\"indent1\">Idiopathic urticaria</td> </tr> <tr> <td class=\"indent1\">Idiopathic histaminergic angioedema</td> </tr> <tr> <td class=\"indent1\">Idiopathic mast cell activation syndrome</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Primary mast cell disorders are conditions in which clonal populations of mast cells arise from an affected progenitor. These cells demonstrate intrinsic defects in proliferation and activation pathways and abnormal genetic and surface markers. Secondary mast cell disorders are conditions in which mast cells are normal in quantity and function and are responding to an external stimulus, such as an allergen, autoantibody, drug, or products of complement activation. Idiopathic mast cell disorders are conditions in which there is no identifiable cause of mast cell activation.</div><div id=\"graphicVersion\">Graphic 74166 Version 12.0</div></div></div>"},"74167":{"type":"graphic_picture","displayName":"Infected dog bite","title":"An infected dog bite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An infected dog bite</div><div class=\"cntnt\"><img style=\"width:298px; height:324px;\" src=\"images/EM/74167_Infecteddogbite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the sutured hand wounds, including the puncture wound at the base of the thumb.</div><div class=\"graphic_reference\">Reproduced with permission from: Ludwig S. Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74167 Version 12.0</div></div></div>"},"74168":{"type":"graphic_table","displayName":"Bowel wall layers on ultrasound","title":"Bowel wall layers on ultrasound","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bowel wall layers on ultrasound</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Layer echogenicity</td>\n<td class=\"subtitle1\">Anatomic structure</td>\n</tr>\n<tr>\n<td>Lumen</td>\n<td>Echo-poor (fluid)/echo-rich (air) depending on content</td>\n</tr>\n<tr>\n<td>Luminal echo-rich layer</td>\n<td>Echo-line between lumen and mucosa</td>\n</tr>\n<tr>\n<td>Luminal echo-poor layer</td>\n<td>Mucosa</td>\n</tr>\n<tr>\n<td>Echo-rich layer</td>\n<td>Submucosa</td>\n</tr>\n<tr>\n<td>Echo-poor layer</td>\n<td>Muscularis propria</td>\n</tr>\n<tr>\n<td>Echo-rich layer</td>\n<td>Serosa</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74168 Version 2.0</div></div></div>"},"74169":{"type":"graphic_table","displayName":"Hyperkalemia management rapid overview","title":"Hyperkalemia management rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hyperkalemia management rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Signs and symptoms are uncommon and tend to occur only when serum potassium is &#62;7.0 meq/L; can include muscle weakness and ventricular arrhythmias.</td> </tr> <tr> <td class=\"indent1\">There are two major mechanisms of hyperkalemia:</td> </tr> <tr> <td class=\"indent2\">Increased potassium release from cells (eg, severe hyperglycemia, rhabdomyolysis).</td> </tr> <tr> <td class=\"indent2\">Reduced potassium excretion in urine (eg, hypoaldosteronism, renal failure).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pseudohyperkalemia is a common cause of a reported elevation in serum potassium and must be excluded. It does not reflect true hyperkalemia and does not produce ECG changes.</td> </tr> <tr> <td class=\"subtitle1_single\">ECG manifestations</td> </tr> <tr> <td class=\"indent1\">The relationship between the degree of serum potassium elevation and ECG changes varies from patient to patient, and changes are more common with acute-onset hyperkalemia.</td> </tr> <tr> <td class=\"indent1\">ECG findings commonly progress as follows with more severe elevation of the serum potassium:</td> </tr> <tr> <td class=\"indent2\">Tall peaked T waves.</td> </tr> <tr> <td class=\"indent2\">Shrinking and then loss of P waves.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Widening of the QRS interval and then \"sine wave,\" ventricular arrhythmia, and asystole.</td> </tr> <tr> <td class=\"subtitle1_single\">Early management</td> </tr> <tr> <td class=\"indent1\">Exclude pseudohyperkalemia.</td> </tr> <tr> <td class=\"indent1\">Obtain ECG and place patients with hyperkalemic emergency on continuous cardiac monitoring.<br /> Patients with hyperkalemic emergency include:</td> </tr> <tr> <td class=\"indent2\">Those with clinical manifestations or ECG changes.</td> </tr> <tr> <td class=\"indent2\">Those with serum potassium of &#62;6.5 meq/L.</td> </tr> <tr> <td class=\"indent2\">Those with serum potassium of &#62;5.5 meq/L plus renal impairment and ongoing tissue breakdown or potassium absorption.</td> </tr> <tr> <td class=\"indent1\">In patients with a&nbsp;hyperkalemic emergency:</td> </tr> <tr> <td class=\"indent2\">Give <strong>calcium gluconate </strong>1000 mg (10 mL of 10% solution) IV over two to three minutes. </td> </tr> <tr> <td class=\"indent2\">Give <strong>insulin and glucose </strong>(only give glucose if serum glucose is &#60;250 mg/dL [13.9 mmol/L]). A common regimen consists of a bolus injection of 10 units of regular insulin, followed immediately by 50 mL of 50% dextrose (25 g of glucose). We subsequently infuse 10% dextrose at 50 to 75 mL/hour and closely monitor blood glucose levels every hour for five to six hours.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Give therapy to remove potassium from the body (refer below).</td> </tr> <tr> <td class=\"subtitle1_single\">Remove potassium from the body</td> </tr> <tr> <td class=\"indent1\">Hemodialysis should be performed in patients with ESRD or severe renal impairment.</td> </tr> <tr> <td class=\"indent1\">Diuretics (in hypervolemic patients) or saline infusion with IV diuretics can be administered (eg, 40 mg of furosemide every 12 hours) to nonoliguric patients without severe renal impairment.</td> </tr> <tr> <td class=\"indent1\">A gastrointestinal cation exchanger (eg, patiromer, 8.4 g orally) can be given, especially in patients with severe renal impairment in whom hemodialysis cannot be swiftly performed. Sodium polystyrene sulfonate (15 to 30 g orally) <strong>should not</strong> be given unless there are no other options to effectively remove potassium from the body in a timely fashion.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; IV: intravenous; ESRD: end-stage renal disease.</div><div id=\"graphicVersion\">Graphic 74169 Version 6.0</div></div></div>"},"74170":{"type":"graphic_table","displayName":"Contraindication neobladder","title":"Absolute and relative contraindications for continent cutaneous/orthotopic neobladder urinary diversions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absolute and relative contraindications for continent cutaneous/orthotopic neobladder urinary diversions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute contraindications</td> </tr> <tr> <td>Impaired renal function (creatinine clearance &#8804;50 mL/minute or serum creatinine &#8805;2.0 mg/dL)</td> </tr> <tr> <td>Impaired hepatic function</td> </tr> <tr> <td>Physical or mental impairment to perform self-catheterization</td> </tr> <tr> <td>Positive apical urethral margin (for neobladder)</td> </tr> <tr> <td>Unmotivated patient</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td>Associated comorbid conditions</td> </tr> <tr> <td>Advanced age</td> </tr> <tr> <td>Need for adjuvant chemotherapy</td> </tr> <tr> <td>Prior pelvic radiation</td> </tr> <tr> <td>Bowel disease</td> </tr> <tr> <td>Urethral pathology</td> </tr> <tr> <td>Extensive local disease with soft tissue extension and high risk of local recurrence</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74170 Version 3.0</div></div></div>"},"74174":{"type":"graphic_table","displayName":"Lifetime psych dx IEI","title":"Number of lifetime (current and past) psychiatric diagnoses in 295 patients with symptoms of idiopathic environmental intolerance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Number of lifetime (current and past) psychiatric diagnoses in 295 patients with symptoms of idiopathic environmental intolerance</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td rowspan=\"2\" class=\"subtitle1\">Psychiatric disorder</td>\n    <td colspan=\"2\" class=\"subtitle1\">Number of diagnoses (N = 435)</td>\n</tr>\n<tr>\n    <td class=\"subtitle2\">n</td>\n    <td class=\"subtitle2\">Percent</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Somatoform disorders</td>\n    <td class=\"subtitle2_left\">113</td>\n    <td class=\"subtitle2_left\">26</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Somatoform disorder not otherwise specified</td>\n    <td class=\"indent1\">61</td>\n    <td class=\"indent1\">14</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Pain disorder</td>\n    <td class=\"indent1\">27</td>\n    <td class=\"indent1\">6</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Somatization disorder</td>\n    <td class=\"indent1\">18</td>\n    <td class=\"indent1\">4</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Hypochondriasis</td>\n    <td class=\"indent1\">4</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Mood disorders</td>\n    <td class=\"subtitle2_left\">95</td>\n    <td class=\"subtitle2_left\">22</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Major depression</td>\n    <td class=\"indent1\">62</td>\n    <td class=\"indent1\">14</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Dysthymia</td>\n    <td class=\"indent1\">27</td>\n    <td class=\"indent1\">6</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Bipolar disorder</td>\n    <td class=\"indent1\">4</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Anxiety disorders</td>\n    <td class=\"subtitle2_left\">75</td>\n    <td class=\"subtitle2_left\">17</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Agoraphobia</td>\n    <td class=\"indent1\">24</td>\n    <td class=\"indent1\">6</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Panic disorder</td>\n    <td class=\"indent1\">17</td>\n    <td class=\"indent1\">4</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Obsessive-compulsive disorder</td>\n    <td class=\"indent1\">7</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Generalized anxiety disorder</td>\n    <td class=\"indent1\">6</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Social phobia</td>\n    <td class=\"indent1\">6</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Anxiety disorder not otherwise specified</td>\n    <td class=\"indent1\">6</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Specific phobia</td>\n    <td class=\"indent1\">5</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Posttraumatic stress disorder</td>\n    <td class=\"indent1\">3</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Substance use disorders</td>\n    <td class=\"subtitle2_left\">63</td>\n    <td class=\"subtitle2_left\">14</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Alcohol abuse or dependence</td>\n    <td class=\"indent1\">37</td>\n    <td class=\"indent1\">9</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Sedative abuse or dependence</td>\n    <td class=\"indent1\">12</td>\n    <td class=\"indent1\">3</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Cannabis abuse or dependence</td>\n    <td class=\"indent1\">8</td>\n    <td class=\"indent1\">2 </td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Amphetamine abuse or dependence</td>\n    <td class=\"indent1\">4</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Personality disorders</td>\n    <td class=\"subtitle2_left\">53</td>\n    <td class=\"subtitle2_left\">12</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Obsessive-compulsive</td>\n    <td class=\"indent1\">15</td>\n    <td class=\"indent1\">3</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Avoidant</td>\n    <td class=\"indent1\">8</td>\n    <td class=\"indent1\">2</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Schizoid</td>\n    <td class=\"indent1\">5</td>\n    <td class=\"indent1\">1</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Psychotic disorders</td>\n    <td class=\"subtitle2_left\">16</td>\n    <td class=\"subtitle2_left\">4</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Eating disorders</td>\n    <td class=\"subtitle2_left\">3</td>\n    <td class=\"subtitle2_left\">1</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Other disorders</td>\n    <td class=\"subtitle2_left\">17</td>\n    <td class=\"subtitle2_left\">4</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Hausteiner, C, Bornschein, S, Bickel, H, et al. Psychiatric morbidity and low self-attentiveness in patients with environmental illness. J Nerv Ment Dis 2003; 191:50.</div><div id=\"graphicVersion\">Graphic 74174 Version 1.0</div></div></div>"},"74175":{"type":"graphic_picture","displayName":"Jejunal leiomyoma Light","title":"Jejunal leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jejunal leiomyoma</div><div class=\"cntnt\"><img style=\"width:437px; height:288px;\" src=\"images/GAST/74175_Jejunal_leiomyoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a jejunal leiomyoma shows sheets of short, spindled, and round cells.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 74175 Version 1.0</div></div></div>"},"74177":{"type":"graphic_figure","displayName":"Airway morphology in asthma","title":"Airway morphology of asthma","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Airway morphology of asthma</div><div class=\"cntnt\"><img style=\"width:523px; height:491px;\" src=\"images/PULM/74177_Airway_morphology_in_asthma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Airway wall inflammation, smooth muscle hyperplasia and increased contractility, epithelial damage, and alterations in the mucus-secreting apparatus and the basement membrane are prominent features of airway pathology in asthma.</div><div class=\"graphic_reference\">Adapted from Wenzel S. The role of inflammation in asthma. National Asthma Education and Prevention Program Monograph, 1993.</div><div id=\"graphicVersion\">Graphic 74177 Version 4.0</div></div></div>"},"74178":{"type":"graphic_figure","displayName":"End inspiratory tail","title":"Flow volume loop in mainstem bronchial obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow volume loop in mainstem bronchial obstruction</div><div class=\"cntnt\"><img style=\"width:179px; height:173px;\" src=\"images/PULM/74178_End_inspiratory_tail.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maximum flow-volume curves of patient before insertion of a stent in a narrowed left main bronchus. Both an end-inspiratory tail and a biphasic spirogram are seen.</div><div id=\"graphicVersion\">Graphic 74178 Version 1.0</div></div></div>"},"74180":{"type":"graphic_table","displayName":"Valproate toxicity rapid overview","title":"Valproate toxicity: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Valproate toxicity: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td class=\"indent1\">CNS depression, encephalopathy (acute overdose or therapeutic use)</td> </tr> <tr> <td class=\"indent1\">Vital sign abnormalities (severe acute overdose): Hypotension; also, respiratory depression, tachycardia, hyperthermia</td> </tr> <tr> <td class=\"indent1\">Metabolic acidosis (severe acute overdose)</td> </tr> <tr> <td class=\"indent1\">Electrolyte abnormalities (acute overdose)</td> </tr> <tr> <td class=\"indent1\">Elevated transaminase levels (acute overdose or therapeutic use)</td> </tr> <tr> <td class=\"indent1\">Hyperammonemia (acute overdose or therapeutic use)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Idiosyncratic hepatotoxicity (therapeutic use)</td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"indent1\">Ask about amount ingested (ingestion &#62;200 mg/kg usually causes CNS depression)</td> </tr> <tr> <td class=\"indent1\">Ask whether immediate or sustained release preparation was ingested</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ask about concurrent carnitine supplementation</td> </tr> <tr> <td class=\"subtitle1_single\">Examination</td> </tr> <tr> <td class=\"indent1\">Assess CNS depression</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Look for stigmata of hepatotoxicity (eg, jaundice, hepatomegaly, right upper quadrant abdominal tenderness)</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Measure valproic acid concentration every 2 to 4 hours until declining; check acid-base status, basic electrolytes, liver function tests, ammonia concentration</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"sublist2_start\">Gastrointestinal decontamination</td> </tr> <tr> <td class=\"sublist2\">Give single dose of activated charcoal (1 g/kg; maximum dose 50 g)</td> </tr> <tr> <td class=\"sublist2_start\">Hypotension in acute overdose</td> </tr> <tr> <td class=\"sublist2\">Fluid resuscitation with IV boluses of isotonic crystalloid; vasopressors if necessary</td> </tr> <tr> <td class=\"sublist2\">Consider hemodialysis or hemoperfusion for refractory hypotension or other signs of severe toxicity; consult nephrology early</td> </tr> <tr> <td class=\"sublist2_start\">Carnitine for VPA toxicity associated with hyperammonemia, lethargy, coma, or hepatic dysfunction</td> </tr> <tr> <td class=\"sublist2\">Give carnitine, 100 mg/kg (up to 6 g) IV over 30 minutes; then 15 mg/kg IV every 4 hours</td> </tr> <tr> <td class=\"sublist2_start\">CNS and respiratory depression in acute overdose</td> </tr> <tr> <td class=\"sublist2\">Supportive care: Patients with altered mental status often require tracheal intubation and mechanical ventilation</td> </tr> <tr> <td class=\"sublist2\">Naloxone (if no risk of acute opioid withdrawal) 0.04 mg IV initial dose, gradually escalate repeated doses every several minutes to 2 mg maximum dose per administration; discontinue if no response after total of 10 mg IV</td> </tr> <tr> <td class=\"sublist2\">Benzodiazepine for seizures (eg, lorazepam 2 mg IV; repeat after 5 to 10 minutes as needed for refractory seizures)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; IV: intravenous; VPA: valproic acid.</div><div id=\"graphicVersion\">Graphic 74180 Version 8.0</div></div></div>"},"74181":{"type":"graphic_picture","displayName":"Vitreous toxoplasmosis","title":"Peripheral vitreous toxoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral vitreous toxoplasmosis</div><div class=\"cntnt\"><img style=\"width:346px; height:259px;\" src=\"images/RHEUM/74181_Vitreous_toxoplasmosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funduscopic photograph from a patient with toxoplasmosis shows a peripheral lesion, characterized by a vitreous inflammatory reaction.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 74181 Version 1.0</div></div></div>"},"74182":{"type":"graphic_movie","displayName":"Ultrasound median nerve movement in axial view","title":"Ultrasound median nerve movement in axial view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound median nerve movement in axial view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/74182_USmednervmoveconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:514px; height:274px;\" src=\"images/NEURO/74182_USmednervmovement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial real-time image of the median nerve (N) is at the level of the distal wrist crease. The video clip captures the normal movement of the median nerve with flexion of the fingers and wrist, as the nerve rotates 90 degrees and dives among the flexor tendons (T). Note that the nerve moves between different tendons with subtle variations in wrist flexion.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 74182 Version 3.0</div></div></div>"},"74184":{"type":"graphic_table","displayName":"Rx systemic anthrax","title":"Intravenous antimicrobial therapy for systemic anthrax when meningitis has been excluded*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous antimicrobial therapy for systemic anthrax when meningitis has been excluded*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nonpregnant adults</td> <td class=\"subtitle1\">Pregnant, postpartum, and lactating&nbsp;women</td> <td class=\"subtitle1\">Children and adolescents<br /> (age &#8805;1 month through 17 years)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">A bactericidal agent:</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Preferred for all strains, regardless of penicillin susceptibility or if susceptibility is unknown:</td> </tr> <tr> <td class=\"indent2\">Ciprofloxacin 400 mg every 8 hours</td> <td> <p>Ciprofloxacin 400 mg every 8 hours</p> <p>NOTE: The treatment of pregnant, postpartum, and lactating&nbsp;women is similar to that for nonpregnant adults, except that <strong>ciprofloxacin is strongly preferred for the bactericidal agent</strong></p> At least one agent with transplacental passage is recommended; agents with transplacental passage include ciprofloxacin, levofloxacin, meropenem, ampicillin, penicillin, clindamycin, and rifampin</td> <td>Ciprofloxacin 30 mg/kg per day divided every 8 hours, not to exceed 400 mg per dose</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives if ciprofloxacin is unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class=\"indent2\">Levofloxacin 750 mg every 24 hours <strong>OR</strong></td> <td>Levofloxacin 750 mg every 24 hours <strong>OR</strong></td> <td>Meropenem 60 mg/kg per day divided every 8 hours, not to exceed 2 g per dose <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Moxifloxacin 400 mg every 24 hours <strong>OR</strong></td> <td>Moxifloxacin 400 mg every 24 hours <strong>OR</strong></td> <td rowspan=\"2\">Levofloxacin <ul class=\"decimal_heading\"> <li>&#60;50 kg: 20 mg/kg per day divided every 12 hours, not to exceed 250 mg per dose </li> <li>&#8805;50 kg: 500 mg every 24 hours <strong>OR</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Meropenem 2 g every 8 hours <strong>OR</strong></td> <td>Meropenem 2 g every 8 hours<sup>&#916;</sup> <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Imipenem 1 g every 6 hours<sup>&#9674;</sup> <strong>OR</strong></td> <td>Imipenem 1 g every 6 hours<sup>&#916;</sup><sup>&#9674;</sup> <strong>OR</strong></td> <td>Imipenem 100 mg/kg per day divided every 6 hours, not to exceed 1 g per dose<sup>&#9674;</sup> <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Doripenem 500 mg every 8 hours <strong>OR</strong></td> <td>Doripenem 500 mg every 8 hours<sup>&#916;</sup> <strong>OR</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Vancomycin 60 mg/kg per day divided every 8 hours, not to exceed 2 g per dose; maintain serum trough concentration of 15 to 20 mcg/mL</td> <td>Vancomycin 60 mg/kg per day divided every 8 hours, not to exceed 2 g per dose; maintain serum trough concentration of 15 to 20 mcg/mL</td> <td>Vancomycin 60 mg/kg per day divided every 8 hours, not to exceed 2 g per dose; maintain serum trough concentration of 15 to 20 mcg/mL</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives for penicillin-susceptible strains:</td> </tr> <tr> <td class=\"subtitle4_left\" colspan=\"3\">Preferred:</td> </tr> <tr> <td class=\"indent3\">Penicillin G 4 million units every 4 hours</td> <td>Penicillin G 4 million units every 4 hours<sup>&#916;</sup></td> <td>Penicillin G 400,000 units/kg per day divided every 4 hours, not to exceed 4 million units per dose</td> </tr> <tr> <td class=\"subtitle4_left\" colspan=\"3\">Alternative:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Ampicillin 3 g every 6 hours</td> <td>Ampicillin 3 g every 6 hours<sup>&#916;</sup></td> <td>Ampicillin 200 mg/kg per day divided every 6 hours, not to exceed 3 g per dose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\" colspan=\"3\">PLUS</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">A protein synthesis inhibitor:</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Preferred:</td> </tr> <tr> <td class=\"indent2\">Clindamycin 900 mg every 8 hours <strong>OR</strong></td> <td>Clindamycin 900 mg every 8 hours <strong>OR</strong></td> <td>Clindamycin 40 mg/kg per day divided every 8 hours, not to exceed 900 mg/dose <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Linezolid 600 mg every 12 hours<sup>&#167;</sup></td> <td>Linezolid 600 mg every 12 hours<sup>&#167;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives if clindamycin and linezolid (for adults) or clindamycin (for children) are unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Linezolid (non-CNS infection dose)<sup>&#167;</sup> <ul class=\"decimal_heading\"> <li>&#60;12 years old: 30 mg/kg per day divided every 8 hours, not to exceed 600 mg/dose </li> <li>&#8805;12 years old: 30 mg/kg per day divided every 12 hours, not to exceed 600 mg/dose <strong>OR</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Doxycycline 200 mg loading dose, then 100 mg every 12 hours <strong>OR</strong></td> <td>Doxycycline 200 mg loading dose, then 100 mg every 12 hours<sup>&#165;</sup> <strong>OR</strong></td> <td>Doxycycline<sup>&#165;</sup> <ul class=\"decimal_heading\"> <li>&#60;45 kg: 4.4 mg/kg loading dose, not to exceed 200 mg; then 4.4 mg/kg per day divided every 12 hours, not to exceed 100 mg per dose </li> <li>&#8805;45 kg: 200 mg loading dose; then 100 mg every 12 hours <strong>OR</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Rifampin 600 mg every 12 hours<sup>&#135;</sup></td> <td>Rifampin 600 mg every 12 hours<sup>&#135;</sup></td> <td>Rifampin 20 mg/kg per day divided every 12 hours, not to exceed 300 mg/dose<sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Systemic anthrax includes anthrax meningitis; inhalation, injection, and gastrointestinal anthrax; and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck. In addition to antimicrobial therapy, antitoxin therapy (raxibacumab, obiltoxaximab, or anthrax immunoglobulin) should also be given. Patients should be treated with IV antimicrobial therapy for two weeks and until clinically stable, whichever is longer. These recommendations are based on the susceptibilities of <EM>B. anthracis</EM> isolated during the 2001 bioterrorism event in the United States. In the event of another bioterrorism event, susceptibilities must be rechecked and antimicrobial therapy modified accordingly. Following completion of IV antimicrobial therapy, patients exposed to aerosolized spores will require PEP to complete 60 days of therapy from onset of illness. Refer to the related topic review and table on anthrax PEP.</div><div class=\"graphic_footnotes\">CNS: central nervous system; IV: intravenous; PEP: postexposure prophylaxis.<br />* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.<br />Δ Pharmacokinetic data indicate that penicillin, ampicillin,&nbsp;and carbapenems may require higher doses in pregnant and postpartum women than those recommended for nonpregnant adults.<br /><FONT class=lozenge>◊</FONT> Imipenem is associated with an increased risk of seizures.<br />§ Linezolid should be used with caution in patients with thrombocytopenia because it might exacerbate it. Linezolid use for &gt;14 days has additional bone marrow toxicity.<br />¥ A single 10 to 14 day course of doxycycline is not routinely associated with tooth staining.<br />‡ Rifampin is not a protein synthesis inhibitor. However, it may be used as an alternative agent based on its in vitro synergy for staphylococci in place of a protein synthesis inhibitor if linezolid and clindamycin cannot be given. Rifampin has not been evaluated for <EM>B. anthracis</EM>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014; 20.</LI>&#xD;&#xA;<LI>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 2014; 20.</LI>&#xD;&#xA;<LI>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014; 133:e1411.</LI></OL></div><div id=\"graphicVersion\">Graphic 74184 Version 7.0</div></div></div>"},"74185":{"type":"graphic_table","displayName":"Rabies preexposure prophylaxis","title":"Rabies pre-exposure prophylaxis schedule - United States, 2008","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rabies pre-exposure prophylaxis schedule - United States, 2008</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of vaccination</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Regimen</td> </tr> <tr> <td>Primary</td> <td>Intramuscular</td> <td>Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV); 1 mL (deltoid area), one each on days 0*, 7, and 21 or 28</td> </tr> <tr> <td>Booster<sup>&#182;</sup></td> <td>Intramuscular</td> <td>HDCV or PCECV; 1 mL (deltoid area), day 0 only</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Day 0 is the day the first dose of vaccine is administered.<br />&para; Persons in the continuous-risk category should have a serum sample tested for rabies virus neutralizing antibody every six months, and persons in the frequent-risk category should be tested every two years. An intramuscular booster dose of vaccine should be administered if the serum titer falls to maintain a value of at least complete neutralization at a 1:5 serum dilution by rapid fluorescent focus inhibition test.</div><div class=\"graphic_reference\">Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.</div><div id=\"graphicVersion\">Graphic 74185 Version 3.0</div></div></div>"},"74186":{"type":"graphic_table","displayName":"Combination chemo regimens for HL","title":"Chemotherapeutic regimens used for the treatment of Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapeutic regimens used for the treatment of Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dosage and schedule</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ABVD<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> <td>25 mg/m<sup>2</sup> IV on days 1 and 15</td> <td class=\"divider_bottom\" rowspan=\"4\">Repeat cycle every 28 days</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> <td>10 units*/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr> <td class=\"indent1\">Vinblastine</td> <td>6 mg/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dacarbazine</td> <td>375 mg/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">A+AVD<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">Brentuximab vedotin</td> <td>1.2 mg/kg IV on days 1 and 15</td> <td class=\"divider_bottom\" rowspan=\"4\">Repeat cycle every 28 days</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> <td>25 mg/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr> <td class=\"indent1\">Vinblastine</td> <td>6 mg/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dacarbazine</td> <td>375 mg/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Escalated BEACOPP<sup>[3,4]</sup></td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> <td>10 units*/m<sup>2</sup> IV on day 8</td> <td class=\"divider_bottom\" rowspan=\"8\">Repeat cycle every 21 days</td> </tr> <tr> <td class=\"indent1\">Etoposide</td> <td>200 mg/m<sup>2</sup> IV on days 1 through 3<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> <td>35 mg/m<sup>2</sup> IV on day 1<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide<sup>&#916;</sup></td> <td>1250 mg/m<sup>2</sup> IV on day 1<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.4 mg/m<sup>2</sup> (maximum 2 mg) IV on day 8</td> </tr> <tr> <td class=\"indent1\">Procarbazine</td> <td>100 mg/m<sup>2</sup> oral on days 1 through 7</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>40 mg/m<sup>2</sup> oral on days 1 through 14</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G-CSF</td> <td>SQ starting on day 8</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>STANFORD V<sup>[5]</sup> (with radiation)</strong></td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> <td>25 mg/m<sup>2</sup> IV on days 1 and 15</td> <td rowspan=\"7\"> <p>Repeat cycle every 28 days for a total of 3 cycles</p> Radiotherapy to initial sites 5 cm or larger (dose: 36 Gy) </td> </tr> <tr> <td class=\"indent1\">Vinblastine<sup>&#9674;</sup></td> <td>6 mg/m<sup>2</sup> IV on days 1 and 15</td> </tr> <tr> <td class=\"indent1\">Mechlorethamine</td> <td>6 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class=\"indent1\">Vincristine<sup>&#9674;</sup></td> <td>1.4 mg/m<sup>2</sup> (maximum 2 mg) IV on days 8 and 22</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> <td>5 units*/m<sup>2</sup> IV on days 8 and 22</td> </tr> <tr> <td class=\"indent1\">Etoposide</td> <td>60 mg/m<sup>2</sup> IV on days 15 and 16</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>40 mg/m<sup>2</sup> oral every OTHER day x 9 weeks then taper</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; SQ: subcutaneous; G-CSF: granulocyte colony-stimulating factor.<br />* 1 unit = 1 mg bleomycin.<br />&para; Note that these doses are for the Escalated BEACOPP regimen. The Baseline BEACOPP regimen differs from Escalated BEACOPP because the doses of three of the drugs are reduced:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Etoposide 100 mg/m<sup>2</sup> (instead of 200 mg/m<sup>2</sup>)</li>&#xD;&#xA;    <li>Doxorubicin 25 mg/m<sup>2</sup> (instead of 35 mg/m<sup>2</sup>)</li>&#xD;&#xA;    <li>Cyclophosphamide 650 mg/m<sup>2</sup> (instead of 1250 mg/m<sup>2</sup>)</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; Mesna, total dose is the same as that of cyclophosphamide, administered: 20 percent IV at hour 0; 40 percent orally at hour 2; 40 percent orally at hour 5.<br /><span class=\"lozenge\">&loz;</span> Vinblastine dose reduced to 4 mg/m<sup>2</sup> and vincristine dose to 1 mg/m<sup>2</sup> (maximum 2 mg) during cycle 3 for patients 50 years of age or older.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.</LI>&#xD;&#xA;<LI>Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018; 378:331.</LI>&#xD;&#xA;<LI>Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109:905. </LI>&#xD;&#xA;<LI>Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28:4199.</LI>&#xD;&#xA;<LI>Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13:1080.</LI></OL></div><div id=\"graphicVersion\">Graphic 74186 Version 9.0</div></div></div>"},"74187":{"type":"graphic_diagnosticimage","displayName":"MPM 73yr man","title":"Epithelial diffuse peritoneal malignant mesothelioma in a 73-year-old man who had a long history of asbestos exposure and complained of weight loss","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epithelial diffuse peritoneal malignant mesothelioma in a 73-year-old man who had a long history of asbestos exposure and complained of weight loss</div><div class=\"cntnt\"><img style=\"width:250px; height:520px;\" src=\"images/ONC/74187_MPM_73yr_man.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Intravenous contrast-enhanced CT scan shows sheetlike thickening of the anterior peritoneum (arrows), encasement of the small bowel, and pleating of the small bowel mesentery (arrowheads). (Panel B) Image from a barium examination shows separation of small bowel segments and irregular fold thickening of small bowel segments in the left lower abdomen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. RadioGraphics 2008; 28:583. Copyright ©2008 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 74187 Version 4.0</div></div></div>"},"74188":{"type":"graphic_figure","displayName":"Lateral curvature","title":"Lateral curvature","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Lateral curvature</div><div class=\"cntnt\"><img style=\"width:458px; height:491px;\" src=\"images/PC/74188_Lateral_curvature.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral curvature of the penis in Peyronie's disease</div><div id=\"graphicVersion\">Graphic 74188 Version 1.0</div></div></div>"},"74189":{"type":"graphic_table","displayName":"Cancers associated with hypercalcemia","title":"Malignancies associated with hypercalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignancies associated with hypercalcemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Humoral hypercalcemia (PTHrP):</td> </tr> <tr> <td>Squamous cell carcinomas</td> </tr> <tr> <td>Renal carcinomas</td> </tr> <tr> <td>Bladder carcinoma</td> </tr> <tr> <td>Breast cancer</td> </tr> <tr> <td>Ovarian carcinoma</td> </tr> <tr> <td>Non-Hodgkin lymphoma</td> </tr> <tr> <td>CML</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Osteolytic metastases: </td> </tr> <tr> <td>Breast cancer</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">1,25-dihydroxyvitamin D:</td> </tr> <tr> <td>Lymphoma (non-Hodgkin, Hodgkin, lymphomatosis/granulomatosis)</td> </tr> <tr> <td>Ovarian dysgerminomas</td> </tr> <tr> <td class=\"subtitle1_single\">Ectopic PTH secretion:</td> </tr> <tr> <td>Ovarian carcinoma</td> </tr> <tr> <td>Lung carcinomas</td> </tr> <tr> <td>Neuroectodermal tumor</td> </tr> <tr> <td>Thyroid papillary carcinoma</td> </tr> <tr> <td>Rhabdomyosarcoma</td> </tr> <tr> <td>Pancreatic cancer</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; PTH: parathyroid hormone; PTHrP: parathyroid hormone-related protein.</div><div id=\"graphicVersion\">Graphic 74189 Version 4.0</div></div></div>"},"74190":{"type":"graphic_table","displayName":"Bone mineral density osteoporosis","title":"Diagnostic categories for osteoporosis and low bone mass based upon BMD measurement by DXA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic categories for osteoporosis and low bone mass based upon&nbsp;BMD measurement by DXA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category </td> <td class=\"subtitle1\">Bone mass </td> </tr> <tr> <td>Normal</td> <td> <p>A value for BMD within&nbsp;1 SD&nbsp;of the young adult female reference mean (T-score greater than or equal to -1 SD).</p> </td> </tr> <tr> <td>Low bone mass (osteopenia)</td> <td>A value for BMD more than 1 but less than 2.5&nbsp;SD below the young adult female reference mean (T-score less than -1 and greater than -2.5 SD).</td> </tr> <tr> <td>Osteoporosis</td> <td>A value for BMD 2.5 or more&nbsp;SD below the young adult female reference mean (T-score less than or equal to -2.5 SD).</td> </tr> <tr> <td>Severe (established) osteoporosis</td> <td>A value for BMD more than 2.5&nbsp;SD below the young adult female reference mean in the presence of one or more fragility fractures.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMD: bone mineral density; DXA: dual-energy x-ray absorptiometry; SD: standard deviation.</div><div class=\"graphic_reference\">Data from: WHO scientific group on the assessment of osteoporosis at the primary health care level: Summary meeting report, 2004. Geneva: World Health Organization,&nbsp;2007.</div><div id=\"graphicVersion\">Graphic 74190 Version 8.0</div></div></div>"},"74191":{"type":"graphic_picture","displayName":"Banded gastroplasty","title":"Endoscopic appearance of vertical banded gastroplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearance of vertical banded gastroplasty</div><div class=\"cntnt\"><img style=\"width:396px; height:321px;\" src=\"images/GAST/74191_Banded_gastroplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroflexed endoscopic appearance of a normal vertical banded gastroplasty.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 74191 Version 3.0</div></div></div>"},"74194":{"type":"graphic_picture","displayName":"Rheumatoid nodules","title":"Rheumatoid nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid nodules</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74194_Rheumatoid_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rheumatoid nodules are firm, nontender lesions that typically occur in areas of trauma in individuals with rheumatoid arthritis. Nodules are present near the elbows in this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74194 Version 3.0</div></div></div>"},"74195":{"type":"graphic_figure","displayName":"Influence of cytokines on gut immune homeostasis","title":"Influence of cytokines on gut immune homeostasis","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Influence of cytokines on gut immune homeostasis</div><div class=\"cntnt\"><img style=\"width:592px; height:437px;\" src=\"images/GAST/74195_Influence_cytokines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neutrophil recruitment to the intestinal lamina propria in the early stages of inflammation is induced by IL-8, a chemokine secreted by macrophages and epithelial cells. Antigen-presenting cells including DCs and macrophages drive T helper cell (Th1), Th9, Th17, or Th2 differentiation through the secretion of IL-12 or IL-23, IL-6, transforming growth factor (TGF)-beta, IL1 beta (Th17 or Th9), or IL-4 (Th2). Epithelial cells can also secrete cytokines such as IL-33 and TSLP that can contribute to Th2 differentiation. T effector cells secrete pro-inflammatory cytokines that lead to inflammation. CD1d-restricted natural killer (NK) T cells secrete IL-13 upon activation and lead to Th2 cytokine secretion. Suppression of inflammation can occur through naturally occurring thymic-derived Foxp3+ regulatory cells (Foxp3+ Treg), IL-10 producing T cells (Tr1), or TGF-beta secreting T cells (Th3). Suppressive Foxp3+ T cells can also arise from Foxp3&ndash; T cells upon retinoic acid and TGF-beta stimulation via CD103+ DCs. T-bet, GATA-3, PU.1, ROR-gamma-t, and Foxp3 are transcription factors involved in Th1, Th2, Th9, Th17, and Treg differentiation, respectively.</div><div class=\"graphic_reference\">Adapted with permission from: Maillard MH, Snapper SB. Cytokines and chemokines in mucosal homeostasis. In: Inflammatory Bowel Diseases: Translating Basic Science into Clinical Practice, Targan SR, Shanahan F, Karp LC (Eds), Wiley-Blackwell, Oxford, UK 2010. Copyright &copy; 2010 Wiley-Blackwell.</div><div id=\"graphicVersion\">Graphic 74195 Version 3.0</div></div></div>"},"74196":{"type":"graphic_figure","displayName":"Strong procedure","title":"Strong procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strong procedure</div><div class=\"cntnt\"><img style=\"width:396px; height:459px;\" src=\"images/SURG/74196_Strong-procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Strong's procedure mobilizes the duodenum by dividing the ligament of Treitz. Once the duodenal-jejunal junction is mobilized, the duodenum is positioned to the right of the superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 74196 Version 2.0</div></div></div>"},"74197":{"type":"graphic_table","displayName":"Medications that can cause histamine release","title":"Medications that can cause histamine release","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that can cause histamine release</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Antibiotics</td> </tr> <tr> <td class=\"sublist1\">Ciprofloxacin, vancomycin</td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Narcotic analgesics*</td> </tr> <tr> <td class=\"sublist1_start\">Neuromuscular antagonists</td> </tr> <tr> <td class=\"sublist2_start\">Quaternary amine</td> </tr> <tr> <td class=\"sublist2\">Succinylcholine</td> </tr> <tr> <td class=\"sublist2_start\">Benzylisoquinolinium compounds</td> </tr> <tr> <td class=\"sublist2\">Atracurium, cisatracurium, doxacurium, mivacurium, tubocurarine</td> </tr> <tr> <td class=\"sublist1_start\">Plasma expanders</td> </tr> <tr> <td class=\"sublist1\">Dextran, polygeline (Haemaccel)</td> </tr> <tr> <td>Radiocontrast agents</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">9/13/2007--sent permission request. EM 9/14/2007--Permission granted, requested invoice from Greg, gave figure to Terrence. EM 9/17/2007--received invoice, sent to Tammy. EM The total fee of $&amp;quot;250.00&amp;quot;was originally charged to Histamine_inducing_drugs Four_hr_Vanco_desens</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=736&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The medications listed above can cause nonimmunologic histamine release, which can predispose patients to vancomycin reactions and/or prevent successful vancomycin desensitization.</div><div class=\"graphic_footnotes\">* Fentanyl rarely induces histamine release.<br></div><div class=\"graphic_reference\">Reproduced and modified with permission from: Wazny LD, et al. Desensitization protocols for vancomycin hypersensitivity. The Annals of Pharmacotherapy 2001; 35:1458. Copyright © 2001 Harvey Whitney.</div><div id=\"graphicVersion\">Graphic 74197 Version 8.0</div></div></div>"},"74199":{"type":"graphic_figure","displayName":"Calcium channel blockers post MI","title":"Calcium channel blockers do not change mortality after acute myocardial infarction (MI)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcium channel blockers do not change mortality after acute myocardial infarction (MI)</div><div class=\"cntnt\"><img style=\"width:372px; height:200px;\" src=\"images/CARD/74199_Calcium_blockers_post_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A meta-analysis of controlled trials of calcium channel blockers in post-myocardial infarction patients failed to show any effect on mortality. However, the agents that reduce heart rate, particularly verapamil, showed a trend toward an improved survival while nifedipine, which increases heart rate, showed a trend toward an increased mortality.</div><div class=\"graphic_reference\">Data from Held PH, Yusuf S. In: Cardiovascular Pharmacology and Therapeutics, Singh BN, Dzau V, Vanhoutte PM, Woosley RL (Eds), Churchill Livingstone, New York, 1993, p. 525.</div><div id=\"graphicVersion\">Graphic 74199 Version 3.0</div></div></div>"},"74203":{"type":"graphic_table","displayName":"Melanoma 7th TNM stage group","title":"Seventh TNM stage groupings for cutaneous melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seventh TNM stage groupings for cutaneous melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage </td> <td class=\"subtitle1\">Primary tumor (T) </td> <td class=\"subtitle1\">Regional lymph nodes (N) </td> <td class=\"subtitle1\">Distant metastasis (M) </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clinical staging* </td> </tr> <tr> <td class=\"indent1\">Stage 0 </td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IA </td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IB </td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IIA </td> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T3a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IIB </td> <td>T3b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T4a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IIC </td> <td>T4b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage III </td> <td>Any T</td> <td>N1, N2, or N3</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IV </td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Pathologic staging<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Stage 0 </td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IA </td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IB </td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IIA </td> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T3a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IIB </td> <td>T3b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T4a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IIC </td> <td>T4b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IIIA </td> <td>T1-4a</td> <td>N1a</td> <td>M0</td> </tr> <tr> <td>T1-4a</td> <td>N2a</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Stage IIIB </td> <td>T1-4b</td> <td>N1a</td> <td>M0</td> </tr> <tr> <td>T1-4b</td> <td>N2a</td> <td>M0</td> </tr> <tr> <td>T1-4a</td> <td>N1b</td> <td>M0</td> </tr> <tr> <td>T1-4a</td> <td>N2b</td> <td>M0</td> </tr> <tr> <td>T1-4a</td> <td>N2c</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Stage IIIC </td> <td>T1-4b</td> <td>N1b</td> <td>M0</td> </tr> <tr> <td>T1-4b</td> <td>N2b</td> <td>M0</td> </tr> <tr> <td>T1-4b</td> <td>N2c</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IV </td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical staging includes microstaging of the primary melanoma and clinical/radiologic evaluation for metastases. By convention, it should be used after complete excision of the primary melanoma with clinical assessment for regional and distant metastases.<br />¶&nbsp;Pathologic staging includes microstaging of the primary melanoma and pathologic information about the regional lymph nodes after partial or complete lymphadenectomy. Pathologic Stage 0 or Stage IA patients are the exception; they do not require pathologic evaluation of their lymph nodes.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 74203 Version 16.0</div></div></div>"},"74204":{"type":"graphic_figure","displayName":"Platelet production per nucleus","title":"Megakaryocyte volume and platelet production per nucleus in megakaryocyte disorders","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte volume and platelet production per nucleus in megakaryocyte disorders</div><div class=\"cntnt\"><img style=\"width:531px; height:280px;\" src=\"images/HEME/74204_Platelet_production_per_nuc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow analysis was performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The amount of megakaryocyte cytoplasm per diploid (2N) amount of nuclear DNA was similar to normal in all of the disorders. Right panel: When the platelet production rate was measured in kinetic studies and then divided by the number of diploid nuclear lobes of the megakaryocyte, the amount of platelets produced per diploid amount of nuclear DNA was normal in all disorders except for hypoplastic marrow states and B12 deficiency in which ineffective thrombopoiesis was present.</div><div class=\"graphic_reference\">Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.</div><div id=\"graphicVersion\">Graphic 74204 Version 2.0</div></div></div>"},"74207":{"type":"graphic_picture","displayName":"Scaphoid shift test 4","title":"Scaphoid shift test: Step 4","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Scaphoid shift test: Step 4</div><div class=\"cntnt\"><img style=\"width:480px; height:400px;\" src=\"images/EM/74207_Scaphoid_shift_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While maintaining pressure with your thumb on the scaphoid tubercle, use your other hand to move the wrist into radial deviation. With an intact scapholunate ligament, the scaphoid will flex, despite the pressure, and become more prominent; there will be no clunks or significant pain in the scapholunate space. Pain as the wrist is moved into radial deviation, possibly accompanied by a clunking sensation, constitutes a positive test, and is consistent with a scapholunate ligament tear.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD, FAAFP, FACSM.</div><div id=\"graphicVersion\">Graphic 74207 Version 3.0</div></div></div>"},"74208":{"type":"graphic_table","displayName":"Expressions of MEN1","title":"Expressions of MEN1 with estimated penetrance (in parentheses) at age 40 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expressions of MEN1 with estimated penetrance (in parentheses) at age 40 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Endocrine features</td> <td class=\"subtitle1\">Nonendocrine features</td> </tr> <tr> <td class=\"subtitle2_left\">Primary hyperparathyroidism (90%)</td> <td class=\"divider_bottom\">Lipomas (30%)</td> </tr> <tr> <td class=\"subtitle2_left\">Entero-pancreatic tumor (30 to 70%)</td> <td class=\"divider_bottom\">Facial angiofibromas (85%)</td> </tr> <tr> <td class=\"indent1\">Gastrinoma (30 to 40%)</td> <td>Collagenomas (70%)</td> </tr> <tr> <td class=\"indent1\">Insulinoma (10%)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">NF* including pancreatic polypeptide (20 to 55%<sup>&#182;</sup>)</td> <td>Rare, maybe innate, endocrine or nonendocrine features</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other: glucagonoma, VIPoma, somatostatinoma, etc (2%)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Foregut carcinoid</td> <td class=\"divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Thymic carcinoid NF (2%)</td> <td>Pheochromocytoma (&#60;1%)</td> </tr> <tr> <td class=\"indent1\">Bronchial carcinoid NF (2%)</td> <td>Ependymoma (1%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gastric enterochromaffin-like tumor NF (10%)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Anterior pituitary tumor adenoma (30 to 40%)</td> <td class=\"divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Prolactinoma (20%)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Other: GH + PRL, GH, NF (each 5%)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">ACTH (2%), TSH (rare)</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Adrenal cortical tumor NF (40 percent)</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEN1: multiple endocrine neoplasia type 1; NF: nonfunctioning; GH: growth hormone; PRL: prolactin; ACTH: corticotropin; TSH: thyroid-stimulating hormone.<br />* May synthesize a peptide hormone or other factors (such as small amine) but does not usually oversecrete enough to produce a hormonal expression.<br />¶ Omits nearly 100% prevalence of NF and clinically silent tumors, some of which are detected incidental to pancreatico-duodenal surgery in MEN1.</div><div class=\"graphic_reference\">Reproduced with permission from: Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658. Copyright © 2001 The Endocrine Society.<br />Updated&nbsp;using: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243:265.</LI>&#xD;&#xA;<LI>Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30:643.</LI>&#xD;&#xA;<LI>Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.</LI></OL></div><div id=\"graphicVersion\">Graphic 74208 Version 8.0</div></div></div>"},"74209":{"type":"graphic_figure","displayName":"CCK test for achalasia","title":"The cholecystokinin (CCK) octapeptide test for achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The cholecystokinin (CCK) octapeptide test for achalasia</div><div class=\"cntnt\"><img style=\"width:285px; height:186px;\" src=\"images/GAST/74209_CCK_test_for_achalasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CCK has a dual effect on the lower esophageal sphincter (LES): it stimulates smooth muscle contraction and the release of inhibitory neurotransmitters. Administration of CCK normally causes the LES pressure to fall because the effect on inhibitory neurotransmitters is greater. In patients with achalasia, CCK causes the LES pressure to rise.</div><div class=\"graphic_reference\">Reprinted, courtesy of the Clinical Teaching Project of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 74209 Version 2.0</div></div></div>"},"74210":{"type":"graphic_diagnosticimage","displayName":"Fetal ovarian cyst","title":"Ovarian cyst in female fetus at 34 weeks' gestational age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian cyst in female fetus at 34 weeks' gestational age</div><div class=\"cntnt\"><img style=\"width:372px; height:302px;\" src=\"images/OBGYN/74210_Fetal_ovarian_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal sonogram shows complex cystic mass (arrow) in left abdomen (s = stomach, b = bladder). Through-transmission is seen posterior to cyst. On follow-up scans (not shown), cyst size remained the same but hematoma in cyst decreased in size. Excision was performed when infant was&nbsp;three months old, and pathology revealed intrauterine ovarian torsion.</div><div class=\"graphic_reference\">Reproduced with permission from Trop I, Levine D. Hemorrhage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright © 2001.</div><div id=\"graphicVersion\">Graphic 74210 Version 4.0</div></div></div>"},"74211":{"type":"graphic_picture","displayName":"Plaque type psoriasis PI","title":"Plaque type psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plaque type psoriasis</div><div class=\"cntnt\"><img style=\"width:262px; height:246px;\" src=\"images/PI/74211_PlaquetypepsoriasisPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque type psoriasis causes the skin to form red, scaly patches. These patches are usually raised up over the normal skin around them.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 74211 Version 2.0</div></div></div>"},"74212":{"type":"graphic_table","displayName":"Interpreting Weber and Rinne tests","title":"Interpreting Weber and Rinne tests: Conductive versus sensorineural hearing loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpreting Weber and Rinne tests: Conductive versus sensorineural hearing loss</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">&nbsp;</td>\r\n            <td class=\"subtitle1\">Weber lateralizes</td>\r\n            <td class=\"subtitle1\">Rinne test</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"3\">Conductive loss</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Good ear</td>\r\n            <td>&nbsp;</td>\r\n            <td>AC &#62; BC</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Bad ear</td>\r\n            <td>To bad ear</td>\r\n            <td>BC &#62; AC</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"3\">Sensorineural loss</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Good ear</td>\r\n            <td>To good ear</td>\r\n            <td>AC &#62; BC</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Bad ear</td>\r\n            <td>&nbsp;</td>\r\n            <td>AC &#62; BC</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=60146&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">AC &gt; BC: air conduction better than bone conduction (normal Rinne).<BR>BC &gt; AC: bone conduction better than air conduction (abnormal Rinne).</div><div id=\"graphicVersion\">Graphic 74212 Version 6.0</div></div></div>"},"74214":{"type":"graphic_figure","displayName":"Flow rate and work","title":"Flow rate and work","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Flow rate and work</div><div class=\"cntnt\"><img style=\"width:533px; height:226px;\" src=\"images/PULM/74214_Flow_rate_and_work.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow and airway pressure (Paw) during assist-control ventilation at an inspiratory flow rate of 60 L/min (panel A) and 30 L/min (panel B). In panel A, the small negative phase, smooth rise, and convex appearance of the Paw waveform indicate that the patient is making a slight inspiratory effort to breathe. In panel B, the more pronounced negative phase and excessive scalloping of the Paw waveform indicate that the patient is making a strenuous effort to breathe due to inadequate flow.</div><div class=\"graphic_reference\">Reproduced with permission from: Jubran, A, Tobin, MJ. In: Principles and Practice of Mechanical Ventilation. Tobin, MJ (Ed), McGraw Hill, Inc. New York 2006. Copyright &#169;2006 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 74214 Version 1.0</div></div></div>"},"74216":{"type":"graphic_diagnosticimage","displayName":"Longitudinal view","title":"Longitudinal ultrasound view of a second metacarpophalangeal joint showing various anatomical structures in a standard scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal ultrasound view of a second metacarpophalangeal joint showing various anatomical structures in a standard scan</div><div class=\"cntnt\"><img style=\"width:432px; height:262px;\" src=\"images/RHEUM/74216_Longitudinal_View.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 74216 Version 6.0</div></div></div>"},"74218":{"type":"graphic_figure","displayName":"Impaired coronary artery vasoreactivity predicts CV events","title":"Impaired coronary artery vasoreactivity predicts cardiovascular events","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impaired coronary artery vasoreactivity predicts&nbsp;cardiovascular events</div><div class=\"cntnt\"><img style=\"width:429px; height:529px;\" src=\"images/PC/74218_Coronaryvasoreactivityout.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary artery&nbsp;vasoreactivity was evalauted in 147 patients with documented CHD or risk factors for CHD; flow-dependent dilation, assessed with intracoronary papaverine or adenosine (upper panel), and flow-independent vasodilation, induced by nitroglycerin (lower panel), were divided into tertiles (percent arterial dilation). During a median follow-up of 6.7 years, impaired vascular reactivity was associated with a signficantly higher cardiovascular event rate (cardiovascular death, unstable angina, myocardial infarction, revascularization, stroke, peripheral artery revascularization); the incidence of events was highest in those with the least dilation.</div><div class=\"graphic_footnotes\">CHD: coronary heart disease.</div><div class=\"graphic_reference\">Data from Schachinger V, Britten MB, Zeiher AM. Circulation 2000; 101:1899.</div><div id=\"graphicVersion\">Graphic 74218 Version 4.0</div></div></div>"},"74219":{"type":"graphic_picture","displayName":"Mechanical ptosis","title":"Patient with neurofibromatosis 1 and mechanical ptosis secondary to a plexiform neurofibroma on the right upper lid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with neurofibromatosis 1 and mechanical ptosis secondary to a plexiform neurofibroma on the right upper lid</div><div class=\"cntnt\"><img style=\"width:432px; height:133px;\" src=\"images/NEURO/74219_Mechanical_ptosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with a mechanical ptosis of the right upper lid secondary to a plasmacytoma.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 74219 Version 2.0</div></div></div>"},"74221":{"type":"graphic_waveform","displayName":"Lown Ganong Levine ECG","title":"Lown-Ganong-Levine syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lown-Ganong-Levine syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:254px;\" src=\"images/CARD/74221_Lown_Ganong_Levine_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG of a patient with the Lown-Ganong-Levine syndrome shows a short PR interval of 0.10 second and a normal QRS complex.</div><div id=\"graphicVersion\">Graphic 74221 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"74222":{"type":"graphic_table","displayName":"Prob 10 year survival white men older than 70 RP prostate cancer","title":"Probability (95% confidence interval) of 10-year overall survival in white men ≥70 years old undergoing radical prostatectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability (95% confidence interval) of 10-year overall survival in white men ≥70 years old undergoing radical prostatectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Gleason 6</td> <td class=\"subtitle1\" colspan=\"2\">Gleason 7</td> <td class=\"subtitle1\" colspan=\"2\">Gleason 8 to 10</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Charlson comorbidity index</td> <td class=\"subtitle2\" colspan=\"2\">Charlson comorbidity index</td> <td class=\"subtitle2\" colspan=\"2\">Charlson comorbidity index</td> </tr> <tr> <td><strong>PSA</strong></td> <td><strong>0 to 1</strong></td> <td><strong>&#62;1</strong></td> <td><strong>0 to 1</strong></td> <td><strong>&#62;1</strong></td> <td><strong>0 to 1</strong></td> <td><strong>&#62;1</strong></td> </tr> <tr> <td><strong>0 to 9.9</strong></td> <td>85 (80 to 90)</td> <td>64 (53 to 76)</td> <td>81 (75 to 86)</td> <td>57 (46 to 69)</td> <td>76 (69 to 84)</td> <td>48 (36 to 65)</td> </tr> <tr> <td><strong>10 to 19.9</strong></td> <td>76 (68 to 84)</td> <td>47 (35 to 65)</td> <td>70 (62 to 79)</td> <td>39 (27 to 55)</td> <td>64 (54 to 75)</td> <td>30 (18 to 49)</td> </tr> <tr> <td><strong>&#8805;20</strong></td> <td>72 (63 to 82)</td> <td>41 (28 to 62)</td> <td>66 (57 to 76)</td> <td>32 (21 to 50)</td> <td>59 (48 to 71)</td> <td>24 (14 to 42)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171:1513.</div><div id=\"graphicVersion\">Graphic 74222 Version 2.0</div></div></div>"},"74223":{"type":"graphic_table","displayName":"Comparison of mast cell disorders","title":"Comparison of clinical and diagnostic features for systemic mastocytosis, mast cell activation syndromes, and idiopathic anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of clinical and diagnostic features for systemic mastocytosis, mast cell activation syndromes, and idiopathic anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Systemic mastocytosis</td> <td class=\"subtitle1\">Monoclonal mast cell activation syndrome (MMAS)</td> <td class=\"subtitle1\"><span style=\"color: black;\">Idiopathic</span><span style=\"color: black;\"> mast cell activation syndrome (IMCAS)</span></td> <td class=\"subtitle1\">Idiopathic anaphylaxis</td> </tr> <tr> <td><strong>Baseline tryptase</strong>*</td> <td>&#62;20</td> <td>Normal or mildly increased</td> <td>Normal or mildly increased</td> <td>Normal</td> </tr> <tr> <td><strong>kit D816V</strong></td> <td>+</td> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><strong>Multifocal mast cell aggregates<span style=\"color: black;\"> in the bone marrow</span></strong></td> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><strong>Aberrant CD25 <span style=\"color: black;\">on bone marrow and other non-cutaneous mast cells</span></strong></td> <td>+</td> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><strong>Urticaria pigmentosa</strong></td> <td>+/&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><strong>Mediator-release symptoms</strong></td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td><strong>Hypotensive episodes</strong></td> <td>+/&ndash;</td> <td>+/&ndash;</td> <td>+/&ndash;</td> <td>+/&ndash;</td> </tr> <tr> <td><strong>Urine N-MH or PGD<sub>2</sub></strong></td> <td>Increased at baseline</td> <td>Increased during symptoms</td> <td>Increased during symptoms</td> <td>Increased during symptoms</td> </tr> <tr> <td><strong>Response to antimediator therapy</strong></td> <td>+</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N-MH: N-methylhistamine; PGD<SUB>2</SUB>: prostaglandin D<SUB>2</SUB>.<br />* Elevations in serum tryptase corresponding to symptoms (particularly hypotension) may be seen in all four disorders. Increases in tryptase greater than 1.2 x baseline value + 2 ng/mL are considered significant. For example, if a patient's baseline total tryptase was 5 ng/mL, a value of 8 ng/mL would represent a significant increase.</div><div class=\"graphic_reference\"><SPAN style=\"COLOR: black\">Modified</SPAN><SPAN style=\"COLOR: black\">&nbsp;fro</SPAN>m: Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74223 Version 14.0</div></div></div>"},"74225":{"type":"graphic_figure","displayName":"Proinsulin in prolonged fast","title":"Plasma proinsulin concentrations after a prolonged fast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma proinsulin concentrations after a prolonged fast</div><div class=\"cntnt\"><img style=\"width:238px; height:279px;\" src=\"images/ENDO/74225_Proinsulin_in_prolonged_fas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma glucose and proinsulin concentrations in normal subjects and patients with an insulinoma after a prolonged fast. In patients who become hypoglycemic, a plasma proinsulin concentration above 5 pmol/L is suggestive of an insulinoma. To convert plasma glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Redrawn from Service FJ. Hypoglycemic disorders.&nbsp;N Engl J Med 1995; 332:1144.</div><div id=\"graphicVersion\">Graphic 74225 Version 2.0</div></div></div>"},"74226":{"type":"graphic_picture","displayName":"NSAID induced strictures","title":"Diaphragm-like strictures of the small intestine caused by NSAIDs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaphragm-like strictures of the small intestine caused by NSAIDs</div><div class=\"cntnt\"><img style=\"width:293px; height:349px;\" src=\"images/GAST/74226_NSAID_induced_strictures.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bjarnason I, et al. Side effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the small and large intestine in humans. Gastroenterology 1993; 104:1832. Copyright &copy; 1993 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 74226 Version 3.0</div></div></div>"},"74230":{"type":"graphic_picture","displayName":"Candidal hyphae in cord","title":"Candidal hyphae in cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidal hyphae in cord</div><div class=\"cntnt\"><img style=\"width:396px; height:256px;\" src=\"images/OBGYN/74230_Candidal_hyphae_in_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 74230 Version 2.0</div></div></div>"},"74233":{"type":"graphic_algorithm","displayName":"Eval neonatal resp distress","title":"Evaluation of neonatal respiratory distress","html":"<div class=\"graphic\"><div style=\"width: 674px\" class=\"figure\"><div class=\"ttl\">Evaluation of neonatal respiratory distress</div><div class=\"cntnt\"><img style=\"width:654px; height:966px;\" src=\"images/PEDS/74233_Eval_neonatal_resp_distress.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AAP: American Academy of Pediatrics; CBC: complete blood count; CPAP: continuous positive airway pressure; PPHN: persistent pulmonary hypertension of the newborn; RDS: respiratory distress syndrome; RR: respiratory rate; TTN: transient tachypnea of the newborn.<br />* Refer to AAP guidelines on treatment of sepsis and UpToDate topics on neonatal sepsis.<br />&para; Refer to UpToDate topics on prevention and treatment of neonatal RDS.</div><div id=\"graphicVersion\">Graphic 74233 Version 3.0</div></div></div>"},"74234":{"type":"graphic_figure","displayName":"Peak pollen periods in the United States","title":"Peak pollen periods in the United States","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Peak pollen periods in the United States</div><div class=\"cntnt\"><img style=\"width:551px; height:508px;\" src=\"images/ALLRG/74234_Peak_pollen_periods_US.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74234 Version 2.0</div></div></div>"},"74235":{"type":"graphic_diagnosticimage","displayName":"Subdural hematoma in an infant with mortality","title":"Subdural hematoma in an infant with mortality","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Subdural hematoma in an infant with mortality</div><div class=\"cntnt\"><img style=\"width:480px; height:267px;\" src=\"images/EM/74235_SDH_with_mortality_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An infant presented in coma with pupillary dilatation. There was no significant trauma history. Computed tomography (image A) reveals a large right, concave subdural hematoma and significant brain shift. After urgent craniotomy, the patient had malignant brain swelling due to the underlying traumatic and hypoxic-ischemic injury on follow-up computed tomography (image B) and did not survive. Bilateral retinal hemorrhages and skeletal fractures were also detected.</div><div id=\"graphicVersion\">Graphic 74235 Version 6.0</div></div></div>"},"74236":{"type":"graphic_picture","displayName":"ER early esoph cancer Endosc","title":"Endoscopic resection of an early cancer in a Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Endoscopic resection of an early cancer in a Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:550px; height:354px;\" src=\"images/GAST/74236_EMR_early_esoph_cancer_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 4-cm long segment of Barrett's esophagus with a large island of squamous mucosa in its center.<br />(B) A detailed view of a lesion at the 3 o'clock position.<br />(C) Same lesion shown in the retroflexed position.<br />(D) The lesion has been delineated by placing coagulation markers at its outer surface.<br />(E) The lesion has been elevated by injection of diluted epinephrine solution through a standard sclerotherapy needle.<br />(F) A transparent cap has been attached to the distal tip of the endoscope and a crescent shaped snare is positioned into the distal ridge of the cap.<br />(G) Using the coagulation markers for orientation, the lesion is identified and subsequently sucked into the cap.<br />(H) After closure of the snare, the resulting pseudo-polyp, including the lesion, is pushed outside the cap and removed using electrocoagulation.<br />(I) The created EMR wound shown in the antegrade position; there is still some mucosal swelling due the submucosal lifting.<br />(J) EMR wound shown in the retroflexed position, no markers can be identified indicating an endoscopically complete resection; note the mucosal whitening due to the vasoconstrictive effect of the epinephrine solution used for submucosal lifting.<br />(K) The EMR specimen is subsequently removed from the stomach using retrieval net and pinned down on paraffin to prevent shrinking and curling.<br />(L) Microscopic view of the specimen showing a well differentiated cancer infiltrating into the deeper layers of the muscularis mucosae, there is no infiltration into the submucosa.</div><div class=\"graphic_footnotes\">EMR: endoscopic mucosal resection.</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright © Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 74236 Version 4.0</div></div></div>"},"74237":{"type":"graphic_figure","displayName":"Sitting position for lumbar puncture in an infant","title":"Sitting position for lumbar puncture in an infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sitting position for lumbar puncture in an infant</div><div class=\"cntnt\"><img style=\"width:337px; height:317px;\" src=\"images/PEDS/74237_Sitting_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The assistant grasps one of the infant's arms and one of the legs in each hand while supporting the head to prevent excessive flexion at the neck. Older children should be asked to sit with their legs hanging over the edge of the examining table. They can be flexed over a pillow with the elbows resting on the knees. An assistant may be helpful, even in a cooperative child, in maintaining alignment throughout the procedure.</div><div class=\"graphic_reference\">Adapted from Cronan, KM, Wiley, JF. Lumbar puncture. In: Henretig, FM, King, C, (Eds), Textbook of Pediatric Emergency Procedures, Williams and Wilkins, Baltimore, 1997.</div><div id=\"graphicVersion\">Graphic 74237 Version 2.0</div></div></div>"},"74239":{"type":"graphic_picture","displayName":"Squamous cell carcinoma - gingiva","title":"Squamous cell carcinoma on the gingiva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma on the gingiva</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/74239_Squa_cell_carc_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ulcerated nodule involving the gingiva represents a squamous cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74239 Version 3.0</div></div></div>"},"74240":{"type":"graphic_picture","displayName":"Cutaneous squamous cell carcinoma - cutaneous horn","title":"Cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74240_Cutan_squam_cutaneous_horn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratotic, cutaneous horn on an erythematous base&nbsp;on the preauricular skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74240 Version 5.0</div></div></div>"},"74241":{"type":"graphic_diagnosticimage","displayName":"OCT in acute MI","title":"OCT in acute MI","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">OCT in acute MI</div><div class=\"cntnt\"><img style=\"width:466px; height:473px;\" src=\"images/CARD/74241_OCT_in_acute_MI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracoronary OCT (A-C) and coronary angiogram (D) of the right coronary artery in a patient presenting with acute coronary syndrome with sudden onset of chest pain and transient ST elevations in the inferior ECG leads. The coronary angiogram shows a mild, non flow limiting lesion in the right coronary artery (D). Intracoronary OCT reveals atherosclerosis with concentric, mild intimal thickening (A) and focal thrombosis (B, C). A mural thrombus is protruding into the lumen in 3 o'clock position (asterisk) and is casting a shadow on the arterial wall. Thus OCT is able to reveal the pathophysiologic culprit of the patients clinical symptoms, that is missed by angiography.</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR; ECF: electrocardiogram.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 74241 Version 3.0</div></div></div>"},"74242":{"type":"graphic_table","displayName":"Emergent management of anaphylaxis in infants and children","title":"Rapid overview: Emergent management of anaphylaxis in infants and children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergent management of anaphylaxis in infants and children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis is made clinically:</td> </tr> <tr> <td class=\"indent1\">The most common signs and symptoms are cutaneous (eg, sudden onset of generalized urticaria, angioedema, flushing, pruritus). However, 10 to 20% of patients have no skin findings.</td> </tr> <tr> <td class=\"indent1\"><span style=\"color: #ff0000;\"><strong>Danger signs: Rapid progression of symptoms, evidence of respiratory distress (eg, stridor, wheezing, dyspnea, increased work of breathing, retractions, persistent cough, cyanosis), signs of poor perfusion, abdominal pain, vomiting,&nbsp;dysrhythmia, hypotension, collapse.</strong></span></td> </tr> <tr> <td class=\"subtitle1_single\">Acute management:</td> </tr> <tr> <td class=\"indent1\">The first and most important therapy in anaphylaxis is epinephrine. There are <strong>NO absolute contraindications to epinephrine</strong> in the setting of anaphylaxis.</td> </tr> <tr> <td class=\"indent1\"><strong>Airway:</strong> Immediate intubation if evidence of impending airway obstruction from angioedema. Delay may lead to complete obstruction. Intubation can be difficult and should be performed by the most experienced clinician available. Cricothyrotomy may be necessary.</td> </tr> <tr> <td class=\"indent1\"><strong>IM epinephrine (1 mg/mL preparation):</strong> Epinephrine 0.01 mg/kg should be injected intramuscularly in the mid-outer thigh. For large children (&#62;50 kg), the maximum is 0.5 mg per dose. If there is no response or the response is inadequate, the injection can be repeated in 5 to 15 minutes (or more frequently). If epinephrine is injected promptly IM, patients respond to one, two, or at most, three injections. If signs of poor perfusion are present or symptoms are not responding to epinephrine injections, prepare IV epinephrine for infusion (see below).</td> </tr> <tr> <td class=\"indent1\"><strong>Place patient in recumbent position</strong>, if tolerated, and elevate lower extremities.</td> </tr> <tr> <td class=\"indent1\"><strong>Oxygen:</strong> Give 8 to 10 L/minute via facemask or up to 100% oxygen, as needed.</td> </tr> <tr> <td class=\"indent1\"><strong>Normal saline rapid bolus:</strong> Treat poor perfusion with rapid infusion of 20 mL/kg. Re-evaluate and repeat fluid boluses (20 mL/kg), as needed. Massive fluid shifts with severe loss of intravascular volume can occur. Monitor urine output.</td> </tr> <tr> <td class=\"indent1\"><strong>Albuterol:</strong> For bronchospasm resistant to IM epinephrine, give albuterol 0.15 mg/kg (minimum dose: 2.5 mg) in 3 mL saline inhaled via nebulizer. Repeat, as needed.</td> </tr> <tr> <td class=\"indent1\"><strong>H1 antihistamine:</strong> Consider giving diphenhydramine 1 mg/kg (max 40 mg) IV.</td> </tr> <tr> <td class=\"indent1\"><strong>H2 antihistamine:</strong> Consider giving ranitidine 1 mg/kg (max 50 mg) IV.</td> </tr> <tr> <td class=\"indent1\"><strong>Glucocorticoid:</strong> Consider giving methylprednisolone 1 mg/kg (max 125 mg) IV.</td> </tr> <tr> <td class=\"indent1\"><strong>Monitoring:</strong> Continuous noninvasive hemodynamic monitoring and pulse oximetry monitoring should be performed. Urine output should be monitored in patients receiving IV fluid resuscitation for severe hypotension or shock.</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of refractory symptoms:</td> </tr> <tr> <td class=\"indent1\"><strong>Epinephrine infusion<sup>&#182;</sup>:</strong> In patients with inadequate response to IM epinephrine and IV saline, give epinephrine continuous infusion at 0.1 to 1 mcg/kg/minute, titrated to effect.</td> </tr> <tr> <td class=\"indent1\"><strong>Vasopressors<sup>&#182;</sup>:</strong> Patients may require large amounts of IV crystalloid to maintain blood pressure. Some patients may require a second vasopressor (in addition to epinephrine). All vasopressors should be given by infusion pump, with the doses titrated continuously according to blood pressure and cardiac rate/function monitored continuously and oxygenation monitored by pulse oximetry.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous.<br />* A child is defined as a prepubertal patient weighing less than 40 kg.<br />¶ All patients receiving an infusion of epinephrine and/or another vasopressor require continuous noninvasive monitoring of blood pressure, heart rate and function, and oxygen saturation. We suggest that pediatric centers provide instructions for preparation of standard concentrations and also provide charts for established infusion rate for epinephrine and other vasopressors in infants and children.</div><div id=\"graphicVersion\">Graphic 74242 Version 33.0</div></div></div>"},"74243":{"type":"graphic_table","displayName":"Liver transplant RAI","title":"Histologic rejection activity index for liver transplants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic rejection activity index for liver transplants</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n\n  <tbody>\n\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle1\">Category</td>\n\n\n\n      <td class=\"subtitle1\">Criteria</td>\n\n\n\n      <td class=\"subtitle1\">Score</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td colspan=\"1\" rowspan=\"3\">Portal inflammation</td>\n\n\n\n      <td>Mostly lymphocytic inflammation involving, but not noticeably expanding, a minority of the triads</td>\n\n\n\n      <td>1</td>\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n      \n\n\n\n      <td>Expansion of most of all of the triads, by a\nmixed infiltrate containing lymphocytes with\noccasional blasts, neutrophils and eosinophils</td>\n\n\n\n      <td style=\"text-align: left;\">2</td>\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n      \n\n\n\n      <td>Marked expansion of most or all of the triads by\na mixed infiltrate containing numerous blasts and eosinophils\nwith inflammatory spillover into the periportal parenchyma</td>\n\n\n\n      <td>3</td>\n\n\n\n    </tr>\n\n\n\n\n\n\n    <tr>\n\n\n\n      <td colspan=\"1\" rowspan=\"3\">Bile duct inflammation damage</td>\n\n\n\n      <td>A minority of the ducts are cuffed\nand infiltrated by inflammatory cells and show only mild\nreactive changes such as increased nuclear:cytoplasmic ratio\nof the epithelial cells</td>\n\n\n\n      <td>1</td>\n\n\n\n    </tr>\n\n\n\n\n\n\n\n    <tr>\n\n\n\n      \n\n\n\n      <td>Most or all of the ducts infiltrated by\ninflammatory cells. More than an occasional duct shows\ndegenerative changes such as nuclear pleomorphism,\ndisordered polarity and cytoplasmic vacuolization of\nthe epithelium</td>\n\n\n\n      <td>2</td>\n\n\n\n    </tr>\n\n\n\n\n\n\n\n    <tr>\n\n\n\n      \n\n\n\n      <td>As above for 2, with most or all of the ducts showing degenerative changes or focal lumenal disruption</td>\n\n\n\n      <td>3</td>\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n      <td colspan=\"1\" rowspan=\"3\">Venous endothelial inflammation</td>\n\n\n\n      <td>Subendothelial lymphocytic infiltration involving some, but not a majority of the portal and/or hepatic venules</td>\n\n\n\n      <td>1<br />\n\n\n      </td>\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n      \n\n\n\n      <td>Subendothelial lymphocytic infiltration involving some, but not a majority of the portal and/or hepatic venules</td>\n\n\n\n      <td>2</td>\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n      \n\n\n\n      <td>As above for 2, with moderate or severe\nperivenular inflammation that extends into the\nperivenular parenchyma and is associated with\nperivenular hepatocyte necrosis</td>\n\n\n\n      <td>3</td>\n\n\n\n    </tr>\n\n\n\n\n\n\n  \n  \n  </tbody>\n</table></div><div class=\"graphic_lgnd\">The total score is equal to the sum of the scores in each of the three categories.</div><div class=\"graphic_reference\">Adapted from: Demetris AJ, Batta KP, Dhillon AP, et al. Hepatology 1997; 25:658.</div><div id=\"graphicVersion\">Graphic 74243 Version 2.0</div></div></div>"},"74244":{"type":"graphic_figure","displayName":"Hormonal response to cirrhosis","title":"Hormonal response to cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hormonal response to cirrhosis</div><div class=\"cntnt\"><img style=\"width:436px; height:398px;\" src=\"images/NEPH/74244_Hormonal_response_to_cirrho.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cirrhosis of increasing severity&mdash;no ascites, ascites, and ascites plus RF due to hepatorenal syndrome&mdash;is associated with a progressive increase in plasma renin activity (ng/mL per hour) and in the plasma levels of norepinephrine (pg/mL), and antidiuretic hormone (pg/mL). This progressive rise in the secretion of hypovolemic hormones is associated with a vasodilatation-induced fall in mean arterial pressure (from 89 to 75 mmHg) and a reduction in the plasma sodium concentration (from 138 to 128 mEq/L).</div><div class=\"graphic_footnotes\">RF: renal failure; ADH: antidiuretic hormone.</div><div class=\"graphic_reference\">Data from: Asbert M, Gines A, Gines P, et al. Gastroenterology 1993; 104:1485.</div><div id=\"graphicVersion\">Graphic 74244 Version 3.0</div></div></div>"},"74246":{"type":"graphic_algorithm","displayName":"Rx sexual dys in uremic men","title":"Approach to sexual dysfunction in uremic men","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Approach to sexual dysfunction in uremic men</div><div class=\"cntnt\"><img style=\"width:554px; height:446px;\" src=\"images/NEPH/74246_Rx_sexual_dys_in_uremic_men.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Palmer B. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10:1366. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74246 Version 4.0</div></div></div>"},"74247":{"type":"graphic_diagnosticimage","displayName":"Brain MRI age 10 years juvenile Alexander disease","title":"Late brain MRI of a patient with presumed juvenile Alexander disease, obtained at the age of 10 years","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late brain MRI of a patient with presumed juvenile Alexander disease, obtained at the age of 10 years</div><div class=\"cntnt\"><img style=\"width:362px; height:217px;\" src=\"images/NEURO/74247_MRI_juv_10yr_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is extensive white matter involvement with frontal preponderance (A). The basal ganglia are dark and atrophic on T2-weighted images (A). A thin periventricular rim of low signal intensity is just visible (arrows, A). After contrast administration, enhancement of the entire cerebellar surface and dentate nucleus is seen (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: van der Knaap, MS, Naidu, S, Breiter, SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 74247 Version 3.0</div></div></div>"},"74248":{"type":"graphic_diagnosticimage","displayName":"Choroid plexus cyst","title":"Transverse image of the fetal head of an early second trimester fetus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse image of the fetal head of an early second trimester fetus</div><div class=\"cntnt\"><img style=\"width:435px; height:330px;\" src=\"images/OBGYN/74248_Choroidplexuscyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow demonstrates a unilateral choroid plexus cyst. The cyst is anechoic and surrounded by the more brightly echogenic choroid plexus.</div><div class=\"graphic_reference\">Courtesy of Beryl R Benacerraf, MD.</div><div id=\"graphicVersion\">Graphic 74248 Version 3.0</div></div></div>"},"74249":{"type":"graphic_figure","displayName":"Valt equation","title":"Equation for calculating voltage difference of alternation (V alt)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Equation for calculating voltage difference of alternation (V alt)</div><div class=\"cntnt\"><img style=\"width:312px; height:92px;\" src=\"images/CARD/74249_Valt_equation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74249 Version 1.0</div></div></div>"},"74251":{"type":"graphic_figure","displayName":"Knee ligaments","title":"Ligaments of the knee","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Ligaments of the knee</div><div class=\"cntnt\"><img style=\"width:569px; height:528px;\" src=\"images/EM/74251_Knee_ligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right knee joint as seen from lateral aspect (A), the anterior aspect with the joint flexed (B), and the posterior aspect (C, D).</div><div class=\"graphic_reference\">Reproduced with permission from: Snell, MD. Clinical Anatomy, Seventh Edition. Lippincott, Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74251 Version 1.0</div></div></div>"},"74254":{"type":"graphic_table","displayName":"G6PD deficiency medicines safety","title":"Partial list of medicines and other substances thought to be unsafe or safe in individuals with G6PD deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Partial list of medicines and other substances thought to be unsafe or safe in individuals with G6PD deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Medicines and other substances likely to be <span style=\"color: #ff0000;\">UNSAFE</span> in moderate to severe G6PD deficiency (WHO classes I, II, and III*)<sup>[1-3]</sup>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Anti-infectives</td> </tr> <tr> <td class=\"indent1\">Dapsone</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin and related, including nifuratel<sup>&#182;</sup> and nitrofurazone (nitrofural)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Primaquine</td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Dimercaprol<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Methylene blue (methylthioninium chloride) (antidote, also contained in some urinary tract combination products)</td> </tr> <tr> <td class=\"indent1\">Phenazopyridine</td> </tr> <tr> <td class=\"indent1\">Toluidine blue (tolonium chloride) (diagnostic agent)</td> </tr> <tr> <td class=\"indent1\">Uricase (rasburicase, pegloticase)</td> </tr> <tr> <td class=\"subtitle2_single\">Chemical exposures and foods likely to be <span style=\"color: #ff0000;\">UNSAFE</span> in moderate to severe G6PD deficiency (WHO classes I, II, and III)</td> </tr> <tr> <td class=\"indent1\">Aniline dyes</td> </tr> <tr> <td class=\"indent1\">Naphthalene (mothballs, lavatory deodorant)</td> </tr> <tr> <td class=\"indent1\">Henna compounds (black and red Egyptian) and related dyes used for hair and tattoos</td> </tr> <tr> <td class=\"indent1\">Fava beans</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Some prefer to avoid red wine, legumes, blueberries, soya, and tonic water<sup>[4]</sup>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Medicines previously considered unsafe, but <span style=\"color: #ff0000;\">PROBABLY SAFE</span> given in usual therapeutic doses in G6PD deficiency (WHO classes II and III); NOTE: safety in WHO Class I G6PD deficiency is generally not known<sup>[2]</sup>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Analgesics</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (paracetamol)</td> </tr> <tr> <td class=\"indent1\">Antipyrine (phenazone)</td> </tr> <tr> <td class=\"indent1\">Aspirin (acetylsalicylic acid)</td> </tr> <tr> <td class=\"indent1\">Aminophenazone<sup>&#182;</sup> and related NSAIDs (dipyrone<sup>&#182;</sup>, metamizole<sup>&#182;</sup>)</td> </tr> <tr> <td class=\"subtitle2_single\">Anti-infectives</td> </tr> <tr> <td class=\"indent1\">Antimalarials: chloroquine, mepacrine, quinine</td> </tr> <tr> <td class=\"indent1\">Fluoroquinolones<sup>&#916;</sup>: ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin, ofloxacin</td> </tr> <tr> <td class=\"indent1\">Sulfonamides: co-trimoxazole<sup>&#916;</sup><sup>&#9674;</sup>, sulfacetamide<sup>&#916;</sup> (topical), sulfanilamide<sup>&#916;</sup>, sulfisoxazole, sulfamethoxazole<sup>&#916;</sup><sup>&#9674;</sup>, trimethoprim-sulfamethoxazole<sup>&#916;</sup><sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Other anti-infectives: chloramphenicol, furazolidone<sup>&#916;</sup>, isoniazid, mepacrine</td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Ascorbic acid (vitamin C)</td> </tr> <tr> <td class=\"indent1\">Glyburide (glibenclamide)</td> </tr> <tr> <td class=\"indent1\">Hydroxychloroquine<sup>&#916;</sup> (see chloroquine)</td> </tr> <tr> <td class=\"indent1\">Isosorbide dinitrate</td> </tr> <tr> <td class=\"indent1\">Mesalamine (mesalazine)<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Quinine</td> </tr> <tr> <td class=\"indent1\">Succimer (dimercaptosuccinic acid)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sulfasalazine<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Medicines <span style=\"color: #ff0000;\">GENERALLY CONSIDERED SAFE</span> in usual therapeutic doses in G6PD (WHO classes II and III); NOTE: safety in WHO class I G6PD deficiency is generally not known<sup>[2]</sup>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Some agents listed are associated with nonhemolytic anemias unrelated to G6PD deficiency. For additional information, please refer to individual drug monographs.</td> </tr> <tr> <td class=\"indent1\">Colchicine</td> </tr> <tr> <td class=\"indent1\">Diphenhydramine</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> </tr> <tr> <td class=\"indent1\">Levodopa, levodopa-carbidopa</td> </tr> <tr> <td class=\"indent1\">Para-aminosalicylic acid (aminosalicylic acid)</td> </tr> <tr> <td class=\"indent1\">Para-aminobenzoic acid (PABA)</td> </tr> <tr> <td class=\"indent1\">Phenacetin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Phenylbutazone<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Probenecid<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Procainamide</td> </tr> <tr> <td class=\"indent1\">Pyrimethamine</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> </tr> <tr> <td class=\"indent1\">Sulfadiazine<sup>&#916;</sup><sup>[3]</sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tripelennamine</td> </tr> <tr> <td class=\"indent1\">Vitamin K, Vitamin K synthetic derivatives<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Please consult the G6PD deficiency favism association website for additional information on this subject: <a href=\"http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it\" target=\"_blank\">http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it</a>.</div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate deficiency; WHO: World Health Organization; NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* There is marked variability in reports of drugs that are unsafe in patients with G6PD deficiency. This list is based on evidence supporting a clear association with drug-induced hemolysis. Individual characteristics (ie, degree of G6PD deficiency, dose, presence of infection) will determine actual safety or injury. Medicines known to be unsafe in G6PD deficiency that are no longer in clinical use are excluded from this list.<br />¶&nbsp;Not available in the United States. Available in other countries.<br />Δ Conflicting reports. Considered unsafe for all degrees of G6PD deficiency according to some references.<SUP>[3]</SUP>&nbsp;<br /><FONT class=lozenge>◊</FONT> Sulfamethoxazole may produce a modest shortening in the survival of G6PD-deficient red cells. For additional detail, please refer to UpToDate topic on clinical manifestations of glucose-6-phosphate dehydrogenase.<br />§ There are reports of hemolytic episodes after administration of sulfasalazine (of which mesalamine is a component) in G6PD-deficient patients as well as numerous reports of anemia with the appearance of Heinz bodies in patients who received sulfasalazine who were not G6PD deficient.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64.</LI>&#xD;&#xA;<LI>Youngster I, Arcavi L, Schechmaster R. Medications and glucose6-phosphate dehydrogenase deficiency. Drug Saf 2010; 33:713.</LI>&#xD;&#xA;<LI>Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol 2014; 164:469.</LI>&#xD;&#xA;<LI>G6PD deficiency favism association website: <A href=\"http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it\" target=_blank>http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it</A> (Accessed January 29, 2014).</LI></OL></div><div id=\"graphicVersion\">Graphic 74254 Version 15.0</div></div></div>"},"74255":{"type":"graphic_table","displayName":"Prognosis after MI men women","title":"Six-year prognosis following myocardial infarction: Framingham study, 44-year follow-up for cohort and 20-year follow-up for offspring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six-year prognosis following myocardial infarction: Framingham study, 44-year follow-up for cohort and 20-year follow-up for offspring</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Men</td>\n\n\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Women</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Percent</td>\n\n      <td colspan=\"1\" class=\"subtitle2\">Risk ratio</td>\n\n      <td class=\"subtitle2\">Percent</td>\n\n\n      <td class=\"subtitle2\">Risk ratio</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">Recognized</td>\n\n      \n\n\n      \n\n      \n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Myocardial infarction</td>\n\n      <td>18</td>\n\n\n      <td>2.2</td>\n\n      <td>35</td>\n\n\n      <td>9.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angina pectoris</td>\n\n      <td>27</td>\n\n\n      <td>4.1</td>\n\n      <td>14</td>\n\n\n      <td>2.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac failure</td>\n\n      <td>22</td>\n\n\n      <td>5.4</td>\n\n      <td>48</td>\n\n\n      <td>15.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stroke/transient ischemic attack</td>\n\n      <td>8</td>\n\n\n      <td>2.4</td>\n\n      <td>11</td>\n\n\n      <td>3.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">Unrecognized</td>\n\n      \n\n\n      \n\n      \n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Myocardial infarction</td>\n\n      <td>19</td>\n\n\n      <td>2.0</td>\n\n      <td>18</td>\n\n\n      <td>3.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angina pectoris</td>\n\n      <td>11</td>\n\n\n      <td>1.6</td>\n\n      <td>17</td>\n\n\n      <td>3.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac failure</td>\n\n      <td>27</td>\n\n\n      <td>5.3</td>\n\n      <td>21</td>\n\n\n      <td>6.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stroke/transient ischemic attack</td>\n\n      <td>13</td>\n\n\n      <td>3.5</td>\n\n      <td>7</td>\n\n\n      <td>1.5</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74255 Version 1.0</div></div></div>"},"74258":{"type":"graphic_table","displayName":"Induction agents for lung transplant","title":"Agents for induction of immunosuppression following lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents for induction of immunosuppression following lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"17%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug*</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Suggested dose</td> <td class=\"subtitle1\">Monitoring</td> <td class=\"subtitle1\">Adverse&nbsp;effects<sup>&#182;</sup></td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Alemtuzumab (Campath-1H)</td> <td>Monoclonal rat antibody directed at CD52 on T cells and B cells, causing depletion of these lymphocytes</td> <td> <p>30 mg IV intra-operatively infused over two hours</p> Induction protocols may vary by institution</td> <td>Lymphocyte subsets</td> <td>Lymphopenia: <ul class=\"decimal_heading\"> <li>T cells may remain depressed for up to three years </li> <li>B cells may be depressed for several months </li> </ul> May cause cytokine release syndrome, but milder than compared to muromonab (OKT3)</td> <td>Limited experience in induction therapy</td> </tr> <tr class=\"divider_bottom\"> <td>Anti-thymocyte globulin</td> <td>Polyclonal antibody that causes nonspecific T cell depletion</td> <td> <p>Thymoglobulin&#174; (rabbit origin): 1.5 mg/kg over 6 hours, then two or three additional doses given 24 hours apart</p> <p>Atgam&#174; (horse origin): 7.5 to 15 mg/kg per day for three to five days post transplant</p> Induction protocols may vary by institution</td> <td>Lymphocytes subsets</td> <td>Leukopenia, cytokine release syndrome, infusion reactions, thrombocytopenia, glomerulonephritis serum sickness</td> <td>Premedication includes glucocorticoids (eg, methylprednisolone 125 mg intravenously), antihistamines (eg, diphenhydramine 50 mg orally or intravenously), and antipyretics (eg, acetaminophen 1 g orally) one hour prior to infusion</td> </tr> <tr class=\"divider_bottom\"> <td>Basiliximab</td> <td>Chimeric monoclonal antibody (25 percent mouse, 75 percent human antibody derived antibody) binds with high affinity to CD25 on T cells to inhibit IL-2 mediated T cell proliferation</td> <td>20 mg on the day of transplantation and again on post-op day four</td> <td>N/A</td> <td>Low rate of adverse effects. Rarely: hypersensitivity, cytokine release syndrome</td> <td>Most commonly used induction agent</td> </tr> <tr class=\"divider_bottom\"> <td>Daclizumab (withdrawn from US and other markets)</td> <td>Chimeric monoclonal antibody binds with high affinity to CD25 on T cells to inhibit IL-2 mediated proliferation of T cells</td> <td>1 mg/kg on day of transplant, then every two weeks for a total of five doses</td> <td>N/A</td> <td>Low rate of adverse effects. Rarely: hypersensitivity, cytokine release syndrome</td> <td>10 percent mouse, 90 percent human derived antibody</td> </tr> <tr> <td>Muromonab-CD3 (OKT3) (withdrawn from US and other markets)</td> <td>Mouse monoclonal antibody that binds to the T cell receptor-CD3 complex, causing depletion of T cells</td> <td>2.5 mg/day for patients weighing &#60;80 kg or 5 mg/day for patients &#8805;80 kg, given for 7 to 14 days after transplant</td> <td>Lymphocyte subsets</td> <td>Cytokine release storm (eg, fevers, rigors, vomiting, diarrhea, hemodynamic instability, pulmonary edema)</td> <td> <p>Patients will develop neutralizing antibodies to OKT3, limiting prolonged use and necessitating use of alternative drug if future augmentation of immunosuppression is needed</p> <p>Premedication includes glucocorticoids (eg, methylprednisolone 125 mg intravenously), antihistamines (eg, diphenhydramine 50 mg orally or intravenously), and antipyretics (eg, acetaminophen 1 g orally) one hour prior to infusion</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The US Food and Drug Administration has not approved any medications specifically for lung transplantation, so the doses are suggested based on the experience of large lung transplantation centers.<br />¶ Immunosuppressants may interact with BCG, live vaccines, and other agents that modulate the immune response, cause myelosuppression or agranulocytosis such as clozapine. For additional interactions, effects, and management suggestions, see Lexi-Interact™ drug interactions application included with UpToDate.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6:47.</LI>&#xD;&#xA;<LI>Korom S, et al. Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg 2009; 35:1045.</LI>&#xD;&#xA;<LI>Floreth T, Bhorade SM. Current trends in immunosuppression for lung transplantation. Semin Respir Crit Care Med 2010; 31:172.</LI></OL></div><div id=\"graphicVersion\">Graphic 74258 Version 2.0</div></div></div>"},"74259":{"type":"graphic_diagnosticimage","displayName":"Longitudinal ultrasound scan reverberation","title":"Longitudinal ultrasound scan showing reverberation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal ultrasound scan showing reverberation</div><div class=\"cntnt\"><img style=\"width:349px; height:316px;\" src=\"images/RHEUM/74259_Long_US_scan_reverberation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal ultrasound scan clearly showing the needle and numerous echoes beneath, which is called reverberation.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 74259 Version 1.0</div></div></div>"},"74261":{"type":"graphic_table","displayName":"Peroxisomal disorders","title":"Peroxisomal disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peroxisomal disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders of peroxisome biogenesis</td> </tr> <tr> <td>Zellweger syndrome</td> </tr> <tr> <td>Neonatal adrenoleukodystrophy (NALD)</td> </tr> <tr> <td>Infantile Refsum disease</td> </tr> <tr> <td>Rhizomelic chondrodysplasia punctata type 1</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders with deficiency of a single peroxisomal enzyme</td> </tr> <tr> <td>X-linked adrenoleukodystrophy, including adrenomyeloneuropathy (AMN) due to deficiency of adrenoleukodystrophy protein (ALDP)</td> </tr> <tr> <td>Refsum disease (phytanoyl CoA hydroxylase deficiency)</td> </tr> <tr> <td>Pseudo-NALD (acyl CoA oxidase deficiency)</td> </tr> <tr> <td>D-bifunctional enzyme deficiency</td> </tr> <tr> <td>Dihydroxy-acetone phosphate acyltransferase (DHAP-AT) deficiency (RCDP type 2)</td> </tr> <tr> <td>Alkyl-DHAP synthase deficiency (RCDP type 3)</td> </tr> <tr> <td>2-methylacyl-CoA racemase deficiency</td> </tr> <tr> <td>Acatalasemia (Catalase deficiency)</td> </tr> <tr> <td>Hyperoxaluria type 1 (alanine glyoxylate aminotransferase deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RCDP:&nbsp;rhizomelic chondrodysplasia punctata; DHAP: dihydroxy-acetone phosphate.</div><div id=\"graphicVersion\">Graphic 74261 Version 4.0</div></div></div>"},"74262":{"type":"graphic_table","displayName":"AUDIT","title":"AUDIT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AUDIT</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td class=\"subtitle1_single\">How often did you have a\ndrink containing alcohol in the past year?</td>\n</tr><tr>\n<td>Consider a drink to be a can or bottle of beer, a glass of\nwine, a wine cooler, or one cocktail or a shot of hard liquor.</td>\n</tr><tr>\n<td class=\"subtitle2_single\">Response:</td>\n</tr><tr>\n<td class=\"indent1\">Never: 0 points</td>\n</tr><tr>\n<td class=\"indent1\">Monthly or less: 1 point</td>\n</tr><tr>\n<td class=\"indent1\">2 to 4 times per month: 2 points</td>\n</tr><tr>\n<td class=\"indent1\">2 to 3 times per week: 3 points</td>\n</tr><tr>\n<td class=\"indent1\">4 or more times per week: 4 points</td>\n</tr><tr>\n<td class=\"subtitle1_single\">How many drinks did you have\non a typical day when you were drinking in the past year?</td>\n</tr><tr>\n<td class=\"subtitle2_single\">Response:</td>\n</tr><tr>\n<td class=\"indent1\">0-2 drinks: 0 points</td>\n</tr><tr>\n<td class=\"indent1\">3 to 4 drinks: 1 point</td>\n</tr><tr>\n<td class=\"indent1\">5 to 6 drinks: 2 points</td>\n</tr><tr>\n<td class=\"indent1\">7 to 9 drinks: 3 points</td>\n</tr><tr>\n<td class=\"indent1\">10 or more drinks: 4 points</td>\n</tr><tr>\n<td class=\"subtitle1_single\">How often did you have 6 or\nmore drinks on one occasion in the past year?</td>\n</tr><tr>\n<td class=\"subtitle2_single\">Response:</td>\n</tr><tr>\n<td class=\"indent1\">Never: 0 points</td>\n</tr><tr><td class=\"indent1\">Less than monthly: 1\npoint</td></tr><tr><td class=\"indent1\">Monthly: 2 points</td></tr><tr><td class=\"indent1\">Weekly: 3 points</td></tr><tr><td class=\"indent1\">Daily or almost daily: 4 points</td></tr>\n</tbody></table></div><div class=\"graphic_lgnd\">A cutoff of 4 points or more identified 86 percent of patients with heavy drinking and/or active alcohol abuse or dependence with a specificity of 72 percent (false positive rate 18 percent).</div><div class=\"graphic_reference\">Data from: Bush, K, Kivlahan, DR, McDonell, MB, et al. The AUDIT Alcohol Consumption Questions: An effective brief screening test for problem drinking. Arch Intern Med 1998; 158:1789.</div><div id=\"graphicVersion\">Graphic 74262 Version 1.0</div></div></div>"},"74264":{"type":"graphic_diagnosticimage","displayName":"Lung cancer extension CT","title":"Transdiaphragmatic extension of lung carcinoma on CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transdiaphragmatic extension of lung carcinoma on CT</div><div class=\"cntnt\"><img style=\"width:338px; height:276px;\" src=\"images/PULM/74264_Lung_cancer_extension_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT sections through the lower chest and liver show an irregular low-attenuation lesion in the right hepatic lobe (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74264 Version 3.0</div></div></div>"},"74266":{"type":"graphic_table","displayName":"Causes polyarticular joint pain","title":"Major causes of inflammatory polyarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of inflammatory polyarthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Infectious arthritis</strong> <ul class=\"decimal_heading\"> <li>Bacterial <ul> <li>Lyme disease </li> <li>Bacterial endocarditis </li> </ul> </li> <li>Viral </li> <li>Other infections </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Postinfectious (reactive) arthritis</strong> <ul class=\"decimal_heading\"> <li>Rheumatic fever </li> <li>Reactive arthritis </li> <li>Enteric infection </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other seronegative spondyloarthritides</strong> <ul class=\"decimal_heading\"> <li>Ankylosing spondylitis </li> <li>Psoriatic arthritis </li> <li>Inflammatory bowel disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rheumatoid arthritis</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Inflammatory osteoarthritis</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Crystal-induced arthritis</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Systemic rheumatic illnesses</strong> <ul class=\"decimal_heading\"> <li>Systemic lupus erythematosus </li> <li>Systemic vasculitis </li> <li>Systemic sclerosis </li> <li>Polymyositis/dermatomyositis </li> <li>Still's disease </li> <li>Beh&#231;et's syndrome </li> <li>Relapsing polychondritis </li> <li>Autoinflammatory disorders </li> </ul> </td> </tr> <tr> <td><strong>Other systemic illnesses</strong> <ul class=\"decimal_heading\"> <li>Sarcoidosis </li> <li>Palindromic rheumatism </li> <li>Familial Mediterranean fever </li> <li>Malignancy </li> <li>Hyperlipoproteinemias </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74266 Version 5.0</div></div></div>"},"74268":{"type":"graphic_table","displayName":"ESC 2008 CM nonfamilial","title":"Non-familial types of cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-familial types of cardiomyopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HCM</td> <td class=\"subtitle1\">DCM</td> <td class=\"subtitle1\">ARVC</td> <td class=\"subtitle1\">RCM</td> <td class=\"subtitle1\">Unclassified</td> </tr> <tr> <td> <p>Obesity</p> <p>Infants of diabetic mothers</p> <p>Athletic training</p> Amyloid (AL/prealbumin)</td> <td> <p>Myocarditis (infective/toxic/immune)</p> <p>Kawasaki disease</p> <p>Eosinophilic (Churg Strauss syndrome)</p> <p>Viral persistence</p> <p>Drugs</p> <p>Pregnancy</p> <p>Endocrine</p> <p>Nutritional - thiamine, carnitine, selenium, hypophosphataemia, hypocalcaemia</p> <p>Alcohol</p> Tachycardiomyopathy</td> <td>Inflammation?</td> <td> <p>Amyloid (AL/prealbumin)</p> <p>Scleroderma</p> Endomyocardial fibrosis <ul> <li>Hypereosinophilic syndrome </li> <li>Idiopathic </li> <li>Chromosomal cause </li> <li>Drugs (serotonin, methysergide, ergotamine, mercurial agents, busulfan) </li> </ul> <p>Carcinoid heart disease</p> <p>Metastatic cancers</p> <p>Radiation</p> Drugs (anthracyclines)</td> <td>Takotsubo cardiomyopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; ARVC: arrhythmogenic right ventricular cardiomyopathy; RCM: restrictive cardiomyopathy.</div><div class=\"graphic_reference\">Reproduced with permission from: Elliott P, Anderson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial disease. Eur Heart J 2008; 29:270. Copyright &copy; 2008 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 74268 Version 12.0</div></div></div>"},"74269":{"type":"graphic_table","displayName":"Characteristics of SCA types","title":"Characteristics of the autosomal dominant spinocerebellar ataxias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of the autosomal dominant spinocerebellar ataxias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Distinguishing features</td> <td class=\"subtitle1\" colspan=\"2\">Gene locus and protein</td> </tr> <tr> <td>SCA1</td> <td>Pyramidal signs, peripheral neuropathy</td> <td>ATXN1</td> <td>CAG repeat, ataxin-1</td> </tr> <tr> <td>SCA2</td> <td>Slow saccades; less often myoclonus, areflexia</td> <td>ATXN2</td> <td>CAG repeat, ataxin-2</td> </tr> <tr> <td>SCA3 (MJD)</td> <td>Slow saccades, persistent stare, extrapyramidal signs, peripheral neuropathy</td> <td>ATXN3</td> <td>CAG repeat, ataxin-3 (MJD1)</td> </tr> <tr> <td>SCA4</td> <td>Sensory neuropathy</td> <td>16q22.1</td> <td>&nbsp;</td> </tr> <tr> <td>SCA5</td> <td>Early onset but slow progression</td> <td>SPTBN2</td> <td>Beta III spectrin</td> </tr> <tr> <td>SCA6</td> <td>May have very late onset, mild, may lack family history, nystagmus</td> <td>CACNA1A</td> <td>CAG repeat, alpha 1A P/Q calcium channel subunit</td> </tr> <tr> <td>SCA7</td> <td>Macular degeneration</td> <td>ATXN7</td> <td>CAG repeat, ataxin-7</td> </tr> <tr> <td>SCA8</td> <td>Mild disease</td> <td> <p>ATXN8</p> ATXN8OS</td> <td>CTG*CAG repeat</td> </tr> <tr> <td>SCA9</td> <td>Not assigned</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>SCA10</td> <td>Generalized or complex partial seizures</td> <td>ATXN10</td> <td>ATTCT repeat, ataxin-10</td> </tr> <tr> <td>SCA11</td> <td>Mild disease</td> <td>TTBK2</td> <td>Tau tubulin kinase-2</td> </tr> <tr> <td>SCA12</td> <td>Tremor, dementia</td> <td>PPP2R2B</td> <td>CAG repeat in 5' region, protein phosphatase 2A</td> </tr> <tr> <td>SCA13</td> <td>Mental retardation</td> <td>KCNC3</td> <td>Voltage gated potassium channel KCNC3</td> </tr> <tr> <td>SCA14</td> <td>Intermittent myoclonus with early onset disease</td> <td>PRKCG</td> <td>Protein kinase C gamma</td> </tr> <tr> <td>SCA15/16</td> <td>Slowly progressive</td> <td>ITPR1</td> <td>Inositol 1,4,5-triphosphate receptor 1</td> </tr> <tr> <td>SCA17</td> <td>Gait ataxia, dementia</td> <td>TBP</td> <td>CAG repeats, TATA binding protein</td> </tr> <tr> <td>SCA18</td> <td>Pyramidal signs, weakness, sensory axonal neuropathy</td> <td>7q22-q32</td> <td>&nbsp;</td> </tr> <tr> <td>SCA19/22</td> <td>Predominantly cerebellar syndrome, sometimes with cognitive impairment or myoclonus</td> <td>KCND3 gene</td> <td>Voltage-gated potassium channel Kv4.3</td> </tr> <tr> <td>SCA20</td> <td>Palatal tremor and dysphonia</td> <td>11q12</td> <td>&nbsp;</td> </tr> <tr> <td>SCA21</td> <td>Mild to severe cognitive impairment</td> <td>TMEM240</td> <td>Transmembrane protein 240</td> </tr> <tr> <td>SCA23</td> <td>Distal sensory deficits</td> <td>PDYN</td> <td>Prodynorphin</td> </tr> <tr> <td>SCA24</td> <td>Recessive inheritance; redesignated as SCAR4</td> <td>1p36</td> <td>&nbsp;</td> </tr> <tr> <td>SCA25</td> <td>Sensory neuropathy, facial tics, gastrointestinal symptoms</td> <td>2p21-p13</td> <td>&nbsp;</td> </tr> <tr> <td>SCA26</td> <td>Pure cerebellar ataxia</td> <td>EEF2</td> <td>Eukaryotic translation elongation factor 2</td> </tr> <tr> <td>SCA27</td> <td>Cognitive impairment</td> <td>FGF14</td> <td>Fibroblast growth factor 14</td> </tr> <tr> <td>SCA28</td> <td>Ophthalmoparesis and ptosis</td> <td>AFG3L2</td> <td>Catalytic subunit of the mitochondrial AAA protease</td> </tr> <tr> <td>SCA29</td> <td>Early onset, nonprogressive ataxia; may be an allelic variant of SCA15</td> <td>3p26</td> <td>&nbsp;</td> </tr> <tr> <td>SCA30</td> <td>Slowly progressive, relatively pure ataxia</td> <td>4q34.3-q35.1</td> <td>&nbsp;</td> </tr> <tr> <td>SCA31</td> <td>Decreased muscle tone</td> <td>BEAN</td> <td>(TGGAA)n repeat</td> </tr> <tr> <td>SCA32</td> <td>Cognitive impairment, affected males with azoospermia and testicular atrophy</td> <td>7q32-q33</td> <td>&nbsp;</td> </tr> <tr> <td>SCA33</td> <td>Not assigned</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>SCA34</td> <td>Skin lesions consisting of papulosquamous erythematous ichthyosiform plaques</td> <td>ELOVL4</td> <td>ELOVL fatty acid elongase 4</td> </tr> <tr> <td>SCA35</td> <td>Late onset, slowly progressive gait and limb ataxia</td> <td>TGM6</td> <td>Transglutaminase 6</td> </tr> <tr> <td>SCA36</td> <td>Late onset, truncal ataxia, dysarthria, variable motor neuron disease and sensorineural hearing loss</td> <td>NOP56</td> <td>GGCCTG repeat</td> </tr> <tr> <td>SCA37</td> <td>Late onset, falls, dysarthria, clumsiness, abnormal vertical eye movements</td> <td>1p32</td> <td>&nbsp;</td> </tr> <tr> <td>SCA38&nbsp;</td> <td>Slowly progressive pure cerebellar phenotype</td> <td>ELOVL5</td> <td>ELOVL fatty acid elongase 5</td> </tr> <tr> <td>SCA39</td> <td>Not assigned</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>SCA40</td> <td>Hyperreflexia and spasticity</td> <td>CCDC88</td> <td>Coiled-coil domain-containing 88C</td> </tr> <tr> <td>DRPLA</td> <td>Chorea, seizures, myoclonus, dementia</td> <td>ATN1</td> <td>CAG repeat, atrophin-1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DRPLA: dentatorubral pallidoluysian atrophy; MJD: Machado-Joseph disease; SCA: spinocerebellar ataxia.</div><div class=\"graphic_reference\">Data from: <A href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim\" target=_blank>Online Mendelian Inheritance in Man</A>&nbsp;and <A spellcheck=true href=\"http://neuromuscular.wustl.edu/ataxia/domatax.html\">Neuromuscular Disease Center, Washington University</A>.</div><div id=\"graphicVersion\">Graphic 74269 Version 11.0</div></div></div>"},"74270":{"type":"graphic_diagnosticimage","displayName":"ERCP ascaris infestation","title":"Ascaris infestation of the bile duct","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Ascaris infestation of the bile duct</div><div class=\"cntnt\"><img style=\"width:509px; height:251px;\" src=\"images/PEDS/74270_ERCP_ascaris_infestation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Contrast injected into the papilla of vater shows ascaris worms obstructing the common bile duct and impinging on the main pancreatic duct. B) The worms are removed using a tripod basket.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK, 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 74270 Version 2.0</div></div></div>"},"74272":{"type":"graphic_diagnosticimage","displayName":"Pancreatic imaging in SDS","title":"Pancreatic imaging in Shwachman-Diamond syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic imaging in Shwachman-Diamond syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:463px;\" src=\"images/PEDS/74272_Pancreatic_imaging_in_SDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal pancreas in a seven-year-old girl. A transverse sonogram of the upper abdomen shows the normal pancreas (arrows), which is isoechoic to liver. <br />(B)&nbsp;Pancreas in a three-year old boy with Shwachman-Diamond syndrome. Transverse sonogram of the upper abdomen reveals an enlarged, diffusely echogenic pancreas (arrows) due to fatty infiltration. Note normal adjacent liver (L).<br />(C) Normal pancreas in a 16-year-old girl. A transverse computed tomography image demonstrates a normal pancreas. The density of the pancreas (arrows) is similar to liver. <br />(D)&nbsp;Pancreas in a five-year-old boy with Shwachman-Diamond syndrome. Transverse contrast-enhanced computed tomography image shows diffuse fatty infiltration of the pancreas (arrowheads). Similar computed tomography findings can be seen with cystic fibrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Shimamura A. Schwachman-Diamond Syndrome. Seminars in Hematology 2006; 43:178. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 74272 Version 4.0</div></div></div>"},"74274":{"type":"graphic_diagnosticimage","displayName":"Chagas heart radionuclide angio","title":"Radionuclide angiogram in chronic Chagas disease","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Radionuclide angiogram in chronic Chagas disease</div><div class=\"cntnt\"><img style=\"width:452px; height:290px;\" src=\"images/CARD/74274_Chagas_heart_radionuclide_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient has chronic Chagas disease and megesophagus but no clinical signs of cardiac invovlvement. The radionuclide angiogram shows preservation of left ventricular function but moderate right ventricular dysfunction with an ejection fraction (EF) of 37 percent.</div><div id=\"graphicVersion\">Graphic 74274 Version 3.0</div></div></div>"},"74275":{"type":"graphic_picture","displayName":"Abnormally short frenulum","title":"Abnormally short frenulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormally short frenulum</div><div class=\"cntnt\"><img style=\"width:379px; height:363px;\" src=\"images/PEDS/74275_Abnormallyshortfrenulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormally short frenulum, inserting at or near the tip of the tongue.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 74275 Version 2.0</div></div></div>"},"74278":{"type":"graphic_picture","displayName":"Melanoma- superficial spreading","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74278_Melanoma_superfic_spread.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial spreading melanoma showing asymmetry, border irregularities, and variegation of color.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74278 Version 5.0</div></div></div>"},"74279":{"type":"graphic_picture","displayName":"Skin lesions of disseminated fusariosis","title":"Skin lesions of disseminated fusariosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesions of disseminated fusariosis</div><div class=\"cntnt\"><img style=\"width:272px; height:450px;\" src=\"images/ID/74279_Skinlesionsdissemfus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin lesions of disseminated fusariosis diagnosed in a patient after allogeneic hematopoietic stem cell transplantation.</div><div class=\"graphic_reference\">Reproduced with permission from: Steinbach WJ, Marr KA. Mold infections after hematopoeitic stem cell transplantation. In: Transplant Infections, 3rd Ed, Bowden RA, Ljungman P, Snydman DR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74279 Version 8.0</div></div></div>"},"74280":{"type":"graphic_table","displayName":"Diagnosis gonadotroph adenoma","title":"Hormonal criteria for the diagnosis of gonadotroph adenomas* (any one or combination of the following)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormonal criteria for the diagnosis of gonadotroph adenomas* (any one or combination of the following)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Men</td> <td class=\"subtitle1\">Women</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Supranormal basal serum concentrations</strong></td> <td> <p>FSH<sup>&#182;</sup></p> <p>alpha, LH-beta, or FSH-beta subunits</p> LH and testosterone</td> <td> <p>FSH but not LH</p> Any subunit relative to intact FSH and LH</td> </tr> <tr> <td><strong>Supranormal response to TRH</strong></td> <td> <p>FSH</p> <p>LH</p> LH-beta (most common)</td> <td> <p>FSH</p> <p>LH</p> LH-beta (most common)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone; TRH: thyrotropin-releasing hormone.<br />* Assuming the patient has a sellar mass.<br />¶ Assuming the patient does not have a history of primary hypogonadism.</div><div id=\"graphicVersion\">Graphic 74280 Version 6.0</div></div></div>"},"74281":{"type":"graphic_picture","displayName":"Microfollicular adenoma FNA","title":"Microfollicular adenoma: Findings on fine needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microfollicular adenoma: Findings on fine needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/ENDO/74281_Microfollicular_adenoma_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate of a thyroid nodule showing microfollicles with little or no colloid in the backround. There is no clumping or pleomorphism. Nevertheless, surgical excision was advised because of the microfollicular pattern. The nodule was benign.</div><div id=\"graphicVersion\">Graphic 74281 Version 2.0</div></div></div>"},"74282":{"type":"graphic_picture","displayName":"Stenosis after bypass","title":"Stomal stenosis after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stomal stenosis after gastric bypass</div><div class=\"cntnt\"><img style=\"width:400px; height:324px;\" src=\"images/GAST/74282_Stenosis_after_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moderate stomal stenosis after gastric bypass.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 74282 Version 4.0</div></div></div>"},"74283":{"type":"graphic_waveform","displayName":"Persistent ST segment elevation post-MI","title":"Persistent ST segment elevation post-MI","html":"<div class=\"graphic normal\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Persistent ST segment elevation post-MI</div><div class=\"cntnt\"><img style=\"width:526px; height:158px;\" src=\"images/CARD/74283_Aneurysm_post_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of an anterior wall aneurysm following an acute myocardial infarction is suspected because of persistent ST elevation in leads V2 to V4. Inverted T waves are evidence of the old infarct.</div><div id=\"graphicVersion\">Graphic 74283 Version 5.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"74286":{"type":"graphic_waveform","displayName":"EP study tracings AF","title":"Intracardiac and surface ECG recordings during electrophysiologic study in a person with atrial fibrillation (AF)","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface ECG recordings during electrophysiologic study in a person with atrial fibrillation (AF)</div><div class=\"cntnt\"><img style=\"width:534px; height:398px;\" src=\"images/CARD/74286_Electrogram_atrial_fibrilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the atrioventricular (AV) junction region (HBE1-2, HBE3-4), and the right ventricular apex (RVA3-4) in a patient with atrial fibrillation. The patient has extremely symptomatic, medically refractory atrial fibrillation with rapid ventricular rates and recurrent heart failure. The mapping catheter (HBE) has been maneuvered from the area of maximal His bundle activity to a more proximal position, where a larger atrial (A) and smaller His electrogram (H) are recorded.</div><div class=\"graphic_footnotes\">V: ventricular electrogram.</div><div id=\"graphicVersion\">Graphic 74286 Version 4.0</div></div></div>"},"74287":{"type":"graphic_diagnosticimage","displayName":"Caustic esophageal stricture","title":"Esophageal stricture after caustic ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal stricture after caustic ingestion</div><div class=\"cntnt\"><img style=\"width:435px; height:214px;\" src=\"images/PEDS/74287_Caustic_esophageal_strictur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows an esophageal stricture six weeks after lye ingestion. A gastrostomy with retrograde string placement was performed with multiple dilatations by string bougie. The patient was able to eat normally for two to three weeks after each dilatation, but required monthly dilatation. Right panel shows the stricture after two years and multiple dilatations. A colonic replacement was performed shortly after the last study.</div><div class=\"graphic_reference\">Courtesy of George D Ferry, MD.</div><div id=\"graphicVersion\">Graphic 74287 Version 2.0</div></div></div>"},"74289":{"type":"graphic_picture","displayName":"Diffuse choroidal hemangioma in SWS","title":"Diffuse choroidal hemangioma (capillary-venous malformation) in a patient with Sturge-Weber syndrome and glaucoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse choroidal hemangioma (capillary-venous malformation) in a patient with Sturge-Weber syndrome and glaucoma</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/PEDS/74289_Sturge-Weber_glaucoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of a diffuse capillary-venous malformation in a patient with Sturge-Weber syndrome. Note \"tomato catsup\" appearance to fundus and increased cupping of the optic nerve head.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74289 Version 3.0</div></div></div>"},"74290":{"type":"graphic_figure","displayName":"Viral infection cardiomyopathy","title":"Virus-immune hypothesis in dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Virus-immune hypothesis in dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:396px; height:321px;\" src=\"images/CARD/74290_Viral_infection_cardiomyopa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following acute viral myocarditis, subjects who are not genetically predisposed to autoimmunity develop a self-limited disease and recover completely. In contrast, in individuals with a genetic predisposition to autoimmunity, a viral infection may initiate a chronic autoimmune myocarditis leading to dilated cardiomyopathy.</div><div class=\"graphic_reference\">Data from Caforio ALP, Baboonian C, McKenna WJ. Eur Heart J 1997; 18:1053.</div><div id=\"graphicVersion\">Graphic 74290 Version 2.0</div></div></div>"},"74291":{"type":"graphic_figure","displayName":"Buddy taping of the toes","title":"Buddy taping of the toes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buddy taping of the toes</div><div class=\"cntnt\"><img style=\"width:180px; height:257px;\" src=\"images/EM/74291_Buddy_taping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fractured toe is secured to the adjacent toe with adhesive strips. Sheet wadding between the toes helps to prevent maceration.</div><div id=\"graphicVersion\">Graphic 74291 Version 3.0</div></div></div>"},"74294":{"type":"graphic_picture","displayName":"Reticulocytosis","title":"Reticulocytes after supravital staining","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reticulocytes after supravital staining</div><div class=\"cntnt\"><img style=\"width:386px; height:252px;\" src=\"images/HEME/74294_Reticulocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supravital stain of a peripheral blood smear shows blue-stained residual reticulin (ribosomal RNA) in reticulocytes.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 74294 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"74299":{"type":"graphic_table","displayName":"Symptoms and signs leptomeningeal metastases","title":"Symptoms and signs of leptomeningeal metastases from solid tumors at presentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of leptomeningeal metastases from solid tumors at presentation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Symptom, percent</td>\n\n      \n\n      <td class=\"subtitle1\">Sign, percent</td>\n\n      \n\n    </tr>\n\n      <tr>\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Cerebral hemisphere</td>\n    </tr> \n\n    <tr>\n\n      <td class=\"indent1\"><p>Headache, 33</p>\n\t\t\t<p>Mental change, 17</p>\n\t\t\t<p>Difficulty walking, 13</p>\n\t\t\t<p>Nausea/vomiting, 11</p>\n\t\t\t<p>Unconsciousness, 2</p>\n\t\t\t<p>Dysphagia, 2</p>\n\t\t\t<p>Dizziness, 2</p></td>\n\n      <td><p>Mental status change, 31</p>\n\t\t\t<p>Seizures, 6</p>\n\t\t\t<p>- Focal, 6</p>\n\t\t\t<p>- General, 3</p>\n\t\t\t<p>Sensory disturbance, 6</p>\n\t\t\t<p>Diabetes insipidus, 2</p>\n\t\t\t<p>Hemiparesis, 1</p></td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Cranial nerves</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"><p>Diplopia, 20</p>\n\t\t\t<p>Hearing loss, 8</p>\n\t\t\t<p>Visual loss, 6</p>\n\t\t\t<p>Facial numbness, 6</p>\n\t\t\t<p>Decreased hearing, 3</p>\n\t\t\t<p>Tinnitus, 2</p>\n\t\t\t<p>Hoarseness, 2</p>\n\t\t\t<p>Dysphagia, 1</p>\n\t\t\t<p>Vertigo, 1</p></td>\n\n      \n\n      <td><p>Oculomotor paresis (III, IV, VI), 20</p>\n\t\t\t<p>Facial weakness (VII), 18</p>\n\t\t\t<p>Diminished hearing (VIII), 9</p>\n\t\t\t<p>Optic neuropathy (II), 6</p>\n\t\t\t<p>Trigeminal neuropathy (V), 6</p>\n\t\t\t<p>Hypoglossal neuropathy (XII), 6</p>\n\t\t\t<p>Blindness (II), 3</p>\n\t\t\t<p>Diminished gag reflex (IX, X), 3</p></td>\n\n      \n\n    </tr>\n\n   \n    <tr>\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Spinal roots, meninges</td>\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\"><p>Weakness, 37</p>\n\t\t\t<p>Paresthesias, 34</p>\n\t\t\t<p>Back/neck pain, 21</p>\n\t\t\t<p>Radicular pain, 26</p>\n\t\t\t<p>Bladder/bowel dysfunction, 13</p></td>\n\n      \n\n      <td><p>Reflex asymmetry, 71</p>\n\t\t\t<p>Motor weakness, 60</p>\n\t\t\t<p>Sensory loss, 27</p>\n\t\t\t<p>Pain on straight leg raising, 12</p>\n\t\t\t<p>Decreased rectal tone, 11</p>\n\t\t\t<p>Nuchal rigidity, 7</p></td>\n\n      \n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from data from: Wasserstrom W, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982;49:759-772. Percentages based on entire series.</div><div id=\"graphicVersion\">Graphic 74299 Version 2.0</div></div></div>"},"74301":{"type":"graphic_picture","displayName":"Angiodysplasia colon light","title":"Angiodysplasia of the colon","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiodysplasia of the colon</div><div class=\"cntnt\"><img style=\"width:287px; height:349px;\" src=\"images/GAST/74301_Angiodysplasia_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a colonic biopsy in angiodysplasia shows mucosal and submucosal vascular dilatation and congestion.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 74301 Version 2.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"74302":{"type":"graphic_table","displayName":"Mania versus depression","title":"Differentiating dysphoric mania from depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiating dysphoric mania from depression</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Dysphoric mania</td>\n\t\t\t\t\t<td class=\"subtitle1\">Depression</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Rage</td>\n\t\t\t\t\t<td>Mild irritability</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Poor insight into condition</td>\n\t\t\t\t\t<td>Good insight into condition</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased energy</td>\n\t\t\t\t\t<td>Fatigued</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hypersexuality</td>\n\t\t\t\t\t<td>Loss of sexual interest</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Grandiose plans</td>\n\t\t\t\t\t<td>Diminished expectations</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased speech production</td>\n\t\t\t\t\t<td>Diminished speech production</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased rate of speech</td>\n\t\t\t\t\t<td>Decreased rate of speech</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased use of telephone</td>\n\t\t\t\t\t<td>Decreased desire for social contact</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Flamboyant style of dress</td>\n\t\t\t\t\t<td>Drab clothing</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Psychosis relatively common</td>\n\t\t\t\t\t<td>Psychosis relatively uncommon</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Raison, Charles L, Demetrashvili, Marina, Capuron, Lucile, Miller, Andrew H. Neuropsychiatric adverse effects of interferon-[alpha]: Recognition and Management. CNS Drugs 2005; 19:105. Copyright &#169;2005 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 74302 Version 2.0</div></div></div>"},"74304":{"type":"graphic_table","displayName":"ISTH DIC scoring system","title":"International Society on Thrombosis and Haemostasis (ISTH) scoring system for disseminated intravascular coagulation (DIC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Society on Thrombosis and Haemostasis (ISTH) scoring system for disseminated intravascular coagulation (DIC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\"> <li>Risk assessment: Does the patient have an underlying disorder known to be associated with overt DIC?* </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul class=\"decimal_heading\"> <li>If yes, proceed. </li> <li>If no, do not use this scoring system. </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Obtain the following laboratory tests: </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul class=\"decimal_heading\"> <li>Platelet count </li> <li>Fibrin-related markers (eg, fibrin degradation products [FDPs], soluble fibrin monomers, D-dimer<sup>&#182;</sup>) </li> <li>Prothrombin time (PT) </li> <li>Fibrinogen </li> </ul> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li><strong>Assign score for each laboratory parameter:</strong> </li> </ol> </td> <td><strong>Score:</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Platelet count (per microL):</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>&#62;100,000 </li> </ul> </td> <td>0</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>50,000 to 100,000 </li> </ul> </td> <td>1</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>&#60;50,000/microL = </li> </ul> </td> <td>2</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Fibrin-related markers (eg, FDPs, D-dimer<sup>&#182;</sup>):</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>No increase </li> </ul> </td> <td>0</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Moderate increase </li> </ul> </td> <td>2</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Strong increase </li> </ul> </td> <td>3</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">PT:</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Prolonged &#60;3 seconds </li> </ul> </td> <td>0</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Prolonged 3 to 6 seconds </li> </ul> </td> <td>1</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Prolonged &#62;6 seconds </li> </ul> </td> <td>2</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Fibrinogen level:</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>&#62;100 mg/dL (&#62;1.0 g/L) </li> </ul> </td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <ul> <li>&#60;100 mg/dL (&#62;100 g/L) </li> </ul> </td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Calculate total score: Add individual scores for each laboratory parameter. </li> </ol> </td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Score interpretation: </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul class=\"decimal_heading\"> <li>&#8805;5: Compatible with overt DIC. Repeat scoring daily. </li> <li>&#60;5: Suggestive (not affirmative) for non-overt DIC. Repeat in 1 to 2 days. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Causes of DIC in children include infection, trauma, burns, malignancy, acute and chronic liver disease (including Reye syndrome), microangiopathic disorders (eg, Kasabach-Merritt syndrome), and congenital thrombotic disorders (eg, homozygous deficiencies of protein C and S, antithrombin III deficiency). Additional causes in neonates include birth asphyxia, respiratory distress syndrome, meconium aspiration, amniotic fluid aspiration, necrotizing enterocolitis.<br />&para; Although D-dimer is not explicitly included in this scoring system, elevated D-dimer is a strong indicator of fibrinolysis and is more specific than FDPs.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor FB, Toh CH, Hoots WK, et al. Towards definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation. Thromb Haemost 2001; 86:1327. Copyright &copy; 2001 Schattauer GmbH.</div><div id=\"graphicVersion\">Graphic 74304 Version 14.0</div></div></div>"},"74308":{"type":"graphic_picture","displayName":"Fusarium hematoxylin and eosin stain","title":"<EM>Fusarium</EM> hematoxylin and eosin stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium</EM> hematoxylin and eosin stain</div><div class=\"cntnt\"><img style=\"width:384px; height:288px;\" src=\"images/ID/74308_Fusar_hematox_eosin_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hematoxylin and eosin stain of a skin biopsy showing septate hyaline hyphae branching at acute angles of 45°.</div><div id=\"graphicVersion\">Graphic 74308 Version 4.0</div></div></div>"},"74309":{"type":"graphic_picture","displayName":"M leprae in skin during and after treatment","title":"Decline of <em>Mycobacterium leprae</em> in skin during and after treatment","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Decline of <em>Mycobacterium leprae</em> in skin during and after treatment</div><div class=\"cntnt\"><img style=\"width:520px; height:596px;\" src=\"images/ID/74309_Decline_M_leprae_skin_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative portions of sequential, annual biopsies of skin lesions from one lepromatous patient are shown, starting with the initial, pretreatment biopsy (t = 0). The patient was treated with the National Hansen's Disease Program recommended multidrug treatment (MDT) regimen of daily rifampin, dapsone, and clofazimine. Bacterial morphology had changed at&nbsp;one year; organisms are numerous but show evidence of degeneration. Treatment was discontinued at the time of the biopsy taken at&nbsp;two years. The bacterial load continued to decline slowly after MDT was discontinued, but rare organisms could still be observed after&nbsp;six years. Clinically, the cutaneous lesions resolved and did not relapse. (Fite stains, all at 1000x magnification.)</div><div class=\"graphic_footnotes\">yr: year.<br />* Treatment was stopped after&nbsp;two years.</div><div id=\"graphicVersion\">Graphic 74309 Version 6.0</div></div></div>"},"74310":{"type":"graphic_picture","displayName":"Steroid-induced acne","title":"Steroid-induced acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Steroid-induced acne</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/74310_Steroid_induced_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright ©2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74310 Version 2.0</div></div></div>"},"74312":{"type":"graphic_picture","displayName":"Omental cake ovarian CA","title":"Ovarian cancer metastatic to the omentum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian cancer metastatic to the omentum</div><div class=\"cntnt\"><img style=\"width:420px; height:288px;\" src=\"images/ONC/74312_Omental_cake_ovarian_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large omental cake (C) overlying small bowel.</div><div class=\"graphic_reference\">Courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 74312 Version 1.0</div></div></div>"},"74313":{"type":"graphic_table","displayName":"Neonatal risk factors: SNHL or AN","title":"Risk factors for sensorineural hearing loss or auditory neuropathy in the newborn","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for sensorineural hearing loss or auditory neuropathy&nbsp;in the newborn</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Acquired prenatal factors</td> </tr> <tr> <td>Perinatal infections (CMV, syphilis, toxoplasmosis, rubella, HIV, Zika virus)</td> </tr> <tr> <td>Maternal diabetes</td> </tr> <tr> <td>Prenatal medication (antimalarials, aminoglycosides, isotretinoin)</td> </tr> <tr> <td><span class=\"subtitle5\">Maternal substance use disorder</span></td> </tr> <tr> <td>Lack of prenatal care</td> </tr> <tr> <td class=\"subtitle1\">Acquired postnatal factors</td> </tr> <tr> <td>Very low birth weight (&#60;1500 g)</td> </tr> <tr> <td>Perinatal ischemia/asphyxia</td> </tr> <tr> <td>Severe hyperbilirubinemia (requiring exchange transfusion)</td> </tr> <tr> <td> <p>Other:</p> <p class=\"indent2\">Low Apgar score (&#60;4 at one min or &#60;6 at five min)</p> <p class=\"indent2\">Mechanical ventilation &#62;5 days</p> <p class=\"indent2\">Meningitis (bacterial, fungal)</p> <p class=\"indent2\">Ototoxic medications (aminoglycosides,* diuretics)</p> <p class=\"indent2\">ECMO</p> <p class=\"indent2\">PPHN</p> <p class=\"indent2\">Hypothyroidism</p> </td> </tr> <tr> <td class=\"subtitle1\">Genetic disorders<sup>&#182;</sup></td> </tr> <tr> <td>Autosomal recessive (eg, mutations in the <em>GJB2</em> gene)</td> </tr> <tr> <td>Autosomal dominant (eg, Waardenburg syndrome)</td> </tr> <tr> <td>X-linked (eg, X-linked congenital sensorineural hearing loss)</td> </tr> <tr> <td>Mitochondrial (eg, Kearns-Sayre syndrome)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus infection; HIV: human immunodeficiency virus; ECMO: extracorporeal membrane oxygenation; PPHN: persistent pulmonary hypertension of the newborn.<br />* Certain genetic predispositions appear to increase an infant's risk of aminoglycoside-related hearing loss.<br />¶ Refer to UpToDate content on the etiology of hearing impairment in children and hereditary disorders related to hearing impairment.</div><div id=\"graphicVersion\">Graphic 74313 Version 6.0</div></div></div>"},"74315":{"type":"graphic_picture","displayName":"Great toe digital block II","title":"Great toe digital block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Great toe digital block</div><div class=\"cntnt\"><img style=\"width:370px; height:278px;\" src=\"images/EM/74315_Digital_block_great_toe_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform a three-sided toe block or four-sided ring block, insert the needle just distal to the MTP (metatarsal/phalangeal) joint at the lateral edge of the toe. Slowly advance the needle straight from the dorsal to the plantar surface, injecting as the needle is advanced. This picture shows the position of the needle after it has been advanced.</div><div class=\"graphic_reference\">Courtesy of Robert Baldor, MD.</div><div id=\"graphicVersion\">Graphic 74315 Version 3.0</div></div></div>"},"74317":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis of childhood on genitalia","title":"Linear IgA bullous dermatosis of childhood","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis of childhood</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74317_Line_IgA_bull_der_ch_genit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tense vesicles and bullae are present on the vulvar skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74317 Version 3.0</div></div></div>"},"74319":{"type":"graphic_table","displayName":"Side effects TCAs","title":"Side effects of tricyclic antidepressants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects of tricyclic antidepressants</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Anticholinergic</td></tr>\n\t\t\t\t\t\t<tr><td>Dry mouth</td></tr>\n\t\t\t\t\t\t<tr><td>Constipation</td></tr>\n\t\t\t\t\t\t<tr><td>Urinary retention</td></tr>\n\t\t\t\t\t\t<tr><td>Blurred vision</td></tr>\n\t\t\t\t\t\t<tr><td>Paralytic ileus</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Cardiovascular</td></tr>\n\t\t\t\t\t\t<tr><td>Tachycardia</td></tr>\n\t\t\t\t\t\t<tr><td>Palpitations</td></tr>\n\t\t\t\t\t\t<tr><td>Arrhythmias</td></tr>\n\t\t\t\t\t\t<tr><td>Hypertension</td></tr>\n\t\t\t\t\t\t<tr><td>Hypotension</td></tr>\n\t\t\t\t\t\t<tr><td>Heart block</td></tr>\n\t\t\t\t\t\t<tr><td>Myocardial infarction</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Gastrointestinal</td></tr>\n\t\t\t\t\t\t<tr><td>Nausea</td></tr>\n\t\t\t\t\t\t<tr><td>Vomiting</td></tr>\n\t\t\t\t\t\t<tr><td>Dyspepsia</td></tr>\n\t\t\t\t\t\t<tr><td>Anorexia</td></tr>\n\t\t\t\t\t\t<tr><td>Altered taste</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Neurologic</td></tr>\n\t\t\t\t\t\t<tr><td>Ataxia</td></tr>\n\t\t\t\t\t\t<tr><td>Tremors</td></tr>\n\t\t\t\t\t\t<tr><td>Paresthesias</td></tr>\n\t\t\t\t\t\t<tr><td>Mental clouding</td></tr>\n\t\t\t\t\t\t<tr><td>Sedation</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74319 Version 1.0</div></div></div>"},"74320":{"type":"graphic_picture","displayName":"Gangrene due to RV","title":"Gangrene of the foot and toes resulting from rheumatoid vasculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gangrene of the foot and toes resulting from rheumatoid vasculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/RHEUM/74320_Gangrene_due_to_RV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gangrene due to rheumatoid vasculitis.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 74320 Version 2.0</div></div></div>"},"74322":{"type":"graphic_diagnosticimage","displayName":"MRI Chiari III malformation","title":"MRI demonstrating a Chiari III malformation with cervico-occipital encephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI demonstrating a Chiari III malformation with cervico-occipital encephalocele</div><div class=\"cntnt\"><img style=\"width:428px; height:403px;\" src=\"images/NEURO/74322_Chiari_type_III_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal MRI scan shows the bony defect involving the inferior occiput, foramen magnum, and posterior elements of C1 and C2 with herniation of the cerebellum (arrow), dilated posterior aspect of the fourth ventricle (small arrowhead), brainstem, upper cervical cord (large arrowheads), and meninges (dashed arrow) into the posterior sac.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An atlas of differential diagnosis. Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74322 Version 6.0</div></div></div>"},"74323":{"type":"graphic_diagnosticimage","displayName":"Osteitis in congenital syphilis","title":"Congenital syphilis: Osteitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Osteitis</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/PEDS/74323_Osteitis_cong_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the extensive destruction, with metaphyseal (arrows) and diaphyseal radiolucencies throughout the humerus, radius, and ulna. Observe the exuberant periosteal overgrowth, with expansile deformity of the bones of the upper extremity. Syphilitic granulation tissue may extend from the metaphysis to the diaphysis, creating an extension of the infectious focus. Reactive sclerosis often surrounds the osteolytic lesions, with associated periostitis of the long tubular bones.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, 3rd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74323 Version 3.0</div></div></div>"},"74325":{"type":"graphic_diagnosticimage","displayName":"Stenosis subclavian vein","title":"Stenosis subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stenosis subclavian vein</div><div class=\"cntnt\"><img style=\"width:432px; height:223px;\" src=\"images/NEPH/74325_Stenosis_subclavian_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stenosis of the subclavian vein is shown on the left. The appearance of the lesion after treatment with angioplasty is shown on the right.</div><div class=\"graphic_reference\">Courtesy of Gerald Beathard, MD.</div><div id=\"graphicVersion\">Graphic 74325 Version 2.0</div></div></div>"},"74326":{"type":"graphic_picture","displayName":"Cord edema","title":"Cord edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cord edema</div><div class=\"cntnt\"><img style=\"width:432px; height:350px;\" src=\"images/OBGYN/74326_Cord_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 74326 Version 1.0</div></div></div>"},"74328":{"type":"graphic_picture","displayName":"Anatomy male genitalia","title":"Anatomy of the male genitalia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anatomy of the male genitalia</div><div class=\"cntnt\"><img style=\"width:504px; height:281px;\" src=\"images/PEDS/74328_Anatomy_male_genitalia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Girardin, BW, Faugno, DK, Seneski, PC, et al. Color Atlas of Sexual Assault. Mosby-Year Book, Inc. 1997:12. Copyright &#169; 1997 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 74328 Version 1.0</div></div></div>"},"74329":{"type":"graphic_algorithm","displayName":"Female infants UTI","title":"Diagnostic algorithm for febrile female infants aged 3 to 24 months suspected of having a UTI","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for febrile female infants aged 3 to 24 months suspected of having a UTI</div><div class=\"cntnt\"><img style=\"width:540px; height:589px;\" src=\"images/PEDS/74329_Female_infants_UTI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; LR: likelihood ratio.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaikh N, Morone NE, Lopez L, et al. Does this child have a urinary tract infection? JAMA 2008; 298:2895. Copyright &#169; 2008 American Medical Association.</div><div id=\"graphicVersion\">Graphic 74329 Version 3.0</div></div></div>"},"74330":{"type":"graphic_diagnosticimage","displayName":"Frykman I radius fracture lateral view","title":"Frykman I radius fracture lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frykman I radius fracture lateral view</div><div class=\"cntnt\"><img style=\"width:288px; height:432px;\" src=\"images/EM/74330_Frykman_I_lateral_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the lateral x-ray of the same fracture, the angulation and dorsal displacement of the distal fragment is apparent. Such fractures are often referred to by the eponym Colles. Note this is not a true lateral: the images of the radius and ulna are not superimposed, and the pisiform (arrow) is seen dorsal to the distal pole of the scaphoid.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 74330 Version 5.0</div></div></div>"},"74331":{"type":"graphic_table","displayName":"AIP HISORt criteria","title":"Summary of criteria for diagnosing autoimmune pancreatitis (revised HISORt criteria)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of criteria for diagnosing autoimmune pancreatitis (revised HISORt criteria)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td><strong><span class=\"red\">(H)</span> Histology</strong> suggestive of autoimmine pancreatitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong><span class=\"red\">(I)</span></strong> Pancreatic <strong>imaging</strong> suggestive of autoimmine pancreatitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong><span class=\"red\">(S)</span> Serology</strong> (IgG4 &#8805;2 times the upper limit of normal)</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong><span class=\"red\">(O)</span></strong> <strong>Other</strong> organ involvement</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Biliary strictures, parotid/lacrimal gland involvement, mediastinal lymphadenopathy, retroperitoneal fibrosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong><span class=\"red\">(Rt)</span>&nbsp;Response to steroid treatment</strong>&nbsp;- Resolution/marked improvement of pancreatic and extrapancreatic manifestations</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Adapted from: Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7:1097.</div><div id=\"graphicVersion\">Graphic 74331 Version 4.0</div></div></div>"},"74332":{"type":"graphic_table","displayName":"Indications for IDUS","title":"Indications for intraductal ultrasound","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for intraductal ultrasound</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Biliary tract</td>\n</tr>\n<tr>\n<td>1. Suspected but undetected choledocholithiasis</td>\n</tr>\n<tr>\n<td>2. Distinguish benign from malignant bile duct strictures</td>\n</tr>\n<tr>\n<td>3. Local tumor staging</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Pancreas</td>\n</tr>\n<tr>\n<td>1. Distinguish benign from malignant pancreatic duct strictures</td>\n</tr>\n<tr>\n<td>2. Local tumor staging</td>\n</tr>\n<tr>\n<td>3. Characterize cystic tumors</td>\n</tr>\n<tr>\n<td>4. Localize islet cell tumors not identified by endoscopic ultrasound</td>\n</tr>\n<tr>\n<td>5. Assess for multifocal islet cell tumors in MEN-I</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74332 Version 1.0</div></div></div>"},"74336":{"type":"graphic_figure","displayName":"Effect theophylline withdrawal","title":"Effect of withdrawing theophylline on airway lymphocytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of withdrawing theophylline on airway lymphocytes</div><div class=\"cntnt\"><img style=\"width:433px; height:290px;\" src=\"images/PULM/74336_Effect_theophylline_withdra.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in activated lymphocyte counts in bronchial biopsy specimens of 8 patients in whom theophylline was abruptly withdrawn. Withdrawal of theophylline to placebo was associated with increased activated lymphocytes in bronchial biopsy specimens.</div><div class=\"graphic_reference\">Figure drawn from data published in Kidney, J, Dominguez, M, Taylor, PM, et al. Am J Respir Crit Care Med 1995; 151:1907.</div><div id=\"graphicVersion\">Graphic 74336 Version 1.0</div></div></div>"},"74337":{"type":"graphic_picture","displayName":"Steroid injection skin hypopigmentation","title":"Skin depigmentation following glucocorticoid injection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin depigmentation following glucocorticoid injection</div><div class=\"cntnt\"><img style=\"width:504px; height:431px;\" src=\"images/RHEUM/74337_Steroid_injection_vitiligo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmentation of the skin caused by a glucocorticoid injection of the elbow is apparent in this image.</div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 74337 Version 2.0</div></div></div>"},"74339":{"type":"graphic_table","displayName":"Heart failure classification for children","title":"NYHA and modified Ross heart failure classification for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NYHA and modified Ross heart failure classification for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">&nbsp;</td> <td class=\"subtitle1_single\">NYHA</td> <td class=\"subtitle1_single\">Ross&nbsp;</td> </tr> <tr> <td><strong>Class I</strong></td> <td>No limitations of physical activity</td> <td>No limitations or symptoms&nbsp;</td> </tr> <tr> <td><strong>Class II</strong></td> <td>May experience fatigue, palpitations, dyspnea, or angina during moderate exercise but not during rest</td> <td> <p>Infants: Mild tachypnea or diaphoresis with feeding</p> <p>Older children: Mild to moderate dyspnea on exertion</p> </td> </tr> <tr> <td><strong>Class III</strong></td> <td>Symptoms with minimal exertion that interfere with normal daily activity</td> <td> <p>Infants: Growth failure and marked tachypnea or diaphoresis with feeding</p> <p>Older children: Marked dyspnea on exertion</p> </td> </tr> <tr> <td><strong>Class IV</strong></td> <td>Unable to carry out any physical activity because they typically have symptoms of HF at rest that worsen with any exertion</td> <td>Symptoms at rest such as tachypnea, retractions, grunting, or diaphoresis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HF: Heart failure; NYHA: New York Heart Association.</div><div class=\"graphic_reference\">Reproduced from: Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary [Corrected]. J Heart Lung Transplant 2014; 33:888. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74339 Version 2.0</div></div></div>"},"74340":{"type":"graphic_picture","displayName":"Cutaneous sporotrichosis","title":"Cutaneous sporotrichosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous sporotrichosis</div><div class=\"cntnt\"><img style=\"width:264px; height:248px;\" src=\"images/ID/74340_Cutaneous_sporotrichosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesions on the back of a patient with cutaneous sporotrichosis who was thrown from his truck following a motor vehicle accident.</div><div class=\"graphic_reference\">Courtesy of Carol A. Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 74340 Version 2.0</div></div></div>"},"74345":{"type":"graphic_figure","displayName":"Concentration of sFlt-1 in preeclampsia","title":"Concentration of sFlt-1 in women who developed preeclampsia and normal controls","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Concentration of sFlt-1 in women who developed preeclampsia and normal controls</div><div class=\"cntnt\"><img style=\"width:496px; height:257px;\" src=\"images/OBGYN/74345_Conc_sFlt-1_preeclampsia.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Levine, RJ, Maynard, SE, Qian, C, et al. N Engl J Med 2004; 350:672.</div><div id=\"graphicVersion\">Graphic 74345 Version 2.0</div></div></div>"},"74346":{"type":"graphic_picture","displayName":"Adenocarcinoma colon Endosc","title":"Adenocarcinoma of the colon","html":"<div class=\"graphic normal\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the colon</div><div class=\"cntnt\"><img style=\"width:556px; height:183px;\" src=\"images/GAST/74346_Adenocarcinoma_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adenocarcinoma of the colon may have a variety of appearances on endoscopy. Panel A: a typical exophytic mass; Panel B: a friable polypoid mass; Panel C: circumferential adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 74346 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"74347":{"type":"graphic_diagnosticimage","displayName":"IDUS showing CHD PV HA","title":"Intraductal ultrasound showing a normal common hepatic duct, cystic duct, portal vein, and hepatic artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal ultrasound showing a normal common hepatic duct, cystic duct, portal vein, and hepatic artery</div><div class=\"cntnt\"><img style=\"width:441px; height:323px;\" src=\"images/GAST/74347_IDUS_showing_CHD_PV_HA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal intraductal ultrasound demonstrating the common hepatic duct (CHD), cystic duct, portal vein (PV), and hepatic artery (HA).</div><div class=\"graphic_reference\">Courtesy of Drs. Micheal J Levy, Enrique Vazquez-Sequeiros, and Maurits J Wiersema.</div><div id=\"graphicVersion\">Graphic 74347 Version 4.0</div></div></div>"},"74348":{"type":"graphic_picture","displayName":"Instruments closed reduction nasal fracture","title":"Instruments for the closed reduction of a nasal fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Instruments for the closed reduction of a nasal fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:395px;\" src=\"images/EM/74348_Instr_clos_reduct_nasal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Asch forceps.<br> (B) Vienna speculum.<br> (C) Bayonet forceps.<br> (D) Cottonoid with oxymetazoline.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 74348 Version 2.0</div></div></div>"},"74349":{"type":"graphic_table","displayName":"Joints to be immobilized based on fracture location","title":"Joints to be immobilized based on fracture location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Joints to be immobilized based on fracture location</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Bone</td> <td class=\"subtitle1\">Anatomical location</td> <td class=\"subtitle1\">Sub-location</td> <td class=\"subtitle1\">DIPJ</td> <td class=\"subtitle1\">PIPJ</td> <td class=\"subtitle1\">MCPJ</td> <td class=\"subtitle1\">Wrist</td> <td class=\"subtitle1\">Forearm</td> <td class=\"subtitle1\">Location of splint (dorsal/volar)</td> </tr> <tr> <td rowspan=\"4\">Distal phalanx</td> <td>Tuft</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Shaft</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td rowspan=\"2\">Base (intra-articular)</td> <td>Dorsal</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Palmar</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Middle phalanx</td> <td>Head</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Neck</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Shaft</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar for distal to FDS<br /> Dorsal for proximal to FDS</td> </tr> <tr> <td rowspan=\"3\">Base (intra-articular)</td> <td>Dorsal</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Pilon</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Palmar</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Dorsal</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Proximal phalanx</td> <td>Head</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Neck</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Shaft</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Base</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Metacarpal</td> <td>Head</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Neck</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Shaft</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>Dorsal</td> </tr> <tr> <td>Base</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>Dorsal</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Thumb</td> <td>Distal phalanx</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Proximal phalanx</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Volar</td> </tr> <tr> <td>Metacarpal</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>Volar</td> </tr> <tr class=\"divider_top\"> <td>Carpus</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>Volar</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DIPJ: distal interphalangeal joint; PIPJ: proximal interphalangeal joint; MCPJ: metacarpophalangeal joint; FDS: flexor digitorum superficialis.</div><div id=\"graphicVersion\">Graphic 74349 Version 1.0</div></div></div>"},"74350":{"type":"graphic_table","displayName":"Categories of treatment for pain in cancer patients","title":"Categories of treatment for pain in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of treatment for pain in cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pharmacological</td> </tr> <tr> <td>Opioid analgesics</td> </tr> <tr> <td>Non-opioid analgesics</td> </tr> <tr> <td>Non-traditional analgesics (adjuvant analgesics)</td> </tr> <tr> <td class=\"subtitle1_single\">Interventional</td> </tr> <tr> <td>Injection therapies</td> </tr> <tr> <td>Neural blockade</td> </tr> <tr> <td>Implant therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Rehabilitative</td> </tr> <tr> <td>Therapeutic exercise</td> </tr> <tr> <td>Occupational therapy</td> </tr> <tr> <td>Hydrotherapy</td> </tr> <tr> <td>Treatment for specific disorders (eg, lymphedema)</td> </tr> <tr> <td class=\"subtitle1_single\">Psychological</td> </tr> <tr> <td>Psychoeducational interventions</td> </tr> <tr> <td>Cognitive behavioral therapy</td> </tr> <tr> <td>Relaxation therapy, guided imagery, other types of stress management</td> </tr> <tr> <td>Other forms of psychotherapy</td> </tr> <tr> <td class=\"subtitle1_single\">Neurostimulation</td> </tr> <tr> <td>Transcutaneous</td> </tr> <tr> <td>Transcranial</td> </tr> <tr> <td>Implanted</td> </tr> <tr> <td class=\"subtitle1_single\">Integrative (complementary or alternative)</td> </tr> <tr> <td>Acupuncture</td> </tr> <tr> <td>Massage</td> </tr> <tr> <td>Physical or movement</td> </tr> <tr> <td>Others</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Portenoy RK. Treatment of cancer pain. Lancet 2011; 377:2236. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74350 Version 1.0</div></div></div>"},"74351":{"type":"graphic_picture","displayName":"HEp-2 cells stained homogeneous","title":"Anti-DNA antibodies stain the nuclei of HEp-2 cells in a homogeneous pattern","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Anti-DNA antibodies stain the nuclei of HEp-2 cells in a homogeneous pattern</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/RHEUM/74351_HEp2_cells_stained_homogen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human serum containing anti-DNA antibodies stain the nuclei of HEp-2 cells in a homogeneous pattern (A and C). DAPI staining in panels B and D indicates the location of nuclei. In dividing cells (indicated by white arrow in C and D), staining is associated with the separating chromosomes. The anti-DNA antibody reference serum was obtained from the Centers for Disease Control repository of ANA standards.</div><div id=\"graphicVersion\">Graphic 74351 Version 1.0</div></div></div>"},"74352":{"type":"graphic_figure","displayName":"Oncotic pressures in nephrosis","title":"Little change in oncotic pressure gradient in nephrotic syndrome","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Little change in oncotic pressure gradient in nephrotic syndrome</div><div class=\"cntnt\"><img style=\"width:484px; height:256px;\" src=\"images/NEPH/74352_Oncotic_pressures_in_nephro.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma and interstitial oncotic pressures in patients with the nephrotic syndrome due to minimal change disease before (open circles) and after (closed circles) steroid-induced remission of the proteinuria. Both parameters are reduced in the nephrotic state, resulting in little change in the transcapillary oncotic pressure gradient and therefore little tendency to promoting edema formation.</div><div class=\"graphic_reference\">Data from Koomans, HA, Kortlandt, W, Geers, AB, Dorhout Mees, EJ, Nephron 1985; 40:391.</div><div id=\"graphicVersion\">Graphic 74352 Version 1.0</div></div></div>"},"74353":{"type":"graphic_table","displayName":"LS nerve muscle function","title":"Basic lower extremity nerve and muscle function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic lower extremity nerve and muscle function</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Nerve (nerve roots)</td>\n\t    <td class=\"subtitle1\">Major muscles</td>\n\t    <td class=\"subtitle1\">Motor function</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Femoral</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L2-L4)</td>\n\t    <td>Quadriceps</td>\n\t    <td>Knee extension</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L1-L3)</td>\n\t    <td>Iliopsoas; sartorius</td>\n\t    <td>Hip flexion</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Obturator</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L2-L4)</td>\n\t    <td>Adductor L.</td>\n\t    <td>Hip adduction</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Superior gluteal</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L4-S1)</td>\n\t    <td>Gluteus medius</td>\n\t    <td>Hip abduction</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Inferior gluteal</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L5-S2)</td>\n\t    <td>Gluteus maximus</td>\n\t    <td>Hip extension</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Several nerve branches involved</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L5-S2)</td>\n\t    <td>Obturator; piriformis; gemelli</td>\n\t    <td>Hip ext rotation</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Common peroneal</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L4-S3)</td>\n\t    <td>Tibialis anterior</td>\n\t    <td>Foot dorsiflexion</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(Posterior sciatic)</td>\n\t    <td>Fibularis L. &amp; B.</td>\n\t    <td>Foot eversion</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L5,S1)</td>\n\t    <td>Extensor digit. L.</td>\n\t    <td>Toe extension</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Tibial</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(L5-S2)</td>\n\t    <td>Hamstrings</td>\n\t    <td>Knee flexion</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(Anterior sciatic) (S1, S2)</td>\n\t    <td>Gastrocnemius; soleus</td>\n\t    <td>Foot plantar flexion</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">(S2, S3)</td>\n\t    <td>Flexor digit. L.</td>\n\t    <td>Toe flexion</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">B: brevis; L: longus.</div><div id=\"graphicVersion\">Graphic 74353 Version 1.0</div></div></div>"},"74355":{"type":"graphic_figure","displayName":"Plantar grasp","title":"Infant plantar grasp","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Infant plantar grasp</div><div class=\"cntnt\"><img style=\"width:509px; height:411px;\" src=\"images/PEDS/74355_Plantar_grasp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plantar reflex is well established by 32 weeks conceptional age and disappears by three months of age. During the normal plantar grasp, the toes plantar flex around the examiner's finger when it is brought across the ball of the foot.</div><div id=\"graphicVersion\">Graphic 74355 Version 2.0</div></div></div>"},"74356":{"type":"graphic_picture","displayName":"Degenerative biceps tendon rupture","title":"Degenerative biceps tendon rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Degenerative biceps tendon rupture</div><div class=\"cntnt\"><img style=\"width:220px; height:361px;\" src=\"images/EM/74356_Bicipital_tendon_rupture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 64-year-old man&nbsp;who takes&nbsp;warfarin chronically&nbsp;experienced a \"spontaneous\" rupture of the right long head of the biceps. Biceps tendon ruptures&nbsp;can be&nbsp;dramatic; most develop some degree of ecchymosis, although the bruising here is accentuated by anticoagulation.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 74356 Version 4.0</div></div></div>"},"74357":{"type":"graphic_picture","displayName":"Isolating the vas during vasectomy","title":"Isolating the vas during vasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isolating the vas during vasectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:329px;\" src=\"images/PC/74357_Isolating_the_vas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A loop of vas deferens is brought up through the wound, divided, and a segment removed.</div><div class=\"graphic_reference\">Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &#169;1999 Timothy Clenney, MD, MPH.</div><div id=\"graphicVersion\">Graphic 74357 Version 2.0</div></div></div>"},"74358":{"type":"graphic_picture","displayName":"Wing block","title":"Wing block","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Wing block</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/EM/74358_Wing_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Holding the syringe at a 45 degree angle to the plane of the table and perpendicular to the long axis of the digit, insert the needle a short distance to enter the deep intradermal tissue of the dorsum of the digit at a point approximately 3 mm proximal to an imaginary point where a linear extension of the lateral and proximal nail folds would intersect. Inject the anesthetic into the intradermal tissue, first infiltrating the proximal nail fold; the needle can be advanced to allow infiltration along the proximal nail fold. The needle is then partially withdrawn and redirected to allow infiltration of the intradermal tissue along the lateral nail fold. As the anesthetic is injected, the folds blanch and distend creating a wing-like appearance.</div><div id=\"graphicVersion\">Graphic 74358 Version 2.0</div></div></div>"},"74359":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - multiple plaques","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/74359_Kaposis_sarc_mult_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple oval, violaceous plaques are present on the upper extremities and trunk in this patient with AIDS-related Kaposi's sarcoma. Lesions tend to follow skin relaxed tension lines.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74359 Version 3.0</div></div></div>"},"74361":{"type":"graphic_table","displayName":"Blantyre coma score","title":"Blantyre coma score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blantyre coma score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eye movement</td> </tr> <tr> <td class=\"indent1\">Watches or follows</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Fails to watch or follow</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Best motor response</td> </tr> <tr> <td class=\"indent1\">Localizes painful stimulus</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Withdraws limb from painful stimulus</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">No response or inappropriate response</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Best verbal response</td> </tr> <tr> <td class=\"indent1\">Cries appropriately with pain or, if verbal, speaks</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Moan or abnormal cry with pain</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No vocal response to pain</td> <td class=\"centered\">0</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Fully conscious children score 5; children who do not respond to painful stimuli score 0. Response to pain should be assessed via firm nailbed pressure, sternal pressure, and pressure over the supraorbital ridge. Blantyre coma score &le;2 is associated with mortality.</div><div class=\"graphic_reference\">Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989; 71:441.</div><div id=\"graphicVersion\">Graphic 74361 Version 3.0</div></div></div>"},"74362":{"type":"graphic_waveform","displayName":"Bilateral BBB tutorial","title":"Bilateral bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Bilateral bundle branch block</div><div class=\"cntnt\"><img style=\"width:531px; height:109px;\" src=\"images/CARD/74362_Bilateral_BBB_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blocked or delayed conduction in both the left and right bundle branches leads to wide QRS complexes, which in this case have coexisting complexes with a left or right bundle branch block morphology. The first two beats have the appearance of a right bundle branch block, followed by four normal beats, and then beats with the appearance of a left bundle branch block.</div><div id=\"graphicVersion\">Graphic 74362 Version 2.0</div></div></div>"},"74366":{"type":"graphic_table","displayName":"Genetic markers in type 1 diabetes","title":"Importance of genetic markers in susceptibility to type 1 diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Importance of genetic markers in susceptibility to type 1 diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Genetic marker</td> <td class=\"subtitle1\">No relatives with type 1 diabetes</td> <td class=\"subtitle1\">First-degree relative with type 1 diabetes</td> </tr> <tr> <td>DQB*0302/*0201</td> <td>1 in 25</td> <td>1 in 4</td> </tr> <tr> <td>DQB*0302/*0302</td> <td>1 in 60</td> <td>1 in 10</td> </tr> <tr> <td>DQB*0302/*0602</td> <td>1 in 1500</td> <td>Unknown</td> </tr> <tr> <td>DQB*0302/Other</td> <td>1 in 60</td> <td>1 in 10</td> </tr> <tr> <td>DQB*0201/*0201</td> <td>1 in 350</td> <td>1 in 10</td> </tr> <tr> <td>DQB*0201/*Other</td> <td>1 in 400</td> <td>1 in 20</td> </tr> <tr> <td>Other</td> <td>1 in 5000</td> <td>1 in 40</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Risk estimates for susceptibility to type 1 diabetes in Caucasians according to presence or absence of type 1 diabetes susceptibility genes and family history. DQB*0302 and DQB*0201 are associated with high susceptibility, while DQB*0602 is a protective gene. The risk is highest in patients who are heterozygous for both high-susceptibility genes&nbsp;(DQB*0302 and DQB*0201).</div><div class=\"graphic_reference\">Data from: Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428.</div><div id=\"graphicVersion\">Graphic 74366 Version 4.0</div></div></div>"},"74367":{"type":"graphic_picture","displayName":"Gastric adenoma Light","title":"Gastric adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric adenoma</div><div class=\"cntnt\"><img style=\"width:294px; height:347px;\" src=\"images/GAST/74367_Gastric_adenoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power light micrograph of a small sessile adenoma located in the gastric antrum. The darkly-staining dysplastic epithelium is seen on the superficial layer while residual antral epithelium with a few cystic tubules is seen in the basal half.</div><div class=\"graphic_reference\">From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 74367 Version 2.0</div></div></div>"},"74368":{"type":"graphic_figure","displayName":"Sites pelvic organ support","title":"Pelvic organ support quantitation","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Pelvic organ support quantitation</div><div class=\"cntnt\"><img style=\"width:461px; height:424px;\" src=\"images/OBGYN/74368_Sites_pelvic_organ_support.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Six sites (points Aa, Ba, C, D, Bp, Ap), genital hiatus (gh), perineal body (pb), and total vaginal length (tvl) used for pelvic organ support quantitation.</div><div class=\"graphic_reference\">Reproduced with permission from Bump, RC, Mattiasson, A, B&#216;, K, et al, Am J Obstet Gynecol 1996; 175:10. Copyright &#169;1996 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 74368 Version 1.0</div></div></div>"},"74369":{"type":"graphic_picture","displayName":"Rouleaux in myeloma","title":"Rouleaux formation in multiple myeloma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rouleaux formation in multiple myeloma</div><div class=\"cntnt\"><img style=\"width:360px; height:226px;\" src=\"images/HEME/74369_Rouleaux_in_myeloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with multiple myeloma shows red blood cell rouleaux (arrows), giving the appearance of stacked coins.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 74369 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"74370":{"type":"graphic_waveform","displayName":"12-lead ECG left lateral WPW I","title":"12-lead electrocardiogram (ECG) of a left lateral accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a left lateral accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:508px; height:307px;\" src=\"images/CARD/74370_Left_lateral_WPW_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in sinus rhythm from a patient with the Wolff-Parkinson-White syndrome shows a maximally preexcited QRS. The PR is short, the QRS has a right bundle branch block morphology, there is a prominent RS complex in V1, the QRS is negative, and the delta wave is isoelectric in leads I and aVL, localizing the accessory pathway to the left lateral annulus.</div><div id=\"graphicVersion\">Graphic 74370 Version 3.0</div></div></div>"},"74371":{"type":"graphic_figure","displayName":"Stroke breathing patterns","title":"Respiratory patterns associated with neurological injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory patterns associated with neurological injury</div><div class=\"cntnt\"><img style=\"width:340px; height:346px;\" src=\"images/PULM/74371_Stroke_breathing_patterns.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74371 Version 1.0</div></div></div>"},"74374":{"type":"graphic_table","displayName":"Drugs that affect sleep in children","title":"Selected drugs with effects on sleep and wakefulness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected drugs with effects on sleep and wakefulness in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Clinical use</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Sleep and wakefulness effects</td> <td class=\"subtitle1\">Alteration of sleep pattern</td> </tr> <tr class=\"divider_bottom\"> <td>Selective serotonin reuptake inhibitors (SSRIs)*</td> <td>Depression, anxiety, panic disorder</td> <td>Fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram</td> <td>Insomnia, daytime sleepiness, akathisia. Exceptions: paroxetine and fluvoxamine are relatively sedating.</td> <td>SSRIs may decrease total sleep time and increase awakenings, particularly during initiation of treatment. May also prolong latency to and decrease overall REM sleep<sup>[1-4]</sup>. Abrupt withdrawal of short acting SSRIs may worsen insomnia.</td> </tr> <tr class=\"divider_bottom\"> <td>Serotonin and norepinephrine reuptake inhibitors (SNRIs)*</td> <td>ADHD, autism, depression, pain</td> <td>Venlaflaxine, duloxetine</td> <td>Insomnia, daytime sleepiness, akathisia.</td> <td>SNRIs may decrease total sleep time and increase awakenings, particularly during initiation of treatment. May also prolong latency to and decrease overall REM sleep<sup>[1-4]</sup>. Abrupt withdrawal of short acting SNRIs may worsen insomnia.</td> </tr> <tr class=\"divider_bottom\"> <td>Serotonin-2 receptor antagonists/reuptake inhibitors (SARIs)</td> <td>Depression, adjunct to SSRI or SNRI to improve sleep</td> <td>Trazodone, nefazodone, mirtazapine</td> <td>Sedation, increased sleep time.</td> <td>SARIs may increase total sleep time and increase deep (N3) sleep<sup>[2-4]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Aminoketones*</td> <td>ADHD, depression, fatigue</td> <td>Bupropion</td> <td>Insomnia, agitation.</td> <td>Aminoketones may alter REM density and activity, and cause abnormal dreams<sup>&#182;</sup>.<sup>[2]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Tricyclic and tetracyclics*</td> <td class=\"divider_bottom\" rowspan=\"2\">Depression, pain, enuresis</td> <td>More sedating: amitriptyline, doxepin, nortriptyline, clomipramine</td> <td>Sedation, daytime sleepiness. Increased total sleep time in non-depressed patients.</td> <td>When dosed in evening these drugs can shorten sleep latency, decrease awakenings, prolong REM latency and reduce REM sleep<sup>[2,3]</sup>. Clomipramine is a potent suppressor of REM sleep<sup>[4]</sup>. Antihistaminic and antimuscarinic side effects may cause daytime sedation and altered cognition.</td> </tr> <tr class=\"divider_bottom\"> <td>More activating: desipramine, trimipramine, protriptyline</td> <td>Insomnia, daytime sleepiness, akathisia (motor restlessness).</td> <td>These drugs may prolong REM latency and suppress REM sleep (potentially beneficial in depressed patients). They also may cause increased wakefulness and decreased total sleep time, particularly during the initial weeks of treatment<sup>[2,4]</sup>. Antihistaminic and antimuscarinic side effects may cause daytime sedation and altered cognition.</td> </tr> <tr class=\"divider_bottom\"> <td>Monoamine oxidase inhibitors (MAOIs)*</td> <td>Refractory depression, Parkinson disease</td> <td>Isocarboxazid<sup>&#916;</sup>, phenelzine<sup>&#916;</sup>, moclobemide, tranylcypromine<sup>&#916;</sup>, selegiline, rasagiline</td> <td>Insomnia, daytime sleepiness.</td> <td>MAOIs cause nearly complete suppression of REM sleep, which is potentially beneficial in severely depressed patients. They also cause increased awakenings and decreased total sleep time<sup>[2,4]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Benzodiazepines</td> <td>Seizures, anxiety, muscle relaxant, nausea/vomiting</td> <td>Lorazepam, diazepam</td> <td>Daytime sedation. Worsening of sleep-related breathing disorders. Rebound insomnia upon abrupt withdrawal.</td> <td>Benzodiazepines cause reduced sleep latency, increase total sleep time, reduce awakenings, suppress deep (N3) sleep and alter REM density<sup>[4]</sup>. Long-acting agents are associated with more day-time hangover. Short-acting agents are associated with rebound insomnia when withdrawn.</td> </tr> <tr class=\"divider_bottom\"> <td>Stimulants</td> <td>ADHD, narcolepsy</td> <td>Methylphenidate, dextroamphetamine</td> <td>Insomnia. Increased wakefulness. Rare reports of disturbed sleep, nightmares, hallucinations.</td> <td>These stimulants prolong latency of sleep onset, reduce total sleep time and decrease deep (N3) sleep time<sup>[4,6]</sup>. The negative effects on sleep may be caused by the direct stimulant effect of these medications as well as rebound of ADHD symptoms as the dose wears off.</td> </tr> <tr class=\"divider_bottom\"> <td>Selective norepinephrine reuptake inhibitor</td> <td>ADHD</td> <td>Atomoxetine</td> <td>Somnolence or insomnia. Increased wakefulness. Sleep disturbance, abnormal dreams. Among pediatric patients in clinical trials somnolence reported more frequently than insomnia.</td> <td>Among pediatric patients with ADHD, atomoxetine caused less delay in sleep latency and less reduction in total sleep time than methylphenidate<sup>[6]</sup>.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Anticonvulsants</td> <td class=\"divider_bottom\" rowspan=\"2\">Epilepsy, bi-polar disorder, migraine prophylaxis, neuropathic pain</td> <td>Phenytoin, valproate, carbemazepine, topiramate, gabapentin</td> <td>Somnolence. Daytime sleepiness.</td> <td>This group tends to decrease sleep latency and REM sleep (except gabapentin); they also may increase deep (N3) sleep<sup>[4]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Lamotrigene, tiagabine, felbamate, levetiracetam</td> <td>Increased wakefulness. Administer early in day.</td> <td>This group may increase deep (N3) sleep and improve sleep efficiency (levetiracetam)<sup>&#182;</sup>.<sup>[4]</sup></td> </tr> <tr> <td>Antipsychotics (first generation)<sup>&#9674;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Bipolar disorder, psychomotor agitation, schizophrenia</td> <td>Haloperidol, thioridazine, chlorpromazine</td> <td>Daytime sedation especially chlorpromazine and thioridazine.</td> <td>This drug class tends to decrease sleep latency, cause fewer awakenings and increase total sleep time.</td> </tr> <tr class=\"divider_bottom\"> <td>Antipsychotics (second generation)<sup>&#9674;</sup></td> <td>Aripirazole, clozapine, olanzapine, quetiapine risperidone, ziprasidone</td> <td>Daytime sedation. Aripiprazole is least sedating. Clozapine, quetiapine and olanzapine are most sedating.</td> <td>Olanzapine, ziprasidone and risperidone suppress REM sleep, increase deep (N3) sleep and improve sleep continuity<sup>[1,4]</sup>; they may counteract detrimental effects of certain SSRIs on sleep<sup>[1]</sup>. Sleep improvements are attributed to 5HT-2A/2C receptor blockade.</td> </tr> <tr class=\"divider_bottom\"> <td>Alpha-2 agonists</td> <td>Hypertension, ADHD, pain, migraine prophylaxis</td> <td>Clonidine, methyldopa</td> <td>Daytime sedation.</td> <td>These drugs cause decreased latency of sleep onset and partial suppression of REM sleep<sup>[4,5]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Beta-antagonists</td> <td>Hypertension, heart failure</td> <td>Proranolol<sup>&#916;</sup>, metoprolol, nadolol, atenolol</td> <td>Disturbed sleep, insomnia, nightmares, hallucinations<sup>[5]</sup>.</td> <td>Beta-antagonists tend to suppress REM sleep. The lipophilic beta-antagonists (eg, propranolol, labetalol) may cause more sleep disturbance than hydrophilic agents (eg, atenolol)<sup>[4]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Beta-agonists (inhaled)</td> <td>Inhaled bronchodilator</td> <td>Inhaled albuterol (salbutamol), salmeterol</td> <td>Long acting forms appear to improve sleep in asthmatics.</td> <td>The long-acting forms of these drugs tend to increase sleep time including deep (N3) sleep in asthmatics, due to control of nocturnal asthma symptoms<sup>[4,5]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Methylxanthines</td> <td>Bronchodilation, antiinflammatory (asthma)</td> <td>Theophylline, aminophylline</td> <td>Insomnia. Increased wakefulness.</td> <td>Methylxanthines tend to delay sleep latency, increase awakenings, and decrease total sleep time. They do not improve total sleep time or sleep quality of asthmatics<sup>[4,5]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>HMG CoA reductase (hydroxymethylglutaryl CoA reductase) inhibitors or statins</td> <td>Hypercholesterolemia</td> <td>Simvastatin, lovastatin, pravastatin</td> <td>Reports of disturbed sleep and nightmares.</td> <td>These effects are limited to case descriptions and are not well documented.</td> </tr> <tr class=\"divider_bottom\"> <td>Glucocorticoids</td> <td>Immunosuppression, anti-inflammatory, anti-emetic</td> <td>Dexamethasone, prednisone, prednisolone</td> <td>Insomnia, increased wakefulness and fatigue.</td> <td>Glucocorticoids tend to decrease total sleep time, and may decrease deep (N3) sleep time. REM sleep suppression is reported with certain glucocorticoids<sup>&#182;</sup>.<sup>[5]</sup> These effects are dose-related and PM dosing may cause greater sleep disturbance.</td> </tr> <tr> <td>Antihistamines (first generation)</td> <td class=\"divider_bottom\" rowspan=\"2\">Allergic rhinitis, pruritus, anti-emetic</td> <td>Diphenhydramine, hydroxyzine, doxylamine, promethazine</td> <td>Daytime sleepiness may result in decreased night sleep time, increased awakenings.</td> <td>These drugs are associated with decreased sleep latency and fewer night awakenings in adolescents and adults, but may cause paradoxical excitation in young children.</td> </tr> <tr class=\"divider_bottom\"> <td>Antihistamines (second generation)</td> <td>Loratadine, cetirizine, fexofenadine</td> <td>Few effects on sleep or wakefulness at moderate doses. Daytime sleepiness at higher dosing.</td> <td>Effects on sleep are minimized because there is little CNS penetration with usual dosing for seasonal allergies. Cetirizine may be more sedating.</td> </tr> <tr class=\"divider_bottom\"> <td>Opioid analgesics</td> <td>Analgesia</td> <td>Morphine, hydromorphone, oxycodone, methadone</td> <td>Daytime sleepiness and fatigue. Dose related worsening of sleep related respiratory disorders. Insomnia and disturbed sleep if abrupt withdrawal.</td> <td>These drugs increase night awakenings and decrease deep (N3) and REM sleep. Chronic methadone has fewer effects on sleep<sup>[4]</sup>.</td> </tr> <tr> <td>Decongestants</td> <td>Cold and allergy symptoms</td> <td>Phenylephrine, pseudoephedrine</td> <td>Insomnia, anxiety, agitation.</td> <td>These drugs cause decreased total sleep time and increased awakenings. Systemic decongestants are generally not recommended in pediatric patients.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Specific effects of medication on sleep and wakefulness in children will vary depending on drug dose, time of administration, time-released formulation, age of child, and relevant co-morbidity such as depression, anxiety, ADHD, psychoses or underlying sleep disorder. Much of the information in this table is based on data from adults, and scant information is available about effects in children.</div><div class=\"graphic_footnotes\">ADHD: attention deficit/hyperactivity disorder; REM sleep: rapid eye movement sleep; N3 sleep: deep non-REM sleep, also known as slow wave sleep, considered important for restorative function of sleep.<br />* Agents in these classes may precipitate or exacerbate night-time movement disorders (eg, bruxism, restless legs). Effects on sleep and wakefulness can differ between depressed and non-depressed patients. For additional information, see UpToDate topic: Initial treatment of depression in adults, table \"Side effects of antidepressant medications.\"<br />¶ Conflicting or limited data.<br />Δ Agents associated with more prominent sleep effects. No data for linezolid.<br /><FONT class=lozenge>◊</FONT> For additional information see UpToDate topic reviews: First-generation antipsychotic medications; and Second-generation antipsychotic medications: Pharmacology, administration and comparative side effects.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sharpley AL, et al. Olanzapine increases slow-wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005; 66:450. </LI>&#xD;&#xA;<LI>Wilson S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005; 65:927. </LI>&#xD;&#xA;<LI>Holshoe JM. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009; 45:191. </LI>&#xD;&#xA;<LI>Roux FJ, Kryger MH. Medication effects on sleep. Clin Chest Med 2010; 31:397. </LI>&#xD;&#xA;<LI>Novak M, Shapiro CM. Drug-induced sleep disturbances: focus on nonpsychotropic mediations. Drug Saf 1997; 16:133. </LI>&#xD;&#xA;<LI>Gruber R. Sleep characteristics of children and adolescents with attention deficit-hyperactivity disorder. Child Adolesc Psychiatric Clin N Am 2009; 18:863. </LI></OL></div><div id=\"graphicVersion\">Graphic 74374 Version 5.0</div></div></div>"},"74375":{"type":"graphic_figure","displayName":"Mechanism for humeral fracture from abuse","title":"Mechanism for humeral fracture from abuse","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Mechanism for humeral fracture from abuse</div><div class=\"cntnt\"><img style=\"width:454px; height:360px;\" src=\"images/EM/74375_Mechhumeralfx3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although the exact mechanism of injury may vary in child abuse, fracture of the proximal humerus may result from twisting at the elbow or forearm.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74375 Version 14.0</div></div></div>"},"74376":{"type":"graphic_table","displayName":"Diagnostic criteria for acute pericarditis and myopericarditis","title":"Diagnostic criteria for acute pericarditis and myopericarditis in the clinical setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for acute pericarditis and myopericarditis in the clinical setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute pericarditis (at least&nbsp;two criteria of&nbsp;four should be present)*:</td> </tr> <tr> <td class=\"indent1\">1. Typical chest pain</td> </tr> <tr> <td class=\"indent1\">2. Pericardial friction rub</td> </tr> <tr> <td class=\"indent1\">3. Suggestive ECG changes (typically widespread ST segment elevation)</td> </tr> <tr> <td class=\"indent1\">4. New or worsening pericardial effusion</td> </tr> <tr> <td class=\"subtitle1_single\">Myopericarditis:</td> </tr> <tr> <td class=\"indent1\">1. Definite diagnosis of acute pericarditis, <strong>PLUS</strong></td> </tr> <tr> <td class=\"indent1\">2. Suggestive symptoms (dyspnea, palpitations, or chest pain) and ECG abnormalities beyond normal variants, not documented previously (ST/T abnormalities, supraventricular or ventricular tachycardia or frequent ectopy, atrioventricular block), <strong>OR</strong> focal or diffuse depressed LV function of uncertain age by an imaging study</td> </tr> <tr> <td class=\"indent1\">3. Absence of evidence of any other cause</td> </tr> <tr> <td class=\"indent1\">4. One of the following features: Evidence of elevated cardiac enzymes (creatine kinase-MB fraction, or troponin I or T), <strong>OR</strong> new onset of focal or diffuse depressed LV function by an imaging study, <strong>OR</strong> abnormal imaging consistent with myocarditis (MRI with gadolinium, gallium-67 scanning, anti-myosin antibody scanning)</td> </tr> <tr> <td class=\"subtitle1_single\">Case definitions for myopericarditis include:</td> </tr> <tr> <td class=\"indent1\"><strong>Suspected myopericarditis:</strong> Criteria 1 plus 2 and 3</td> </tr> <tr> <td class=\"indent1\"><strong>Probable myopericarditis:</strong> Criteria 1, 2, 3, and 4</td> </tr> <tr> <td class=\"indent1\"><strong>Confirmed myopericarditis<sup>&#182;</sup>:</strong> Histopathologic evidence of myocarditis by endomyocardial biopsy or on autopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; LV: left ventricular; MRI: magnetic resonance imaging.<br />* Pericardial effusion confirms the clinical diagnosis, but its absence does not exclude it.<br />¶ In clinical practice, a confirmed diagnosis would require an endomyocardial biopsy that is not warranted in self-limited cases with predominant pericarditis.</div><div class=\"graphic_reference\">Reproduced with permission from: Imazio M, Trinchero R. Triage and management of acute pericarditis. Int J Cardiol 2006, doi:10.1016/j.ijcard.2006.07.100. Copyright © 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 74376 Version 7.0</div></div></div>"},"74377":{"type":"graphic_figure","displayName":"Lung ca IV PI","title":"Stage IV lung cancer","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Stage IV lung cancer</div><div class=\"cntnt\"><img style=\"width:543px; height:542px;\" src=\"images/PI/74377_Lung_ca_IV_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a stage IV cancer. In stage IV cancer, the tumor has spread (metastasized) somewhere distant from the original tumor. This could include spread to the other side of the chest or to other places in the body such as the bones, the brain, the liver, or the adrenal glands. Stage IV cancer can also cause fluid collections to build up inside the chest, which are called malignant effusions.</div><div id=\"graphicVersion\">Graphic 74377 Version 6.0</div></div></div>"},"74378":{"type":"graphic_picture","displayName":"Mirena IUD PI","title":"Mirena IUD","html":"<div class=\"graphic\"><div style=\"width: 872px\" class=\"figure\"><div class=\"ttl\">Mirena IUD</div><div class=\"cntnt\"><img style=\"width:852px; height:559px;\" src=\"images/PI/74378_Mrn_IUD_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intrauterine device (IUD), called Mirena, is inserted into the uterus. While there it delivers a hormone called \"progestin\" into the body to prevent pregnancy.</div><div class=\"graphic_reference\">Image used with permission. Copyright &copy; 2015 Bayer Healthcare Pharmaceuticals, Inc.</div><div id=\"graphicVersion\">Graphic 74378 Version 10.0</div></div></div>"},"74379":{"type":"graphic_algorithm","displayName":"Dx GN child serology IFM","title":"Use of serologic testing and immunofluoresence microscopy in the diagnosis of glomerulonephritis in children","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Use of serologic testing and immunofluoresence microscopy in the diagnosis of glomerulonephritis in children</div><div class=\"cntnt\"><img style=\"width:605px; height:413px;\" src=\"images/PEDS/74379_Dx_GN_child_serology_IFM.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GN: glomerulonephritis; GBM: glomerular basement membrane; ANCA: antineutrophil cytoplasmic antibodies; IFM: immunofluorescent microscopy; Ig: immunoglobulin; MPGN: membranoproliferative glomerulonephritis; SLE: systemic lupus erythematous; HSP: Henoch-Schönlein purpura.</div><div class=\"graphic_reference\">Reproduced with permission from: Niaudet P. Nephritic Syndrome. In: Comprehensive Pediatric Nephrology, Geary DF, Schaefer F (Eds), Mosby, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74379 Version 4.0</div></div></div>"},"74380":{"type":"graphic_picture","displayName":"Positive patch test","title":"Positive patch tests","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positive patch tests</div><div class=\"cntnt\"><img style=\"width:403px; height:253px;\" src=\"images/PEDS/74380_Positive_patch_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positive epicutaneous (patch) tests on the back of a patient with allergic contact dermatitis.</div><div class=\"graphic_reference\">Courtesy of William L Weston, MD.</div><div id=\"graphicVersion\">Graphic 74380 Version 1.0</div></div></div>"},"74381":{"type":"graphic_diagnosticimage","displayName":"Importance breast compress","title":"Importance of breast compression","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of breast compression</div><div class=\"cntnt\"><img style=\"width:391px; height:427px;\" src=\"images/PC/74381_Breast_compression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MLO view obtained with inadequate compression (Panel A), raises the question of an irregular asymmetry (arrows). On repeat imaging (Panel B) with better compression, the breast parenchyma is better visualized, with no underlying abnormality. Breast compression minimizes superimposition of tissues, and decreases patient motion, thereby improving the diagnostic quality of the study.</div><div class=\"graphic_footnotes\">MLO: mediolateral oblique.</div><div id=\"graphicVersion\">Graphic 74381 Version 2.0</div></div></div>"},"74382":{"type":"graphic_table","displayName":"BTS CAP guidelines","title":"British Thoracic Society guidelines: Initial empirical treatment regimens for community-acquired pneumonia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">British Thoracic Society guidelines: Initial empirical treatment regimens for community-acquired pneumonia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pneumonia severity (based on clinical judgement supported by CURB65 severity score)</td> <td class=\"subtitle1\">Treatment site</td> <td class=\"subtitle1\">Preferred treatment</td> <td class=\"subtitle1\">Alternative treatment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Low severity</strong> (eg, CURB65 = 0 to 1 <strong>or</strong> CRB65 score = 0, &#60;3 percent mortality)</td> <td>Home</td> <td>Amoxicillin 500 mg orally three times daily</td> <td>Doxycycline 200 mg loading dose then 100 mg orally once daily <strong>or</strong> clarithromycin 500 mg orally twice daily</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Low severity</strong> (eg, CURB65 = 0 to 1, &#60;3 percent mortality) but admission indicated for reasons other than pneumonia severity (eg, social reasons/unstable comorbid illness)</td> <td>Hospital</td> <td> <p>Amoxicillin 500 mg orally three times daily</p> If oral administration not possible: amoxicillin 500 mg IV three times daily*</td> <td>Doxycycline 200 mg loading dose then 100 mg orally once daily <strong>or</strong> clarithromycin 500 mg orally twice daily</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Moderate severity</strong> (eg, CURB65 = 2, 9 percent mortality)</td> <td>Hospital</td> <td> <p>Amoxicillin 500 mg to 1 gram orally three times daily <em>plus</em> clarithromycin 500 mg orally twice daily</p> If oral administration not possible: amoxicillin 500 mg IV three times daily* <strong>or</strong> benzylpenicillin (penicillin G) 1.2 grams IV four times daily <strong>plus</strong> clarithromycin 500 mg IV twice daily*</td> <td>Doxycycline 200 mg loading dose then 100 mg orally <strong>or</strong> levofloxacin 500 mg orally once daily <strong>or</strong> moxifloxacin 400 mg orally once daily<sup>&#182;</sup></td> </tr> <tr> <td><strong>High severity</strong> (eg, CURB65 = 3 to 5, 15 to 40 percent mortality)</td> <td>Hospital (consider critical care review)</td> <td> <p><strong>Antibiotics given as soon as possible</strong></p> <p>Co-amoxiclav (amoxicillin-clavulanate potassium) 1.2 grams IV three times daily* <strong>plus</strong> clarithromycin 500 mg IV twice daily*</p> (If <em>Legionella</em> strongly suspected, consider adding levofloxacin<sup>&#916;</sup>)</td> <td> <p>Benzylpenicillin (penicillin G) 1.2 grams IV four times daily <strong>plus</strong> either levofloxacin 500 mg IV twice daily <strong>or</strong> ciprofloxacin 400 mg IV twice daily</p> <p><strong>OR</strong></p> <p>Cefuroxime 1.5 grams IV three times daily <strong>or</strong> cefotaxime 1 gram IV three times daily <strong>or</strong> ceftriaxone 2 grams IV once daily, <strong>plus</strong> clarithromycin 500 mg IV twice daily*</p> (If <em>Legionella</em> strongly suspected, consider adding levofloxacin<sup>&#916;</sup>)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides the 2009 guideline recommendations of the British Thoracic Society for reference purposes. Refer to the UpToDate text for information about choosing between the different guidelines and about the preferred doses and durations of the individual antibiotics.</div><div class=\"graphic_footnotes\">CAP: community-acquired pneumonia; IV: intravenous.<br />* Intravenous preparation not available in the United States.<br />¶ Following reports of an increased risk of adverse hepatic reactions associated with oral moxifloxacin, in October 2008 the European Medicines Agency (EMEA) recommended that moxifloxacin \"should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection.\"<br />Δ Caution: Risk of QT prolongation with macrolide-quinolone combination.</div><div class=\"graphic_reference\">Reproduced with permission from: Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3:iii1. Copyright © 2009 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 74382 Version 12.0</div></div></div>"},"74383":{"type":"graphic_picture","displayName":"Microscopy pilot wheel","title":"The pilot's wheel of paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The pilot's wheel of paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:356px; height:396px;\" src=\"images/ID/74383_Microscopy_pilot_wheel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paracoccidioidomycosis. The lung contains <EM>P. brasiliensis</EM>, which displays a mother cell surrounded by multiple budding yeasts.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, MD, and Farber JL, MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright ©1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74383 Version 4.0</div></div></div>"},"74384":{"type":"graphic_picture","displayName":"Fibrillary glomerulonephritis light","title":"Fibrillary glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrillary glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:285px;\" src=\"images/NEPH/74384_Fibrillary_GN_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in fibrillary glomerulonephritis shows diffuse expansion of the mesangium by amorphous, acellular material (arrows). Electron microscopy and Congo red staining are necessary to distinguish this light microscopic appearance from amyloidosis or light chain deposition disease.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 74384 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"74387":{"type":"graphic_table","displayName":"Diagnostic criteria SUNCT SUNA","title":"Diagnostic criteria for short-lasting unilateral neuralgiform headache attacks (SUNCT and SUNA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for short-lasting unilateral neuralgiform headache attacks (SUNCT and SUNA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic criteria for short-lasting unilateral neuralgiform headache attacks</td> </tr> <tr> <td class=\"indent1\">A. At least 20 attacks fulfilling criteria B-D</td> </tr> <tr> <td class=\"indent1\">B. Moderate or severe unilateral head pain, with orbital, supra-orbital, temporal and/or other trigeminal distribution, lasting for 1 to 600 seconds and occurring as single stabs, a series of stabs, or in a sawtooth pattern</td> </tr> <tr> <td class=\"indent1\">C. At least one of the following cranial autonomic symptoms or signs, ipsilateral to the pain:</td> </tr> <tr> <td class=\"indent2\">1. Conjunctival injection and/or lacrimation</td> </tr> <tr> <td class=\"indent2\">2. Nasal congestion and/or rhinorrhea</td> </tr> <tr> <td class=\"indent2\">3. Eyelid edema</td> </tr> <tr> <td class=\"indent2\">4. Forehead and facial sweating</td> </tr> <tr> <td class=\"indent2\">5. Forehead and facial flushing</td> </tr> <tr> <td class=\"indent2\">6. Sensation of fullness in the ear</td> </tr> <tr> <td class=\"indent2\">7. Miosis and/or ptosis</td> </tr> <tr> <td class=\"indent1\">D. Attacks have a frequency of at least one a day for more than half of the time when the disorder is active</td> </tr> <tr> <td class=\"indent1\">E. Not better accounted for by another ICHD-3 diagnosis</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria for SUNCT (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing)</td> </tr> <tr> <td class=\"indent1\">A. Attacks fulfilling criteria for short-lasting unilateral neuralgiform headache attacks</td> </tr> <tr> <td class=\"indent1\">B. Both of conjunctival injection and lacrimation (tearing)</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria for SUNA (short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms)</td> </tr> <tr> <td class=\"indent1\">A. Attacks fulfilling criteria for short-lasting unilateral neuralgiform headache attacks</td> </tr> <tr> <td class=\"indent1\">B. Only one or neither of conjunctival injection and lacrimation (tearing)</td> </tr> <tr> <td class=\"subtitle1_single\">Episodic SUNCT or SUNA:</td> </tr> <tr> <td class=\"indent1\">Attacks occurring in periods lasting from seven days to one year, separated by pain-free periods lasting one month or more</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic SUNCT or SUNA:</td> </tr> <tr> <td class=\"indent1\">Attacks occurring for more than one year without remission, or with remission periods lasting less than one month</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: The International Classification of Headache Disorders, 3rd edition</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 74387 Version 12.0</div></div></div>"},"74388":{"type":"graphic_figure","displayName":"Growth puberty chart in boys","title":"Growth and pubertal development in boys","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Growth and pubertal development in boys</div><div class=\"cntnt\"><img style=\"width:334px; height:350px;\" src=\"images/ENDO/74388_Growth_puberty_chart_in_boy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal standards for height and pubertal development in boys. The units for penis stage and pubic hair growth range from 2+ to 5+ and for testes volume from 4 mL to 12 mL. Each tick on the lines of pubertal development represents a percentile ranging from 97th to the 3rd percentile.</div><div class=\"graphic_reference\">Data from: Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.&nbsp;Arch Dis Child 1976; 51:170.</div><div id=\"graphicVersion\">Graphic 74388 Version 2.0</div></div></div>"},"74390":{"type":"graphic_picture","displayName":"Collagenous colitis Light II","title":"Collagenous colitis","html":"<div class=\"graphic normal\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Collagenous colitis</div><div class=\"cntnt\"><img style=\"width:461px; height:288px;\" src=\"images/GAST/74390_Collagenous_colitis_Light1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a colonic biopsy from a patient with collagenous colitis. The characteristic change is thickened subepithelial collagenous band in the colonic mucosa that stains in bright blue (arrows).</div><div class=\"graphic_reference\">Courtesy of Prof Dr G Herrmann, Frankfurt.</div><div id=\"graphicVersion\">Graphic 74390 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"74391":{"type":"graphic_picture","displayName":"Condyloma acuminata","title":"Anal condyloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anal condyloma</div><div class=\"cntnt\"><img style=\"width:334px; height:252px;\" src=\"images/OBGYN/74391_Condyloma_acuminata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph shows the characteristic verrucous, pink or skin-colored, papilliform appearance of anal condyloma acuminata.</div><div class=\"graphic_reference\">Reproduced by permission from the American Society of Colon and Rectal Surgeons.</div><div id=\"graphicVersion\">Graphic 74391 Version 4.0</div></div></div>"},"74392":{"type":"graphic_table","displayName":"Avoiding warfarin assoc ICH","title":"Avoiding ICH during warfarin therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Avoiding ICH during warfarin therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Elderly patients and those with intrinsic cerebrovascular disease are at high risk.</td>\n</tr>\n\n<tr>\n<td>Keep INRs &#8804;3.0.</td>\n</tr>\n\t\n<tr>\n<td>Warfarin combined with aspirin should be used with caution in elderly patients and those with cerebrovascular disease and the benefits versus risks carefully weighed.</td>\n</tr>\n\n<tr>\n<td>Modest blood pressure lowering profoundly reduces ICH risk; systolic blood pressure should optimally be lowered to &#60;140 mmHg.</td>\n</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/24/2007 - permission requested to LWW. sending to Terrence to make.mt 4/24/2007 - granted.mt 4/25/2008--Requested renewal (JD). 6/6/2008--Renewal granted (JD). 5/30/2009--Renewal granted via Rightslink (JD). 6/6/2010--Renewal granted via Rightslink (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24832&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Avoiding_warfarin_assoc_ICH.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36:1588. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74392 Version 9.0</div></div></div>"},"74393":{"type":"graphic_picture","displayName":"Sweet syndrome plaque","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/74393_Sweets_syndrome_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A brightly erythematous plaque with a pustular component is visible on this patient with Sweet syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74393 Version 5.0</div></div></div>"},"74394":{"type":"graphic_table","displayName":"Melanoma specific structures diagnostic accuracy","title":"Diagnostic accuracy of melanoma specific structures<sup>[1-4]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic accuracy of melanoma specific structures<sup>[1-4]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Melanoma specific structure</td> <td class=\"subtitle1\" colspan=\"2\">Sensitivity (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Specificity (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Positive predictive value (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Negative predictive value (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Odds ratio*</td> </tr> <tr> <td class=\"subtitle2\">Amelanotic melanoma</td> <td class=\"subtitle2\">Pigmented melanoma</td> </tr> <tr> <td><strong>1. Atypical network</strong><sup>[1,3,5-14]</sup></td> <td class=\"centered\">21</td> <td class=\"centered\">35-82</td> <td class=\"centered\">62-89</td> <td class=\"centered\">18-67</td> <td class=\"centered\">71-88</td> <td class=\"centered\">1.1-9</td> </tr> <tr> <td><strong>2. Peripheral streaks</strong> (pseudopods and radial streaming)<sup>[1,3,5-10,13-15]</sup></td> <td class=\"centered\">5</td> <td class=\"centered\">9-32</td> <td class=\"centered\">77-99</td> <td class=\"centered\">22-77</td> <td class=\"centered\">54-86</td> <td class=\"centered\">1.6-5.8</td> </tr> <tr> <td><strong>3. Negative pigment network</strong> (asymmetrically located and disordered)<sup>[5,16]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">22</td> <td class=\"centered\">95</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.8</td> </tr> <tr> <td><strong>4. Blotch (off-centered)</strong><sup>[13,14]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">4.1-4.9</td> </tr> <tr> <td><strong>5. Atypical dots and/or globules</strong><sup>[3,6,7,13,14]</sup></td> <td class=\"centered\">24</td> <td class=\"centered\">25-40</td> <td class=\"centered\">74-92</td> <td class=\"centered\">13-79</td> <td class=\"centered\">61-86</td> <td class=\"centered\">2.9-4.8</td> </tr> <tr> <td colspan=\"7\"><strong>6. Regression structures</strong></td> </tr> <tr> <td class=\"indent1\">Scar-like areas<sup>[1,3,5,8]</sup></td> <td class=\"centered\">23</td> <td class=\"centered\">17-36</td> <td class=\"centered\">93-99</td> <td class=\"centered\">89</td> <td class=\"centered\">70</td> <td class=\"centered\">4.4-18.3</td> </tr> <tr> <td class=\"indent1\">Peppering<sup>[3,17]</sup></td> <td class=\"centered\">22</td> <td class=\"centered\">85</td> <td class=\"centered\">93-99</td> <td class=\"centered\">27</td> <td class=\"centered\">99</td> <td class=\"centered\">3.5</td> </tr> <tr> <td class=\"indent1\">Scar-like areas and peppering<sup>[3,5,6,13,14]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">22-42</td> <td class=\"centered\">93-99</td> <td class=\"centered\">78</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3.9-7.8</td> </tr> <tr> <td class=\"indent1\">Blue-white veil overlying macular areas and scar-like areas and peppering<sup>[11,12,18]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">44<sup>&#182;</sup></td> <td class=\"centered\">91<sup>&#916;</sup></td> <td class=\"centered\">3.1-8.7</td> </tr> <tr> <td><strong>7. Blue-white veil overlying raised areas</strong><sup>[1,3,5,6,8,9,13,14]</sup></td> <td class=\"centered\">11</td> <td class=\"centered\">17-75</td> <td class=\"centered\">86-99</td> <td class=\"centered\">52-73</td> <td class=\"centered\">55-70</td> <td class=\"centered\">2.5-13</td> </tr> <tr> <td><strong>8. Atypical vascular structures</strong><sup>[3,6,10,13,14,19-21]</sup></td> <td class=\"centered\">63</td> <td class=\"centered\">9.4</td> <td class=\"centered\">54-96</td> <td class=\"centered\">69</td> <td class=\"centered\">53</td> <td class=\"centered\">1.5-7.4</td> </tr> <tr> <td class=\"indent1\">Dotted + serpentine<sup>[3]</sup></td> <td class=\"centered\">30</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">85</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2.3</td> </tr> <tr> <td class=\"indent1\">Serpentine vessels<sup>[3,22]</sup></td> <td class=\"centered\">34</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">80</td> <td class=\"centered\">68</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2.1</td> </tr> <tr> <td class=\"indent1\">Polymorphous vessels<sup>[3,22]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">68</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2.1</td> </tr> <tr> <td class=\"indent1\">Milky-red areas<sup>[3,22]</sup></td> <td class=\"centered\">51</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">71</td> <td class=\"centered\" rowspan=\"2\"><br /> <p>77.8</p> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2.5</td> </tr> <tr> <td class=\"indent1\">Red globules<sup>[3,22]</sup></td> <td class=\"centered\">21</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">88</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2.0</td> </tr> <tr> <td><strong>9. Crystalline structures</strong> (also known as Chrysalis and shiny white streaks)<sup>[23]</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">9.7</td> </tr> <tr> <td><strong>10. Brown peripheral structureless areas</strong><sup>[3,6]</sup></td> <td class=\"centered\">19</td> <td class=\"centered\">63</td> <td class=\"centered\">93-96</td> <td class=\"centered\">94</td> <td class=\"centered\">73</td> <td class=\"centered\">2.9-28</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The odds ratios for the diagnosis of melanoma shown in the table are statistically significant since the 95% confidence intervals do not include the unit.<br />¶ When involving &gt;50 percent of the lesion.<br />Δ When involving &lt;50 percent of the lesion.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Soyer HP, Smolle J, Leitinger G, et al. Diagnostic reliability of dermoscopic criteria for detecting malignant melanoma. Dermatol 1995; 190:25.</LI>&#xD;&#xA;<LI>Marghoob AA, Korzenko AJ, Changchien L, et al. The beauty and the beast sign in dermoscopy. Dermatol Surg 2007; 33:1388.</LI>&#xD;&#xA;<LI>Menzies SW, Kreusch J, Byth K, et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma . Arch Dermatol 2008; 144:1120.</LI>&#xD;&#xA;<LI>Stoecker WV, Stolz W. Dermoscopy and the diagnostic challenge of amelanotic and hypomelanotic melanoma. Arch Dermatol 2008; 144:1207.</LI>&#xD;&#xA;<LI>Menzies SW, Ingvar C, McCarthy WH. A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res 1996; 6:55.</LI>&#xD;&#xA;<LI>Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759.</LI>&#xD;&#xA;<LI>Haenssle HA, Korpas B, Hansen-Hagge C, et al. Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk. J Am Acad Dermatol 2010; 62:785.</LI>&#xD;&#xA;<LI>Salopek TG, Kopf AW, Stefanato CM, et al. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 2001; 19:337.</LI>&#xD;&#xA;<LI>Kenet RO, Kang S, Kenet BJ, et al. Clinical diagnosis of pigmented lesions using digital epiluminescence microscopy. Grading protocol and atlas. Arch Dermatol 1993; 129:157.</LI>&#xD;&#xA;<LI>Pizzichetta MA, Stanganelli I, Bono R, et al. Dermoscopic features of difficult melanoma. Dermatol Surg 2007; 33:91.</LI>&#xD;&#xA;<LI>Soyer HP, Argenziano G, Zalaudek I, et al. Three-point checklist of dermoscopy. A new screening method for early detection of melanoma.Dermatology 2004; 208:27.</LI>&#xD;&#xA;<LI>Zalaudek I, Argenziano G, Soyer HP, et al. Three-point checklist of dermoscopy: an open internet study. Br J Dermatol 2006; 154:431.</LI>&#xD;&#xA;<LI>Argenziano G, Fabbrocini G, Carli P, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134:1563.</LI>&#xD;&#xA;<LI>Argenziano G, Chimenti S, Talamini R, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</LI>&#xD;&#xA;<LI>Dal Pozzo V, Benelli C, Roscetti E. The seven features for melanoma: a new dermoscopic algorithm for the diagnosis of malignant melanoma. Eur J Dermatol 1999; 9:303.</LI>&#xD;&#xA;<LI>Marghoob AA. Unpublished data.</LI>&#xD;&#xA;<LI>Braun RP, Gaide O, Oliviero M, et al. The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. Br J Dermatol 2007; 157:907.</LI>&#xD;&#xA;<LI>Zalaudek I, Argenziano G, Ferrara G, et al. Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study. Br J Dermatol 2004; 150:64.</LI>&#xD;&#xA;<LI>Bono A, Maurichi A, Moglia D, et al. Clinical and dermatoscopic diagnosis of early amelanotic melanoma. Melanoma Res 2011; 11:491.</LI>&#xD;&#xA;<LI>Pizzichetta MA, Talamini R, Stanganelli I, et al. Amelanotic/hypomelanotic melanoma: Clinical and dermoscopic features. Br J Dermatol 2004; 150:1117.</LI>&#xD;&#xA;<LI>Puig S, Argenziano G, Zalaudek I, et al. Melanomas that failed dermoscopic detection: A combined clinicodermoscopic approach for not missing melanoma. Dermatol Surg 2007; 33:1262.</LI>&#xD;&#xA;<LI>Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485.</LI>&#xD;&#xA;<LI>Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol 2011. Epub ahead of print.</LI></OL>Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 74394 Version 6.0</div></div></div>"},"74395":{"type":"graphic_waveform","displayName":"Typical atrial flutter","title":"Typical atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Typical atrial flutter</div><div class=\"cntnt\"><img style=\"width:581px; height:314px;\" src=\"images/CARD/74395_Typical_atrial_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in type I counterclockwise typical atrial flutter. The biphasic flutter (F) waves are prominently negative (lead II) in counterclockwise typical flutter. The patient is on a beta-blocker which explains the predominant 4:1 conduction pattern.</div><div id=\"graphicVersion\">Graphic 74395 Version 4.0</div></div></div>"},"74397":{"type":"graphic_diagnosticimage","displayName":"Transverse fracture of the medial sesamoid - A","title":"Transverse fracture of the medial sesamoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse fracture of the medial sesamoid</div><div class=\"cntnt\"><img style=\"width:408px; height:540px;\" src=\"images/EM/74397_Trans_fx_medial_sesamoid_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In contrast to a bipartite sesamoid, the fracture line (white arrow) is relatively straight, and the corners of the fragments are more abrupt and less rounded. The fracture borders are also less distinct than the adjacent edges of the partite sesamoid and lack a rim of cortication. Lack of cortication is easier to appreciate on the lateral view.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 74397 Version 3.0</div></div></div>"},"74400":{"type":"graphic_table","displayName":"Early symptoms and signs of autism","title":"Early symptoms and signs of autism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early symptoms and signs of autism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Parental concerns about deficits in social skills</td> </tr> <tr> <td>Parental concerns about deficits in language skills or behavior</td> </tr> <tr> <td>Parental concerns about frequent tantrums or intolerance to change</td> </tr> <tr> <td>Delayed language and social/communication skills</td> </tr> <tr> <td>No babbling by 9 months</td> </tr> <tr> <td>No pointing or gestures by 12 months</td> </tr> <tr> <td>Lack of orientation to name by 12 months</td> </tr> <tr> <td>No single words by 16 months</td> </tr> <tr> <td>Lack of pretend or symbolic play by 18 months</td> </tr> <tr> <td>No spontaneous, meaningful (not repetitive or echolalic) two-word phrases by 24 months</td> </tr> <tr> <td>Any loss of any language or social skills at any age</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.</div><div id=\"graphicVersion\">Graphic 74400 Version 3.0</div></div></div>"},"74401":{"type":"graphic_figure","displayName":"Aggressive lipid lowering improves the outcome after CABG","title":"Aggressive lipid lowering improves the outcome after coronary artery bypass graft","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Aggressive lipid lowering improves the outcome after coronary artery bypass graft</div><div class=\"cntnt\"><img style=\"width:509px; height:349px;\" src=\"images/CARD/74401_Lipid_therapy_after_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Post Coronary Artery Bypass Graft trial, which enrolled 1351 patients, aggressive lipid-lowering therapy with lovastatin and, if needed, cholestyramine insignificantly reduced the composite clinical end point of death, myocardial infarction, need for revascularization procedures, or stroke by 18% at the end of the trial. However, at the end of the 7.5-year extended follow-up period, there was a significant 24% reduction in the composite clinical endpoint (p = 0.001).</div><div class=\"graphic_reference\">Data from: Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157.</div><div id=\"graphicVersion\">Graphic 74401 Version 4.0</div></div></div>"},"74402":{"type":"graphic_table","displayName":"Five \"A's\" for addressing smoking cessation","title":"Five \"A's\" for assessing for tobacco use and addressing smoking cessation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five \"A's\" for assessing for tobacco use and addressing smoking cessation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Technique</td> </tr> <tr> <td><strong>A</strong>sk</td> <td>Implement an officewide system that ensures that, for every patient at every clinic visit, tobacco-use status is queried and documented. Repeated assessment is not necessary in the case of the adult who has never used tobacco or has not used tobacco for many years, and for whom this information is clearly documented in the medical record.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>A</strong>dvise</td> <td>Strongly urge all tobacco users to quit in a clear, strong, personalized manner.</td> </tr> <tr> <td class=\"sublist1_start\">Advice should be:</td> </tr> <tr> <td class=\"sublist1\">Clear - \"I think it is important for you to quit smoking now and I can help you.\" \"Cutting down while you are ill is not enough.\"</td> </tr> <tr> <td class=\"sublist1\">Strong - \"As your clinician, I need you to know that quitting smoking is the most important thing you can do to protect your health now and in the future. The clinic staff and I will help you.\"</td> </tr> <tr> <td class=\"sublist1\">Personalized - Tie tobacco use to current health/illness and/or its social and economic costs, motivation level/readiness to quit, and/or the impact of tobacco use on children and others in the household.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>A</strong>ssess</td> <td class=\"sublist1_start\">Determine the patient's willingness to quit smoking within the next 30 days:</td> </tr> <tr> <td class=\"sublist1\">If the patient is willing to make a quit attempt at this time, provide assistance.</td> </tr> <tr> <td class=\"sublist1\">If the patient will participate in an intensive treatment, deliver such a treatment or refer to an intensive intervention.</td> </tr> <tr> <td class=\"sublist1\">If the patient clearly states he or she is unwilling to make a quit attempt at this time, provide a motivational intervention.</td> </tr> <tr> <td class=\"sublist1\">If the patient is a member of a special population (eg, adolescent, pregnant smoker), provide additional information specific to that population.</td> </tr> <tr class=\"divider_top\"> <td><strong>A</strong>ssist</td> <td>Provide aid for the patient to quit. These actions are summarized in the accompanying table.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>A</strong>rrange</td> <td>Schedule follow-up contact, either in person or by telephone. Follow-up contact should occur soon after the quit date, preferably during the first week. A second follow-up contact is recommended within the first month. Schedule further follow-up contacts as indicated.</td> </tr> <tr> <td>Congratulate success during each follow-up. If tobacco use has occurred, review circumstances and elicit recommitment to total abstinence. Remind the patient that a lapse can be used as a learning experience. Identify problems already encountered and anticipate challenges in the immediate future. Assess pharmacotherapy use and problems. Consider use or referral to more intensive treatment.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fiore MC, Jaen C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. 2008.</div><div id=\"graphicVersion\">Graphic 74402 Version 11.0</div></div></div>"},"74406":{"type":"graphic_picture","displayName":"Histoplasmosis lung granuloma","title":"Pulmonary histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary histoplasmosis</div><div class=\"cntnt\"><img style=\"width:366px; height:240px;\" src=\"images/ID/74406_Histoplasmosislunggranulo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a hematoxylin and eosin-stained section of lung (low power) from a patient with histoplasmosis. Note the granuloma and inflammation in the surrounding lung tissue.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 74406 Version 2.0</div></div></div>"},"74409":{"type":"graphic_figure","displayName":"SUNCT SUNA attacks","title":"The three types of clinical picture of attacks of SUNCT/SUNA","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">The three types of clinical picture of attacks of SUNCT/SUNA</div><div class=\"cntnt\"><img style=\"width:562px; height:501px;\" src=\"images/NEURO/74409_SUNCT_SUNA_attacks.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cohen, AS, Matharu, MS, Goadsby, PJ. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA)-a prospective clinical study of SUNCT and SUNA. Brain 2006; 129 (10):2746. Copyright &#169;2006 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 74409 Version 1.0</div></div></div>"},"74410":{"type":"graphic_figure","displayName":"Subarachnoid spaces and cisterns","title":"Subarachnoid spaces and cisterns as seen in a median section of the brain","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Subarachnoid spaces and cisterns as seen in a median section of the brain</div><div class=\"cntnt\"><img style=\"width:542px; height:437px;\" src=\"images/ONC/74410_Subarachnoidspacediagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superior cistern (located dorsal to the midbrain) together with the subarachnoid space at the sides of the midbrain are referred to clinically as the cisterna ambiens. The superior cistern is important because it contains internal cerebral veins which join caudally to form the great cerebral vein (of Galen). It also contains the posterior cerebral and superior cerebellar arteries. The choroid plexuses in the roof of the third and fourth ventricles are shown in red.</div><div id=\"graphicVersion\">Graphic 74410 Version 4.0</div></div></div>"},"74411":{"type":"graphic_picture","displayName":"Seborrheic dermatitis face 2 PI","title":"Facial seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Facial seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:644px; height:270px;\" src=\"images/DERM/74411_Seborrheicdermface2PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows a person with seborrheic dermatitis affecting the cheeks and the area between the nose and lips.</div><div id=\"graphicVersion\">Graphic 74411 Version 4.0</div></div></div>"},"74412":{"type":"graphic_picture","displayName":"Thompson squeeze test for Achilles tendon","title":"Thompson squeeze test for Achilles tendon","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Thompson squeeze test for Achilles tendon</div><div class=\"cntnt\"><img style=\"width:540px; height:395px;\" src=\"images/EM/74412_Thompson_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This test is performed with the patient's feet hanging over the edge of the examining table. When the examiner squeezes the calf muscle, on the uninjured side there is normal plantar flexion of the foot; on the side with a complete Achilles tendon rupture, there is no plantar flexion. It is important to note that in patients with significant but incomplete rupture of the tendon, the patient may still demonstrate a normal Thompson test as well as substantial strength.</div><div id=\"graphicVersion\">Graphic 74412 Version 4.0</div></div></div>"},"74413":{"type":"graphic_picture","displayName":"Follicular large cell NHL","title":"Follicular lymphoma grade 3 (follicular large cell lymphoma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma grade 3 (follicular large cell lymphoma)</div><div class=\"cntnt\"><img style=\"width:325px; height:328px;\" src=\"images/HEME/74413_Follicular_large_cell_NHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This field is predominated by large noncleaved cells (centroblasts) which vary in size.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 74413 Version 2.0</div></div></div>"},"74414":{"type":"graphic_picture","displayName":"Lisch nodules","title":"Lisch nodules in a patient with neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lisch nodules in a patient with neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:389px; height:268px;\" src=\"images/PEDS/74414_Lisch_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The iris of a patient with neurofibromatosis type 1 (NF1), showing multiple Lisch nodules (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Friedman JM, Gutmann H, MacCollin M, Riccardi VM (Eds). Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, 3rd ed, Johns Hopkins University Press, Baltimore 1999. Photograph courtesy of RA Lewis, MD.</div><div id=\"graphicVersion\">Graphic 74414 Version 4.0</div></div></div>"},"74415":{"type":"graphic_table","displayName":"Dangerous household products","title":"Common dangerous household products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common dangerous household products</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Potentially hazardous agents</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cleaning agents and solvents</td> </tr> <tr> <td class=\"indent1\">Bleaches</td> <td>Sodium hypochlorite (\"Clorox\")</td> </tr> <tr> <td class=\"indent1\">Window cleaner</td> <td>Ammonia</td> </tr> <tr> <td class=\"indent1\">Carpet cleaner</td> <td>Ammonia, turpentine, naphthalene, 1,1,1-trichloroethane</td> </tr> <tr> <td class=\"indent1\">Oven and drain cleaners</td> <td>Potassium hydroxide, sodium hydroxide</td> </tr> <tr> <td class=\"indent1\">Dry-cleaning fluids, spot removers</td> <td>1,1,1-trichloroethane, perchloroethylene, petroleum distillates</td> </tr> <tr> <td class=\"indent1\">Rust remover</td> <td>Hydrofluoric acid</td> </tr> <tr> <td class=\"indent1\">Paint and varnish solvents</td> <td>Turpentine, xylene, toluene, methanol, methylene, chloride, acetone</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disinfectants</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Cresol, phenol, hexachlorophene</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pesticides</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Malathion, dichlorvos, carbaryl, methoxychlor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Emissions from heating or cooling devices</td> </tr> <tr> <td class=\"indent1\">Gas stove or pilot light</td> <td>Nitrogen oxides</td> </tr> <tr> <td class=\"indent1\">Indoor use of charcoal grill</td> <td>Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Leaks from refrigerator or air conditioner cooling systems</td> <td>Fluorocarbons (\"Freon\")</td> </tr> <tr> <td class=\"indent1\">Sun lamps</td> <td>Ultraviolet radiation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Goldman RH, Peters JM. JAMA 1981; 246:2831.</div><div id=\"graphicVersion\">Graphic 74415 Version 4.0</div></div></div>"},"74416":{"type":"graphic_diagnosticimage","displayName":"CMV pneumonia","title":"CMV pneumonia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CMV pneumonia</div><div class=\"cntnt\"><img style=\"width:356px; height:300px;\" src=\"images/PULM/74416_CMV_pneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing multifocal patchy pneumonia due to cytomegalovirus infection.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74416 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"74417":{"type":"graphic_picture","displayName":"Crystals in synovial fluid","title":"Crystals in synovial fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crystals in synovial fluid</div><div class=\"cntnt\"><img style=\"width:368px; height:264px;\" src=\"images/RHEUM/74417_Crystals_in_synovial_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crystals commonly encountered by color compensated polarized light microscopic examination of synovial fluid aspirated from inflamed joints or irrigated from tophi of patients with gout. The four panels show: needle-shaped urate crystals without inflammatory cells from a tophus (upper left); intra- and extracellular urate crystals during acute gouty arthritis (upper right); an intracellular calcium pyrophosphate (CPP)&nbsp;crystal during an episode of acute CPP crystal arthritis (pseudogout) (lower left); and cholesterol crystals from a chronic joint effusion aspirated from a patient with rheumatoid arthritis (lower right). Note the characteristic needle-shaped urate crystals, rhomboid-shaped CPP crystal, and notched shield-shaped cholesterol crystals.</div><div class=\"graphic_reference\">Courtesy of Michael A Becker, MD.</div><div id=\"graphicVersion\">Graphic 74417 Version 6.0</div></div></div>"},"74418":{"type":"graphic_waveform","displayName":"Pressures mitral regurgitation","title":"Pressure tracings in mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure tracings in mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:406px; height:281px;\" src=\"images/CARD/74418_Pressures_mitral_regurgitat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneously recorded pressures from the left atrium (LA) and left ventricle in a patient with mitral regurgitation. There is a tall &quot;V&quot; wave in the LA occurring during ventricular systole, reflecting a large regurgitant volume of blood ejected into the LA.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.</div><div id=\"graphicVersion\">Graphic 74418 Version 3.0</div></div></div>"},"74419":{"type":"graphic_figure","displayName":"Chromophore absorption spectrum","title":"Chromophore absorption spectrum","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Chromophore absorption spectrum</div><div class=\"cntnt\"><img style=\"width:487px; height:298px;\" src=\"images/DERM/74419_Chromophore-absorption-spectrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absorption spectra vary among chromophores. Absorption of light by melanin progressively decreases with increasing wavelengths of light. In contrast, the absorption of light by water molecules generally increases as wavelengths increase. Oxyhemoglobin has two peaks of light absorption within the visible light range.</div><div id=\"graphicVersion\">Graphic 74419 Version 3.0</div></div></div>"},"74420":{"type":"graphic_picture","displayName":"Herpes zoster ophthalmicus","title":"Herpes zoster ophthalmicus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes zoster ophthalmicus</div><div class=\"cntnt\"><img style=\"width:309px; height:432px;\" src=\"images/ID/74420_Herpes_zoster_opthalmicus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lesions of herpes zoster progress through stages, beginning as red macules and papules that, in the course of 7 to 10 days, evolve into vesicles and form pustules and crusts (scabs). A common site is the distribution of the opthalmic division of the trigeminal nerve.</div><div class=\"graphic_reference\">Reproduced with permission from: Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84:274. Copyright © 2009 Quadrant HealthCom, Inc.</div><div id=\"graphicVersion\">Graphic 74420 Version 9.0</div></div></div>"},"74421":{"type":"graphic_diagnosticimage","displayName":"Moyamoya and ischemic stroke","title":"A nine-year-old boy with moyamoya disease who presented with repeated episodes of transient left hemiparesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A nine-year-old boy with moyamoya disease who presented with repeated episodes of transient left hemiparesis</div><div class=\"cntnt\"><img style=\"width:359px; height:399px;\" src=\"images/NEURO/74421_Nine_year_old_MMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Noncontrast head CT scan shows low density area of infarction in the right basal ganglia (arrow).<br />(B) MRI FLAIR image depicting a high signal intensity area in the right basal ganglia and multiple small hyperintense areas in both basal ganglia consistent with infarction.<br />(C and D) Selective intra-arterial digital subtraction angiogram (anteroposterior projection) shows severe stenoses of the distal right and left internal carotid arteries. Abnormal network of blood vessels (puff of smoke or moyamoya vessels) in the vicinity of the stenotic areas were noted (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Nijasri Suwanwela, MD.</div><div id=\"graphicVersion\">Graphic 74421 Version 6.0</div></div></div>"},"74422":{"type":"graphic_picture","displayName":"Light microscopy seminoma","title":"Seminoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seminoma</div><div class=\"cntnt\"><img style=\"width:386px; height:258px;\" src=\"images/ONC/74422_Light_microscopy_seminoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a testicular seminoma. Many of the seminoma cells have clear cytoplasm and a \"fried egg\" appearance (black arrow). Intermixed clusters of smaller lymphocytes are typical.</div><div class=\"graphic_reference\">Courtesy of Michael Weinstein, MD, PhD.</div><div id=\"graphicVersion\">Graphic 74422 Version 2.0</div></div></div>"},"74424":{"type":"graphic_diagnosticimage","displayName":"Spot magnification MLO view","title":"Medial lateral oblique mammographic view","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Medial lateral oblique mammographic view</div><div class=\"cntnt\"><img style=\"width:469px; height:242px;\" src=\"images/ONC/74424_Spot_magnification_MLO_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These images illustrate the benefits of spot compression and magnification. In the left panel (A), a medial lateral oblique (MLO) mammographic image, there is a mass at the posterior edge of the film (arrows) which is incompletely characterized. The borders of the lesion can be better characterized with regional spot compression and magnification. The spot magnification MLO view (B) shows that the lesion has irregular borders and spiculation. In addition, associated microcalcifications are seen. The lesion can now be characterized as suspicious, BIRADS 4c, requiring biopsy. Pathology revealed infiltrating duct cell carcinoma with papillary features.</div><div class=\"graphic_footnotes\">BIRADS: breast imaging reporting and data system.</div><div id=\"graphicVersion\">Graphic 74424 Version 3.0</div></div></div>"},"74429":{"type":"graphic_figure","displayName":"Scope of pelvic exenteration","title":"Scope of pelvic exenteration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scope of pelvic exenteration</div><div class=\"cntnt\"><img style=\"width:404px; height:651px;\" src=\"images/OBGYN/74429_Scope_of_pelvic_exenteratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of lines of resection.</div><div id=\"graphicVersion\">Graphic 74429 Version 1.0</div></div></div>"},"74430":{"type":"graphic_table","displayName":"Extended LMW heparin hip repl","title":"Relative risk for all episodes of deep venous thrombosis after elective hip arthroplasty during the out-of-hospital time interval","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative risk for all episodes of deep venous thrombosis after elective hip arthroplasty during the out-of-hospital time interval</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Study</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Patients with events, n/n (percent)</td>\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Relative risk (95% CI)</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td class=\"subtitle2_left\"> LMW Heparin</td>\n\n      <td class=\"subtitle2_left\">Placebo </td>\n\n      \n\n    </tr>\n\n    <tr>\n\n\n      <td>N Engl J Med 1996; 335:696</td>\n\n      <td>21/117 (17.9)</td>\n\n      <td>45/116 (38.8)</td>\n\n      <td>0.46 (0.30-0.73)</td>\n\n    </tr>\n\n    \n    <tr>\n\n\n      <td>Lancet 1996; 348: 224</td>\n\n      <td>6/85 (7.1)</td>\n\n      <td>17/88 (19.3)</td>\n\n      <td>0.37 (0.15-0.88)</td>\n\n    </tr>\n\n    \n    <tr>\n\n\n      <td>Thromb Haemost 1997; 77:26</td>\n\n      <td>11/93 (11.8)</td>\n\n      <td>23/89 (25.8)</td>\n\n      <td>0.46 (0.24-0.88)</td>\n\n    </tr>\n\n    \n    <tr>\n\n\n      <td>Thromb Res 1998; 89:281</td>\n\n      <td>5/113 (4.4)</td>\n\n      <td>12/102 (11.8)</td>\n\n      <td>0.38 (0.14-1.03)</td>\n\n    </tr>\n\n    \n    <tr>\n\n\n      <td>Arch Int Med 2000; 160:2208</td>\n\n      <td>14/291 (4.8)</td>\n\n      <td>14/133 (10.5)</td>\n\n      <td>0.46 (0.22-0.93)</td>\n\n    </tr>\n\n    \n    <tr>\n\n\n      <td colspan=\"1\">J Bone Joint Surg 2001; 83-A: 336</td>\n\n      <td>15/152 (9.9)</td>\n\n      <td>39/138 (28.2)</td>\n\n      <td>0.35 (0.20-0.60)</td>\n\n    </tr>\n\n    \n    <tr>\n\n\n      <td>Total</td>\n\n      <td>72/911 (7.9)</td>\n\n      <td>150/666 (22.5)</td>\n\n      <td>0.41 (0.32-0.54)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from: Hull, R, Pineo, G, Stein, P, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Annals of Internal Medicine 2001; 135:858. Copyright &#169; 2001 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 74430 Version 1.0</div></div></div>"},"74431":{"type":"graphic_diagnosticimage","displayName":"Cardiac bronchus","title":"Cardiac bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac bronchus</div><div class=\"cntnt\"><img style=\"width:360px; height:263px;\" src=\"images/PULM/74431_Cardiac_bronchus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows an extra bronchus originating medial to the right lower lobe bronchus. In cross-section, the extra bronchus appears as an additional lucent ring shadow. This is an incidental finding.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74431 Version 4.0</div></div></div>"},"74433":{"type":"graphic_table","displayName":"Comparison of PGHS1 and PGHS2","title":"Comparison of COX-1 and COX-2 enzymes and their functions and localization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of COX-1 and COX-2 enzymes and their functions and localization</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">PGHS-1 (COX-1)</td>\n\n      <td class=\"subtitle1\">PGHS-2 (COX-2)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Size</td>\n\n      <td>65.5 kDa (576 amino acids)</td>\n\n      <td>65.5 kDa</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Regulation</td>\n\n      <td>Constitutive</td>\n\n      <td>Inducible (phorbol ester, oncogenes, cytokines; inhibited by glucocorticoids)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Subcellular localization</td>\n\n      <td>Lumenal surface of endoplasmic reticulum (also perinuclear membrane)</td>\n\n      <td>Lumenal surface of perinuclear membrane (also endoplasmic reticulum)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tissue localization</td>\n\n      <td>Platelets, endothelial cells, stomach, kidney, and most tissues</td>\n\n      <td>Prostate, brain, activated macrophages, fibroblasts, and\nsynoviocytes; capable of expression in most tissues with appropriate\nstimulation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Homology</td>\n\n      <td colspan=\"2\" rowspan=\"1\">Approximately 60 percent identical,\n75 percent homologous, with conservation in heme binding sites, active\nsite (aspirin acetylation site is Serine 530 in PGHS-1, Serine 516 in\nPGHS-2), glycosylation sites, and the epidermal growth factor domain</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Selective inhibitors</td>\n\n      <td>Valeryl salicylate</td>\n\n      <td colspan=\"1\">6-methoxy-2-napthyl-acetic acid (active metabolite of Nabumetone), NS-398, DuP-697, Sc-58635, SC-58550, SC-58125</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74433 Version 2.0</div></div></div>"},"74434":{"type":"graphic_figure","displayName":"Rhythm versus rate control AF RACE","title":"Rate control versus rhythm control in RACE","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Rate control versus rhythm control in RACE</div><div class=\"cntnt\"><img style=\"width:459px; height:341px;\" src=\"images/CARD/74434_Rhythm_v_rate_control_AF_RA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of the RACE trial in which 522 patients with recurrent persistent atrial fibrillation (AF) were randomly assigned to rhythm or rate control. The primary end point was a composite of cardiovascular death, heart failure, thromboembolism, bleeding, pacemaker placement, and antiarrhythmic drug side effects. There was an almost significant trend toward a lower incidence of the primary end point with rate control (17.2 versus 22.6 percent with rhythm control, hazard ratio 0.73, 90 percent CI 0.53 to 1.01).</div><div class=\"graphic_reference\">Data from Van Gelder IC, Hagens VE, Bosker HA, et al. N Engl J Med 2002; 347:1834.</div><div id=\"graphicVersion\">Graphic 74434 Version 3.0</div></div></div>"},"74435":{"type":"graphic_table","displayName":"Monitoring for metabolic side effects of antipsychotic drugs","title":"Monitoring for metabolic side effects of antipsychotic drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring for metabolic side effects of antipsychotic drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"7\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Baseline</td> <td class=\"subtitle1\">4 weeks</td> <td class=\"subtitle1\">8 weeks</td> <td class=\"subtitle1\">12 weeks</td> <td class=\"subtitle1\">Quarterly</td> <td class=\"subtitle1\">Annually</td> <td class=\"subtitle1\">At least every 5 years</td> </tr> <tr> <td><strong>Personal or family history</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Weight (body mass index)</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Waist circumference</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Blood pressure</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Fasting plasma glucose</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Fasting lipid profile</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">*</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For patients taking olanzapine, quetiapine, clozapine.</div><div class=\"graphic_reference\">Copyright &copy; 2004 American Diabetes Association. From Diabetes Care, Vol. 27, 2004: 596-601. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 74435 Version 6.0</div></div></div>"},"74436":{"type":"graphic_picture","displayName":"Cocaine purpura","title":"Purpura due to cocaine adulterated with levamisole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpura due to cocaine adulterated with levamisole</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/74436_Cocaine_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpura are present on the skin.</div><div id=\"graphicVersion\">Graphic 74436 Version 1.0</div></div></div>"},"74438":{"type":"graphic_picture","displayName":"Funisitis","title":"Funisitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Funisitis</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/74438_Funisitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph of an umbilical vein with migration of fetal inflammatory cells into the inner third of vein wall.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 74438 Version 3.0</div></div></div>"},"74439":{"type":"graphic_diagnosticimage","displayName":"Transpedicle CT needle bone bx","title":"Transpedicle approach to CT-guided needle biopsy of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transpedicle approach to CT-guided needle biopsy of bone</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/ONC/74439_Transpedicle_CT_needle__bon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan image with bone windows, demonstrating a transpedicle approach to CT-guided needle biopsy of a bone tumor involving the spine. This technique allows access to approximately&nbsp;two-thirds of the vertebral body, avoids the spinal nerve roots, and is relatively painless.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 74439 Version 3.0</div></div></div>"},"74441":{"type":"graphic_table","displayName":"Urinary clues to inborn errors of metabolism","title":"Urinary clues to inborn errors of metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urinary clues to inborn errors of metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td class=\"subtitle1\">&nbsp;</td>\n\t\t<td class=\"subtitle1\">Potential\ndisorder</td>\n\t\t\n</tr>\n<tr><td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Urine color</td>\n\t\t</tr>\n<tr>\n<td class=\"indent1\">Black (upon standing/oxidation)</td>\n\t\t\n<td>Homogentisic aciduria (alkaptonuria)</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Blue</td>\n\t\t\n<td>Tryptophan malabsorption</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Pink</td>\n\t\t\n<td>Disorders with hematuria, kidney stone formation</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Port wine (upon standing/oxidation)</td>\n\t\t\n<td>Porphyrias</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Yellow-orange</td>\n\t\t\n<td>Disorders with increased uric acid</td>\n\t\t\n</tr>\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Urine\nodor*</td>\n\t\t\n</tr>\n\n<tr><td class=\"indent1\">Acrid, sweaty feet</td>\n\t\t\n<td>Glutaric acidemia II</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Cabbage</td>\n\t\t\n<td>Tyrosinemia</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Fishy</td>\n\t\t\n<td>Trimethlylaminuria, dimethylglycinuria</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Maple syrup, curry</td>\n\t\t\n<td>Maple syrup urine disease</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Mousy</td>\n\t\t\n<td>Phenylketonuria</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Sweaty feet</td>\n\t\t\n<td>Isovaleric acidemia</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Sweet</td>\n\t\t\n<td>Beta-ketothiolase deficiency</td>\n\t\t\n</tr>\n<tr>\n<td class=\"indent1\">Swimming pool</td>\n\t\t\n<td>Hawkinsinuria</td>\n\t\t\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Only in acute phases or depending on food intake.</div><div class=\"graphic_reference\">Adapted from: Wappner RS, Hainline BE. Inborn errors of metabolism. In: Oski's Pediatrics. Principles and Practice, 3rd ed, McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, 1999. p.1823 and Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p.1327.</div><div id=\"graphicVersion\">Graphic 74441 Version 3.0</div></div></div>"},"74443":{"type":"graphic_picture","displayName":"Erythema migrans Biopsy I","title":"Erythema migrans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema migrans</div><div class=\"cntnt\"><img style=\"width:358px; height:235px;\" src=\"images/RHEUM/74443_Erythema_migrans_Biopsy_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy obtained from within 1 cm of the peripheral margin of an erythema migrans lesion showing endothelial cell injury with incipient fibrin deposition and regenerative alterations of the endothelium. There is luminal attenuation and a very sparse infiltrate. Similar changes are noted in the central nervous system, synovium, and myocardium in advanced Lyme disease.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 74443 Version 1.0</div></div></div>"},"74444":{"type":"graphic_table","displayName":"Speech and language delay resources","title":"Resources related to speech and language delay/disorder for parents and clinicians","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources related to speech and language delay/disorder for parents and clinicians</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Books for parents</td> </tr> <tr> <td colspan=\"2\">Agin M, Geng L, and Nichol M. The Late Talker: What To Do If Your Child Isn't Talking Yet, St. Martin's Press, New York 2003.</td> </tr> <tr> <td colspan=\"2\">Feit D, with Feldman H. The Parent's Guide to Speech and Language Problems, McGraw-Hill, New York 2007.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Websites</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Apraxia</td> </tr> <tr> <td class=\"indent1\">Apraxia Kids</td> <td><a href=\"http://www.apraxia-kids.org/\" target=\"_blank\">www.apraxia-kids.org</a></td> </tr> <tr> <td class=\"indent1\">The Cherab Foundation</td> <td><a href=\"http://www.cherabfoundation.org/\">www.cherabfoundation.org</a> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Autism</td> </tr> <tr> <td class=\"indent1\">Autism Speaks</td> <td><a href=\"http://www.autismspeaks.org/\" target=\"_blank\">www.autismspeaks.org</a></td> </tr> <tr> <td class=\"indent1\">CDC's Learn the Signs/Act Early</td> <td><a href=\"http://www.cdc.gov/ncbddd/actearly/index.html\" target=\"_blank\">www.cdc.gov/ncbddd/actearly/index.html</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bilingual language development</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">American Speech-Language-Hearing Association</td> <td><a href=\"http://www.asha.org/public/speech/development/bilingualchildren.htm\" target=\"_blank\">www.asha.org/public/speech/development/bilingualchildren.htm</a></td> </tr> <tr> <td><a href=\"http://www.asha.org/public/speech/development/second.htm\" target=\"_blank\">www.asha.org/public/speech/development/second.htm</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Early language and literacy development</td> </tr> <tr> <td class=\"indent1\">Afasic England. Unlocking speech and language</td> <td><a href=\"http://www.afasicengland.org.uk/\" target=\"_blank\">www.afasicengland.org.uk</a></td> </tr> <tr> <td class=\"indent1\">I Can</td> <td><a href=\"http://www.ican.org.uk/\" target=\"_blank\">www.ican.org.uk</a></td> </tr> <tr> <td class=\"indent1\">National Center for Learning Disabilities: Get Ready to Read</td> <td><a href=\"http://www.getreadytoread.org/\" target=\"_blank\">www.getreadytoread.org</a></td> </tr> <tr> <td class=\"indent1\">Reach Out and Read</td> <td><a href=\"http://www.reachoutandread.org/\" target=\"_blank\">www.reachoutandread.org</a></td> </tr> <tr> <td class=\"indent1\">Reading Rockets</td> <td><a href=\"http://www.readingrockets.org/\" target=\"_blank\">www.readingrockets.org</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General child development</td> </tr> <tr> <td class=\"indent1\">American Academy of Pediatrics Bright Futures</td> <td><a href=\"http://www.brightfutures.org/\" target=\"_blank\">www.brightfutures.org</a></td> </tr> <tr> <td class=\"indent1\">American Academy of Pediatrics Section on Developmental and Behavioral Pediatrics</td> <td><a href=\"http://www.aap.org/sections/dbpeds\" target=\"_blank\">www.aap.org/sections/dbpeds</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Language disorders</td> </tr> <tr> <td class=\"indent1\">American Speech-Language-Hearing Association</td> <td><a href=\"http://www.asha.org/public/speech/disorders/ChildSandL.htm\" target=\"_blank\">www.asha.org/public/speech/disorders/ChildSandL.htm</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Stuttering</td> </tr> <tr> <td class=\"indent1\">National Stuttering Association</td> <td><a href=\"http://www.nsastutter.org/\" target=\"_blank\">www.nsastutter.org</a></td> </tr> <tr> <td class=\"indent1\">The Stuttering Foundation</td> <td><a href=\"http://www.stutteringhelp.org/\" target=\"_blank\">www.stutteringhelp.org</a></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74444 Version 7.0</div></div></div>"},"74445":{"type":"graphic_picture","displayName":"Nuclear cystogram: VUR","title":"Nuclear cystogram demonstrating moderate to severe vesicoureteral reflux","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Nuclear cystogram demonstrating moderate to severe vesicoureteral reflux</div><div class=\"cntnt\"><img style=\"width:764px; height:645px;\" src=\"images/PEDS/74445_Nuclear_cystogram_VUR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Series of images from a nuclear cystogram starting with filling the bladder (filling&nbsp;voiding 1) to demonstrating unilateral reflux to the kidney (filling voidings 6 to 8).<br />(B) Enlarged single nuclear cystogram demonstrating reflux from the bladder to the kidney.</div><div id=\"graphicVersion\">Graphic 74445 Version 3.0</div></div></div>"},"74446":{"type":"graphic_picture","displayName":"Injury perpendicular exposure","title":"In-vitro experiments on human gallbladders with direct perpendicular exposure of the gallbladder mucosa to a laser","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">In-vitro experiments on human gallbladders with direct perpendicular exposure of the gallbladder mucosa to a laser</div><div class=\"cntnt\"><img style=\"width:389px; height:254px;\" src=\"images/GAST/74446_Injury_perpendicular_exposu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The laser fiber tip has created a narrow channel penetrating the wall up to the serosa.</div><div class=\"graphic_reference\">From: Lingenfelser TH, Routschka A, Grossman T, et al. Flashlamp exited pulsed dye laser and electrohydraulic lithotripsy: In vitro study on tissue effects. J Stone Dis 1993; 5:118. Copyright © 1993 Futrua Publishing Company, Inc.</div><div id=\"graphicVersion\">Graphic 74446 Version 3.0</div></div></div>"},"74448":{"type":"graphic_table","displayName":"High low sodium foods PI","title":"Ways to cut down on salt (sodium)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to cut down on salt (sodium)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Avoid these foods</td> <td class=\"subtitle1\">Try these foods instead</td> </tr> <tr class=\"divider_bottom\"> <td>Cured and smoked foods such as bacon, sausage, hot dogs, ham, lunch meats, and corn beef</td> <td>Fresh turkey, chicken, and lean beef</td> </tr> <tr class=\"divider_bottom\"> <td>Canned fish (such as sardines)</td> <td>Unsalted tuna</td> </tr> <tr class=\"divider_bottom\"> <td>Canned meats</td> <td>Fresh unprocessed meats, vegetable protein, and fish; or frozen and canned meats, vegetable protein, and fish that are labeled \"low sodium\"</td> </tr> <tr class=\"divider_bottom\"> <td>Salted pretzels, crackers, potato chips, and nuts</td> <td>Low-sodium and unsalted versions of these foods</td> </tr> <tr class=\"divider_bottom\"> <td>Most cheeses</td> <td>Low-sodium cheeses</td> </tr> <tr class=\"divider_bottom\"> <td>Sauces (tomato and cream etc), tomato juices</td> <td>Low-sodium versions of these foods, such as low-sodium tomato juice</td> </tr> <tr> <td rowspan=\"4\">Processed, instant, and convenience foods such as frozen dinners, packaged meals, canned soups, and boxed pasta blends</td> <td class=\"sublist1_start\">Cook and freeze your own low-sodium meals, soups, and broths</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>If you must use convenience or processed foods, read the labels and choose items with 140-200 mg of sodium per serving per food, or </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>For an entire convenience meal (frozen dinner), try to stay under 500-600 mg sodium. </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>If you do used canned foods, use \"sodium free\" varieties or rinse the canned food under water. This reduces the sodium content by about 40 percent. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74448 Version 6.0</div></div></div>"},"74451":{"type":"graphic_algorithm","displayName":"Algorithm for treatment of nausea and vomiting of pregnancy","title":"Management algorithm for treatment of nausea and vomiting of pregnancy (NVP)","html":"<div class=\"graphic\"><div style=\"width: 1016px\" class=\"figure\"><div class=\"ttl\">Management algorithm for treatment of nausea and vomiting of pregnancy (NVP)</div><div class=\"cntnt\"><img style=\"width:996px; height:768px;\" src=\"images/OBGYN/74451_Algo_trtmnt_NVP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women with heartburn/acid reflux may benefit from acid-reducing medications as adjunctive therapy anytime during the course of illness. Antacids containing aluminum or calcium are preferred. Preferred H2 blockers are ranitidine or cimetidine. There is less experience using proton pump inhibitors (eg, lansoprazole or esomeprazole).</div><div class=\"graphic_footnotes\">* Eat small amounts of food every one to two hours to avoid an empty or full stomach. It can be helpful to eliminate spicy, odorous, high-fat, acidic, and very sweet foods, and substitute protein-dominant, salty, low-fat, bland, and/or dry foods. Fluids should be consumed at least 30 minutes before or after solid food to minimize the effect of a full stomach. Fluids are better tolerated if cold, clear, and carbonated or sour. Avoid lying down after eating.<br />¶ Examples of some triggers include stuffy rooms, odors, heat, humidity, noise, visual or physical motion, and gastric irritants (eg, coffee, iron supplements).<br />Δ Doxylamine succinate 10 mg and pyridoxine 10 mg may be given separately or as a combination pill. We begin with 20 mg of each drug at bedtime. If ineffective, we give an additional 10 mg of each drug in the morning and in the afternoon.<br /><FONT class=lozenge>◊</FONT> We generally treat refractory cases with a short course of glucocorticoids but may begin with chlorpromazine in selected patients, such as those in whom the side effects of glucocorticoids may be more serious.<br />§ We usually begin with a diet consisting of bananas, rice, applesauce, and toast (BRAT diet) and then advance as tolerated to usual diet suggested for women with nausea and vomiting of pregnancy.</div><div id=\"graphicVersion\">Graphic 74451 Version 12.0</div></div></div>"},"74452":{"type":"graphic_algorithm","displayName":"Neutropenic fever reassessment after 2 to 4 days","title":"Reassessment of the patient with neutropenic fever after two to four days of empiric therapy","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Reassessment of the patient with neutropenic fever after two to four days of empiric therapy</div><div class=\"cntnt\"><img style=\"width:614px; height:508px;\" src=\"images/ID/74452_Febr_neutro_aft_2_to_4_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; CT: computed tomography; IV: intravenous; MRI: magnetic resonance imaging.<br> * We consider patients to be high-risk if they have either of the following characteristics: neutropenia (ANC &lt;500 cells/microL following cytotoxic chemotherapy) anticipated to last &gt;7 days OR significant comorbid conditions. It should be noted that in the Infectious Diseases Society of America guidelines, an ANC ≤100 cells/microL is used as the cutoff for high-risk neutropenia.<br> Δ Fever in a neutropenic patient is defined as a single temperature &gt;38.3°C (101°F) or a sustained temperature &gt;38.0°C (100.4°F) for &gt;1 hour.</div><div class=\"graphic_reference\">Adapted with permission from: Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56. Copyright © 2011 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 74452 Version 14.0</div></div></div>"},"74453":{"type":"graphic_picture","displayName":"Disseminated intravascular coagulation acral purpura","title":"Acral purpura in disseminated intravascular coagulation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acral purpura in disseminated intravascular coagulation</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74453_Dis_intrav_coag_acral_pupur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple purpuric lesions are present on the hand of this patient with disseminated intravascular coagulation. Several lesions exhibit a retiform shape.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74453 Version 5.0</div></div></div>"},"74454":{"type":"graphic_figure","displayName":"Wound eversion B","title":"Proper technique for wound edge eversion","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Proper technique for wound edge eversion</div><div class=\"cntnt\"><img style=\"width:497px; height:410px;\" src=\"images/EM/74454_Wound_eversion_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proper technique for everting the edges of a wound is illustrated in the panels on the left. <br />(A) The needle has been inserted at a 90 degree angle. <br />(B) The suture loop is as wide at the base as it is at the skin surface. The width and depth of the suture loop are the same on both sides of the wound. In the panels on the right, improper technique has resulted in inversion of the wound edges, which will interfere with wound healing. <br />(C) The needle has entered the skin at an angle. <br />(D) The base of the wound is narrower than the skin surface.</div><div id=\"graphicVersion\">Graphic 74454 Version 5.0</div></div></div>"},"74457":{"type":"graphic_table","displayName":"Diagnosis early mycosis fungoides","title":"Diagnosis of early mycosis fungoides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis of early mycosis fungoides</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Scoring system</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical</td> </tr> <tr> <td class=\"indent1\">Basic</td> <td>2 points for basic criteria and two additional criteria</td> </tr> <tr> <td class=\"indent1\">Persistent and/or progressive patches/thin plaques</td> <td>1 point for basic criteria and one additional criterion</td> </tr> <tr> <td class=\"sublist2_start\"><em>Additional</em>:</td> <td class=\"divider_bottom\" rowspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">1. Non-sun-exposed location</td> </tr> <tr> <td class=\"sublist2\">2. Size/shape variation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">3. Poikiloderma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Histopathologic</td> </tr> <tr> <td class=\"indent1\">Basic</td> <td>2 points for basic criteria and two additional criteria</td> </tr> <tr> <td class=\"indent1\">Superficial lymphoid infiltrate</td> <td>1 point for basic criteria and one additional criterion</td> </tr> <tr> <td class=\"sublist2_start\"><em>Additional</em>:</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">1. Epidermotropism without spongiosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">2. Lymphoid atypia<sup>*</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Molecular biologic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1. Clonal T cell receptor gene rearrangement</td> <td>1 point for clonality</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Immunopathologic</td> </tr> <tr> <td class=\"indent1\">1. &#60;50% CD2+, CD3+, and/or CD5+ T cells</td> <td rowspan=\"3\">1 point for one or more criteria</td> </tr> <tr> <td class=\"indent1\">2. &#60;10% CD7+ T cells</td> </tr> <tr> <td class=\"indent1\">3. Epidermal/dermal discordance of CD2, CD3, CD5, or CD7<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A total of 4 points is required for the diagnosis of mycosis fungoides based on any combination of points from the clinical, histopathologic, molecular biologic, and immunopathologic criteria.</div><div class=\"graphic_footnotes\">* Lymphoid atypia is defined as cells with enlarged hyperchromatic nuclei and irregular or cerebriform nuclear contours.<br />¶ T cell antigen deficiency confined to the epidermis.</div><div class=\"graphic_reference\">Reproduced with permission from: Pimpinelli, N, Olsen, EA, Santucci, M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053. Copyright &copy;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 74457 Version 4.0</div></div></div>"},"74459":{"type":"graphic_figure","displayName":"Car seat preterm infant","title":"Car seat for preterm infant","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Car seat for preterm infant</div><div class=\"cntnt\"><img style=\"width:530px; height:425px;\" src=\"images/PEDS/74459_Carseatpreterminfant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Car seat with a distance of 5 1/2 inches (14 cm) or less from the crotch strap to the seat back and 10 inches (24.5 cm) or less from the lower harness strap to the seat bottom. B) The preterm infant should be positioned with his/her buttocks and back flat against the back of the car safety seat. Car inserts are placed on both sides of the infant to provide lateral support for the head and neck. The shoulder straps are at the lowest slots ensuring that the shoulders are above the slots. The harness should fit snugly and the retainer clip positioned on the infant's chest.</div><div id=\"graphicVersion\">Graphic 74459 Version 2.0</div></div></div>"},"74460":{"type":"graphic_figure","displayName":"Rectal temperature PI","title":"Measuring rectal temperature","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Measuring rectal temperature</div><div class=\"cntnt\"><img style=\"width:540px; height:514px;\" src=\"images/PI/74460_Rectal_temperature_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lay your child face down across your lap. Put a dab of petroleum jelly (sample brand name:&nbsp;Vaseline) on the end of the thermometer. Then gently insert the thermometer into the child's anus until the silver tip is not visible (1/4 to 1/2 inch [6 to 12 millimeters] inside the anus). Hold the thermometer in place. A glass thermometer takes about 2 minutes. Most digital thermometers need less than 1 minute.</div><div id=\"graphicVersion\">Graphic 74460 Version 7.0</div></div></div>"},"74461":{"type":"graphic_figure","displayName":"Glucagon injection sites PI","title":"Where to give a glucagon shot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Where to give a glucagon shot</div><div class=\"cntnt\"><img style=\"width:254px; height:613px;\" src=\"images/PI/74461_Glucagon_injection_sites_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A glucagon shot can be given in the buttock, arm, or thigh (as shown by the shaded areas).</div><div id=\"graphicVersion\">Graphic 74461 Version 5.0</div></div></div>"},"74462":{"type":"graphic_diagnosticimage","displayName":"Mitral valve disease PA","title":"Mitral valve disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve disease</div><div class=\"cntnt\"><img style=\"width:346px; height:343px;\" src=\"images/PULM/74462_Mitral_valve_disease_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrates cephalization of pulmonary vascular flow, as well as pulmonary arterial hypertension with dilated central pulmonary arteries.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74462 Version 3.0</div></div></div>"},"74466":{"type":"graphic_diagnosticimage","displayName":"Toxoplasma encephalitis MRI","title":"MRI scan of patient with Toxoplasma encephalitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI scan of patient with Toxoplasma encephalitis</div><div class=\"cntnt\"><img style=\"width:296px; height:344px;\" src=\"images/ID/74466_Toxoplasma_encephalitis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple ring enhancing lesions with mass effect are visible after injection of gadolinium in this T1-weighted image.</div><div id=\"graphicVersion\">Graphic 74466 Version 3.0</div></div></div>"},"74471":{"type":"graphic_figure","displayName":"Survival advanced MF","title":"Mycosis fungoides: Impact of extracutaneous disease on survival","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides: Impact of extracutaneous disease on survival</div><div class=\"cntnt\"><img style=\"width:500px; height:283px;\" src=\"images/HEME/74471_Survival_advanced_MF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial survival of 600 patients with mycosis fungoides managed at Stanford University calculated from the date of referral. 1:543 patients with disease apparently limited to the skin (clinical stages I/II/III); 2:57 patients with extracutaneous disease (clinical stage IV) at the time of presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Kim YH, Hoppe RT. Mycosis fungoides and Sézary Syndrome. Semin Oncol 1999; 26:276.</div><div id=\"graphicVersion\">Graphic 74471 Version 3.0</div></div></div>"},"74472":{"type":"graphic_diagnosticimage","displayName":"Unstable metacarpal neck fracture","title":"Unstable metacarpal neck fracture ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unstable metacarpal neck fracture </div><div class=\"cntnt\"><img style=\"width:442px; height:334px;\" src=\"images/SURG/74472_Unstable_meta_neck_fing_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unstable metacarpal neck fractures can be treated by closed reduction and percutaneously inserted K-wires.</div><div id=\"graphicVersion\">Graphic 74472 Version 4.0</div></div></div>"},"74473":{"type":"graphic_picture","displayName":"Proximal subungual onychomycosis - fingernails","title":"Proximal subungual onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Proximal subungual onychomycosis</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/DERM/74473_Prox_sub_onych_fingernails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whitish discoloration originating under the surface of the proximal nail plate is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74473 Version 4.0</div></div></div>"},"74474":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid DIF","title":"Direct immunofluorescence study in ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence study in ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/DERM/74474_Ocular_cicatricial_pemp_DIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows the presence of linear deposits of IgG at the epithelial basement membrane, an abnormal finding and one that is supportive of the diagnosis of OCP. IgG is also present on the surface epithelium, typical of conjunctivitis from any cause. IgG is also normally found in the substantia propria (connective tissue layer) of human conjunctiva, and is shown to be present in this specimen.</div><div id=\"graphicVersion\">Graphic 74474 Version 1.0</div></div></div>"},"74475":{"type":"graphic_table","displayName":"Clinical summary cardioversion","title":"Clinical summary: Synchronized cardioversion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical summary: Synchronized cardioversion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">1. Assess patient:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Perform cardioversion immediately in hemodynamically unstable patients and those with altered mental status (lethargic, agitated).</td> </tr> <tr> <td class=\"sublist1\">&#8226; Administer supplemental oxygen and intravenous sedation and analgesia to stable patients undergoing cardioversion.</td> </tr> <tr> <td>2. Turn the machine on.</td> </tr> <tr> <td>3. Attach ECG leads to stable patients.</td> </tr> <tr> <td>4. Select the lead that displays the tallest R wave.</td> </tr> <tr> <td>5. Set machine to synchronous mode.</td> </tr> <tr> <td>6. Apply electrode conduction paste or gel to the paddles or open the electrode pads.</td> </tr> <tr> <td>7. Apply paddles or pad to appropriate positions on chest (anterior pad or paddle to right of sternum just under the clavicle, apex pad or paddle in the midaxillary line at the level of the nipple). Paddles must be applied firmly*.</td> </tr> <tr> <td>8. Select an initial energy dose of 0.5 to 1 Joules/kg.</td> </tr> <tr> <td>9. Charge unit by simultaneously pressing the charge button on the paddles or by pressing the charge button on the machine if electrode pads are being used.</td> </tr> <tr> <td>10. Ensure all personnel are clear from the patient and the patient's stretcher by loudly stating \"All Clear!\" prior to shock delivery.</td> </tr> <tr> <td>11. Deliver current by either depressing discharge buttons simultaneously on the paddles or by pressing the discharge button on the machines if electrode pads are being used.</td> </tr> <tr> <td>12. Assess clinical and electrical response to shock delivery.</td> </tr> <tr> <td>13. Proceed according to pediatric advanced life support guidelines.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">8/19/2009--Requested permission (JD). 9/27/2009--Permission granted; figure to Terrence, agreement mailed back to Arnetta (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10818&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* Anterior/posterior paddle position is acceptable but less practical during a critical resuscitation.</div><div class=\"graphic_reference\">Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74475 Version 13.0</div></div></div>"},"74476":{"type":"graphic_picture","displayName":"Lymphocytic infiltrate autoimmune POI","title":"Lymphocytic infiltration in autoimmune primary ovarian insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic infiltration in autoimmune primary ovarian insufficiency</div><div class=\"cntnt\"><img style=\"width:436px; height:301px;\" src=\"images/ENDO/74476_Lymphocytic_inf_ovary_pof.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stains panels A and C; immunoperoxidase stains panels B and D.<br />(A) Heavy lymphocytic infiltration of the theca (middle).<br />(B) Same area as A, with the heavy infiltration of lymphocytes highlighted by staining for the leukocyte common antigen.<br />(C) High power magnification of an early secondary follicle showing&nbsp;three layers of granulosa cells surrounding an unremarkable oocyte.<br />(D) Same area as C, showing absence of lymphocytic infltration (no leukocyte common antigen positive cells with immunoperoxidase stain).</div><div class=\"graphic_reference\">Reproduced with permission from: Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Treatment of autoimmune premature ovarian failure. Hum Reprod 1999; 14:1777. Copyright © 1999 Oxford University Press/Human Reproduction.</div><div id=\"graphicVersion\">Graphic 74476 Version 5.0</div></div></div>"},"74477":{"type":"graphic_figure","displayName":"Estimating pessary size","title":"Estimating size of vaginal pessary required","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estimating size of vaginal pessary required</div><div class=\"cntnt\"><img style=\"width:393px; height:323px;\" src=\"images/OBGYN/74477_Estimating_pessary_size.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A bimanual examination is performed to judge the distance from the posterior fornix to the posterior pubic symphysis. (B) The spot where the pubic symphysis rests on the examining hand is mentally marked. Sample pessaries are then held up to the examining hand to estimate the proper pessary size.</div><div id=\"graphicVersion\">Graphic 74477 Version 2.0</div></div></div>"},"74478":{"type":"graphic_table","displayName":"Prescribing cascades","title":"Examples of prescribing cascades","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of prescribing cascades</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Initial drug therapy</td> <td class=\"subtitle1\">Adverse drug event</td> <td class=\"subtitle1\">Subsequent drug therapy</td> </tr> <tr> <td>Antipsychotics</td> <td>Extrapyramidal signs and symptoms</td> <td>Antiparkinsonian therapy</td> </tr> <tr> <td>Cholinesterase inhibitors</td> <td>Urinary incontinence</td> <td>Incontinence treatment</td> </tr> <tr> <td>Thiazide diuretics</td> <td>Hyperuricemia</td> <td>Gout treatment</td> </tr> <tr> <td>NSAIDs</td> <td>Increased blood pressure</td> <td>Antihypertensive therapy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Medication prescribing cascades occur when patients are prescribed medications to treat the adverse side effects of previously prescribed medications. This leads to polypharmacy and further increases the risk for adverse drug events. Periodic review of medication lists, especially in older adults, can minimize this risk.</div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs.</div><div class=\"graphic_reference\">Data from: Rochon PA, Gurwitz JH. Optimizing drug therapy for elderly people: the prescribing cascade. BMJ 1997; 315:1096 and Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165:808.</div><div id=\"graphicVersion\">Graphic 74478 Version 4.0</div></div></div>"},"74479":{"type":"graphic_picture","displayName":"Lung biopsy in scleroderma ILD","title":"Lung biopsy in scleroderma-associated interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung biopsy in scleroderma-associated interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:351px; height:230px;\" src=\"images/PULM/74479_Fibrosis_in_SD_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung biopsy from a patient with scleroderma and a reticular pattern on high resolution CT scan that shows thickening of the alveolar septa with collagen (stained pink), a mild lymphocytic infiltrate, and tissue destruction. The arrow points to an example of an alveolar septum thickened by collagen deposition.&nbsp;These findings are consistent with fibrotic nonspecific interstitial pneumonia (NSIP).</div><div class=\"graphic_reference\">Courtesy of Professor B Corrin, Royal Brompton and National Heart Hospital, London, UK.</div><div id=\"graphicVersion\">Graphic 74479 Version 3.0</div></div></div>"},"74480":{"type":"graphic_picture","displayName":"Plasma cell granuloma low","title":"Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung</div><div class=\"cntnt\"><img style=\"width:319px; height:212px;\" src=\"images/PULM/74480_Plasma_cell_granuloma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low magnification photomicrograph of inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung. The tumor is composed of a combination of spindle cells and mononuclear inflammatory cells.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 74480 Version 2.0</div></div></div>"},"74483":{"type":"graphic_figure","displayName":"Melanoma - Impact of lymph node involvement on prognosis","title":"Melanoma - Impact of lymph node involvement on prognosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melanoma - Impact of lymph node involvement on prognosis</div><div class=\"cntnt\"><img style=\"width:439px; height:639px;\" src=\"images/ONC/74483_Melanoma-nodal-prog.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twenty-year survival rates comparing the different N categories (top) and the stage groupings (bottom) for stage III melanoma.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 74483 Version 15.0</div></div></div>"},"74484":{"type":"graphic_table","displayName":"Breast lobules differences","title":"Characteristics of human breast lobules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of human breast lobules</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Lobule type\n   </td>\n   <td  class=\"subtitle1\">\n   Lobule area (mm<sup>2</sup>)\n   </td>\n   <td  class=\"subtitle1\">\n   No. of components per lobule\n   </td>\n   <td  class=\"subtitle1\">\n   No. of cells/cross section\n   </td>\n   </tr>\n   <tr>\n   <td>Type 1</td>\n   <td>0.048&#177;0.044</td>\n   <td  colspan=\"1\">\n   11.2&#177;6.3\n   </td>\n   <td>32.4&#177;14.1</td>\n   </tr>\n   <tr>\n   <td>Type 2</td>\n   <td>0.060&#177;0.026</td>\n   <td  colspan=\"1\">\n   47.0&#177;11.7\n   </td>\n   <td>13.1&#177;4.8</td>\n   </tr>\n   <tr>\n   <td>Type 3</td>\n   <td>0.129&#177;0.049</td>\n   <td  colspan=\"1\">\n   81.0&#177;16.6\n   </td>\n   <td>11.0&#177;2.0</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: Russo J,&nbsp;et al, Breast Cancer Res and Treat 1992;&nbsp;23:211-218 and Russo J, Russo IH. Development of human mammary gland. In: Neville MC, Daniel CW, eds. The mammary gland. New York, Plenum, 1987; p 67.</div><div id=\"graphicVersion\">Graphic 74484 Version 5.0</div></div></div>"},"74486":{"type":"graphic_figure","displayName":"Anterior view of shoulder anatomy PI","title":"Anterior view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Anterior view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:600px; height:436px;\" src=\"images/PI/74486_Shoulder_anat_ant_muscle_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74486 Version 4.0</div></div></div>"},"74487":{"type":"graphic_figure","displayName":"Mastoid anatomy","title":"Anatomy of the mastoid bone","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Anatomy of the mastoid bone</div><div class=\"cntnt\"><img style=\"width:525px; height:402px;\" src=\"images/PEDS/74487_Mastoid_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74487 Version 1.0</div></div></div>"},"74488":{"type":"graphic_table","displayName":"Test results in hearing loss","title":"Summary of test results in normal, conductive, and sensorineural hearing loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of test results in normal, conductive, and sensorineural hearing loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Weber test lateralizes&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Rinne test&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Pure tone audiometry</td> <td class=\"subtitle1\" rowspan=\"2\">Tympanometry</td> <td class=\"subtitle1\" rowspan=\"2\">ABR</td> </tr> <tr> <td class=\"subtitle2\">Air</td> <td class=\"subtitle2\">Bone</td> </tr> <tr> <td>Normal hearing</td> <td>No</td> <td>Positive</td> <td>Normal (0 to 20 dB)</td> <td>Normal (0 to 20 dB)</td> <td>Type A</td> <td>Normal</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Conductive hearing loss</td> </tr> <tr> <td class=\"sublist1\">Good ear</td> <td class=\"sublist_other\">No</td> <td class=\"sublist_other\">Positive</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Type A</td> <td class=\"sublist_other\">Normal</td> </tr> <tr> <td class=\"sublist1\">Bad ear</td> <td class=\"sublist_other\">Yes</td> <td class=\"sublist_other\">Negative</td> <td class=\"sublist_other\">Abnormal (&#62;20 dB)</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Type B, C,&nbsp;AS, or AD</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Sensorineural hearing loss</td> </tr> <tr> <td class=\"sublist1\">Good ear</td> <td class=\"sublist_other\">Yes</td> <td class=\"sublist_other\">Positive</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Normal</td> <td class=\"sublist_other\">Type A</td> <td class=\"sublist_other\">Normal</td> </tr> <tr> <td class=\"sublist1\">Bad ear</td> <td class=\"sublist_other\">No</td> <td class=\"sublist_other\">Positive</td> <td class=\"sublist_other\">Abnormal (&#62;20 dB)</td> <td class=\"sublist_other\">Abnormal (&#62;20 dB)</td> <td class=\"sublist_other\">Type A</td> <td class=\"sublist_other\">Abnormal (delayed or absent waves)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABR: auditory brainstem response; dB: decibels; AS: type A tympanogram with reduced compliance (shallow); AD: type A tympanogram with increased compliance (deep).</div><div id=\"graphicVersion\">Graphic 74488 Version 2.0</div></div></div>"},"74489":{"type":"graphic_figure","displayName":"Compartments of neck","title":"Anatomical regions of the neck","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Anatomical regions of the neck</div><div class=\"cntnt\"><img style=\"width:537px; height:486px;\" src=\"images/PC/74489_Compartments_of_neck.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74489 Version 3.0</div></div></div>"},"74491":{"type":"graphic_table","displayName":"Parasites causing nodular lesions","title":"Parasitic infections associated with nodular lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parasitic infections associated with nodular lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infection </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Coenurosis</td> <td>Usually single, subcutaneous nodule</td> </tr> <tr> <td>Cysticercosis</td> <td>Painless, rubbery nodules; often multiple</td> </tr> <tr> <td>Dirofilariasis</td> <td>Subcutaneous nodule</td> </tr> <tr> <td>Dracunculiasis</td> <td>Papular or nodular lesion breaks down to discharge the worm</td> </tr> <tr> <td>Echinococcosis</td> <td>Soft, subcutaneous cysts of variable sizes</td> </tr> <tr> <td>Fascioliasis</td> <td>Painful or itchy subcutaneous nodules</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Filariasis </td> </tr> <tr> <td class=\"sublist1\">Loaisis </td> <td class=\"sublist_other\">Painful or itchy swellings </td> </tr> <tr> <td class=\"sublist1\">Onchocerciasis </td> <td class=\"sublist_other\">Subcutaneous nodules; papular, itchy rash </td> </tr> <tr> <td class=\"sublist1\"><em>Wuchereria bancrofti </em></td> <td class=\"sublist_other\">Recurrent lymphangitis; scrotal mass </td> </tr> <tr> <td>Gnathostomiasis</td> <td>Edematous, recurrent, migratory subcutaneous swellings</td> </tr> <tr> <td>Paragonimiasis</td> <td>Subcutaneous nodules</td> </tr> <tr> <td>Sarcocystis</td> <td>Subcutaneous nodules, eosinophilic myositis</td> </tr> <tr> <td>Schistosomiasis</td> <td>Verrucous, vegetating lesions</td> </tr> <tr> <td>Sparganosis</td> <td>Edematous, painful migratory swellings</td> </tr> <tr> <td>Visceral larva migrans</td> <td>Tender nodular rash</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74491 Version 5.0</div></div></div>"},"74492":{"type":"graphic_table","displayName":"Parent rx renal abscess in adults","title":"Parenteral antibiotic therapy of renal or perinephric abscess in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antibiotic therapy of renal or perinephric abscess in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Regimens for empiric therapy</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Piperacillin-tazobactam</td> <td>3.375 g every 4 hours or 4.5 g every 6 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ticarcillin-clavulanate*</td> <td>3.1 g every 4 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Cefepime</td> <td>1 g every 8 hours or 2 g every 12 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Meropenem</td> <td>1 g every 8 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Imipenem</td> <td>500 mg every 6 hours</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Regimens for therapy when susceptibility data are available</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ceftriaxone</td> <td>1 g every 24 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ciprofloxacin</td> <td>400 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Levofloxacin</td> <td>500 to 750 mg every 24 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Aztreonam</td> <td>1 g every 8 hours</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Regimens for empiric therapy in the setting of S. aureus bacteremia</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">MSSA</td> <td>Nafcillin</td> <td>2 g every 4 hours</td> </tr> <tr> <td>Oxacillin</td> <td>2 g every 4 hours</td> </tr> <tr> <td>Cefazolin</td> <td>2 g every 8 hours</td> </tr> <tr> <td class=\"indent1\">MRSA<sup>&#182;</sup></td> <td>Vancomycin</td> <td>15 to 20 mg/kg every 12 hours (maximum 2 g per dose)<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses listed are for patients with normal renal function. Dose adjustments may be warranted in the setting of impaired renal function.</div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus.<br />* Not available in the United States.<br />&para; For alternative agents with activity against MRSA, refer to the topic on treatment of invasive MRSA infections in adults.<br />&Delta; This is a suggested initial dose for vancomycin. For further discussion of serum concentration monitoring and dose modifications, refer to the topic on vancomycin dosing and monitoring in adults.</div><div id=\"graphicVersion\">Graphic 74492 Version 5.0</div></div></div>"},"74493":{"type":"graphic_movie","displayName":"TEE pacerwire vegetation","title":"Transesophageal echocardiography (TEE) pacerwire vegetation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography (TEE) pacerwire vegetation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/74493_teepacerwirevegetconv.mp4\" style=\"width:320px;height:244px\"></div><img style=\"width:319px; height:228px;\" src=\"images/CARD/74493_teepacerwirevegetation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dan Sexton, MD. Duke University.</div><div id=\"graphicVersion\">Graphic 74493 Version 3.0</div></div></div>"},"74495":{"type":"graphic_diagnosticimage","displayName":"MR normal fetal chest","title":"Fetal magnetic resonance image T2w of a normal chest at 32 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Fetal&nbsp;magnetic resonance image&nbsp;T2w of a normal chest at 32 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:586px; height:233px;\" src=\"images/OBGYN/74495_MR_normal_fetal_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A), coronal (B) and sagittal (C) images demonstrate homogeneous high signal lung parenchyma with normal pulmonary vessels coursing through them. The heart is black due to flowing blood.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 74495 Version 3.0</div></div></div>"},"74497":{"type":"graphic_diagnosticimage","displayName":"Isolated fracture of the medial malleolus","title":"Isolated fracture of the medial malleolus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isolated fracture of the medial malleolus</div><div class=\"cntnt\"><img style=\"width:331px; height:576px;\" src=\"images/EM/74497_Isolated_medial_malleolar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fracture of the medial malleolus (white arrow) is clearly seen on this view. Care must be taken to exclude additional injuries (eg, proximal fibular fracture) commonly&nbsp;associated with fractures of the medial or posterior malleoli.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 74497 Version 3.0</div></div></div>"},"74498":{"type":"graphic_table","displayName":"Dosing formulation monitor","title":"Summary of immunosuppression dosing, formulations, and monitoring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of immunosuppression dosing, formulations, and monitoring</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Formulations</td> <td class=\"subtitle1\">Monitoring</td> </tr> <tr> <td>Prednisone</td> <td>Daily</td> <td>Tablets, suspension, parenteral by substitution</td> <td>Blood pressure, glucose, lipids</td> </tr> <tr> <td>Azathioprine</td> <td>Daily</td> <td>Tablets, suspension, parenteral</td> <td>CBC, liver tests, pancreas toxicity</td> </tr> <tr> <td>Mycophenolate mofetil</td> <td>Twice daily</td> <td>Tablets, suspension</td> <td>CBC, abdominal symptoms</td> </tr> <tr> <td>Myocphenolate sodium</td> <td>Twice daily</td> <td>Tablets</td> <td>CBC, abdominal symptoms</td> </tr> <tr> <td>Cyclosporine</td> <td>Twice daily</td> <td>Capsules, suspension, parenteral</td> <td>Drug level, creatinine, lipids, K(+), Mg(2+), CNS toxicity</td> </tr> <tr> <td>Tacrolimus</td> <td>Twice daily</td> <td>Capsules, suspension, parenteral</td> <td>Drug level, creatinine, glucose, lipids, K(+), Mg(2+), CNS toxicity</td> </tr> <tr> <td>Sirolimus</td> <td>Daily</td> <td>Tablets, suspension</td> <td>CBC, drug level, lipids</td> </tr> <tr> <td>Everolimus</td> <td>Daily</td> <td>Tablets</td> <td>CBC, drug level, lipids</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 74498 Version 4.0</div></div></div>"},"74500":{"type":"graphic_figure","displayName":"Risk factors acute hepatitis C","title":"Sources of infection for persons with hepatitis C","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sources of infection for persons with hepatitis C</div><div class=\"cntnt\"><img style=\"width:407px; height:233px;\" src=\"images/GAST/74500_Risk_factors_acute_hep_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Nosocomial; health-care work; perinatal.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 74500 Version 3.0</div></div></div>"},"74502":{"type":"graphic_figure","displayName":"Longitudinal recovery in MRI","title":"Rate of recovery during longitudinal relaxation in MRI","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Rate of recovery during longitudinal relaxation in MRI</div><div class=\"cntnt\"><img style=\"width:482px; height:244px;\" src=\"images/PULM/74502_Longitudinal_recovery_in_MR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recovery of the longitudinal component of magnetization to its equilibrium value is exponential with a time constant T<sub>1</sub>. T<sub>1</sub> depends upon field strength, temperature, and tissue composition.</div><div id=\"graphicVersion\">Graphic 74502 Version 1.0</div></div></div>"},"74503":{"type":"graphic_figure","displayName":"WHO head circumference for age girls 0 to 24 months","title":"Head circumference-for-age percentiles, girls 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Head circumference-for-age percentiles, girls 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:562px; height:423px;\" src=\"images/PEDS/74503_WHO_head_cirum_girls_0to24.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 74503 Version 3.0</div></div></div>"},"74505":{"type":"graphic_figure","displayName":"Flow cytometric analysis of adhesion molecules on neutrophils","title":"Flow cytometric analysis of adhesion molecules on neutrophils","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Flow cytometric analysis of adhesion molecules on neutrophils</div><div class=\"cntnt\"><img style=\"width:511px; height:200px;\" src=\"images/ALLRG/74505_Adhesion_mol_anal.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LAD II presents with absence of CD15. LAD I presents with absence of CD18.</div><div class=\"graphic_footnotes\">LAD: leukocyte adhesion deficiency.</div><div id=\"graphicVersion\">Graphic 74505 Version 3.0</div></div></div>"},"74506":{"type":"graphic_picture","displayName":"Mallet finger PI","title":"Mallet finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallet finger</div><div class=\"cntnt\"><img style=\"width:432px; height:334px;\" src=\"images/PI/74506_Mallet_finger_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A &quot;mallet finger&quot; is a finger injury that makes the finger tip stay bent.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 74506 Version 1.0</div></div></div>"},"74507":{"type":"graphic_diagnosticimage","displayName":"TTE vs TEE abscess aortic root","title":"Aortic root abscess and mitral valve vegetations","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Aortic root abscess and mitral valve vegetations</div><div class=\"cntnt\"><img style=\"width:492px; height:237px;\" src=\"images/CARD/74507_TTE_vs_TEE_abscess_aortic_r.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis precordial view (panel A) from a transthoracic echocardiogram in a patient with clinical endocarditis and acute severe aortic regurgitation shows a deformed posterior aortic root and thickend anterior mitral leaflet (arrow), which are nonspecific. The transesophageal echocardiographic views (panels B and C) show a vegetation of the mitral valve (arrow, panel B) and a large abscess cavity of the aortic root (arrow, panel C).</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 74507 Version 3.0</div></div></div>"},"74509":{"type":"graphic_table","displayName":"Hepatic resection for metastatic colorectal cancer","title":"Results of hepatic resection for metastatic colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of hepatic resection for metastatic colorectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Author and year</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Five year OS, percent</td> <td class=\"subtitle1\">Median survival, months</td> </tr> <tr> <td>Hughes KS; 1986</td> <td>607</td> <td>33</td> <td>NR</td> </tr> <tr> <td>Scheele J; 1995</td> <td>434</td> <td>33</td> <td>40</td> </tr> <tr> <td>Nordlinger B; 1996</td> <td>1568</td> <td>28</td> <td>NR</td> </tr> <tr> <td>Jamison RL; 1997</td> <td>280</td> <td>27</td> <td>33</td> </tr> <tr> <td>Fong Y; 1999</td> <td>1001</td> <td>37</td> <td>42</td> </tr> <tr> <td>Iwatsuki S; 1999</td> <td>305</td> <td>32</td> <td>NR</td> </tr> <tr> <td>Choti M; 2002</td> <td>133</td> <td>58</td> <td>NR</td> </tr> <tr> <td>Abdalla E; 2004</td> <td>190</td> <td>58</td> <td>NR</td> </tr> <tr> <td>Fernandez FG; 2004</td> <td>100</td> <td>58</td> <td>NR</td> </tr> <tr> <td>Wei AC; 2006</td> <td>423</td> <td>47</td> <td>NR</td> </tr> <tr> <td>Rees M; 2008</td> <td>929</td> <td>36</td> <td>42.5</td> </tr> <tr> <td>de Jong M; 2009</td> <td>1669</td> <td>47</td> <td>36</td> </tr> <tr> <td>Morris EJ; 2010</td> <td>3116</td> <td>44</td> <td>NR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported; OS: overall survival.</div><div id=\"graphicVersion\">Graphic 74509 Version 6.0</div></div></div>"},"74512":{"type":"graphic_figure","displayName":"LV diastolic pressure and lungs","title":"Elevated left ventricular end-diastolic pressure causes pulmonary congestion","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Elevated left ventricular end-diastolic pressure causes pulmonary congestion</div><div class=\"cntnt\"><img style=\"width:498px; height:248px;\" src=\"images/CARD/74512_LVdiastolicpressureandl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart is seen in diastole when the mitral valve is open and the left ventricle (LV), left atrium (LA), and pulmonary veins form a common chamber, continuous with the pulmonary capillary bed. The LV end diastolic pressure determines the pulmonary capillary pressure and the presence or absence of pulmonary congestion or edema.</div><div id=\"graphicVersion\">Graphic 74512 Version 2.0</div></div></div>"},"74513":{"type":"graphic_table","displayName":"Bronchial wall puncture","title":"Techniques used for transbronchial wall penetration during TBNA*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques used for transbronchial wall penetration during TBNA*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Jabbing method</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The needle is thrust through the intercartilaginous space with a quick, firm jab to the catheter, while the scope is fixed at the nose or mouth.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hub against the wall method</td>\n\n    </tr>\n\n    <tr>\n\n      <td>With the needle in the retracted position, the distal end of the catheter (the metal hub) can be placed directly in contact with the target and held firmly while the needle is pushed out of the catheter for its spontaneous penetration through the tracheobronchial wall.</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Piggyback method</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Once the needle is advanced and locked in position, the catheter is fixed against the proximal end of the insertion port using the index finger in a single port scope or the little finger in a dual port scope to prevent recoil when resistance is met. The bronchoscope and catheter are then pushed forward as a single unit, until the entire needle penetrates the tracheobronchial wall.</td>\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cough method</td>\n\n    </tr>\n\n    <tr>\n\n      <td>While the jabbing or piggyback technique is applied, the patient is asked to give a hard cough for the spontaneous penetration of the needle.</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* These techniques may be used alone or in combination for successful penetration of the needle through the tracheobronchial wall.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 74513 Version 1.0</div></div></div>"},"74515":{"type":"graphic_picture","displayName":"Fixed cutaneous sporotrichosis","title":"Fixed cutaneous sporotrichosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fixed cutaneous sporotrichosis</div><div class=\"cntnt\"><img style=\"width:504px; height:328px;\" src=\"images/ID/74515_Fixedcutaneoussporotricho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fungating lesion on upper limb (hand).</div><div class=\"graphic_reference\">Reproduced with permission from: da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis:&nbsp;A study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 74515 Version 3.0</div></div></div>"},"74517":{"type":"graphic_movie","displayName":"TEE mechanical mitral valve vegetations","title":"Transesophageal echocardiogram (TEE) of a mechanical mitral valve prosthesis with vegetations","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) of a mechanical mitral valve prosthesis with vegetations</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/74517_prmvendtconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:247px; height:380px;\" src=\"images/CARD/74517_prmvendt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows multiple hazy echos on the prosthetic mitral valve compatible with vegetations from endocarditis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 74517 Version 3.0</div></div></div>"},"74520":{"type":"graphic_diagnosticimage","displayName":"Normal sonohysterogram","title":"Transvaginal sonohysterography of a perimenopausal patient with abnormal uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal sonohysterography of a perimenopausal patient with abnormal uterine bleeding</div><div class=\"cntnt\"><img style=\"width:367px; height:280px;\" src=\"images/OBGYN/74520_Normal_sonohysterogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endometrium surrounding the fluid is thin, measuring 1.9 and 2.0 mm at the anterior and posterior walls, respectively. This is a typical picture of a patient with dysfunctional anovulatory bleeding best treated hormonally.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 74520 Version 2.0</div></div></div>"},"74521":{"type":"graphic_figure","displayName":"PEG rHuMGDF after chemotherapy","title":"PEG-rHuMGDF stimulates platelet recovery after chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">PEG-rHuMGDF stimulates platelet recovery after chemotherapy</div><div class=\"cntnt\"><img style=\"width:467px; height:312px;\" src=\"images/HEME/74521_PEG_rHuMGDF_after_chemother.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with lung cancer were treated with paclitaxel and carboplatin on day 1 and subsequently with either placebo (blue open circles, n = 12) or various doses of PEG-rHuMGDF (red closed circles, n = 38) and the platelet counts measured daily. The administration of PEG-rHuMGDF was associated with accelerated recovery of the platelet count. Twenty-one days after administration of the chemotherapy, 93 percent of the PEG-rHuMGDF-treated patients but none of those given placebo had recovered to their baseline platelet values (inset).</div><div class=\"graphic_reference\">Data from Fanucchi, M, Glaspy, J, Crawford, J, et al, N Engl J Med 1997; 336:404.</div><div id=\"graphicVersion\">Graphic 74521 Version 1.0</div></div></div>"},"74523":{"type":"graphic_table","displayName":"Automatic external defibrillator use in children","title":"Key points regarding the use of Automatic External Defibrillators (AED) in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points regarding the use of Automatic External Defibrillators (AED) in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8226; VF is the initial rhythm in 9 to 19 percent of children experiencing out-of-hospital cardiac arrests.</td> </tr> <tr> <td>&#8226; Survival with VF is better than survival with asystole.</td> </tr> <tr> <td>&#8226; Defibrillation is indicated for the treatment of VF and pulseless VT.</td> </tr> <tr> <td>&#8226; AEDs are computerized machines that automatically diagnose VF and use voice prompts to instruct rescuers to <strong>defibrillate</strong>, if appropriate.</td> </tr> <tr> <td>&#8226; AEDs have demonstrated both high sensitivity in detecting VF and high specificity in identifying nonshockale rhythms in children.</td> </tr> <tr> <td>&#8226; For infants and children with VF or pulseless VT, shock delivery may be accomplished by the following devices (in order of preference):<br /> <ol> <li>Manual defibrillator (when used by a trained provider) </li> <li>AED with a dose attenutation device </li> <li>AED without a dose attenuation device </li> </ol> </td> </tr> <tr> <td>&#8226; For in-hospital defibrillation, there are no data comparing manual defibrillators with AEDs or clear guidelines specifying the use of one over the other. </td> </tr> <tr> <td>&#8226; AEDs cannot be used for cardioversion.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VF: ventricular fibrillation; VT: ventricular tachycardia.</div><div id=\"graphicVersion\">Graphic 74523 Version 5.0</div></div></div>"},"74524":{"type":"graphic_diagnosticimage","displayName":"Garden type II hip fracture","title":"Garden type II hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Garden type II hip fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:297px;\" src=\"images/EM/74524_HipfxGarden2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type II fractures are complete, but undisplaced. These rare fractures have a break in the trabeculations, but no shift in alignment.</div><div class=\"graphic_reference\">Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74524 Version 12.0</div></div></div>"},"74526":{"type":"graphic_picture","displayName":"Granular cell tumor","title":"Granular cell tumor in the esophagus","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Granular cell tumor in the esophagus</div><div class=\"cntnt\"><img style=\"width:458px; height:256px;\" src=\"images/GAST/74526_Granular_cell_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Endoscopic image of a subepithelial 3.5 cm esophageal mass later shown to be a granular cell tumor. B) Endosonographic image revealing a hypoechoic mass arising from the submucosa.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO.</div><div id=\"graphicVersion\">Graphic 74526 Version 3.0</div></div></div>"},"74527":{"type":"graphic_table","displayName":"Causes genital tract bleeding","title":"Causes of abnormal genital tract bleeding in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of abnormal genital tract bleeding in women</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Genital tract disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Uterus</td> </tr> <tr> <td class=\"sublist2_start\">Benign growths:</td> </tr> <tr> <td class=\"sublist2\">Endometrial polyps</td> </tr> <tr> <td class=\"sublist2\">Endometrial hyperplasia</td> </tr> <tr> <td class=\"sublist2\">Adenomyosis</td> </tr> <tr> <td class=\"sublist2\">Leiomyomas (fibroids)</td> </tr> <tr> <td class=\"sublist2_start\">Cancer:</td> </tr> <tr> <td class=\"sublist2\">Endometrial adenocarcinoma</td> </tr> <tr> <td class=\"sublist2\">Sarcoma</td> </tr> <tr> <td class=\"sublist2_start\">Infection:</td> </tr> <tr> <td class=\"sublist2\">Pelvic inflammatory disease</td> </tr> <tr> <td class=\"sublist2\">Endometritis</td> </tr> <tr> <td class=\"indent1\">Ovulatory dysfunction</td> </tr> <tr> <td class=\"subtitle2_single\">Cervix</td> </tr> <tr> <td class=\"sublist2_start\">Benign growths:</td> </tr> <tr> <td class=\"sublist2\">Cervical polyps</td> </tr> <tr> <td class=\"sublist2\">Ectropion</td> </tr> <tr> <td class=\"sublist2\">Endometriosis</td> </tr> <tr> <td class=\"sublist2_start\">Cancer:</td> </tr> <tr> <td class=\"sublist2\">Invasive carcinoma</td> </tr> <tr> <td class=\"sublist2\">Metastatic (uterus, choriocarcinoma)</td> </tr> <tr> <td class=\"sublist2_start\">Infection:</td> </tr> <tr> <td class=\"sublist2\">Cervicitis</td> </tr> <tr> <td class=\"subtitle2_single\">Vulva</td> </tr> <tr> <td class=\"sublist2_start\">Benign growths:</td> </tr> <tr> <td class=\"sublist2\">Skin tags</td> </tr> <tr> <td class=\"sublist2\">Sebaceous cysts</td> </tr> <tr> <td class=\"sublist2\">Condylomata</td> </tr> <tr> <td class=\"sublist2\">Angiokerataoma</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"subtitle2_single\">Vagina</td> </tr> <tr> <td class=\"sublist2_start\">Benign growths:</td> </tr> <tr> <td class=\"sublist2\">Gartner duct cysts</td> </tr> <tr> <td class=\"sublist2\">Polyps</td> </tr> <tr> <td class=\"sublist2\">Adenosis (aberrant glandular tissue)</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"sublist2_start\">Vaginitis/infection:</td> </tr> <tr> <td class=\"sublist2\">Bacterial vaginosis</td> </tr> <tr> <td class=\"sublist2\">Sexually transmitted infections</td> </tr> <tr> <td class=\"sublist2\">Atrophic vaginitis</td> </tr> <tr> <td class=\"subtitle2_single\">Upper genital tract disease</td> </tr> <tr> <td class=\"indent1\">Pelvic inflammatory disease</td> </tr> <tr> <td class=\"indent1\">Fallopian tube cancer</td> </tr> <tr> <td class=\"indent1\">Ovarian cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Pregnancy complications</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Sexual intercourse</td> </tr> <tr> <td class=\"indent1\">Sexual abuse</td> </tr> <tr> <td class=\"indent1\">Foreign bodies (including intrauterine device)</td> </tr> <tr> <td class=\"indent1\">Pelvic trauma (eg, motor vehicle accident)</td> </tr> <tr> <td class=\"indent1\">Straddle injuries</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"sublist2_start\">Contraception:</td> </tr> <tr> <td class=\"sublist2\">Hormonal contraceptives</td> </tr> <tr> <td class=\"sublist2\">Intrauterine devices</td> </tr> <tr> <td class=\"indent1\">Postmenopausal hormone therapy</td> </tr> <tr> <td class=\"indent1\">Anticoagulants</td> </tr> <tr> <td class=\"indent1\">Tamoxifen</td> </tr> <tr> <td class=\"indent1\">Corticosteroids</td> </tr> <tr> <td class=\"indent1\">Chemotherapy</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Antipsychotic drugs</td> </tr> <tr> <td class=\"indent1\">Antibiotics (eg, due to toxic epidermal necrolysis or Stevens-Johnson syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic disease</td> </tr> <tr> <td class=\"sublist2_start\">Diseases involving the vulva:</td> </tr> <tr> <td class=\"sublist2\">Crohn's disease</td> </tr> <tr> <td class=\"sublist2\">Beh&#231;et syndrome</td> </tr> <tr> <td class=\"sublist2\">Pemphigoid</td> </tr> <tr> <td class=\"sublist2\">Pemphigus</td> </tr> <tr> <td class=\"sublist2\">Erosive lichen planus</td> </tr> <tr> <td class=\"sublist2\">Lymphoma</td> </tr> <tr> <td class=\"sublist2_start\">Bleeding disorders:</td> </tr> <tr> <td class=\"sublist2\">von Willebrand disease</td> </tr> <tr> <td class=\"sublist2\">Thrombocytopenia or platelet dysfunction</td> </tr> <tr> <td class=\"sublist2\">Acute leukemia</td> </tr> <tr> <td class=\"sublist2\">Some coagulation factor deficiencies</td> </tr> <tr> <td class=\"sublist2\">Advanced liver disease</td> </tr> <tr> <td class=\"indent1\">Thyroid disease</td> </tr> <tr> <td class=\"indent1\">Polycystic ovary syndrome</td> </tr> <tr> <td class=\"indent1\">Chronic liver disease</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> </tr> <tr> <td class=\"indent1\">Hormone-secreting adrenal and ovarian tumors</td> </tr> <tr> <td class=\"indent1\">Renal disease</td> </tr> <tr> <td class=\"indent1\">Emotional or physical stress</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Excessive exercise</td> </tr> <tr> <td class=\"subtitle1_single\">Diseases not affecting the genital tract</td> </tr> <tr> <td class=\"indent1\">Urethritis</td> </tr> <tr> <td class=\"indent1\">Bladder cancer</td> </tr> <tr> <td class=\"indent1\">Urinary tract infection</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Hemorrhoids</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Endometriosis</td> </tr> <tr> <td class=\"indent1\">Vascular tumors and anomalies in the genital tract, including enhanced myometrial vascularity (also known as uterine arterial venous malformation)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74527 Version 10.0</div></div></div>"},"74528":{"type":"graphic_picture","displayName":"Porphyria cutanea tarda","title":"Porphyria cutanea tarda","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porphyria cutanea tarda</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/GAST/74528_Porphyria_cutanea_tarda.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and erosions are visible on the dorsum of the hand in a patient with porphyria cutanea tarda related to underlying hepatitis C virus infection.</div><div class=\"graphic_reference\">Courtesy of Jean-Fran&#231;ois Dufour, MD.</div><div id=\"graphicVersion\">Graphic 74528 Version 1.0</div></div></div>"},"74529":{"type":"graphic_picture","displayName":"Scedosporium apiospermum microscopy","title":"<EM>Scedosporium apiospermum </EM>microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Scedosporium apiospermum </EM>microscopy</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/ID/74529_S_apiospermum_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic appearance of <EM>S. apiospermum </EM>illustrating cylindrical uninucleate conidiogenous cell (arrow) with conidium attached.</div><div class=\"graphic_reference\">Courtesy of Barbara D. Alexander, MD, MHS and Sylvia F. Costa, MD.</div><div id=\"graphicVersion\">Graphic 74529 Version 4.0</div></div></div>"},"74531":{"type":"graphic_table","displayName":"Multidisciplinary approach to treating dyspnea","title":"Multidisciplinary approach to the treatment of dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multidisciplinary approach to the treatment of dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Minimize production of symptom</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Exercise training (lower- or upper-limb endurance training, neuroelectrical muscle stimulation)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Breathing techniques (pursed-lips breathing, diaphragmatic breathing)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Maximize nutrition</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Supplemental oxygen</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Diminish perception of symptom</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fan blowing cool air on face</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Distraction strategies (imagery, cognitive-behavioral therapy, acupuncture, music, guided imagery)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Stimulation of respiratory afferent nerves (chest wall vibration)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pharmacotherapy (opioids)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Reduce the impact of symptom</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Energy conservation (advance activity planning, attention to posture and ergonomics)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Accommodation strategies (change in living arrangement, altered activities, frequent rests)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Modify the experience of the symptom</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Action plan for exacerbations</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Address patient's interpretation of symptom meaning</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>If present, treat associated mood/anxiety disorder</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=45289&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div id=\"graphicVersion\">Graphic 74531 Version 4.0</div></div></div>"},"74533":{"type":"graphic_table","displayName":"Cerebral palsy subtypes","title":"Causes and clinical features of cerebral palsy subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and clinical features of cerebral palsy subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Proportion of CP cases</td> <td class=\"subtitle1\" rowspan=\"2\">Common causes</td> <td class=\"subtitle1\" rowspan=\"2\">Infants affected</td> <td class=\"subtitle1\" colspan=\"2\">Common clinical features</td> </tr> <tr> <td class=\"subtitle2\">Infants and young children</td> <td class=\"subtitle2\">Children &#62;5 years old</td> </tr> <tr> <td><strong>Spastic subtypes</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <ul class=\"sublist2\"> <li>Increased tone </li> <li>Signs of upper motor neuron syndrome <ul> <li>Brisk deep tendon reflexes </li> <li>Extensor plantar response </li> <li>Clonus </li> </ul> </li> <li>Contractures of affected muscles </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Spastic diplegia*</td> <td>13 to 25%</td> <td> <ul> <li>Most commonly associated with PVL </li> </ul> </td> <td> <ul> <li>Preterm infants </li> <li>Risk increases with decreasing gestational age </li> </ul> </td> <td> <ul> <li>First few months: hypotonia of the lower limbs with delayed functional maturation </li> <li>By 6 months: spasticity involving ankle plantar flexors and hip adductors </li> <li>Crawling may be combat style </li> </ul> </td> <td> <ul> <li>Lower limbs are more affected than the upper limbs </li> <li>Affected patients have flexion, adduction, and internal rotation of the hips with contractures of the hip flexors and hamstring muscles </li> <li>Variable degrees of flexion at the elbows and knees </li> <li>Reduced limb length and muscle bulk in lower extremities </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Spastic hemiplegia*</td> <td>21 to 40%</td> <td> <ul> <li>Neonatal stroke </li> <li>Prenatal circulatory disturbances </li> <li>Brain maldevelopment </li> </ul> </td> <td> <ul> <li>Term infants of normal birth weight </li> </ul> </td> <td> <ul> <li>Motor asymmetry (may not be apparent in the newborn period) </li> <li>Early (before age 12 months) hand dominance </li> <li>Inability to use both hands in midline or to reach out with the affected limb </li> <li>Abnormal posturing on one side </li> <li>In prone position, the affected upper limb provides decreased support, and movement of the affected leg is diminished </li> <li>In a sitting position, the affected leg tends to extend </li> <li>Protective reactions that appear at five to eight months of age are asymmetric </li> <li>Over first one to two years, movement and tone on the affected side typically decrease before tone and tendon reflexes abnormally increase </li> <li>Typical posture (see description to the right) appears by age two years in most cases </li> </ul> </td> <td> <ul> <li>One side of the body is affected </li> <li>The arm typically is more affected than the leg </li> <li>The arm is adducted at the shoulder and flexed at the elbow, the forearm is pronated, and the wrist and fingers are flexed with the hand closed </li> <li>The hip is partially flexed and adducted, and the knee and ankle are flexed; the foot may remain in the equinovarus or calcaneovalgus position </li> <li>Most children also have sensory deficits </li> <li>In mildly affected patients, postural abnormalities are more apparent during walking or running; however, unless severe intellectual disability is present, independent walking usually occurs at the appropriate age or is only slightly delayed </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spastic quadriplegia*</td> <td>20 to 43%</td> <td> <ul> <li>Congenital infection </li> <li>Cerebral dysgenesis </li> <li>Perinatal or postnatal events </li> </ul> </td> <td> <ul> <li>Most commonly term SGA infants, but can also occur in preterm infants </li> </ul> </td> <td> <ul> <li>Moderate or severe psychomotor delay </li> <li>Poor head control </li> <li>Spasticity may begin by two to three months of age </li> <li>Adduction of the thighs results in typical scissoring of the legs </li> <li>By 9 to 10 months of age, infants when pulled to sitting are unable to flex the legs and have poor truncal balance </li> </ul> </td> <td> <ul> <li>All limbs are affected </li> <li>Upper limbs may be equally or more involved than lower limbs </li> <li>Children often are severely handicapped </li> <li>Feeding difficulties, chronic respiratory&nbsp;insufficiency, and seizure disorder&nbsp;are common </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Dyskinetic subtypes</strong></td> <td class=\"divider_bottom\" rowspan=\"3\">12 to 14%</td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>Most cases are caused by severe perinatal asphyxia resulting in injury to the thalamus, basal ganglia, hippocampus, reticular formation, and/or cerebellum </li> <li>Severe hyperbilirubinemia (kernicterus) can cause choreoathetotic CP </li> </ul> </td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>Predominantly term infants </li> </ul> </td> <td class=\"divider_bottom\" rowspan=\"3\">In early infancy: <ul class=\"decimal_heading\"> <li>Reduced spontaneous movement </li> <li>Hypotonia at rest, variable tone with movement or emotion </li> <li>Oromotor incoordination </li> <li>Persistence of primitive reflexes </li> <li>Involuntary grimacing </li> <li>Drooling </li> <li>Delayed psychomotor development </li> <li>Head can be persistently turned </li> </ul> <br /> Age two to three years: <ul class=\"decimal_heading\"> <li>Involuntary movements are apparent </li> <li>Abnormal posturing: <ul> <li>Extension patterns in the supine position </li> <li>Flexion with shoulder retraction in the prone position </li> <li>Head usually is persistently turned to one side </li> </ul> </li> </ul> </td> <td> <ul> <li>Involuntary movements </li> <li>Contractures are not common but may evolve later in life </li> <li>Variable degree of dysarthria and intellectual disability </li> </ul> </td> </tr> <tr> <td>Choreoathetotic CP: <ul class=\"decimal_heading\"> <li>Chorea consists of rapid, irregular, unpredictable contractions of individual muscles or small muscle groups that involve the face, bulbar muscles, proximal extremities, and fingers and toes </li> <li>Athetosis consists of slow, smooth, writhing movements that involve distal muscles </li> <li>Movements may be induced or accentuated by emotion or change in posture </li> <li>Athetosis is most apparent during reaching </li> <li>Stress, excitement, or fever may exacerbate chorea </li> <li>Primitive reflexes often are retained </li> <li>Oropharyngeal difficulties occur commonly </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dystonic CP: <ul class=\"decimal_heading\"> <li>Repetitive, patterned, twisting, and sustained movements of the trunk and limbs that may be either slow or rapid </li> <li>Pyramidal signs and anarthria may occur </li> <li>\"Tension\", a sudden involuntary increase in tone affecting both flexor and extensor muscles, may occur during attempted movement or with emotion </li> <li>Tendon reflexes are normal or may be difficult to elicit </li> <li>Clonus and extensor plantar responses are absent </li> </ul> </td> </tr> <tr> <td><strong>Ataxic CP</strong></td> <td>4 to 13%</td> <td> <ul> <li>Most cases are caused by early prenatal events </li> <li>Etiology is frequently unknown </li> <li>Some cases have genetic causes, including:&nbsp; <ul> <li>Cerebellar hypoplasia </li> <li>Granule cell deficiency </li> <li>Joubert syndrome </li> </ul> </li> <li>Rarely associated with congenital hypoplasia of the cerebellum </li> </ul> </td> <td> <ul> <li>Term infants </li> </ul> </td> <td> <ul> <li>Hypotonia<sup>&#182;</sup> and incoordination </li> <li>Motor milestones and language skills typically are delayed </li> </ul> </td> <td> <ul> <li>Ataxic movements </li> <li>Widespread disorder of motor function </li> <li>Ataxia usually improves with time </li> <li>Speech typically is slow, jerky, and explosive </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CP: cerebral palsy; PVL: periventricular leukomalacia; SGA: small for gestational age.<br />* The suffix \"paresis\" denotes weakness and \"plegia\" means paralysis. However, these terms often are used interchangeably and do not necessarily imply a difference in severity.<br />&para; A separate category of \"hypotonic CP\" (also called \"atonic CP\") has been described, though it is generally absent from contemporary classifications. The majority of patients with \"hypotonic CP\" in early infancy later develop spastic, dyskinetic, and particularly ataxic CP.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 2000; 42:816.</li>&#xD;&#xA;    <li>Noritz GH, Murphy NA, Neuromotor Screening Expert Panel. Motor delays: early identification and evaluation. Pediatrics 2013; 131:e2016. </li>&#xD;&#xA;    <li>Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil 2006; 28:183.</li>&#xD;&#xA;</ol></div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 74533 Version 8.0</div></div></div>"},"74534":{"type":"graphic_figure","displayName":"Wuchereria life cycle","title":"<em>Wuchereria</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\"><em>Wuchereria</em> life cycle</div><div class=\"cntnt\"><img style=\"width:568px; height:467px;\" src=\"images/ID/74534_Wuchereria_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different species of the following genera of mosquitoes are vectors of <EM>W. bancrofti</EM> filariasis depending on geographical distribution. Among them are: <EM>Culex</EM> (<EM>C. annulirostris</EM>, <EM>C. bitaeniorhynchus</EM>, <EM>C. quinquefasciatus</EM>, and <EM>C. pipiens</EM>); <EM>Anopheles</EM> (<EM>A. arabinensis</EM>, <EM>A. bancroftii</EM>, <EM>A. farauti</EM>, <EM>A. funestus</EM>, <EM>A. gambiae</EM>, <EM>A. koliensis</EM>, <EM>A. melas</EM>, <EM>A. merus</EM>, <EM>A. punctulatus</EM>, and <EM>A. wellcomei</EM>); <EM>Aedes</EM> (<EM>A. aegypti</EM>, <EM>A. aquasalis</EM>, <EM>A. bellator</EM>, <EM>A. cooki</EM>, <EM>A. darlingi</EM>, <EM>A. kochi</EM>, <EM>A. polynesiensis</EM>, <EM>A. pseudoscutellaris</EM>, <EM>A. rotumae</EM>, <EM>A. scapularis</EM>, and <EM>A. vigilax</EM>); <EM>Mansonia</EM> (<EM>M. pseudotitillans</EM>, <EM>M. uniformis</EM>); <EM>Coquillettidia</EM> (<EM>C. juxtamansonia</EM>). During a blood meal, an infected mosquito introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound <STRONG>(1)</STRONG>. They develop in adults that commonly reside in the lymphatics <STRONG>(2)</STRONG>. The female worms measure 80 to 100 mm in length and 0.24 to 0.30 mm in diameter, while the males measure about 40 mm by 0.1 mm. Adults produce microfilariae measuring 244 to 296 mcm by 7.5 to 10 mcm, which are sheathed and have nocturnal periodicity, except the South Pacific microfilariae, which have the absence of marked periodicity. The microfilariae migrate into lymph and blood channels moving actively through lymph and blood <STRONG>(3)</STRONG>. A mosquito ingests the microfilariae during a blood meal <STRONG>(4)</STRONG>. After ingestion, the microfilariae lose their sheaths and some of them work their way through the wall of the proventriculus and cardiac portion of the mosquito's midgut and reach the thoracic muscles <STRONG>(5)</STRONG>. There, the microfilariae develop into first-stage larvae <STRONG>(6)</STRONG> and subsequently into third-stage infective larvae <STRONG>(7)</STRONG>. The third-stage infective larvae migrate through the hemocoel to the mosquito's proboscis <STRONG>(8)</STRONG> and can infect another human when the mosquito takes a blood meal <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Lymphatic filariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/lymphaticFilariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/lymphaticFilariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 74534 Version 7.0</div></div></div>"},"74535":{"type":"graphic_table","displayName":"Causes of the ill-appearing infant","title":"Causes of the ill-appearing infant*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of the ill-appearing infant*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Bacterial sepsis due to:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Urinary tract infection/pyelonephritis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Bacteremia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Meningitis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pneumonia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cellulitis or skin abscess </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Bacterial gastroenteritis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Omphalitis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Mastitis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Septic arthritis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Osteomyelitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pertussis (apnea)</td> </tr> <tr> <td class=\"indent1\">Infant botulism</td> </tr> <tr> <td class=\"indent1\">Overwhelming viral illness due to:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Disseminated herpes simplex virus infection </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Enteroviral myocarditis or hepatitis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Bronchiolitis (apnea) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Influenza </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Child abuse</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical conditions</td> </tr> <tr> <td class=\"indent1\">Malrotation with volvulus</td> </tr> <tr> <td class=\"indent1\">Pyloric stenosis</td> </tr> <tr> <td class=\"indent1\">Incarcerated hernia</td> </tr> <tr> <td class=\"indent1\">Intussusception</td> </tr> <tr> <td class=\"indent1\">Congenital aganglionic megacolon (Hirschsprung disease)</td> </tr> <tr> <td class=\"indent1\">Necrotizing enterocolitis</td> </tr> <tr> <td class=\"indent1\">Appendicitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Posterior urethral valves</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cyanotic </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Obstructive </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Aberrant coronary artery </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Supraventricular tachycardia and other arrhythmias</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Kawasaki disease</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Acquired: (eg, hypoglycemia, hyponatremia, hypernatremia, hypocalcemia)</td> </tr> <tr> <td class=\"indent1\">Inborn errors of metabolism (eg, urea cycle defects, galactosemia, organic acidemias, and disorders of carbohydrate metabolism or fatty acid oxidation)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Acute bilirubin encephalopathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methemoglobinemia due to severe dehydration and metabolic acidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic exposures</td> </tr> <tr> <td class=\"indent1\">Iatrogenic unintentional overdose (eg, acetaminophen, methadone, or metoclopramide)</td> </tr> <tr> <td class=\"indent1\">Malicious drug exposure (eg, ethanol, drugs of abuse, or other medications [medical child abuse])</td> </tr> <tr> <td class=\"indent1\">Ingestion of substances in breast milk (eg, maternal drugs of abuse such as heroin, cocaine, PCP, or marijuana)</td> </tr> <tr> <td class=\"indent1\">Environmental toxins (carbon monoxide poisoning or methemoglobinemia from nitrate or other oxidant exposure)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on the ill-appearing infant younger than 90 days of age.</div><div id=\"graphicVersion\">Graphic 74535 Version 5.0</div></div></div>"},"74536":{"type":"graphic_picture","displayName":"Vitreous hemorrhage","title":"Vitreous hemorrhage: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitreous hemorrhage: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:322px;\" src=\"images/ENDO/74536_Vitreous_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph displaying vitreous hemorrhage arising from neovascularization at the disc (NVD).</div><div id=\"graphicVersion\">Graphic 74536 Version 3.0</div></div></div>"},"74537":{"type":"graphic_figure","displayName":"Dissection of myoma","title":"Dissection of myoma during myomectomy","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Dissection of myoma during myomectomy</div><div class=\"cntnt\"><img style=\"width:492px; height:452px;\" src=\"images/OBGYN/74537_Dissection_of_myoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 74537 Version 2.0</div></div></div>"},"74538":{"type":"graphic_figure","displayName":"Anatomy of the supraglottic larynx","title":"Anatomy of the supraglottic larynx","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Anatomy of the supraglottic larynx</div><div class=\"cntnt\"><img style=\"width:537px; height:488px;\" src=\"images/EM/74538_Supraglottic_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74538 Version 2.0</div></div></div>"},"74541":{"type":"graphic_figure","displayName":"Dissection of recurrent laryngeal nerve lateral view","title":"Dissection of recurrent laryngeal nerve lateral view","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Dissection of recurrent laryngeal nerve lateral view</div><div class=\"cntnt\"><img style=\"width:496px; height:550px;\" src=\"images/SURG/74541_Recurrent_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of recurrent laryngeal nerve and parathyroid.</div><div id=\"graphicVersion\">Graphic 74541 Version 8.0</div></div></div>"},"74542":{"type":"graphic_figure","displayName":"Pseudopod structures in peptide YY cells","title":"Pseudopod structures in peptide YY cells","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Pseudopod structures in peptide YY cells</div><div class=\"cntnt\"><img style=\"width:592px; height:445px;\" src=\"images/GAST/74542_Pseudopod_struct_pep_YY.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peptide YY cells (L cells) in the ileum and colon possess long pseudopod-like processes that extend from the gut lumen to the cells in the lamina propria.</div><div class=\"graphic_reference\">Reproduced with permission from: Bohorquez DV, Chandra R, Samsa LA, et al. Characterization of pseudopod-like basal processes in ileal and colonic PYY cells. J Mol Histol 2011; 42:3. Copyright &#169; 2011 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 74542 Version 2.0</div></div></div>"},"74543":{"type":"graphic_figure","displayName":"Hymenolepis diminuta life cycle","title":"<EM>Hymenolepis diminuta</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\"><EM>Hymenolepis diminuta</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:580px; height:467px;\" src=\"images/ID/74543_Hymenolepis_dimin_life_cyc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eggs of <EM>Hymenolepis diminuta</EM> are passed out in the feces of the infected definitive host (rodents, humans) <STRONG>(1)</STRONG>. The mature eggs are ingested by an intermediate host (various arthropod adults or larvae) <STRONG>(2)</STRONG>, and oncospheres are released from the eggs and penetrate the intestinal wall of the host <STRONG>(3)</STRONG>, which develop into cysticercoid larvae. Species from the genus <EM>Tribolium</EM> are common intermediate hosts for <EM>H. diminuta</EM>. The cysticercoid larvae persist through the arthropod's morphogenesis to adulthood. <EM>H. diminuta</EM> infection is acquired by the mammalian host after ingestion of an intermediate host carrying the cysticercoid larvae <STRONG>(4)</STRONG>. Humans can be accidentally infected through the ingestion of insects in precooked cereals or other food items and directly from the environment (eg, oral exploration of the environment by children). After ingestion, the tissue of the infected arthropod is digested releasing the cysticercoid larvae in the stomach and small intestine. Eversion of the scoleces <STRONG>(5)</STRONG> occurs shortly after the cysticercoid larvae are released. Using the four suckers on the scolex, the parasite attaches to the small intestine wall. Maturation of the parasites occurs within 20 days and the adult worms can reach an average of 30 cm in length <STRONG>(6)</STRONG>. Eggs are released in the small intestine from gravid proglottids <STRONG>(7)</STRONG> that disintegrate after breaking off from the adult worms. The eggs are expelled to the environment in the mammalian host's feces <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hymenolepiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/hymenolepiasis/index.html\">http://www.cdc.gov/dpdx/hymenolepiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 74543 Version 5.0</div></div></div>"},"74544":{"type":"graphic_picture","displayName":"Waring blender syndrome","title":"Red cell fragmentation (\"Waring blender syndrome\") due to defective heart valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Red cell fragmentation (\"Waring blender syndrome\") due to defective heart valve</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/HEME/74544_Waring_blender_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with the &quot;Waring blender&quot; syndrome due to defective prosthetic heart valve. The smear shows marked red cell fragmentation with multiple sharp edges and small fragmented cells.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 74544 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"74549":{"type":"graphic_figure","displayName":"The effect of age on cadmium-induced nephrotoxicity","title":"The effect of age on cadmium-induced nephrotoxicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The effect of age on cadmium-induced nephrotoxicity</div><div class=\"cntnt\"><img style=\"width:437px; height:363px;\" src=\"images/NEPH/74549_Urine_cadmium_LMW_proteinur.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Study in Swedish battery workers showing the influence of age on the relation between urine cadmium excretion and tubular injury (as manifested by the prevalence of beta2-microglobulinemia). A 10 percent prevalence of tubular proteinuria was associated with a urine cadmium level of approximately 2 nanomoles/mmol creatinine in subjects 60 years or older versus 4 to 5 nanomol/mmol creatinine in younger subjects.</div><div class=\"graphic_footnotes\">U-Cd: urine cadmium.</div><div class=\"graphic_reference\">Data from: J&auml;rup L, Elinder CG. Dose-response relations between urinary cadmium and tubular proteinuria in cadmium-exposed workers. Am J Ind Med 1994; 26:759.</div><div id=\"graphicVersion\">Graphic 74549 Version 3.0</div></div></div>"},"74550":{"type":"graphic_picture","displayName":"Thumb spica cast 9","title":"Thumb spica cast: Final appearance","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Final appearance</div><div class=\"cntnt\"><img style=\"width:504px; height:208px;\" src=\"images/EM/74550_Thumb_spica_cast_9.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above depicts the proper position for the hand and thumb in a completed thumb spica cast.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 74550 Version 3.0</div></div></div>"},"74552":{"type":"graphic_picture","displayName":"Hailey-Hailey 2","title":"Perianal Hailey-Hailey disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal Hailey-Hailey disease</div><div class=\"cntnt\"><img style=\"width:293px; height:504px;\" src=\"images/DERM/74552_Hailey_Hailey_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, erythematous, and crusty perianal plaque in a patient with Hailey-Hailey disease.</div><div id=\"graphicVersion\">Graphic 74552 Version 6.0</div></div></div>"},"74553":{"type":"graphic_figure","displayName":"Digit symbol test","title":"Digit symbol test","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Digit symbol test</div><div class=\"cntnt\"><img style=\"width:514px; height:227px;\" src=\"images/NEURO/74553_Digit-symbol-test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In digit symbol tests, subjects are provided nine digit symbol pairs (top)&#160;and are then asked to write the correct symbol for a series of digits (below). The test is scored based on speed and accuracy.</div><div id=\"graphicVersion\">Graphic 74553 Version 1.0</div></div></div>"},"74555":{"type":"graphic_figure","displayName":"Distal pancreatectomy with splenectomy","title":"Distal pancreatectomy with splenectomy","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Distal pancreatectomy with splenectomy</div><div class=\"cntnt\"><img style=\"width:517px; height:458px;\" src=\"images/SURG/74555_Resection_with_splenectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Operative bed following distal pancreatectomy and splenectomy.</div><div id=\"graphicVersion\">Graphic 74555 Version 4.0</div></div></div>"},"74556":{"type":"graphic_picture","displayName":"Acute eosinophilic pneum Low","title":"Acute eosinophilic pneumonia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute eosinophilic pneumonia</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/74556_Acute_eosinophilic_pneum_Lo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph from a patient with acute eosinophilic pneumonia illustrates air space exudate and alveolar septal thickening resembling that seen in the organizing phase of diffuse alveolar damage.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 74556 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"74557":{"type":"graphic_picture","displayName":"Mediastinal choriocarcinoma Low","title":"Mediastinal choriocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal choriocarcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/PULM/74557_Mediastinal_choriocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Choriocarcinoma is characterized by a dual cell population: mononucleated cytotrophoblastic cells and multinucleated giant syncytio- trophoblastic cells, bordering an area of hemorrhage. (Hematoxylin and eosin, magnification x50).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 74557 Version 1.0</div></div></div>"},"74558":{"type":"graphic_table","displayName":"Prevention of barotrauma","title":"Prevention of barotrauma and bronchopleural fistula in ventilated patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of barotrauma and bronchopleural fistula in ventilated patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Use small tidal volumes (eg, 6 mL/kg predicted body weight or less) in high-risk clinical settings</td> </tr> <tr> <td class=\"sublist1\">Acute respiratory distress syndrome</td> </tr> <tr> <td class=\"sublist1\">Obstructive lung disease, particularly in the presence of auto-PEEP</td> </tr> <tr> <td class=\"sublist1\">Minute ventilation &#62;12 to 15 L/min</td> </tr> <tr> <td>Avoid hyperventilation (ie, arterial PCO<sub>2</sub> &#60;40 mmHg), and consider permissive hypercapnia in circumstances listed above, unless contraindicated</td> </tr> <tr> <td class=\"sublist1_start\">Use PEEP cautiously in patients at increased risk for alveolar rupture</td> </tr> <tr> <td class=\"sublist1\">Acute respiratory distress syndrome</td> </tr> <tr> <td class=\"sublist1\">Obstructive lung disease (eg, COPD, asthma)</td> </tr> <tr> <td class=\"sublist1\">Unilateral, patchy, or cavitary lung disease</td> </tr> <tr> <td class=\"sublist1\">Nosocomial pneumonia or sepsis</td> </tr> <tr> <td class=\"sublist1\">Necrotizing pneumonia</td> </tr> <tr> <td>Monitor static respiratory system compliance as PEEP is applied or increased, and back off on PEEP if compliance falls with increasing levels</td> </tr> <tr> <td class=\"sublist1_start\">Monitor all ventilated patients for auto-PEEP, and take specific measures to reduce auto-PEEP if its presence could be harmful to the patient:</td> </tr> <tr> <td class=\"sublist1\">Normo- or hypercapnia</td> </tr> <tr> <td class=\"sublist1\">High inspiratory flow rate (eg, 70 to 100 L/min)</td> </tr> <tr> <td class=\"sublist1\">Low-compressible-volume, low-compliance ventilator circuit</td> </tr> <tr> <td>Wean from positive-pressure ventilation as rapidly as possible</td> </tr> <tr> <td>Use extreme care in high-risk patients when placing subclavian or internal jugular lines or performing thoracentesis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEEP: positive end expiratory pressure; COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 74558 Version 5.0</div></div></div>"},"74559":{"type":"graphic_diagnosticimage","displayName":"Scaphoid fracture dislocation x-ray","title":"Adult scaphoid fracture-dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adult scaphoid fracture-dislocation</div><div class=\"cntnt\"><img style=\"width:288px; height:426px;\" src=\"images/EM/74559_Scaphoid_fx_dislocation_xra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of the wrist reveals a trans-scaphoid fracture dislocation. the white line shows lunate fossa, black outlines the capitate base. This clearly depicts the trans-scaphoid fracture-dislocation.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 74559 Version 3.0</div></div></div>"},"74560":{"type":"graphic_table","displayName":"Probiotics in primary prevention of allergic disease","title":"Summary of studies using probiotics in primary prevention of allergic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of studies using probiotics in primary prevention of allergic disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Investigator(s)/publication date(s)/study location</td> <td class=\"subtitle1\" colspan=\"4\">Study protocol</td> <td class=\"subtitle1\" colspan=\"4\">Results</td> <td class=\"subtitle1\" rowspan=\"2\">Comments</td> </tr> <tr> <td class=\"subtitle2\">Participants</td> <td class=\"subtitle2\">Type of probiotic(s) and dose</td> <td class=\"subtitle2\">Prenatal duration</td> <td class=\"subtitle2\">Postnatal duration</td> <td class=\"subtitle2\">Reduction in eczema</td> <td class=\"subtitle2\">Reduction in sensitization</td> <td class=\"subtitle2\">Reduction in other allergic disease</td> <td class=\"subtitle2\">Effect on colonization</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kalliom&#228;ki, et al.</p> <p>2001, 2003, 2007</p> Turku, Finland</td> <td> <p>Any first degree relative with allergic disease</p> n = 132 completed (of initial 159)</td> <td><em>Lactobacillus rhamnosus</em> GG (1 x 10<sup>10</sup> CFU daily)</td> <td>Two to four weeks before delivery</td> <td> <p>Six months</p> (To breastfeeding mother, only directly to infant if not breastfeeding)</td> <td> <p>YES</p> At two, four, and seven years</td> <td>NO</td> <td>NO*</td> <td>YES</td> <td>* Trends of more rhinitis and asthma in the probiotic groups at four and seven years of age.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Rautava, et al.</p> <p>2006</p> Turku, Finland</td> <td> <p>Any need for artificial feeding before two months of age</p> n = 72 completed (of initial 81)</td> <td> <p><em>Lactobacillus rhamnosus</em> GG (1 x 10<sup>10</sup> CFU daily)</p> <p>and</p> <em>Bifidobacterium lactis</em> Bb-12 (1 x 10<sup>10</sup> CFU daily)</td> <td>Not given</td> <td> <p>Before 2 months until 12 months</p> (In infant formula)</td> <td>NO</td> <td>NO</td> <td>NO</td> <td>Not known</td> <td>The study was designed to assess effect of probiotics on susceptibility to infections (not allergy prevention). Increased serum sCD14 and IgA in probiotic group.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Kocourkov&#225;, et al.</p> <p>2007</p> Prague, Czechia</td> <td class=\"sublist1_start\"><strong>Three groups:</strong></td> <td class=\"divider_bottom\" rowspan=\"3\"><em>E. coli serotype</em> O83:K24:H31 (8 x 10<sup>8</sup> CFU given three times/week)</td> <td class=\"divider_bottom\" rowspan=\"3\">Not given</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>From day&nbsp;2 until one month</p> (Direct to infant)</td> <td class=\"divider_bottom\" rowspan=\"3\">YES<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">NO</td> <td class=\"divider_bottom\" rowspan=\"3\">NO</td> <td class=\"divider_bottom\" rowspan=\"3\">YES<sup>&#916;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>&#182;&nbsp;Possible allergy preventing effect (mostly eczema) noted.</p> &#916; Reduced number of pathogenic organisms at three months.</td> </tr> <tr> <td class=\"sublist1\"> <p>- Allergic mother, colonized</p> <p>- Allergic mother, not colonized</p> - Nonallergic mother</td> </tr> <tr class=\"divider_bottom\"> <td>n = 144 completed</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Taylor, et al.</p> <p>2007</p> <p>Prescott, et al.</p> <p>2008</p> <p>Jensen, et al.</p> <p>2012</p> Perth, Australia</td> <td> <p>Mother with SPT+ allergic disease</p> n = 189 completed (of initial 230)</td> <td><em>Lactobacillus acidophilus</em> (LAVRI-A1) (3 x 10<sup>8</sup> CFU daily)</td> <td>Not given</td> <td> <p>Six months</p> (Direct to infant)</td> <td> <p>NO</p> At one year</td> <td>NO<sup>&#9674;</sup></td> <td>NO</td> <td>YES</td> <td>&#9674; Sensitization more common in probiotic group at&nbsp;1 year, but not at 2.5 or 5 years.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kukkonen, et al.</p> <p>2007</p> Helsinki/Tampere, Finland</td> <td> <p>One or both parents with allergic disease</p> n = 925 completed (of initial 1223)</td> <td><em>Lactobacillus rhamnosus</em> GG and LC705 (both 5 x 10<sup>9</sup> CFU twice daily); and <em>Bifidobacterium breve</em> Bb99 and <em>Cutibacterium </em>(formerly <em>Proprionibacterium</em>) <em>freudenreichii</em> ssp. shermanii JS (both 2 x 10<sup>9</sup> CFU twice daily)</td> <td>Two to four weeks before delivery</td> <td> <p>Six months</p> (Direct to infant)<sup>&#167;</sup></td> <td> <p>YES</p> At two years</td> <td>NO<sup>&#165;</sup></td> <td>NO</td> <td>YES</td> <td> <p>&#167; Probiotic group also received prebiotic supplement (galacto-oligosaccharides).</p> &#165; Trend for less IgE-associated allergic disease (p = 0.052).</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Abrahamsson, et al.</p> <p>2007, 2013</p> Link&#246;ping, Sweden</td> <td> <p>Any first degree relative with allergic disease</p> n = 188 completed (of initial 232)</td> <td><em>Lactobacillus reuteri</em> (1 x 10<sup>8</sup> CFU daily)</td> <td>Two to four weeks before delivery</td> <td> <p>12 months</p> (Direct to infant)</td> <td> <p>YES<sup>&#135;</sup></p> <p>At two years </p> <p>NO</p> At seven years</td> <td>NO<sup>&#135;</sup></td> <td>NO</td> <td>Not known</td> <td> <p>&#135; Probiotic groups: Less IgE-associated eczema in the second, but not the seventh, year and less sensitization at two years in subgroup with atopic mothers.</p> No difference in lung function measures and FeNO between the groups at seven years.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kopp, et al.</p> <p>2007</p> Freiburg, Germany</td> <td> <p>Any first degree relative with allergic disease</p> n = 94 completed (of initial 105)</td> <td><em>Lactobacillus rhamnosus</em> GG (1 x 10<sup>10</sup> CFU daily)</td> <td>Four to six weeks before delivery</td> <td> <p>Six months</p> (Direct to infant for six months if not breastfeeding; to mother for three months and then to infant for three months if breastfeeding)</td> <td> <p>NO</p> At two years</td> <td>NO</td> <td>NO<sup>&#134;</sup></td> <td>Not known</td> <td>&#134; Probiotic groups: Increased rate of recurrent episodes of wheezing bronchitis.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Wickens, et al.</p> <p>2008, 2012, 2013</p> Wellington and Auckland, New Zealand</td> <td> <p>One or both parents with allergic disease</p> n = 474 (of initial 512)</td> <td> <p><em>Lactobacillus rhamnosus</em> HN001 (n = 157) (1 x 10<sup>10</sup> CFU daily)</p> <p><strong>OR</strong></p> <em>Bifidobacterium lactis</em> HN019 (1 x 10<sup>10</sup> CFU daily) (n = 158)</td> <td>Two to five weeks before delivery</td> <td> <p>Two years</p> (To infant regardless of feeding method)</td> <td> <p>YES**</p> At two, four, and six years with <em>L. rhamnosus</em></td> <td> <p>YES</p> Lower cumulative prevalence of sensitization at six years with <em>L. rhamnosus</em></td> <td> <p>YES</p> Reduced prevalence of rhinoconjunctivitis at four years with both <em>L. rhamnosus</em> and <em>B. lactis</em></td> <td>YES</td> <td> <p>** Directly compared two probiotics; reduction in eczema at two, four, and six years with <em>L. rhamnosus.</em></p> No difference in lung function measures and FeNO between the groups at six years.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Soh, et al.</p> <p>2009</p> <p>Loo, et al. 2014</p> Singapore</td> <td> <p>Any first degree relative with SPT+ allergic disease</p> n = 245 (of initial 253)</td> <td><em>Lactobacillus rhamnosus</em> (LPR) (1 x 10<sup>9</sup> CFU daily) and <em>Bifidobacterium longum</em> (BL999) (6 x 10<sup>8</sup> CFU daily)</td> <td>Not given</td> <td> <p>Six months</p> (In infant formula)</td> <td> <p>NO</p> <p>At one year</p> <p>NO</p> <p>At five years</p> </td> <td> <p>NO</p> <p>NO</p> <p>At five years</p> </td> <td> <p>Not known</p> <p>NO</p> <p>At five years</p> </td> <td>Not known</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Huurre, et al.</p> <p>2008</p> Turku, Finland</td> <td> <p>Mother with current atopic disease</p> n = 140 completed (of initial 171)</td> <td><em>Lactobacillus rhamnosus</em> GG and <em>Bifidobacterium lactis</em> (Bb-12) (1 x 10<sup>10</sup> CFU daily)</td> <td>From first trimester</td> <td> <p>Variable</p> (To breastfeeding mother until end of exclusive breastfeeding)</td> <td>NO</td> <td>NO<sup>&#182;&#182;</sup></td> <td>Not known</td> <td>Not known</td> <td>&#182;&#182;&nbsp;Probiotics had no effect on infant sensitization at 12 months (except in subgroup with maternal sensitisation).</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kuitunen, Savilahti, et al.</p> <p>2009</p> Helsinki, Finland</td> <td> <p>Same study as Kukkonen, et al.</p> <p>2007</p> n = 891 (of initial 1223)</td> <td><em>Lactobacillus rhamnosus</em> GG and LC705 (both 5 x 10<sup>9</sup> CFU twice daily) and <em>Bifidobacterim breve</em> Bb99 and<em> Cutibacterium </em>(formerly <em>Propionibacterium</em>)<em> freudenreichii</em> ssp. <em>shermanii</em> JS (2 x 10<sup>9</sup> CFU twice daily)</td> <td>Four weeks before delivery</td> <td> <p>Six months</p> (Direct to infant)</td> <td> <p>NO<sup>&#916;&#916;</sup></p> Five year follow-up</td> <td> <p>NO<sup>&#916;&#916;</sup></p> Five year follow-up</td> <td> <p>NO</p> Five year follow-up</td> <td>Not known</td> <td>&#916;&#916; No overall allergy-preventive effect at five years. In subgroup of caesarean-delivered children: Probiotics associated with reduction in eczema and sensitization.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>West, et al.</p> <p>2009, 2013</p> Ume&aring;, Sweden</td> <td> <p>Unselected population approximately two-thirds in both groups with first degree relative with allergic disease</p> n = 171 completed (of initial 179)</td> <td><em>Lactobacillus paracasei</em> ssp. <em>paracasei</em> F19 (1 x 10<sup>8</sup> CFU daily)</td> <td>Not given</td> <td> <p>4 to 13 months, during weaning</p> (In infant cereal)</td> <td> <p>YES</p> <p>During first year</p> <p>NO</p> At eight to nine years of age</td> <td>NO</td> <td>NO</td> <td>YES</td> <td> <p>A significant difference in Th1/Th2 responses at 13 months (higher Th1/Th2 in probiotic group).</p> No difference in lung function measures and FeNO between the groups at eight to nine years.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Niers, et al.</p> <p>2009</p> <p>Gorissen, et al. 2014</p> <p><span style=\"color: #ff0000;\"></span>Utrecht, Netherlands</p> </td> <td> <p>Allergic disease in either parent plus at least one sibling</p> n = 98 completed (of initial 156)</td> <td><em>Lactococcus lactis</em> W58, <em>Bifidobacterium lactis</em> W52, and <em>Bifidobacterium bifidum</em> W23 (1 x 10<sup>9</sup> CFU each daily)</td> <td>Six weeks before delivery</td> <td> <p>12 months</p> (Direct to infant)</td> <td> <p>YES</p> <p>NO</p> <p>At six years</p> </td> <td> <p>NO</p> <p>(Trend for more sensitization with probiotics)</p> <p>NO</p> <p>At six years</p> </td> <td> <p>NO</p> <p>NO</p> <p>At six years</p> <p>(Trend for more allergic rhinitis)</p> </td> <td>YES</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kim, et al.</p> <p>2010</p> Seoul</td> <td> <p>Any first degree relative with allergic disease</p> n = 68 completed (of initial 112)</td> <td><em>Bifidobacterium bifidum</em> BGN4, <em>Bifidobacterium lactis</em> AD011, and <em>Lactobacillus acidophilus</em> AD031 (1.6 x 10<sup>9</sup> CFU of each daily)</td> <td>Four to eight weeks before delivery</td> <td> <p>Six months</p> (Three months to breastfeeding mother and then direct to infant for three months)</td> <td>YES<sup>&#9674;&#9674;</sup></td> <td>NO</td> <td>NO</td> <td>Not known</td> <td>&#9674;&#9674; Reduced cumulative incidence and prevalence of eczema at 12 months.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Dotterud, et al.</p> <p>2010</p> Trondheim, Norway</td> <td> <p>Unselected population approximately two-thirds in both groups with first degree relative with allergic disease</p> n = 278 (of initial 415)</td> <td><em>Lactobacillus rhamnosus</em> GG, <em>Lactobacillus acidophilus</em> LA5, and <em>Bifidobacterium lactis</em> Bb-12 (5 x 10<sup>10</sup> CFU of each daily)</td> <td>From 36 weeks gestation</td> <td> <p>Three months</p> (To breastfeeding mother)</td> <td>YES</td> <td>NO</td> <td>NO</td> <td>Not known</td> <td>Reduced eczema in first two years compared with placebo group, the effect most obvious in children without a family history of atopy.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Boyle, et al.</p> <p>2011</p> Melbourne, Australia</td> <td> <p>Any first degree relative with allergic disease</p> n = 212 (of initial 250)</td> <td><em>Lactobacillus rhamnosus</em> GG (1.8 x 10<sup>10</sup> CFU daily)</td> <td>From 36 weeks gestation</td> <td>Not given</td> <td>NO</td> <td>NO</td> <td>NO</td> <td>YES</td> <td>No effect on eczema at 12 months, two year follow-up still in progress.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Ou, et al.</p> <p>2012</p> Kaohsiung, Taiwan</td> <td> <p>Mother with atopic disease and IgE &#62;100 kU/L and/or positive specific IgE</p> n = 128 completed (of initial 191)</td> <td> <p><em>Lactobacillus rhamnosus</em> GG</p> (1 x 10<sup>10</sup> CFU daily)</td> <td>From second trimester</td> <td>For six months to mother if breastfeeding and direct to infant if not breastfeeding</td> <td>NO</td> <td>NO</td> <td>NO</td> <td>Not known</td> <td>Symptom scores of maternal allergic disease reduced in probiotic group. Mothers with IgE &#62;100 kU/L improved most and improvement was associated with higher IL-12 p70 levels.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Allen, et al.</p> <p>2014</p> Swansea, UK</td> <td> <p>Any first degree relative with allergic disease</p> n = 378 completed at two years (of 454)</td> <td><em>Lactobacillus salivaris</em>&nbsp;CUL61, <em>Lactobacillus paracasei</em> CUL08, <em>Bifidobacterium&nbsp;</em>animalis subspecies lactis CUL34,&nbsp;and <em>Bifidobacterium bifidum</em> CUL20 (total of&nbsp;10<sup>10</sup> CFU daily)</td> <td>Two to four weeks before delivery</td> <td> <p>Six months</p> (Direct to infant regardless of feeding method)</td> <td>NO</td> <td>YES<br /> At two years</td> <td>NO</td> <td>Not known</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Cabana, et al.</p> San Francisco, United States</td> <td> <p>Either parent with asthma</p> n = 276 intended</td> <td><em>Lactobacillus rhamnosus</em> GG (1 x 10<sup>10</sup> CFU daily)</td> <td>Not given</td> <td> <p>Six months</p> (Direct to infant)</td> <td>Pending</td> <td>Pending</td> <td>Pending</td> <td>Pending</td> <td>&nbsp;</td> </tr> <tr> <td> <p>Rautava, Isolauri, et al.</p> 2012</td> <td>Mother with SPT+ allergic disease</td> <td> <p><em>L. rhamnosus</em> LPR and <em>B. longum</em> BL999</p> <p><strong>OR</strong></p> <p><em>L. paracasei</em> and <em>B. longum</em> BL9</p> <p><strong>OR</strong></p> <p>Placebo</p> Daily dose of each probiotic was 1 x 10<sup>9</sup> CFU</td> <td>Two months before delivery</td> <td>Two months during breastfeeding to mother only</td> <td> <p>YES</p> At two years and in both probiotic groups</td> <td>NO</td> <td>Not known</td> <td>Not known</td> <td>All mothers received vitamin and mineral supplementation in combination with probiotics or placebo.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows a list of the published and ongoing randomized, controlled trials, which have used probiotics for the primary prevention of allergic disease.<br /><STRONG>Search strategy for published studies:</STRONG> We included the following keywords: (probiotic OR Lactobacillus OR Bifidobacterium OR prebiotic OR symbiotic) AND (allergy OR allergic disease OR atopic dermatitis OR eczema). We then selected all randomized, controlled trials using the intervention of interest in humans and assessed allergic outcomes.</div><div class=\"graphic_footnotes\">n: number; CFU: colony-forming unit; s: soluble; CD: cluster of differentiation; IgA: immunoglobulin A; SPT: skin prick testing; IgE: immunoglobulin E; FeNO: fractional exhaled nitric oxide; IL-12: interleukin-12; Th1/2: T helper cells 1/2.</div><div class=\"graphic_reference\">Reproduced with permission from: Johannsen H, Prescott SL. Practical prebiotics, probiotics and synbiotics for allergist: How useful are they? Clin Exp Allergy 2009; 39:1801. Copyright © 2009 John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 74560 Version 20.0</div></div></div>"},"74561":{"type":"graphic_table","displayName":"Proportion of preterm birth by etiology","title":"Proportion of preterm birth by etiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proportion of preterm birth by etiology</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Etiology</td>\r\n            <td class=\"subtitle1\">Frequency (percent)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Spontaneous preterm labor</td>\r\n            <td>30 to 50</td>\r\n        </tr>\r\n        <tr>\r\n            <td>PPROM</td>\r\n            <td>5 to 40</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Multiple gestation</td>\r\n            <td>10 to 30</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Preeclampsia/eclampsia</td>\r\n            <td>12</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Antepartum bleeding</td>\r\n            <td>6 to 9</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Fetal growth restriction</td>\r\n            <td>2 to 4</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Other</td>\r\n            <td>8 to 9</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">PPROM: preterm premature rupture of membranes.</div><div class=\"graphic_reference\">Adapted from: Slattery MM, Morrison JJ. Lancet 2002; 360:1489.</div><div id=\"graphicVersion\">Graphic 74561 Version 3.0</div></div></div>"},"74562":{"type":"graphic_picture","displayName":"Chondro histology","title":"Histology of grade 1, 2, and 3 chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Histology of grade 1, 2, and 3 chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:516px; height:176px;\" src=\"images/ONC/74562_Chondro_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While cellularity is low in a&nbsp;grade 1 chondrosarcoma (now&nbsp;referred to as an atypical cartilaginous tumour/chondrosarcoma grade 1 [ACT/CS1])&nbsp;(A) with chondroid matrix and absent mitoses, in grade 2 chondrosarcoma (B) mitoses are found (inset). In grade 3 chondrosarcoma (C), a high cellularity with muco-myxoid matrix changes is seen with cytonuclear atypia (hematoxylin and eosin staining, ∼500X).</div><div class=\"graphic_reference\">Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright ©2008 AlphaMed Press.</div><div class=\"contractual\"><br/><a href=\"http://www.theoncologist.com/\">http://www.TheOncologist.com</a></div><div id=\"graphicVersion\">Graphic 74562 Version 4.0</div></div></div>"},"74563":{"type":"graphic_picture","displayName":"Normal epiglottis and acute epiglottitis","title":"Normal epiglottis and acute epiglottitis","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Normal epiglottis and acute epiglottitis</div><div class=\"cntnt\"><img style=\"width:484px; height:244px;\" src=\"images/PEDS/74563_Acute_epiglottitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal epiglottis.<br />(B) Characteristic erythematous, edematous epiglottis of acute epiglottitis.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 74563 Version 3.0</div></div></div>"},"74564":{"type":"graphic_table","displayName":"Features differentiating between ulcerative colitis and CD","title":"Features differentiating between ulcerative colitis and Crohn disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features differentiating&nbsp;between ulcerative colitis and Crohn disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Ulcerative colitis</td> <td class=\"subtitle1\">Crohn disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Hematochezia</td> <td>Common</td> <td>Less common</td> </tr> <tr> <td class=\"indent1\">Passage of mucus or pus</td> <td>Common</td> <td>Rare</td> </tr> <tr> <td class=\"indent1\">Small-bowel disease</td> <td>No (except backwash ileitis)</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Can affect upper-gastrointestinal tract</td> <td>No</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Abdominal mass</td> <td>Rare</td> <td>Sometimes in right lower quadrant</td> </tr> <tr> <td class=\"indent1\">Extraintestinal manifestations</td> <td>Common</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Small-bowel obstruction</td> <td>Rarely</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Colonic obstruction</td> <td>Rarely</td> <td>Common</td> </tr> <tr> <td class=\"indent1\">Fistulas and perianal disease</td> <td>No*</td> <td>Common</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Biochemical features</td> </tr> <tr> <td class=\"indent1\">Antineutrophil cytoplasmic antibodies</td> <td>Common</td> <td>Less common</td> </tr> <tr> <td class=\"indent1\">Anti-Saccharomyces cerevisiae antibodies</td> <td>Rarely</td> <td>Common</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pathological features</td> </tr> <tr> <td class=\"indent1\">Transmural mucosal inflammation</td> <td>No</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Distorted crypt architecture</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Cryptitis and crypt abscesses</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Granulomas</td> <td>No<sup>&#182;</sup></td> <td>Yes (seen in 25 to 40% of mucosal biopsies)</td> </tr> <tr> <td class=\"indent1\">Fissures and skip lesions</td> <td>Rarely</td> <td>Common</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table describes typical features distinguishing between classic ulcerative colitis and Crohn disease. On occasion, patients with ulcerative colitis may have \"nonclassic\" features, including gastritis and mild perianal disease, as discussed separately.</div><div class=\"graphic_footnotes\">* Small anal skin tags are sometimes seen in ulcerative colitis; this finding does not constitute perianal disease.&nbsp;<br />¶ Rarely, patients with ulcerative colitis may have granulomas associated with ruptured mucosal crypts (sometimes termed, \"cryptolytic\" granulomas). True granulomas that are associated with Crohn disease are well-defined and epithelioid.<SUP>[1]</SUP> The two types of granulomas are sometimes difficult to distinguish.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mahadeva U, Martin JP, et al. Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis. Histopathology 2002; 41:50.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted with permission from: Baumgert DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369:1641. Copyright &copy; 2007 Elsevier. ​</div><div id=\"graphicVersion\">Graphic 74564 Version 8.0</div></div></div>"},"74565":{"type":"graphic_picture","displayName":"Prismatic structure of enamel","title":"Scanning electron micrograph of dental enamel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scanning electron micrograph of dental enamel</div><div class=\"cntnt\"><img style=\"width:366px; height:280px;\" src=\"images/PEDS/74565_Prismatic_structure_of_enam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This scanning electron micrograph shows the prismatic structure of human dental enamel.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright &#169; 2000 WB Saunders.</div><div id=\"graphicVersion\">Graphic 74565 Version 3.0</div></div></div>"},"74566":{"type":"graphic_picture","displayName":"Tube extrusion","title":"Tympanostomy tube extrusion","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Tympanostomy tube extrusion</div><div class=\"cntnt\"><img style=\"width:477px; height:474px;\" src=\"images/PEDS/74566_Tubeextrusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inner flange of the tube becomes visible as it presses against the eardrum and begins to extrude as the tube tips posteriorly (Panels A and B above). Note that the tympanosclerosis is distant from the tube site (arrow in Panel B). When both flanges are clearly in view, extrusion is complete (Panel C above). A residual healing perforation remains in the eardrum.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright © 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 74566 Version 14.0</div></div></div>"},"74567":{"type":"graphic_table","displayName":"Factors predisposing to heat intolerance among active adults","title":"Factors predisposing to heat intolerance among active adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors predisposing to heat intolerance among active adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Functional:</td> </tr> <tr> <td>Low physical fitness</td> </tr> <tr> <td>Lack of acclimatization</td> </tr> <tr> <td>Low work efficiency</td> </tr> <tr> <td>Reduced skin area to mass ratio (eg, large muscle mass, obesity)</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired:</td> </tr> <tr> <td>Use of alcohol prior to activity</td> </tr> <tr> <td>Medications/supplements (eg, stimulants)</td> </tr> <tr> <td>Dehydration</td> </tr> <tr> <td>Viral or bacterial infection</td> </tr> <tr> <td>Previous heat stroke</td> </tr> <tr> <td>Sweat gland dysfunction</td> </tr> <tr> <td>Large skin area with burn scars</td> </tr> <tr> <td>X-ray radiation</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital:</td> </tr> <tr> <td>Ectodermal dysplasia</td> </tr> <tr> <td>Chronic idiopathic anhidrosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Epstein Y. Heat intolerance: Predisposing factor or residual injury? Med Sci Sports Exerc. 1990; 22:29-35.</div><div id=\"graphicVersion\">Graphic 74567 Version 1.0</div></div></div>"},"74568":{"type":"graphic_picture","displayName":"Viral findings VZV vasc","title":"Pathological and virological findings in the arteries of patients who died from VZV vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathological and virological findings in the arteries of patients who died from VZV vasculopathy</div><div class=\"cntnt\"><img style=\"width:404px; height:479px;\" src=\"images/ID/74568_Viral_findings_VZV_vasc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A cerebral artery with multinucleated giant cells (arrow). (B) Multiple herpesvirions within a cerebral artery. (C) VZV DNA in the posterior cerebral artery (lane 3) and basilar artery (lane 5). (D) VZV antigen (red) in the media of a cerebral artery.</div><div class=\"graphic_reference\">Panels A and B courtesy of Don&nbsp;Gilden, MD; Panels C and D reproduced with permission from: Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, et al. Varicella zoster virus, a cause of waxing and waning vasculitis: The New England Journal of Medicine case 5-1995 revisited. Neurology 1996; 47:1441. Copyright © 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74568 Version 11.0</div></div></div>"},"74571":{"type":"graphic_table","displayName":"Card inelig adjuv trastuz","title":"Cardiac ineligibility criteria in the NSABP B-31 and NCCTG N9831 adjuvant trastuzumab trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiac ineligibility criteria in the NSABP B-31 and NCCTG N9831 adjuvant trastuzumab trials</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Angina pectoris requiring antianginal medication</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Arrhythmia requiring medication</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Severe conduction abnormality</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Clinically significant valvular heart disease</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cardiomegaly on chest radiography</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Left ventricular hypertrophy on echocardiogram (NSABP B-31 only)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Poorly controlled hypertension</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Clinically significant pericardial effusion (NCCTG trial N9831 only)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>History of myocardial infarction, heart failure, or cardiomyopathy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>LVEF below the lower limit of normal</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74571 Version 1.0</div></div></div>"},"74572":{"type":"graphic_picture","displayName":"Allergic contact derm PI","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:322px; height:216px;\" src=\"images/PI/74572_AllergcontactdermPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows a person with allergic contact dermatitis. The skin is red and raised in the places that were touched by the allergen.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 74572 Version 2.0</div></div></div>"},"74574":{"type":"graphic_table","displayName":"Compression stockings in chronic venous disorders","title":"Compression stockings in chronic venous disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Compression stockings in chronic venous disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Pressure</td> <td class=\"subtitle1\">Level of support</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">CEAP*</td> </tr> <tr> <td>OTC<sup>&#182;</sup></td> <td>&#60;15 mmHg</td> <td>Minimal</td> <td>Asymptomatic individuals as needed for comfort</td> <td>0,1</td> </tr> <tr> <td>I</td> <td>15-20 mmHg</td> <td>Mild</td> <td>Minor varicosities; tired aching legs; minor ankle, leg, or foot swelling</td> <td>1,2,3</td> </tr> <tr> <td>II</td> <td>20-30 mmHg</td> <td>Moderate</td> <td>Moderate to severe varicosities, moderate swelling, phlebitis, following vein ablation</td> <td>3,4</td> </tr> <tr> <td>III</td> <td>30-40 mmHg</td> <td>Firm</td> <td>Severe varicosities, severe swelling, management of active ulceration, following DVT, post-surgery</td> <td>4,5,6</td> </tr> <tr> <td>IV</td> <td>&#62;40 mmHg</td> <td>Extra firm</td> <td>Lymphedema</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical-Etiologic-Anatomic-Physiologic classification of chronic venous disorders.<br />¶ OTC: Over-the-counter, no prescription needed.</div><div id=\"graphicVersion\">Graphic 74574 Version 5.0</div></div></div>"},"74576":{"type":"graphic_figure","displayName":"Surgical knots","title":"Surgical knots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical knots</div><div class=\"cntnt\"><img style=\"width:437px; height:311px;\" src=\"images/SURG/74576_Knots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Square knot and surgeon's knot.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 74576 Version 2.0</div></div></div>"},"74577":{"type":"graphic_diagnosticimage","displayName":"Red marrow normal adult","title":"Distribution of bone marrow in a normal adult","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distribution of bone marrow in a normal adult</div><div class=\"cntnt\"><img style=\"width:285px; height:504px;\" src=\"images/HEME/74577_Red_marrow_normal_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photos illustrate the distribution of erythropoietic (red) marrow in the normal adult, as outlined by uptake of transferrin-bound radioactive iron three hours after injection (scintigram on the left). The patient's body outline is shown in the photo on the right for localization purposes. Erythropoietic marrow is most prominent in the spine (arrow) and pelvis (arrowhead), with lesser amounts in the ribs. There is no uptake of iron in skull, arms, or in the long bones of the legs below the upper portion of the femur.</div><div class=\"graphic_reference\">Supplied by Stephen A. Landaw, MD.</div><div id=\"graphicVersion\">Graphic 74577 Version 3.0</div></div></div>"},"74578":{"type":"graphic_table","displayName":"Sxs signs childhood cancer","title":"Symptoms and signs of childhood cancer mimicking normal childhood illnesses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of childhood cancer mimicking normal childhood illnesses</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Symptom/sign</td>\n<td class=\"subtitle1\">Possible malignancy</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_left\">Generalized malaise, fever, adenopathy</td>\n<td>Lymphoma, leukemia, EWS, NBL</td>\n</tr>\n\t\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Head and neck</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Headache, nausea, vomiting</td>\n<td>Brain tumor, leukemia</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Febrile seizure</td>\n<td>Brain tumor</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Earache</td>\n<td>STS</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Rhinitis</td>\n<td>STS</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Epistaxis</td>\n<td>Leukemia</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Pharyngitis</td>\n<td>STS</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Adenopathy</td>\n<td>NBL, thyroid, STS, lymphoma, leukemia</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Thorax</td>\n</tr>\n\n<tr>\n<td class=\"subtitle3_left\" colspan=\"2\">Extrathoracic</td>\n</tr>\n\n<tr>\n<td class=\"indent2\">Soft tissue mass</td>\n<td>STS, PNET</td>\n</tr>\n\n<tr>\n<td class=\"indent2\">Bony mass</td>\n<td>EWS, NBL</td>\n</tr>\n\n<tr>\n<td class=\"subtitle3_left\" colspan=\"2\">Intrathoracic</td>\n</tr>\n\n<tr>\n<td class=\"indent2\">Adenopathy</td>\n<td>Lymphoma, leukemia</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">External: soft tissue</td>\n<td>STS, PNET</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Internal: diarrhea, vomiting, hepatomegaly, and/or splenomegaly</td>\n<td>NBL, lymphoma, hepatic tumor, leukemia</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Genitourinary</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Hematuria</td>\n<td>Wilms' tumor, STS</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Trouble voiding</td>\n<td>Prostatic or bladder STS</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Vaginitis</td>\n<td>STS</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Peritesticular mass</td>\n<td>STS</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">Musculoskeletal</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Soft tissue mass(es)</td>\n<td>RMS, other STS, PNET</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Bony mass/pain</td>\n<td>Osteosarcoma, EWS, NHL, NBL, leukemia</td>\n</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">10/3/2008--Requested permission (JD). 10/20/2008--Permission granted from LWW and Dr Steuber is also a co-author on the card; figures to Terrence (JD). 2/4/2010--Renewal requested (JD). 3/26/2010--Renewal granted; agreement mailed back to Arnetta (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=56281&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Sxs_signs_childhood_cancer.htm</title></head></div><div class=\"graphic_footnotes\">EWS: Ewing's sarcoma; NBL: neuroblastoma; NHL: non-Hodgkin's lymphoma; PNET: primitive neuroectodermal tumor; RMS: rhabdomyosarcoma; STS: soft tissue sarcoma, including rhabdomyosarcoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Kilburn LB, Siegel SE, Steuber CP. Clinical Assessment and Differential Diagnosis of the Child with Suspected Cancer. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010.&nbsp;Copyright © 2010 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74578 Version 10.0</div></div></div>"},"74580":{"type":"graphic_figure","displayName":"Pattern of benign calcification","title":"Patterns of benign calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patterns of benign calcification</div><div class=\"cntnt\"><img style=\"width:363px; height:350px;\" src=\"images/PULM/74580_Pattern_of_benign_calcifica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of different patterns of benign calcification. In clockwise orientation from top left: target, diffuse, popcorn, and lamellated calcification.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74580 Version 1.0</div></div></div>"},"74584":{"type":"graphic_table","displayName":"Who should be tested LTBI","title":"Who should be tested for latent tuberculosis infection (LTBI)?","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Who should be tested for latent&nbsp;tuberculosis infection (LTBI)?</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Individuals&nbsp;with increased risk of new TB infection</td> </tr> <tr> <td class=\"indent1\">Close contacts of patients with&nbsp;untreated active respiratory TB*</td> </tr> <tr> <td class=\"indent1\">Casual contacts of patients with untreated active respiratory TB*</td> </tr> <tr> <td class=\"indent1\">Illicit drug users</td> </tr> <tr> <td class=\"indent1\">Residents or employees of a homeless shelter or correctional facility</td> </tr> <tr> <td class=\"indent1\">Health care workers and other occupations in which there is risk of exposure to patients with untreated active respiratory&nbsp;TB</td> </tr> <tr> <td class=\"subtitle1_single\">Individuals with increased risk of reactivation<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">High risk (test all patients)</td> </tr> <tr> <td class=\"indent1\">HIV infection (any stage of illness)</td> </tr> <tr> <td class=\"indent1\">Transplant, chemotherapy, or other major immunocompromising condition</td> </tr> <tr> <td class=\"indent1\">Lymphoma, leukemia, head and neck cancer</td> </tr> <tr> <td class=\"indent1\">Abnormal chest radiograph with apical fibronodular changes typical of healed TB (not including granuloma)</td> </tr> <tr> <td class=\"indent1\">Silicosis</td> </tr> <tr> <td class=\"indent1\">Renal failure (requiring dialysis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Treatment with TNF-alpha inhibitors</td> </tr> <tr> <td class=\"subtitle2_single\">Moderate risk (test patients in groups with increased prevalence of LTBI)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systemic glucocorticoids (&#8805;15 mg/day for &#8805;1 month)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Slightly increased risk (test patients in groups with increased prevalence of LTBI)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Underweight (&#60;85 percent of ideal body weight); for most individuals, this is equivalent to body mass index (BMI) &#8804;20</td> </tr> <tr> <td class=\"indent1\">Cigarette smoker (&#8805;1 pack/day)</td> </tr> <tr> <td class=\"indent1\">Chest radiograph with solitary granuloma</td> </tr> <tr> <td class=\"indent1\">Individuals born in or former residents of countries with high incidence of TB disease (WITHOUT other risk factors listed above)<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. Individuals with very low likelihood of LTBI should not be tested routinely, as the yield of testing is low and the likelihood of a false-positive test becomes more important. <br />Local epidemiologic patterns and risk groups may vary; consult local or state health departments for more information about populations with increased prevalence of latent TB in the local community.<br />The approach to LTBI testing should be individualized in older patients at lower risk of reactivation. The relationship between the risk of adverse events and increasing age is well documented for isoniazid. Thus far, data are insufficient to determine appropriate age thresholds for LTBI testing if individuals with a positive test are treated with a shorter rifamycin-based regimen. Until further data on the age-related risks of adverse events with these regimens are available, it is reasonable to adhere to the same cautions as for isoniazid.</div><div class=\"graphic_footnotes\">TB: tuberculosis; TNF: tumor necrosis factor; CDC: United States Centers for Disease Control and Prevention.<br />*&nbsp;Close contacts are defined by the CDC as individuals with at least four hours of contact per week. This includes those living in the same household or frequent visitors to the house; it may also include contacts at work or school. Casual contacts are defined by the CDC as individuals with less than four hours of contact per week. This may include healthcare workers and/or contacts at work or school.<br />¶&nbsp;An individual with a false-negative test resulting from faded immune memory who then receives immunosuppression (such as a TNF inhibitor) may be at high risk of reactivation disease. Such individuals warrant a single test if interferon-gamma release assay is used; however, use of tuberculin skin test warrants a two-step test.&nbsp;<br />Δ&nbsp;In general, groups with increased LTBI prevalence include homeless individuals, injection drug users, contacts of active TB cases, and foreign-born individuals who immigrated as adults from countries with TB incidence &gt;100/100,000 (this includes most countries in Africa and Asia, many countries in Eastern Europe, Central America and South America, plus Haiti and the Dominican Republic).<br />◊ The CDC recommends skin testing for all patients in this category. However, population-based studies demonstrate that the relative risk for development of active tuberculosis in this category is moderate (two to&nbsp;four times&nbsp;that of healthy individuals). Therefore, an age cutoff of ≤65 is indicated, so that potential risks of isoniazid toxicity in older adult patients do not outweigh potential benefit. (Refer to separate UpToDate table summarizing relative risk for development of active tuberculosis).<br />§ Individuals born in or former residents of countries with high TB&nbsp;incidence (&gt;100/100,000)&nbsp;are an additional category of individuals with increased prevalence of TB infection. In the United States and the United Kingdom, guidelines favor LTBI testing for such individuals; in Canada, guidelines favor LTBI testing only for groups within the immigrant population who have additional risk factors for progression to active disease.</div><div id=\"graphicVersion\">Graphic 74584 Version 8.0</div></div></div>"},"74586":{"type":"graphic_picture","displayName":"Behcets vulva","title":"Behçet's vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Behçet's vulva</div><div class=\"cntnt\"><img style=\"width:300px; height:417px;\" src=\"images/OBGYN/74586_Behcets_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 74586 Version 3.0</div></div></div>"},"74589":{"type":"graphic_figure","displayName":"Mechanism of acute pain","title":"Mechanism of acute pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of acute pain</div><div class=\"cntnt\"><img style=\"width:398px; height:532px;\" src=\"images/PC/74589_Mechacutepain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue injury leads to release of inflammatory mediators with subsequent nociceptor stimulation. Pain impulses are then transmitted to the dorsal horn of the spinal cord, where they make contact with second-order neurons that cross to the opposite side of the cord and ascend via the spinothalamic tract to the reticular activating system (RAS) and thalamus. The localization and meaning of pain occurs at the level of the somatosensory cortex.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright ©2008.</div><div id=\"graphicVersion\">Graphic 74589 Version 4.0</div></div></div>"},"74592":{"type":"graphic_diagnosticimage","displayName":"Irregular endometrium","title":"Transvaginal pelvic scan of a patient 19 days since her last episode of bleeding","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Transvaginal pelvic scan of a patient 19 days since her last episode of bleeding</div><div class=\"cntnt\"><img style=\"width:465px; height:352px;\" src=\"images/OBGYN/74592_Irregular_endometrium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endometrial surface is irregular. One surface measures 3.8 mm and the other measures 4.0 mm. An irregular surface is not unusual, particularly in patients who have had previous dilation and curettage, myomectomies, childbirth, etc; however, the irregular surface of the endometrium identified here as \"moguls\" can be misleading. Performing the procedure this long after the last bleeding episode can be fraught with error and should be avoided.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 74592 Version 3.0</div></div></div>"},"74593":{"type":"graphic_table","displayName":"Overview of HHT features and their management","title":"Overview of the incidence, presenting findings, evaluation, and management of the major clinical features of hereditary hemorrhagic telangiectasia (HHT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of the incidence, presenting findings, evaluation, and management of the major clinical features of hereditary hemorrhagic telangiectasia (HHT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Presentation patterns</td> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Nasal telangiectasia</td> <td>&#62;90%</td> <td>Nose bleeds are usually the first manifestation of HHT, frequently commencing in childhood.</td> <td>History, inspection</td> <td> <ul> <li>Routine therapy includes nasal lubrication and treatment of iron deficiency when needed. </li> <li>Laser treatment is generally preferred over cauterization. </li> <li>Surgery in expert hands offers good results for selected patients. </li> <li>Medical (systemic) treatments are an alternative and may be highly beneficial, but carry risks of prothrombotic side effects. </li> <li>Emergency treatments such as packing may be required. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Mucocutaneous telangiectasia</td> <td>50 to 80%</td> <td>Increase in size and number with age. Main concerns are cosmetic. May hemorrhage.</td> <td>Inspection (oral, mucosa, conjunctivae, face, trunk, extremities, nail beds)</td> <td> <ul> <li>Generally not indicated, but laser therapy can be used. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Gastrointestinal telangiectasia</td> <td>11 to 40%</td> <td>Onset generally over 30 years: Iron deficiency anemia, occasionally acute gastrointestinal hemorrhage.</td> <td>Flexible endoscopy, endoscopy angiogram, capsule endoscopy</td> <td> <ul> <li>Iron supplementation and transfusion are the mainstays of treatment. </li> <li>Medical (systemic) treatments are available and may be highly beneficial, but they carry risks of prothrombotic side effects. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary AVMs</td> <td>&#62;50%</td> <td>Usually silent. Cyanosis, clubbing, bruit, dyspnea, paradoxical embolism, cerebral abscess.</td> <td>Chest radiography, blood gas measurement, helical CT, angiography, chest echocardiography</td> <td> <ul> <li>Therapeutic embolization. </li> <li>Antibiotic prophylaxis for dental and surgical procedures. </li> <li>Surgical resection may be indicated in highly selected cases. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cerebral AVMs</td> <td>10 to 15%</td> <td>Usually silent. Headache, epilepsy, ischemia, intracerebral hemorrhage.</td> <td>CT, MRI, Doppler sonography, angiography</td> <td> <ul> <li>Most do not require treatment. </li> <li>Therapeutic embolization, neurovascular surgery, or stereotactic radiosurgery in highly selected cases. </li> </ul> </td> </tr> <tr> <td>Hepatic AVMs</td> <td>30 to 70%</td> <td>Usually silent. Hepatic artery-hepatic vein AVMs: Hyperdynamic circulation. Portasystemic shunts: Ascites and encephalopathy.</td> <td>Doppler sonography, CT, MRI</td> <td> <ul> <li>Most do not require treatment. </li> <li>For the small proportion of patients who develop symptoms, standard hepatic medical care is often sufficient to resolve symptoms.</li> <li>Liver transplantation in selected cases.</li> <li>Embolization is a higher-risk procedure; some centers do not perform embolization&nbsp;unless the patient is accepted into a liver transplantation program.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Less-common clinical manifestations include AVMs in other sites, high cardiac output states, and pulmonary hypertension. Refer to UpToDate for additional details of our approach.</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation; CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Adapted and updated&nbsp;from the original table in: Shovlin CL, Letarte M. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.</div><div id=\"graphicVersion\">Graphic 74593 Version 3.0</div></div></div>"},"74594":{"type":"graphic_figure","displayName":"Parasympathetic ganglia neurons","title":"Human airway parasympathetic ganglia neurons have complex morphology and electrophysiology","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Human airway parasympathetic ganglia neurons have complex morphology and electrophysiology</div><div class=\"cntnt\"><img style=\"width:539px; height:373px;\" src=\"images/PULM/74594_parasympathetic_ganglia_neu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Camera lucida drawing of a human bronchial parasympathetic ganglion neuron. The complex morphology of airway ganglia neurons, with an extensive dendritic arbor and multiple synaptic contacts, facilitates integration of synaptic input. B) Digital overlay of consecutive intracellular recordings of human bronchial ganglion membrane potential and synaptic potentials. Stimulation (at arrow, with associated shock artifact) of an extrinsic vagal nerve branch initiates depolarizations known as fast excitatory post-synaptic potentials (fEPSPs). The fEPSPs, most of which are subthreshold for action potential formation, are mediated by acetylcholine acting on airway parasympathetic ganglia neuron nicotinic receptors. C) Temporal dissociation of multiple fEPSPs (following shock artifact [arrow]) in human bronchial ganglia neuron reveals that several preganglionic inputs regulate the excitability of each bronchial ganglia neuron.</div><div class=\"graphic_reference\">Reproduced with permission from: Kajekar R, Rohde HK, Myers AC. The integrative membrane properties of human bronchial parasympathetic Ganglia neurons. Am J Respir Crit Care Med 2001; 164:1927. Copyright © 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 74594 Version 2.0</div></div></div>"},"74595":{"type":"graphic_picture","displayName":"Batwing mastopexy","title":"Batwing mastopexy","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Batwing mastopexy</div><div class=\"cntnt\"><img style=\"width:545px; height:413px;\" src=\"images/SURG/74595_Batwingmastopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Batwing mastopexy lumpectomy for laterally oriented central (periareolar) breast cancer.<br> (A) Preoperative marking including placement of parallel arcs and wings.<br> (B) Initial skin incision.<br> (C) Full-thickness ﬁbroglandular resection down to chest wall with superior-to-inferior mastopexy closure.<br> (D) Final skin closure.</div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74595 Version 8.0</div></div></div>"},"74597":{"type":"graphic_picture","displayName":"Tuberculoid granuloma","title":"Tuberculoid granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculoid granuloma</div><div class=\"cntnt\"><img style=\"width:281px; height:270px;\" src=\"images/DERM/74597_Tubercu_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberculoid granuloma. Epitheliod histiocytes, multinucleated giant cells, and a dense lymphocytic infiltrate are present.</div><div class=\"graphic_reference\">Courtesy of Dr. Ma. Flordeliz Abad-Casintahan.</div><div id=\"graphicVersion\">Graphic 74597 Version 2.0</div></div></div>"},"74598":{"type":"graphic_figure","displayName":"Hand and wrist anatomy palmar view","title":"Hand and wrist anatomy palmar view","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Hand and wrist anatomy palmar view</div><div class=\"cntnt\"><img style=\"width:554px; height:464px;\" src=\"images/EM/74598_Hand_palmar_anatomy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arterial anastomoses of the hand. The radial and ulnar arteries connect to each other through two loops: a superficial palmar arch and a deep palmar arch. This ensures adequate perfusion in the event of lacerations, which are common injuries to the fingers.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Agur AM. Essential Clinical Anatomy, 3rd Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169;2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74598 Version 3.0</div></div></div>"},"74599":{"type":"graphic_table","displayName":"Duration of pneumonia findings","title":"Usual duration of findings in treated community-acquired pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual duration of findings in treated community-acquired pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Duration (days)</td> </tr> <tr> <td>Tachycardia and hypotension</td> <td>2</td> </tr> <tr> <td>Fever, tachypnea, and hypoxia</td> <td>3</td> </tr> <tr> <td>Cough</td> <td>14</td> </tr> <tr> <td>Fatigue</td> <td>14</td> </tr> <tr> <td>Infiltrates on chest radiograph</td> <td>30</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Marrie TJ, Beecroft MD, Herman-Gnjidic Z. Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis. J Infect 2004; 49:302.</LI>&#xD;&#xA;<LI>Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92:1137.</LI>&#xD;&#xA;<LI>Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159:970.</LI></OL></div><div id=\"graphicVersion\">Graphic 74599 Version 2.0</div></div></div>"},"74602":{"type":"graphic_figure","displayName":"Spinal cord white matter tracts","title":"Major white matter tracts of the spinal cord","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Major white matter tracts of the spinal cord</div><div class=\"cntnt\"><img style=\"width:542px; height:353px;\" src=\"images/NEURO/74602_SC_white_matter_tracts.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74602 Version 3.0</div></div></div>"},"74604":{"type":"graphic_table","displayName":"Birth control pills used for emergency contraception","title":"How to use birth control pills for emergency contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to use birth control pills for emergency contraception</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   \t<td  class=\"subtitle1\" rowspan=\"2\">Brand name</td>\n\t<td  class=\"subtitle1\">First dose</td>\n\t<td  class=\"subtitle1\">Second dose</td>\n\t</tr>\n\t\n\t<tr>\n   <td  class=\"subtitle2\">Take these pills as soon as possible after unprotected sex. Emergency contraception works up to 5 days after unprotected sex. The sooner you take it, the better it will work.</td>\n   <td  class=\"subtitle2\">Take these pills 12 hours after taking the first set of pills.</td>\n   </tr>\n\n   <tr>\n   <td>Alesse</td>\n   <td>5 pink pills</td>\n   <td>5 pink pills</td>\n   </tr>\n   <tr>\n   <td>Aviane</td>\n   <td>5 orange pills</td>\n   <td>5 orange pills</td>\n   </tr>\n   <tr>\n   <td>Cryselle</td>\n   <td>4 white pills</td>\n   <td>4 white pills</td>\n   </tr>\n   <tr>\n   <td>Enpresse</td>\n   <td>4 orange pills</td>\n   <td>4 orange pills</td>\n   </tr>\n   <tr>\n   <td>Jolessa</td>\n   <td>4 pink pills</td>\n   <td>4 pink pills</td>\n   </tr>\n   <tr>\n   <td>Lessina</td>\n   <td>5 pink pills</td>\n   <td>5 pink pills</td>\n   </tr>\n   <tr>\n   <td>Levlen</td>\n   <td>4 light orange pills</td>\n   <td>4 light orange pills</td>\n   </tr>\n   <tr>\n   <td>Levlite</td>\n   <td>5 pink pills</td>\n   <td>5 pink pills</td>\n   </tr>\n   <tr>\n   <td>Levora</td>\n   <td>4 white pills</td>\n   <td>4 white pills</td>\n   </tr>\n   <tr>\n   <td>Lo/Ovral</td>\n   <td>4 white pills</td>\n   <td>4 white pills</td>\n   </tr>\n   <tr>\n   <td>Low-Ogestrel</td>\n   <td>4 white pills</td>\n   <td>4 white pills</td>\n   </tr>\n   <tr>\n   <td>Lutera</td>\n   <td>5 white pills</td>\n   <td>5 white pills</td>\n   </tr>\n   <tr>\n   <td>Lybrel</td>\n   <td>6 yellow pills</td>\n   <td>6 yellow pills</td>\n   </tr>\n   <tr>\n   <td>Nordette</td>\n   <td>4 light orange pills</td>\n   <td>4 light orange pills</td>\n   </tr>\n   <tr>\n   <td>Ogestrel</td>\n   <td>2 white pills</td>\n   <td>2 white pills</td>\n   </tr>\n   <tr>\n   <td>Ovral</td>\n   <td>2 white pills</td>\n   <td>2 white pills</td>\n   </tr>\n   <tr>\n   <td>Ovrette</td>\n   <td>20 yellow pills</td>\n   <td>20 yellow pills</td>\n   </tr>\n   <tr>\n   <td>Portia</td>\n   <td>4 pink pills</td>\n   <td>4 pink pills</td>\n   </tr>\n   <tr>\n   <td>Quasense</td>\n   <td>4 white pills</td>\n   <td>4 white pills</td>\n   </tr>\n   <tr>\n   <td>Seasonale</td>\n   <td>4 pink pills</td>\n   <td>4 pink pills</td>\n   </tr>\n   <tr>\n   <td>Seasonique</td>\n   <td>4 blue-green pills</td>\n   <td>4 blue-green pills</td>\n   </tr>\n   <tr>\n   <td>Tri-Levlen</td>\n   <td>4 yellow pills</td>\n   <td>4 yellow pills</td>\n   </tr>\n   <tr>\n   <td>Triphasil</td>\n   <td>4 yellow pills</td>\n   <td>4 yellow pills</td>\n   </tr>\n   <tr>\n   <td>Trivora</td>\n   <td>4 pink pills</td>\n   <td>4 pink pills</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">12.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=49349&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>OCs_used_for_EC_PI.htm</title></head></div><div class=\"graphic_lgnd\">If you want to use birth control pills for emergency contraception, you must take two doses 12 hours apart. Find the brand name of the pills you take in the left-hand column. Then see the second and third columns to find out how many of which color pills to take for that brand name. Keep in mind that birth control pills work but are less effective than Plan B One-Step or Next Choice, and they are more likely to cause nausea and vomiting.</div><div id=\"graphicVersion\">Graphic 74604 Version 5.0</div></div></div>"},"74605":{"type":"graphic_waveform","displayName":"Slow RNS in LEMS","title":"Slow repetitive nerve stimulation in Lambert-Eaton myasthenic syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slow repetitive nerve stimulation in Lambert-Eaton myasthenic syndrome</div><div class=\"cntnt\"><img style=\"width:394px; height:298px;\" src=\"images/NEURO/74605_Slow_RNS_LEMS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slow (3 Hz) repetitive nerve stimulation in Lambert-Eaton myasthenic syndrome, before and after brief exercise. In both situations, there is a prominent decrement. However, after brief exercise, the baseline compound muscle action potential (CMAP) is significantly larger compared with the CMAP before exercise. (Note that the y-axis is in microvolts for stimulation at rest, and in millivolts for stimulation postexercise). In this case, the CMAP increment after brief exercise was 2000 percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders, 2nd ed, Butterworth-Heinemann, Boston 1998. Copyright © 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 74605 Version 2.0</div></div></div>"},"74606":{"type":"graphic_picture","displayName":"Papulonecrotic tuberculid on extremities","title":"Papulonecrotic tuberculid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papulonecrotic tuberculid</div><div class=\"cntnt\"><img style=\"width:256px; height:372px;\" src=\"images/DERM/74606_Papul_tuberculid_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A symmetrical eruption of erythematous to violaceous papules is present on the legs of this patient with papulonecrotic tuberculid.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. M Ramam, New Delhi.</div><div id=\"graphicVersion\">Graphic 74606 Version 1.0</div></div></div>"},"74607":{"type":"graphic_figure","displayName":"Finger pulley system","title":"Finger pulley system","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Finger pulley system</div><div class=\"cntnt\"><img style=\"width:526px; height:169px;\" src=\"images/EM/74607_Finger_pulley1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The retinacular portion of the finger tendon sheath consists of cruciform, annular, and transverse tissues that facilitate smooth gliding of the tendons and form a pulley system that enables effective finger flexion without displacement of the tendons (ie, \"bowstringing\"). The retinacular pulley system is comprised of the palmar aponeurosis (PA) pulley (not shown), five annular (A) pulleys, and three cruciform (C) pulleys.</div><div class=\"graphic_reference\">Reproduced with permission from: Doyle JR. Hand. In: Doyle JR, Botte MJ, eds. Surgical anatomy of the hand and upper extremity. Philadelphia: Lippincott Williams &amp; Wilkins, 2003:522-666. Copyright ©2003 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 74607 Version 3.0</div></div></div>"},"74608":{"type":"graphic_algorithm","displayName":"Rx incompatible crossmatch","title":"Clinical management of patients with incompatible crossmatch","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Clinical management of patients with incompatible crossmatch</div><div class=\"cntnt\"><img style=\"width:513px; height:318px;\" src=\"images/HEME/74608_Rx_incompatible_crossmatch.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74608 Version 3.0</div></div></div>"},"74610":{"type":"graphic_table","displayName":"Est dx MCTD","title":"Two algorithms for establishing a diagnosis of mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Two algorithms for establishing a diagnosis of mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Alarcon-Segovia's criteria</td> <td class=\"subtitle1\">Kahn's criteria</td> </tr> <tr> <td class=\"subtitle2_left\">A. Serological criteria</td> <td class=\"subtitle2_left\">A. Serological criteria</td> </tr> <tr> <td class=\"indent1\">Anti-RNP antibodies with a hemagglutination titer of &#8805;1:1600</td> <td class=\"indent1\">High titer anti-RNP corresponding to a speckled ANA of &#8805;1:1200 titer</td> </tr> <tr> <td class=\"subtitle2_left\">B. Clinical criteria</td> <td class=\"subtitle2_left\">B. Clinical criteria</td> </tr> <tr> <td class=\"indent1\">1. Swollen hands</td> <td class=\"indent1\">1. Swollen fingers</td> </tr> <tr> <td class=\"indent1\">2. Synovitis</td> <td class=\"indent1\">2. Synovitis</td> </tr> <tr> <td class=\"indent1\">3. Myositis*</td> <td class=\"indent1\">3. Myositis</td> </tr> <tr> <td class=\"indent1\">4. Raynaud's phenomenon</td> <td class=\"indent1\">4. Raynaud phenomenon</td> </tr> <tr> <td class=\"indent1\">5. Acrosclerosis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">MCTD is present if:</td> <td class=\"subtitle2_left\">MCTD is present if:</td> </tr> <tr> <td class=\"indent1\">Criterion A is accompanied by three or more clinical criteria - one of which must include synovitis or myositis.</td> <td class=\"indent1\">Criterion A is accompanied by Raynaud phenomenon and two or more of the three remaining clinical criteria.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANA: antinuclear antibody; MCTD: mixed connective tissue disease.<br />* Myalgia is commonly substituted for myositis.</div><div class=\"graphic_reference\">Original figure modified for this publication. Bennett RM. Overlap Syndromes. Kelley's Textbook of Rheumatology, 8th Edition, W.B. Saunders Co, Philadelphia 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74610 Version 4.0</div></div></div>"},"74611":{"type":"graphic_waveform","displayName":"ECG atrial tachycardia from tricuspid annulus","title":"Electrocardiogram (ECG) showing atrial tachycardia originating from the tricuspid annulus.","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing atrial tachycardia originating from the tricuspid annulus.</div><div class=\"cntnt\"><img style=\"width:488px; height:445px;\" src=\"images/CARD/74611_Atrial_tachycard_ECG_1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiographic tracing showing a narrow complex tachycardia with uniform P waves consistent with atrial tachycardia originating from the tricuspid annulus. Prior to the final QRS complex, there is spontaneous return to normal sinus rhythm with P wave of a different morphology.</div><div class=\"graphic_reference\">Courtesy of Peter Kistler, MBBS, FRACP, PhD.</div><div id=\"graphicVersion\">Graphic 74611 Version 7.0</div></div></div>"},"74614":{"type":"graphic_diagnosticimage","displayName":"Ruptured gallbladder with biloma","title":"Ruptured gallbladder with biloma","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Ruptured gallbladder with biloma</div><div class=\"cntnt\"><img style=\"width:500px; height:331px;\" src=\"images/SURG/74614_Ruptured_gallbladder_biloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan of the upper abdomen without intravenous but with oral contrast demonstrates a ruptured gallbladder with a collection of bile (biloma) in the gallbladder fossa. Note that there are multiple gallstones that are located outside of the gallbladder. There is also a small amount of fluid around the liver.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 74614 Version 4.0</div></div></div>"},"74617":{"type":"graphic_diagnosticimage","displayName":"Superior sagittal sinus thrombosis","title":"Superior sagittal sinus thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior sagittal sinus thrombosis</div><div class=\"cntnt\"><img style=\"width:289px; height:515px;\" src=\"images/NEURO/74617_SSS_thrombosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted magnetic resonance imaging discloses an isointense signal in the superior sagittal sinus (arrows), corresponding to a thrombus (A), and the corresponding absence of flow on magnetic resonance venography (B).</div><div id=\"graphicVersion\">Graphic 74617 Version 3.0</div></div></div>"},"74618":{"type":"graphic_algorithm","displayName":"Amenorrhea pain workup","title":"Amenorrhea pain workup","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Amenorrhea pain workup</div><div class=\"cntnt\"><img style=\"width:503px; height:617px;\" src=\"images/OBGYN/74618_Amenorrhea_pain_workup_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Fujimoto, VY, Miller, JH, Klein, NA, Soules, MR. Congenital cervical atresia: Report of seven cases and review of the literature. Am J Obstet Gynecol 1977; 177:1419. Copyright &#169; 1977 Elsevier.</div><div id=\"graphicVersion\">Graphic 74618 Version 4.0</div></div></div>"},"74621":{"type":"graphic_table","displayName":"Emergency treatment acute angle closure glaucoma","title":"Rapid overview: Emergent management of severe acute angle closure glaucoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergent management of severe acute angle closure glaucoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td>Rate of onset and degree of intraocular pressure (IOP) increase determine symptoms</td> </tr> <tr> <td>With rapid increase in IOP, patients can experience sudden onset of eye pain, headache, blurry vision, halos around lights, and nausea and/or vomiting; some symptoms may not be present</td> </tr> <tr> <td>Episode is often triggered by sudden pupillary dilation from darkness (eg, lights go down in theater), sympathetic arousal (eg, emotional upset), medications</td> </tr> <tr> <td>Predisposing medications include: Over-the-counter decongestants, motion sickness medications, adrenergic agents, antipsychotics, antidepressants, and anticholinergics</td> </tr> <tr> <td class=\"subtitle1_single\">Examination</td> </tr> <tr> <td>Signs associated with rapid increase in IOP include: Reduced visual acuity, red/injected conjunctiva, mid-dilated pupil (4 to 6 mm) that reacts poorly to light or is fixed, corneal edema or cloudiness</td> </tr> <tr> <td>Measure IOP: Generally between 40 to 70 mmHg (normal is approximately 8 to 20 mmHg)</td> </tr> <tr> <td>Usually one eye is affected at a time, but both eyes must be carefully examined</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td>Obtain emergent ophthalmology consultation for immediate evaluation and to discuss appropriate medical treatment</td> </tr> <tr> <td>Place the patient supine</td> </tr> <tr> <td class=\"sublist1_start\">For patients with significant decline in vision (eg, with affected eye, patient cannot read text they would normally be able to, or cannot count fingers), provide immediate treatment to reduce IOP (consider possible contraindications to medications [eg, beta blocker contraindicated with severe bronchospasm, 2 or 3&#176; AV block, uncompensated heart failure]):</td> </tr> <tr> <td class=\"sublist1\">Give timolol 0.5 percent,&nbsp;one drop to the affected eye, wait one minute, then</td> </tr> <tr> <td class=\"sublist1\">Give apraclonidine 1 percent,&nbsp;one drop to the affected eye, wait one minute, then</td> </tr> <tr> <td class=\"sublist1\">Give pilocarpine 2 percent,&nbsp;one drop to the affected eye every 15 minutes for&nbsp;two total doses; wait one minute after first dose, then</td> </tr> <tr> <td class=\"sublist1\">Give prednisolone acetate 1 percent,&nbsp;one drop to the affected eye every 15 minutes for&nbsp;four total doses</td> </tr> <tr> <td class=\"sublist1\">Give acetazolamide 500 mg IV (may give by mouth if IV medication not available)</td> </tr> <tr> <td class=\"sublist1\">If IOP remains significantly elevated (&#8805;40 mmHg) 30 minutes after giving this regimen and an ophthalmologist is not immediately available to assume care, give mannitol 1 to 2 g/kg IV</td> </tr> <tr> <td>For all patients, relieve associated symptoms with analgesics (eg, morphine, titrate to effect) and antiemetics (eg, ondansetron, initial dose 8 mg IV)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74621 Version 4.0</div></div></div>"},"74623":{"type":"graphic_figure","displayName":"Forearm volar anatomy","title":"Bones, muscles, and compartments of forearm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bones, muscles, and compartments of forearm</div><div class=\"cntnt\"><img style=\"width:385px; height:767px;\" src=\"images/EM/74623_Forearmvolaranatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In this image, the superficial muscles of the forearm and the palmar aponeurosis are revealed.<br> (B) Here, the flexor digitorum superficialis (FDS) and related structures are shown. Observe the ulnar artery descending obliquely posterior to the FDS to meet and accompany the ulnar nerve.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74623 Version 12.0</div></div></div>"},"74624":{"type":"graphic_diagnosticimage","displayName":"Large endometrial polyp","title":"Elongated polyp in 55-year-old woman who presented with postmenopausal bleeding","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Elongated polyp in 55-year-old woman who presented with postmenopausal bleeding</div><div class=\"cntnt\"><img style=\"width:471px; height:238px;\" src=\"images/OBGYN/74624_Large_endometrial_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal transvaginal sonogram shows lobular 9- to 20-mm-thick endometrium (cursors and arrows) (A). Sagittal sonohysterogram shows 2.3-cm elongated angular polyp (arrow) with 0.8-cm stalk and small 0.7-cm polyp (arrowhead) (B).</div><div class=\"graphic_reference\">Reproduced with permission from Joizzo, JR, Chen, MY, Riccio, GJ, Endometrial Polyps: Sonohysterographic Evaluation. AJR Am J Roentgenol 2001; 176:617. Copyright © 2001 American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 74624 Version 3.0</div></div></div>"},"74625":{"type":"graphic_table","displayName":"Risks platelet stim factors","title":"Potential adverse consequences of thrombopoietic growth factor treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential adverse consequences of thrombopoietic growth factor treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Thrombocytosis</td> </tr> <tr> <td>Thrombosis</td> </tr> <tr> <td>Stimulation of tumor cell growth</td> </tr> <tr> <td>Stimulation of leukemia cell growth</td> </tr> <tr> <td>Interactions with other cytokines</td> </tr> <tr> <td>Autoantibody formation</td> </tr> <tr> <td>Reduction in threshold for platelet activation</td> </tr> <tr> <td>Increased bone marrow reticulin (positive reticulin stain)</td> </tr> <tr> <td>Increased bone marrow collagen (positive trichrome stain)</td> </tr> <tr> <td>Rebound worsening of thrombocytopenia upon stopping treatment</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74625 Version 2.0</div></div></div>"},"74628":{"type":"graphic_waveform","displayName":"Right sided pressures","title":"Normal right-sided pressure tracings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal right-sided pressure tracings</div><div class=\"cntnt\"><img style=\"width:318px; height:291px;\" src=\"images/CARD/74628_Right_sided_pressures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal, simultaneously recorded pressures from the right atrium (RA) and right ventricle (RV). The RA pressure tracing shows a normal pattern of a, c, and v waves and there is no gradient during diastole. The RV systolic and diastolic pressures are normal.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed), Cardiac catheterization Handbook, 2nd ed, Mosby-Year Book, Inc., St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 74628 Version 3.0</div></div></div>"},"74629":{"type":"graphic_table","displayName":"PAIN RULES mnemonic for palliative care","title":"PAIN RULES mnemonic for assessing symptomatology in palliative care*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PAIN RULES mnemonic for assessing symptomatology in palliative care*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>P</strong>ain</td> </tr> <tr> <td><strong>A</strong>norexia and other appetite or oral intake related issues</td> </tr> <tr> <td><strong>I</strong>ncontinence and other genitourinary symptoms</td> </tr> <tr> <td><strong>N</strong>ausea and other gastrointestinal symptoms (constipation, vomiting, diarrhea)</td> </tr> <tr> <td class=\"sublist_other\"><span class=\"small\">&nbsp;</span></td> </tr> <tr> <td><strong>R</strong>espiratory symptoms (dyspnea, cough)</td> </tr> <tr> <td><strong>U</strong>lcerations and other skin complaints</td> </tr> <tr> <td><strong>L</strong>evel of functioning (expressed, for instance, as ECOG or Karnofsky, or other performance scales)</td> </tr> <tr> <td><strong>E</strong>nergy and other related issues such as fatigue or asthenia</td> </tr> <tr> <td><strong>S</strong>edation, sleep and other side effects of treatment (including opioids and chemotherapy)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECOG: Eastern Cooperative Oncology Group.<br> * Prevalence of symptoms derived from J Pain Symptom Manage 2006; 31:58.</div><div id=\"graphicVersion\">Graphic 74629 Version 2.0</div></div></div>"},"74630":{"type":"graphic_picture","displayName":"Histologic appearance of neuroendocrine tumors","title":"Histologic appearance of the spectrum of neuroendocrine tumors arising in the gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of the spectrum of neuroendocrine tumors arising in the gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:548px; height:441px;\" src=\"images/ONC/74630_Exneuroendocrinetumors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of neuroendocrine tumors. Well-differentiated&nbsp;neuroendocrine tumor shows an organoid pattern and difficult-to-find mitotic activity on hematoxylin and eosin (H&amp;E) stain (A), and the proliferative rate (as measured by the Ki-67 labeling index) is very low (&lt;1% in this case) (C). By contrast, poorly differentiated neuroendocrine carcinoma shows frank features of carcinoma with numerous mitotic figures and tumor necrosis on H&amp;E stain (B), and the Ki67 labeling index is very high (&gt;80% in this case) (D). (200x original magnification.)</div><div id=\"graphicVersion\">Graphic 74630 Version 8.0</div></div></div>"},"74631":{"type":"graphic_picture","displayName":"Contact dermatitis bullae","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74631_Contact_dermatitis_bullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and bullae developed on the volar forearm after application of perfume.</div><div class=\"graphic_reference\">Reproduced with permission from: Elder AD, Elenitsas R, Johnson BL, et al. Synopsis and Atlas of Lever's Histopathology of the Skin, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74631 Version 1.0</div></div></div>"},"74632":{"type":"graphic_table","displayName":"Symptoms and signs of cervical root lesions","title":"Symptoms and signs of cervical root lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of&nbsp;cervical root lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Root</td> <td class=\"subtitle1\">Pain</td> <td class=\"subtitle1\">Numbness</td> <td class=\"subtitle1\">Weakness</td> <td class=\"subtitle1\">Reflex affected</td> </tr> <tr> <td>C5</td> <td>Neck, shoulder, scapula</td> <td>Lateral arm (in distribution of axillary nerve)</td> <td>Shoulder abduction, external rotation, elbow flexion, forearm supination</td> <td>Biceps, brachioradialis</td> </tr> <tr> <td>C6</td> <td>Neck, shoulder, scapula, lateral arm, lateral forearm, lateral hand</td> <td>Lateral forearm, thumb and index finger</td> <td>Shoulder abduction, external rotation, elbow flexion, forearm supination and pronation</td> <td>Biceps, brachioradialis</td> </tr> <tr> <td>C7</td> <td>Neck, shoulder, middle finger, hand</td> <td>Index and middle finger, palm</td> <td>Elbow and wrist extension (radial), forearm pronation, wrist flexion</td> <td>Triceps</td> </tr> <tr> <td>C8</td> <td>Neck, shoulder, medial forearm, fourth and fifth digits, medial hand</td> <td>Medial forearm, medial hand, fourth and fifth digits</td> <td>Finger extension, wrist extension (ulnar), distal finger flexion, extension, abduction and adduction, distal thumb flexion</td> <td>None</td> </tr> <tr> <td>T1</td> <td>Neck, medial arm and forearm</td> <td>Anterior arm and medial forearm</td> <td>Thumb abduction, distal thumb flexion, finger abduction and adduction</td> <td>None</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74632 Version 4.0</div></div></div>"},"74634":{"type":"graphic_table","displayName":"Cutaneous reactions multitargeted KI","title":"Cutaneous reactions associated with small molecule kinase inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous reactions associated with small molecule kinase inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Reported cutaneous effects</td> </tr> <tr> <td>Imatinib</td> <td>Edema, hair repigmentation, hypopigmentation, lichenoid eruption, morbilliform eruption, photosensitization, exacerbation of psoriasis, pruritus, Stevens-Johnson syndrome, xerosis</td> </tr> <tr> <td>Dasatinib</td> <td>Acne, HFSR, alopecia, hyperhidrosis, morbilliform eruption, pruritus, urticaria, xerosis, stomatitis</td> </tr> <tr> <td>Nilotinib</td> <td>Alopecia, morbilliform eruption, pruritus, xerosis</td> </tr> <tr> <td>Bosutinib</td> <td>Acne, allergic dermatitis, erythema, folliculitis, maculopapular rash, pruritic rash, skin exfoliation</td> </tr> <tr> <td>Sorafenib</td> <td>HFSR, edema, flushing, stomatitis (mucositis), subungual splinter hemorrhages, squamous hyperproliferation</td> </tr> <tr> <td>Sunitinib</td> <td>HFSR, bullous dermatosis, edema, hair depigmentation, yellow skin discoloration, stomatitis (mucositis), periungual erythema, subungual splinter hemorrhages</td> </tr> <tr> <td>Pazopanib</td> <td>Change in hair color, skin hypopigmentation, alopecia, rash, HFSR</td> </tr> <tr> <td>Vandetanib</td> <td>Rash, acne, dry skin, dermatitis, pruritus, photosensitivity, HFSR</td> </tr> <tr> <td>Regorafenib</td> <td>HFSR, rash, desquamation</td> </tr> <tr> <td>Ponatinib</td> <td>Rash, acneiform eruption, dry skin</td> </tr> <tr> <td>Cabozantinib</td> <td>HFSR, stomatitis, dry mouth, hair color changes, alopecia</td> </tr> <tr> <td>Vemurafenib</td> <td>Rash, photosensitivity, squamous cell carcinoma, keratoacanthoma, alopecia, radiation enhancement</td> </tr> <tr> <td>Dabrafenib</td> <td>Verrucal keratotic lesions, keratoacanthoma, squamous cell carcinoma, rash, alopecia, structural hair changes</td> </tr> <tr> <td>Trametinib</td> <td>Acneiform eruption, pruritus, xerosis</td> </tr> <tr> <td>Axitinib</td> <td> <p>HFSR, rash, cutaneous vasculopathy</p> </td> </tr> <tr> <td><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Osimertinib</span></td> <td>Maculopapular rash, acneiform eruption, xerosis, nail disease, pruritus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HFSR: hand-foot skin reaction.</div><div id=\"graphicVersion\">Graphic 74634 Version 20.0</div></div></div>"},"74635":{"type":"graphic_figure","displayName":"Insulin injection sites PI","title":"Where to give an insulin shot","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Where to give an insulin shot</div><div class=\"cntnt\"><img style=\"width:498px; height:607px;\" src=\"images/PI/74635_Insulin_injection_sites_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shaded areas can be used for insulin shots. You should change areas so that you do not use the same area each time. Insulin gets into the blood more quickly when injected into the belly, as compared with the arms or legs.</div><div id=\"graphicVersion\">Graphic 74635 Version 4.0</div></div></div>"},"74636":{"type":"graphic_table","displayName":"Fetal kidney length","title":"Normal fetal renal lengths","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal fetal renal lengths</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Gestational age, weeks</td>\n\t\t\t\t\t<td class=\"subtitle1\">Mean kidney length, cm</td>\n\t\t\t\t\t<td class=\"subtitle1\">95% CI, cm</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>18</td>\n\t\t\t\t\t<td>2.2</td>\n\t\t\t\t\t<td>1.6 - 2.8</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>19</td>\n\t\t\t\t\t<td>2.3</td>\n\t\t\t\t\t<td>1.5 - 3.1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>20</td>\n\t\t\t\t\t<td>2.6</td>\n\t\t\t\t\t<td>1.8 - 3.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>21</td>\n\t\t\t\t\t<td>2.7</td>\n\t\t\t\t\t<td>2.1 - 3.2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>22</td>\n\t\t\t\t\t<td>2.7</td>\n\t\t\t\t\t<td>2.0 - 3.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>23</td>\n\t\t\t\t\t<td>3.0</td>\n\t\t\t\t\t<td>2.2 - 3.7</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>24</td>\n\t\t\t\t\t<td>3.1</td>\n\t\t\t\t\t<td>1.9 - 4.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>25</td>\n\t\t\t\t\t<td>3.3</td>\n\t\t\t\t\t<td>2.5 - 4.2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>26</td>\n\t\t\t\t\t<td>3.4</td>\n\t\t\t\t\t<td>2.4 - 4.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>27</td>\n\t\t\t\t\t<td>3.5</td>\n\t\t\t\t\t<td>2.7 - 4.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>28</td>\n\t\t\t\t\t<td>3.4</td>\n\t\t\t\t\t<td>2.6 - 4.2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>29</td>\n\t\t\t\t\t<td>3.6</td>\n\t\t\t\t\t<td>2.3 - 4.8</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>30</td>\n\t\t\t\t\t<td>3.8</td>\n\t\t\t\t\t<td>2.9 - 4.6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>31</td>\n\t\t\t\t\t<td>3.7</td>\n\t\t\t\t\t<td>2.8 - 4.6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>32</td>\n\t\t\t\t\t<td>4.1</td>\n\t\t\t\t\t<td>3.1 - 5.1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>33</td>\n\t\t\t\t\t<td>4.0</td>\n\t\t\t\t\t<td>3.3 - 4.7</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>34</td>\n\t\t\t\t\t<td>4.2</td>\n\t\t\t\t\t<td>3.3 - 5.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>35</td>\n\t\t\t\t\t<td>4.2</td>\n\t\t\t\t\t<td>3.2 - 5.2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>36</td>\n\t\t\t\t\t<td>4.2</td>\n\t\t\t\t\t<td>3.3 - 5.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>37</td>\n\t\t\t\t\t<td>4.2</td>\n\t\t\t\t\t<td>3.3 - 5.1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>38</td>\n\t\t\t\t\t<td>4.4</td>\n\t\t\t\t\t<td>3.2 - 5.6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>39</td>\n\t\t\t\t\t<td>4.2</td>\n\t\t\t\t\t<td>3.5 - 4.8</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>40</td>\n\t\t\t\t\t<td>4.3</td>\n\t\t\t\t\t<td>3.2 - 5.3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>41</td>\n\t\t\t\t\t<td>4.5</td>\n\t\t\t\t\t<td>3.9 - 5.1</td>\n\t\t\t\t</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">12/5/2006 perm requested 12/6/2006 granted 11/29/2007--renewal requested. EM 1/8/2008--renewal granted. EM 1/13/2009--Renewal prepayment form received, to Susan (JD). 2/9/2009--Grant of permission received (JD). 2/6/2010--Requested renewal (JD). 3/26/2010--Renewal received, paid for on my AMEX (JD). 5/14/2010--Grant of permision received (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52393&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Fetal_kidney_length.htm</title></head></div><div class=\"graphic_reference\">From: Cohen HL, Cooper J, Eisenberg P, et al. Normal length of fetal kidneys: sonographic study in 397 obstetric patients. AJR Am J Roentgenol 1991; 157:545. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 74636 Version 11.0</div></div></div>"},"74637":{"type":"graphic_picture","displayName":"Sex reversal","title":"Sex reversal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sex reversal</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/PEDS/74637_Sex_reversal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with male phenotypic appearance had a 46,XX karyotype and sex reversal.</div><div class=\"graphic_reference\">Courtesy Christopher P Houk, MD and Lynne L Levitsky, MD.</div><div id=\"graphicVersion\">Graphic 74637 Version 1.0</div></div></div>"},"74639":{"type":"graphic_table","displayName":"Patient diabetes medication history","title":"Patient diabetes medication history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient diabetes medication history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Date</td> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Blood Glucose value, mg/dL</td> <td class=\"subtitle1\">Treatment (regular insulin in units; other treatment as indicated)</td> </tr> <tr> <td rowspan=\"2\">December 2 (admission) </td> <td>5:00 PM</td> <td>139</td> <td>None</td> </tr> <tr> <td>10:00 PM</td> <td>247</td> <td>4</td> </tr> <tr> <td rowspan=\"4\">December 3 </td> <td>7:45 AM</td> <td>368</td> <td>10</td> </tr> <tr> <td>1:00&nbsp;PM (return to floor; missed lunch)</td> <td>402</td> <td>12; IV discontinued</td> </tr> <tr> <td>5:00 PM</td> <td>41</td> <td>No insulin; 12 oz orange juice and several crackers with supper at 6 PM</td> </tr> <tr> <td>10:00 PM</td> <td>383</td> <td>10</td> </tr> <tr> <td rowspan=\"4\">December 4 </td> <td>7:30 AM</td> <td>233</td> <td>4</td> </tr> <tr> <td>11:45 AM</td> <td>361</td> <td>10</td> </tr> <tr> <td>5:10 PM</td> <td>415</td> <td>12</td> </tr> <tr> <td>9:45 PM</td> <td>401</td> <td>12</td> </tr> <tr> <td rowspan=\"2\">December 5 </td> <td>8:15 AM</td> <td>77</td> <td>No insulin; 12 oz orange juice, breakfast</td> </tr> <tr> <td>11:45 AM</td> <td>363</td> <td>10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div id=\"graphicVersion\">Graphic 74639 Version 3.0</div></div></div>"},"74641":{"type":"graphic_picture","displayName":"High frequency EUS probe","title":"High frequency ultrasound cathether","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">High frequency ultrasound cathether</div><div class=\"cntnt\"><img style=\"width:535px; height:369px;\" src=\"images/GAST/74641_High_frequency_EUS_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 20 MHz ultrasound catheter (Olympus&#174; UM-3R; Olympus&#174; America Inc., Melville, NJ.) covered by a balloon sheath that may be inserted through the biopsy channel of the endoscope.</div><div class=\"graphic_reference\">Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 74641 Version 1.0</div></div></div>"},"74642":{"type":"graphic_figure","displayName":"Fibroid embolization 2b","title":"Fibroid embolization 2b","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibroid embolization 2b</div><div class=\"cntnt\"><img style=\"width:290px; height:246px;\" src=\"images/OBGYN/74642_Fibroid_embolization_2b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing embolic particles being released from the catheter and into the uterine arterial branches supplying the fibroid.</div><div id=\"graphicVersion\">Graphic 74642 Version 1.0</div></div></div>"},"74643":{"type":"graphic_diagnosticimage","displayName":"Pneumocystis pneumonia CT I","title":"Pneumocystis jirovecii pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumocystis jirovecii pneumonia</div><div class=\"cntnt\"><img style=\"width:363px; height:227px;\" src=\"images/PULM/74643_Pneumocystis_pneumonia_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pneumocystis jirovecii pneumonia in a patient with AIDS. Ground glass opacities in a patchy distribution are best seen in the anterior segment of the left upper lobe. An accompanying left lower lobe bacterial pneumonia is present.</div><div class=\"graphic_footnotes\">AIDS: autoimmune deficiency syndrome.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74643 Version 5.0</div></div></div>"},"74645":{"type":"graphic_picture","displayName":"Pathology of granuloma annulare - palisading granuloma","title":"Pathology of granuloma annulare - palisading granuloma (H&E 40x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of granuloma annulare - palisading granuloma (H&amp;E 40x)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/74645_Palisadinggranuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning view showing a broad area necrobiosis. This area is surrounded by a peripheral rim of histiocytes and lymphocytes and a few multinucleated giant cells. The adjacent areas of dermis show normal collagen bundles and fibroblast nuclei (H&amp;E 40x).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div id=\"graphicVersion\">Graphic 74645 Version 2.0</div></div></div>"},"74646":{"type":"graphic_picture","displayName":"Endoscopic findings in Crohn disease","title":"Endoscopic findings in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic findings in Crohn disease</div><div class=\"cntnt\"><img style=\"width:442px; height:363px;\" src=\"images/GAST/74646_Endo_find_Crohns_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dominant endoscopic feature in Crohn disease is the presence of ulcerations. Endoscopic findings in Crohn disease include: aphthous ulcers, which are the earliest lesions seen in Crohn disease (panel A); large ulcers interspersed with normal mucosa, which are typical for the segmental distribution of Crohn disease (panel B); a cobblestone appearance that is characterized by nodular thickening, with linear or serpiginous ulcers (panel C); and strictures due to fibrosis (panel D).</div><div class=\"graphic_reference\">Courtesy of Paul Rutgeerts, MD, PhD, FRCP.</div><div id=\"graphicVersion\">Graphic 74646 Version 2.0</div></div></div>"},"74647":{"type":"graphic_picture","displayName":"CD68 cells in muscle granuloma in sarcoidosis","title":"CD68 cells in muscle granuloma in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">CD68 cells in muscle granuloma in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:490px; height:362px;\" src=\"images/RHEUM/74647_CD68_muscle_gran_sarc_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD68+ cells that may be macrophages within a muscle granuloma in sarcoidosis.</div><div class=\"graphic_reference\">Courtesy of Steven A Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 74647 Version 1.0</div></div></div>"},"74648":{"type":"graphic_table","displayName":"Evolution WHO terminology for neuroendocrine neoplasms GI tract","title":"Evolution in WHO terminology for neuroendocrine neoplasms of the digestive tract","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evolution in WHO terminology for neuroendocrine neoplasms of the digestive tract</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">WHO 1980</td> <td class=\"subtitle1\">WHO 2000</td> <td class=\"subtitle1\">WHO 2010</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">I. Carcinoid</td> <td>1. Well-differentiated endocrine tumor (WDET)*</td> <td>1. Neuroendocrine tumor grade 1 (G1) (carcinoid)<sup>&#182;</sup></td> </tr> <tr> <td>2. Well-differentiated endocrine carcinoma (WDEC)*</td> <td>2. Neuroendocrine tumor grade 2 (G2)<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>3. Poorly differentiated endocrine carcinoma/small cell carcinoma (PDEC)</td> <td>3. Neuroendocrine carcinoma (large cell or small cell type)<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>II. Mucocarcinoid</td> <td rowspan=\"2\">4. Mixed exocrine-endocrine carcinoma (MEEC)</td> <td rowspan=\"2\">4. Mixed adenoneuroendocrine carcinoma (MANEC)</td> </tr> <tr class=\"divider_bottom\"> <td>III. Mixed forms carcinoid adenocarcinoma</td> </tr> <tr> <td>IV. Pseudotumor lesions</td> <td>5. Tumor-like lesions (TLL)</td> <td>5. Hyperplastic and preneoplastic lesions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization.<br />* The difference between WDET and WDEC was defined according to staging features in the WHO 2000 classification. G2 NET does not necessarily translate into WDEC of the WHO 2000 classification.<br />¶ Definition in parentheses for the International Classification of Diseases for Oncology (ICD-O) coding.<br />Δ The term \"Neuroendocrine tumor grade 3 (G3)\" has been used for this category but is not advised, since neuroendocrine tumors are by definition well differentiated.</div><div class=\"graphic_reference\">Reproduced with permission from: WHO Classification of Tumours of the Digestive System, 4th edition, Bosman FT, Hruban RH, Theise ND (Eds), IARC Press, Lyon 2010. Copyright &copy; 2010 IARC Press.</div><div id=\"graphicVersion\">Graphic 74648 Version 12.0</div></div></div>"},"74649":{"type":"graphic_algorithm","displayName":"Treatment of convulsive status epilepticus in adults","title":"Treatment of convulsive status epilepticus in adults","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">Treatment of convulsive status epilepticus in adults</div><div class=\"cntnt\"><img style=\"width:793px; height:751px;\" src=\"images/NEURO/74649_Trtmntcnvlsveplptcsadult.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that all infusion rates should be adjusted to individual patients; maximum doses listed are not always required.</div><div class=\"graphic_footnotes\">ABG: arterial blood gas; AED: antiepileptic drug; CBC: complete blood count; IV: intravenous; LFTs: liver function tests; PE: phenytoin equivalent.<br />* There is no definite maximum dose of lorazepam; clinicians should be guided by the clinical effect (including on blood pressure) and seizure control.<br />¶ Cardiac monitoring required. Phenytoin or fosphenytoin may be ineffective for toxin-induced seizures and may intensify seizures caused by cocaine and other local anesthetics.<br />Δ In patients who are actively seizing despite two initial loading doses of lorazepam or other benzodiazepine, preparation for a continuous midazolam or propofol infusion should occur simultaneously with administration of fosphenytoin, valproic acid, or levetiracetam, since the primary role of the nonbenzodiazepine antiseizure drug is to prevent recurrence rather than break the seizures.<br /><FONT class=lozenge>◊</FONT> Begin continuous infusion of one of the three drugs below. Selection of an agent depends upon the need for rapid seizure control, the patient's respiratory and hemodynamic status, and medical comorbidities. Most neurologists start with midazolam or propofol. Clinicians should generally use medications they and the care team are familiar with, in order to avoid unintended complications of therapy.<br />§ May substitute valproic acid, lacosamide, or levetiracetam if allergic to phenytoin or phenobarbital, or if they cause other serious side effects.</div><div id=\"graphicVersion\">Graphic 74649 Version 11.0</div></div></div>"},"74651":{"type":"graphic_picture","displayName":"Circumcised penis PI","title":"Circumcised penis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Circumcised penis</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/PI/74651_Circumcised_penis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 74651 Version 1.0</div></div></div>"},"74652":{"type":"graphic_figure","displayName":"Male and female pattern hair loss PI","title":"Hair loss in men and women","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Hair loss in men and women</div><div class=\"cntnt\"><img style=\"width:458px; height:691px;\" src=\"images/PI/74652_Male_female_hair_loss_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Men and women have different patterns of hair loss.</div><div id=\"graphicVersion\">Graphic 74652 Version 2.0</div></div></div>"},"74654":{"type":"graphic_picture","displayName":"Geographic tongue","title":"Geographic tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Geographic tongue</div><div class=\"cntnt\"><img style=\"width:266px; height:300px;\" src=\"images/PEDS/74654_Geographic_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 74654 Version 2.0</div></div></div>"},"74655":{"type":"graphic_table","displayName":"Lake Louise AMS","title":"Lake Louise score for AMS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lake Louise score for AMS</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1_single\" colspan=\"2\">The sum of response is the AMS Self-report score. Headache and at least one other symptom must be present for the diagnosis of AMS. A score of 3 or more is required for the diagnosis of AMS.</td>\n  </tr>\n  <tr>\n\t<td class=\"subtitle2\">Symptom</td>\n\t<td class=\"subtitle2\">Score</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle3_left\" colspan=\"2\">1. Headache</td>\n  </tr>\n  <tr>\n\t<td class=\"indent2\">None at all</td>\n\t<td>0</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Mild headache</td>\n\t<td>1</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Moderate headache</td>\n\t<td>2</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Severe headache</td>\n\t<td>3</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle3_left\" colspan=\"2\">2. Appetite</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Good appetite</td>\n\t<td>0</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Poor appetite or nausea</td>\n\t<td>1</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Moderate nausea or vomiting</td>\n\t<td>2</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Severe, incapacitating nausea and vomiting</td>\n\t<td>3</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle3_left\" colspan=\"2\">3. Fatigue and/or weakness</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Not tired or weak</td>\n\t<td>0</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Mild fatigue/weakness</td>\n\t<td>1</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Moderate fatigue/weakness</td>\n\t<td>2</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Severe fatigue/weakness</td>\n\t<td>3</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle3_left\" colspan=\"2\">4. Dizziness/lightheadedness</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">None</td>\n\t<td>0</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Mild</td>\n\t<td>1</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Moderate</td>\n\t<td>2</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Severe, incapacitating</td>\n\t<td>3</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle3_left\" colspan=\"2\">5. Difficulty sleeping</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Slept as well as usual</td>\n\t<td>0</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Did not sleep as well as usual</td>\n\t<td>1</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Woke many times, poor night's sleep</td>\n\t<td>2</td>\n  </tr>\n  <tr>\n    <td class=\"indent2\">Could not sleep at all</td>\n\t<td>3</td>\n  </tr>\n  <tr>\n    <td><strong>Total:</strong></td>\n\t<td>&nbsp;</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced from: Roach, RC, B&#228;rtsch, P, Oelz, O, Hackett, PH, Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine, Sutton, JR, Houston, CS, Coates, G (Eds.), Charles S. Houston, Burlington, VT 1993. p.272-4.</div><div id=\"graphicVersion\">Graphic 74655 Version 1.0</div></div></div>"},"74656":{"type":"graphic_figure","displayName":"Osteoporotic spinal fractures","title":"Types of osteoporotic vertebral fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Types of osteoporotic vertebral fracture</div><div class=\"cntnt\"><img style=\"width:363px; height:201px;\" src=\"images/ENDO/74656_Osteoporotic_spinal_fractur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the different types of vertebral fracture seen in osteoporosis. The central depression with the biconcave or codfishing appearance occurs because the edges of the vertebrae, being supported by the outer walls of the vertebrae, are stronger than the central part. In comparison, the anterior aspect of the vertebral body collapses more than the posterior aspect with a wedge fracture, while the entire vertebral body collapses down with a compression fracture.</div><div id=\"graphicVersion\">Graphic 74656 Version 1.0</div></div></div>"},"74658":{"type":"graphic_picture","displayName":"Normal resting PMN EM","title":"Ultrastructure of normal human polymorphonuclear neutrophil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrastructure of normal human polymorphonuclear neutrophil</div><div class=\"cntnt\"><img style=\"width:356px; height:304px;\" src=\"images/HEME/74658_Normal_resting_PMN_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph shows the ultrastructure of a normal human polymorphonuclear neutrophil. Note the heterogeneity of granules.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 74658 Version 2.0</div></div></div>"},"74659":{"type":"graphic_table","displayName":"Characteristics of antibody classes and subclasses","title":"Characteristics of antibody (immunoglobulin) classes and subclasses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of antibody (immunoglobulin) classes and subclasses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Subclass</td> <td class=\"subtitle1\">Molecular weight in&nbsp;kilodaltons</td> <td class=\"subtitle1\">Number of CH domains</td> <td class=\"subtitle1\">Serum concentration, g/L</td> <td class=\"subtitle1\">Serum half-life, days</td> <td class=\"subtitle1\">Properties</td> </tr> <tr> <td>IgG</td> <td>&nbsp;</td> <td>150</td> <td>3</td> <td>5&nbsp;to 15</td> <td>&nbsp;</td> <td rowspan=\"5\">Complement fixation, opsonization, placental transfer; predominant in secondary response</td> </tr> <tr> <td rowspan=\"4\">&nbsp;</td> <td>IgG1</td> <td>(monomer)</td> <td>&nbsp;</td> <td>3&nbsp;to 10</td> <td>23</td> </tr> <tr> <td>IgG2</td> <td>(monomer)</td> <td>&nbsp;</td> <td>1&nbsp;to 3.5</td> <td>23</td> </tr> <tr> <td>IgG3</td> <td>(monomer)</td> <td>&nbsp;</td> <td>0.3&nbsp;to 1</td> <td>8</td> </tr> <tr> <td>IgG4</td> <td>(monomer)</td> <td>&nbsp;</td> <td>0.2&nbsp;to 0.5</td> <td>23</td> </tr> <tr> <td>IgM</td> <td>&nbsp;</td> <td>950 (pentamer)</td> <td>4</td> <td>0.5&nbsp;to 4</td> <td>5</td> <td>Complement fixation, predominant in primary response, B cell receptor</td> </tr> <tr> <td>IgA</td> <td>&nbsp;</td> <td>400</td> <td>3</td> <td>0.5&nbsp;to 3.5</td> <td>6</td> <td rowspan=\"3\">Predominant in secretions</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td>IgA1</td> <td>(dimer)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>IgA2</td> <td>(dimer)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>IgD</td> <td>&nbsp;</td> <td>170 (monomer)</td> <td>3</td> <td>&#60;0.1</td> <td>3</td> <td>B cell receptor</td> </tr> <tr> <td>IgE</td> <td>&nbsp;</td> <td>190 (monomer)</td> <td>4</td> <td>0&nbsp;to 250<span style=\"color: black;\"> mcg/</span><span style=\"color: black;\">L</span></td> <td>3</td> <td>Immediate hypersensitivity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M; IgA: immunoglobulin A; IgD: immunoglobulin D; IgE: immunoglobulin E; CH: constant heavy domain.</div><div id=\"graphicVersion\">Graphic 74659 Version 4.0</div></div></div>"},"74660":{"type":"graphic_table","displayName":"Intraarticular steroid toxicity","title":"Toxicity of intraarticular and soft tissue glucocorticoid injections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicity of intraarticular and soft tissue glucocorticoid injections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major</td> </tr> <tr> <td>Cushing's syndrome (if frequency greater than one/month)</td> </tr> <tr> <td>Radiologic deterioration of joints: \"steroid arthropathy\"; Charcot-like arthropathy; osteonecrosis&nbsp;<span style=\"font-size: 10pt; font-family: 'verdana','sans-serif'; mso-fareast-font-family: 'times new roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'times new roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: en-us; mso-fareast-language: en-us; mso-bidi-language: ar-sa;\">&ndash;</span> low incidence</td> </tr> <tr> <td>Iatrogenic infection&nbsp;<span style=\"font-size: 10pt; font-family: 'verdana','sans-serif'; mso-fareast-font-family: 'times new roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'times new roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: en-us; mso-fareast-language: en-us; mso-bidi-language: ar-sa;\">&ndash;</span> very low incidence</td> </tr> <tr> <td>Tendon rupture due to atrophy</td> </tr> <tr> <td>Fat necrosis or calcification</td> </tr> <tr> <td>Inadvertent injection of median nerve in carpal tunnel syndrome causing nerve atrophy</td> </tr> <tr> <td>Cataracts</td> </tr> <tr> <td class=\"subtitle1_single\">Minor</td> </tr> <tr> <td>Postinjection flare</td> </tr> <tr> <td>Uterine bleeding</td> </tr> <tr> <td>Facial erythema</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74660 Version 4.0</div></div></div>"},"74662":{"type":"graphic_figure","displayName":"DN4 questionnaire","title":"DN4 questionnaire","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DN4 questionnaire</div><div class=\"cntnt\"><img style=\"width:405px; height:558px;\" src=\"images/PC/74662_DN4.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Bouhassira, D, Attal, N, Alchaar, H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114:29. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74662 Version 1.0</div></div></div>"},"74664":{"type":"graphic_picture","displayName":"Lentigo maligna melanoma 2","title":"Lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74664_Lentigo_malig_melan_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lentigo maligna melanoma presenting as a brown patch with irregular and indistinct borders and irregular pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74664 Version 5.0</div></div></div>"},"74665":{"type":"graphic_diagnosticimage","displayName":"Complete placenta previa","title":"Complete placenta previa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Complete placenta previa</div><div class=\"cntnt\"><img style=\"width:504px; height:415px;\" src=\"images/OBGYN/74665_Complete_previa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal study shows the placenta completely covering the internal os (arrow). A central placenta previa occurs when the internal os is approximately equidistant from the anterior and posterior placental edges; 20 to 30 percent of complete previas are central.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 74665 Version 4.0</div></div></div>"},"74666":{"type":"graphic_algorithm","displayName":"Algorithm breast mass over 30","title":"Diagnostic algorithm for palpable breast abnormalities in women aged 30 years and over","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for palpable breast abnormalities in women aged 30 years and over</div><div class=\"cntnt\"><img style=\"width:770px; height:773px;\" src=\"images/ONC/74666_Algobreastmassover30Y.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When lesions are palpable, clinically directed biopsies are often the most efficient. Fine-needle aspiration (FNA) is the biopsy of choice, but if it is not available or reliable at an institution, percutaneous core biopsy can easily be substituted.</div><div class=\"graphic_footnotes\">BI-RADS: Breast Imaging Reporting and Data System; LCIS: lobular carcinoma in situ; MRI: magnetic resonance imaging.<br />* The asterisk indicates a situation in which it may be useful to incorporate a staging MRI into the management of a patient with breast cancer if this technique is available.</div><div class=\"graphic_reference\">Adapted from Esserman L, et al. Current Oncology Reports 2000; 2:572.</div><div id=\"graphicVersion\">Graphic 74666 Version 3.0</div></div></div>"},"74667":{"type":"graphic_table","displayName":"Contrast append colorect CAs","title":"Contrasting features of appendiceal and colorectal cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contrasting features of appendiceal and colorectal cancers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Appendiceal epithelial neoplasm</td> <td class=\"subtitle1\">Colorectal cancer</td> </tr> <tr> <td>Incidence (cases per year in the United States)</td> <td>1500</td> <td>150,000</td> </tr> <tr> <td>Mucinous histology</td> <td>85%</td> <td>15%</td> </tr> <tr> <td>Aggressiveness pathology</td> <td>10%</td> <td>95%</td> </tr> <tr> <td>Lymph-node metastases at initial diagnosis</td> <td>2%</td> <td>50%</td> </tr> <tr> <td>Liver metastases at initial diagnosis</td> <td>2%</td> <td>20%</td> </tr> <tr> <td>Five-year survival with traditional surgical treatment</td> <td>30%</td> <td>70%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sugarbarker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? The Lancet Oncology 2006; 7:69.</div><div id=\"graphicVersion\">Graphic 74667 Version 5.0</div></div></div>"},"74669":{"type":"graphic_table","displayName":"Bone density definitions PI","title":"Definitions of normal bone density, osteopenia, and osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of normal bone density, osteopenia, and osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">T-score</td> <td class=\"subtitle1\">Bone density</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">+1 to <span style=\"white-space: nowrap;\">&ndash;1</span></td> <td><strong>Normal bone density</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bone density that is between 0 and 1 SD below the mean is considered to be normal. This may be reported as a T-score of +1 to <span style=\"white-space: nowrap;\">&ndash;1</span>. Treatment is not usually recommended for people with normal bone density, although preventive measures (eg, calcium supplements, weightbearing exercise) are recommended to prevent osteopenia and osteoporosis.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Between <span style=\"white-space: nowrap;\">&ndash;1</span> and <span style=\"white-space: nowrap;\">&ndash;2.5</span></td> <td><strong>Osteopenia</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bone density that is between 1 and 2.5 SD below the mean is called osteopenia. A person with osteopenia does not yet have osteoporosis but is at risk of developing it if not treated.</td> </tr> <tr> <td rowspan=\"2\"><span style=\"white-space: nowrap;\">&ndash;2.5</span> or less</td> <td><strong>Osteoporosis</strong></td> </tr> <tr> <td class=\"indent1\">Osteoporosis is defined as a BMD 2.5 or more SD below the mean of normal young women. The lower the bone density, the greater the risk of fracture.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The WHO has defined normal bone density as a value within 1 SD from average peak bone mass. SD is a statistical measure that defines how much a patient's result varies from the \"average\" young adult.</div><div class=\"graphic_footnotes\">SD: standard deviation; BMD: bone mineral density; WHO: World Health Organization.</div><div id=\"graphicVersion\">Graphic 74669 Version 5.0</div></div></div>"},"74670":{"type":"graphic_algorithm","displayName":"Postnatal evaluation of unilateral fetal hydronephrosis","title":"Postnatal evaluation of unilateral fetal hydronephrosis*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postnatal evaluation of unilateral fetal hydronephrosis*</div><div class=\"cntnt\"><img style=\"width:434px; height:694px;\" src=\"images/PEDS/74670_Eval_uni_prenat_hydron_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RPD: renal pelvic diameter; US: ultrasound; VUR: vesicoureteral reflux; VCUG: voiding cystourethrogram.<br />* This algorithm is intended for use in conjunction with additional UpToDate content on postnatal evaluation of fetal hydronephrosis. Please refer to the topic on postnatal management of fetal hydronephrosis for more information.</div><div id=\"graphicVersion\">Graphic 74670 Version 6.0</div></div></div>"},"74671":{"type":"graphic_figure","displayName":"Mechs of IGF-1 receptor","title":"Intracellular signalling mechanisms that are activated by the IGF-I receptor","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Intracellular signalling mechanisms that are activated by the IGF-I receptor</div><div class=\"cntnt\"><img style=\"width:597px; height:406px;\" src=\"images/ENDO/74671_Mechs_of_IGF1_receptor.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David R Clemmons, MD.</div><div id=\"graphicVersion\">Graphic 74671 Version 2.0</div></div></div>"},"74672":{"type":"graphic_picture","displayName":"Gastric carcinoid Gross","title":"Gastric carcinoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric carcinoid</div><div class=\"cntnt\"><img style=\"width:413px; height:288px;\" src=\"images/GAST/74672_Gastric_carcinoid_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Full thickness specimen of a gastric carcinoid demonstrates a typical ulcerated mucosal surface and yellowish submucosal cut surface.</div><div class=\"graphic_reference\">From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 74672 Version 2.0</div></div></div>"},"74675":{"type":"graphic_diagnosticimage","displayName":"Knee OA AP x ray","title":"Osteoarthritis of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis of the knee</div><div class=\"cntnt\"><img style=\"width:351px; height:432px;\" src=\"images/RHEUM/74675_Knee_OA_AP_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior plain radiograph of the knee shows osteophyte formation (arrow), joint space narrowing, and subchondral sclerosis.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD, and Celia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 74675 Version 2.0</div></div></div>"},"74676":{"type":"graphic_picture","displayName":"Pseudomonal nail infection","title":"Pseudomonas infection of the nail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomonas infection of the nail</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74676_Pseudomonal_nail_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail infection with pseudomonas typically presents with blue-green discoloration of the nail.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74676 Version 3.0</div></div></div>"},"74677":{"type":"graphic_picture","displayName":"Endoscopic view of Zenkers diverticulum","title":"Endoscopic view of Zenker's diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of Zenker's diverticulum</div><div class=\"cntnt\"><img style=\"width:442px; height:394px;\" src=\"images/GAST/74677_Endosc_Zenkers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The esophageal lumen can be seen at the middle left side of the endoscopic image. A nasogastric tube has been placed. The lumen of the diverticulum can be observed at the lower right side of the image. The nasogastric tube will guide the endoscopist when cutting the diverticulum.</div><div class=\"graphic_reference\">Courtesy of Chris J J Mulder, MD, and Stijn J B van Weyenberg, MD.</div><div id=\"graphicVersion\">Graphic 74677 Version 1.0</div></div></div>"},"74678":{"type":"graphic_table","displayName":"Causes of pruritus","title":"Causes of pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cutaneous disorders</td> </tr> <tr> <td class=\"indent1\">Inflammatory*</td> </tr> <tr> <td class=\"indent1\">Neurodermatitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Idiopathic xerosis in the elderly</td> </tr> <tr> <td class=\"indent1\">Burns and scars</td> </tr> <tr> <td class=\"subtitle1_single\">Renal disease</td> </tr> <tr> <td class=\"indent1\">End stage chronic renal failure</td> </tr> <tr> <td class=\"subtitle1_single\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis</td> </tr> <tr> <td class=\"indent1\">Cholestatic jaundice</td> </tr> <tr> <td class=\"indent1\">Hepatitis C</td> </tr> <tr> <td class=\"indent1\">Cholestasis of pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Hematopoietic disease</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera</td> </tr> <tr> <td class=\"indent1\">Iron deficiency anemia</td> </tr> <tr> <td class=\"indent1\">Mastocytosis</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Non-Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine and metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> </tr> <tr> <td class=\"indent1\">Carcinoid syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious and parasitic disorders</td> </tr> <tr> <td class=\"indent1\">Superficial fungal infections</td> </tr> <tr> <td class=\"indent1\">Scabies</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus infection</td> </tr> <tr> <td class=\"indent1\">Onchocerciasis</td> </tr> <tr> <td class=\"indent1\">Varicella</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune disorders</td> </tr> <tr> <td class=\"indent1\">Dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Scleroderma</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic disorders</td> </tr> <tr> <td class=\"indent1\">Brachioradial pruritus</td> </tr> <tr> <td class=\"indent1\">Notalgia paresthetica</td> </tr> <tr> <td class=\"indent1\">Postherpetic neuralgia</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular accident</td> </tr> <tr> <td class=\"subtitle1_single\">Psychogenic disorders</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">Psychogenic excoriation</td> </tr> <tr> <td class=\"indent1\">Delusional infestation (also called delusional parasitosis)</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Eg, dermatitis, urticaria, psoriasis, pityriasis rosea, pityriasis rubra pilaris, acne, dermatitis herpetiformis, bullous pemphigoid, linear IgA disease.<br />¶ Eg, prurigo nodularis, lichen simplex chronicus, lichen amyloidosis.</div><div id=\"graphicVersion\">Graphic 74678 Version 4.0</div></div></div>"},"74679":{"type":"graphic_figure","displayName":"Declining risk of premature death","title":"The risk of dying prematurely declines as people become physically active","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">The risk of dying prematurely declines as people become physically active</div><div class=\"cntnt\"><img style=\"width:453px; height:269px;\" src=\"images/PC/74679_Decl_risk_prem_death_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Physical Activity Guidelines for Americans. US Department of Heath and Human Services. Available at <a href=\"http://www.health.gov/paguidelines/pdf/paguide.pdf\" target=\"_blank\">http://www.health.gov/paguidelines/pdf/paguide.pdf</a>.</div><div id=\"graphicVersion\">Graphic 74679 Version 3.0</div></div></div>"},"74680":{"type":"graphic_figure","displayName":"Common iliac artery with adequate landing zones","title":"Common iliac artery with adequate landing zones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common iliac artery with adequate landing zones</div><div class=\"cntnt\"><img style=\"width:435px; height:299px;\" src=\"images/SURG/74680_CIAA-adequate-landing-zones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A common iliac artery aneurysm with adequate proximal and distal landing zones is managed with a common iliac artery stent-graft.</div><div id=\"graphicVersion\">Graphic 74680 Version 2.0</div></div></div>"},"74682":{"type":"graphic_table","displayName":"Cryosurg BCC contraindications","title":"Cryosurgery for BCC: Contraindications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cryosurgery for BCC: Contraindications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tumor characteristics</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Indistinct borders*</td> </tr> <tr> <td class=\"indent1\">Recurrent tumor*</td> </tr> <tr> <td class=\"indent1\">Tumor location - overlying nerves, corners of the mouth, vermillion border, inner canthi, lid margin, the free margin of the nasal alae, and the auditory canal*</td> </tr> <tr> <td class=\"indent1\">Size greater than 1 cm on the face</td> </tr> <tr> <td class=\"subtitle2_single\">Pathologic features</td> </tr> <tr> <td class=\"indent1\">Morpheaform, sclerosing, infiltrative, perineural invasion</td> </tr> <tr> <td class=\"subtitle1_single\">Patient Characteristics</td> </tr> <tr> <td>Dark skin type</td> </tr> <tr> <td>Cosmetically-sensitive patient*</td> </tr> <tr> <td>Previous poor response to cryotherapy</td> </tr> <tr> <td>Unable to care for wound</td> </tr> <tr> <td>Cold urticaria, Raynaud's phenomenon (selected sites), cold intolerance, cryofibrinogenemia, or cryoglobulinema*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Absolute contraindication.</div><div id=\"graphicVersion\">Graphic 74682 Version 2.0</div></div></div>"},"74683":{"type":"graphic_picture","displayName":"Tylosis","title":"Tylosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tylosis</div><div class=\"cntnt\"><img style=\"width:291px; height:351px;\" src=\"images/ONC/74683_Tylosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Freedbarg I. Fitzpatrick's Dermatology in General Medicine, 5th ed, McGraw-Hill 1999. p.605. Copyright &#169; 1999 McGraw Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 74683 Version 2.0</div></div></div>"},"74684":{"type":"graphic_form","displayName":"Asthma daily diary PI","title":"Asthma diary","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Asthma diary</div><div class=\"cntnt\"><img style=\"width:599px; height:771px;\" src=\"images/PI/74684_Asthma_daily_diary_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use the symptom severity key to give a numerical value to the severity of your asthma. In the notes section, note any triggers that seem to affect your asthma on the day it occurs. Triggers can include colds or infections, exercise, irritants, allergens, and cold air.</div><div id=\"graphicVersion\">Graphic 74684 Version 3.0</div></div></div>"},"74686":{"type":"graphic_figure","displayName":"Possible locations of undescended testes","title":"Possible locations of undescended and ectopic testes","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Possible locations of undescended and ectopic testes</div><div class=\"cntnt\"><img style=\"width:513px; height:414px;\" src=\"images/PEDS/74686_Undescended_testes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Undescended testes may be located in the abdomen (1), inguinal canal (2), and suprascrotal (prepubic) regions (3). Ectopic testes may be located in the suprapubic (penile) region (4), femoral region (5), perineal region (6), and contralateral hemiscrotum (7).</div><div id=\"graphicVersion\">Graphic 74686 Version 4.0</div></div></div>"},"74687":{"type":"graphic_figure","displayName":"Plaques in carcinoid heart","title":"Location of fibrous plaques in carcinoid heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of fibrous plaques in carcinoid heart disease</div><div class=\"cntnt\"><img style=\"width:292px; height:373px;\" src=\"images/ENDO/74687_Plaques_in_carcinoid_heart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with carcinoid heart disease, distinctive lesions, termed carcinoid plaques,&nbsp;develop on the right side of the heart (tricuspid and/or pulmonic valves); such plagues are occasionally found on the left side of the heart.</div><div class=\"graphic_reference\">Adapted from Roberts WC. Am J Cardiol 1997; 80:251.</div><div id=\"graphicVersion\">Graphic 74687 Version 2.0</div></div></div>"},"74688":{"type":"graphic_picture","displayName":"GAVE APC Endosc","title":"Gastric antral vascular ectasia syndrome (watermelon stomach)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric antral vascular ectasia syndrome (watermelon stomach)</div><div class=\"cntnt\"><img style=\"width:450px; height:224px;\" src=\"images/GAST/74688_GAVE_APC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy of watermelon stomach before and after argon plasma coagulation (APC). Left panel: Gastric antrum showing hermorrhagic striations that are oozing. Right panel: Marked improvement two weeks following the second APC session. Note the superficial healing ulcer (arrow) resulting from the APC treatment.</div><div class=\"graphic_reference\">Courtesy of Jonathan Cohen, MD.</div><div id=\"graphicVersion\">Graphic 74688 Version 2.0</div></div></div>"},"74689":{"type":"graphic_picture","displayName":"H pylori photomicrograph","title":"Helicobacter pylori","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Helicobacter pylori</div><div class=\"cntnt\"><img style=\"width:258px; height:260px;\" src=\"images/GAST/74689_H_pylori_photomicrograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Helicobacter pylori</EM> (<EM>H. pylori</EM>)&nbsp;is a spiral shaped Gram negative bacterium measuring approximately 3.5 microns in length and 0.5 microns in width.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800- 432-8433.</div><div id=\"graphicVersion\">Graphic 74689 Version 2.0</div></div></div>"},"74690":{"type":"graphic_table","displayName":"EVALuate trial","title":"EVAluate trial of complications of hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">EVAluate trial of complications of hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Abdominal trial</td> <td class=\"subtitle1\" colspan=\"2\">Vaginal Trial</td> </tr> <tr> <td class=\"subtitle2\">Abdominal hysterectomy (n = 292)</td> <td class=\"subtitle2\">Laparoscopic hysterectomy (n = 584)</td> <td class=\"subtitle2\">Vaginal hysterectomy (n = 168)</td> <td class=\"subtitle2\">Laparoscopic hysterectomy (n = 336)</td> </tr> <tr> <td>Major hemorrhage</td> <td>7* (2.4)</td> <td>27* (4.6)</td> <td>5 (2.9)</td> <td>17 (5.1)</td> </tr> <tr> <td>Bowel injury</td> <td>3 (1)</td> <td>1 (0.2)</td> <td>0</td> <td>0</td> </tr> <tr> <td>Ureteric injury</td> <td>0</td> <td>5 (0.9)</td> <td>0</td> <td>1 (0.3)</td> </tr> <tr> <td>Bladder injury</td> <td>3 (1)</td> <td>12* (2.1)</td> <td>2 (1.2)</td> <td>3 (0.9)</td> </tr> <tr> <td>Intraoperative conversion</td> <td>1<sup>&#182;</sup> (0.3)</td> <td>23 (3.9)</td> <td>7 (4.2)</td> <td>9 (2.7)</td> </tr> <tr> <td>Wound dehiscence</td> <td>1 (0.3)</td> <td>1(0.2)</td> <td>0</td> <td>1 (0.3)</td> </tr> <tr> <td>Hematoma</td> <td>2 (0.7)</td> <td>4 (0.7)</td> <td>2 (1.2)</td> <td>7 (2.1)</td> </tr> <tr> <td>At least one major complication</td> <td>18 (6.2)</td> <td>65 (11.1)</td> <td>16 (9.5)</td> <td>33 (9.8)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A patient may have more than one complication.</div><div class=\"graphic_footnotes\">* These patients converted procedure before the operation: one patient undergoing abdominal hysterectomy converted to laparoscopic hysterectomy before the operation in the abdominal trial and had a major hemorrhage. Two patients in the abdominal trial who were undergoing laparoscopic hysterectomy converted to abdominal hysterectomy before the operation and had a major hemorrhage. One patient undergoing laparoscopic hysterectomy in the abdominal trial converted to abdominal hysterectomy before the operation and had a major anesthetic problem. One patient undergoing laparoscopic hysterectomy in the abdominal trial converted to abdominal hysterectomy before the operation and had a bladder injury.<br />¶ This patient in the abdominal trial was randomized to abdominal hysterectomy, converted to laparoscopic hysterectomy before the operation and then converted back to abdominal hysterectomy during the operation.</div><div class=\"graphic_reference\">Adapted from Garry R, Fountain J, Mason S, et al. The eVALuate study: Two parallel randomized trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. BMJ 2004; 328:129.</div><div id=\"graphicVersion\">Graphic 74690 Version 5.0</div></div></div>"},"74691":{"type":"graphic_diagnosticimage","displayName":"Plain film radiography of hip osteoarthritis","title":"Plain film radiography of hip osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Plain film radiography of hip osteoarthritis</div><div class=\"cntnt\"><img style=\"width:504px; height:391px;\" src=\"images/RADIOL/74691_Osteoarthritis_of_right_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hip osteoarthritis. Plain film radiograph AP view of the pelvis demonstrates severe narrowing of the superolateral aspect of the right hip joint (arrow) with subarticular cyst formation of the acetabulum and femoral head.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 74691 Version 4.0</div></div></div>"},"74693":{"type":"graphic_table","displayName":"RECIST response criteria solid tumors","title":"Response Evaluation Criteria in Solid Tumors (RECIST)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Response Evaluation Criteria in Solid Tumors (RECIST)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Response assessment</td> <td class=\"subtitle1\">RECIST guideline, version 1.0<sup>[1]</sup></td> <td class=\"subtitle1\">RECIST guideline, version 1.1<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Target lesions</td> </tr> <tr> <td class=\"indent1\">CR</td> <td>Disappearance of all target lesions</td> <td>Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to &#8804;10 mm</td> </tr> <tr> <td class=\"indent1\">PR</td> <td>&#8805;30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline</td> <td>&#8805;30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline</td> </tr> <tr> <td class=\"indent1\">PD</td> <td> <p>&#8805;20 percent increase in the sum of the longest diameter of the target lesions compared&nbsp;with the smallest sum of the longest diameter recorded since treatment started</p> <p><strong>OR</strong></p> <p>The appearance of one or more new lesions</p> </td> <td> <p>&#8805;20 percent increase of at least 5 mm in the sum of the longest diameters of the target lesions compared with the smallest sum of the longest diameter recorded</p> <p><strong>OR</strong></p> <p>The appearance of new lesions, including those detected by FDG-PET</p> </td> </tr> <tr> <td class=\"indent1\">SD</td> <td>Neither PR nor PD</td> <td>Neither PR nor PD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Non-target lesions</td> </tr> <tr> <td class=\"indent1\">CR</td> <td>Disappearance of all non-target lesions and normalization of tumor marker levels</td> <td>Disappearance of all non-target lesions and normalization of tumor marker levels</td> </tr> <tr> <td class=\"indent1\">IR, SD</td> <td>Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits</td> <td>Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits</td> </tr> <tr> <td class=\"indent1\">PD</td> <td>Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions</td> <td> <p>The appearance of one or more new lesions or unequivocal progression</p> <p>If patient has measurable disease, an increase in the overall level, or substantial worsening in non-target lesions, such that tumor burden has increased, even if there is a SD or PR in target lesions</p> <p>If no measurable disease, an increase in the overall tumor burden comparable in magnitude to the increase that would be required to declare PD in measurable disease (eg, an increase in pleural effusions from trace to large, or an increase in lymphangitic disease from localized to widespread)</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CR: complete response; PR: partial response; PD: progressive disease; FDG-PET: fludeoxyglucose-positron emission tomography; SD: stable disease; IR: incomplete response.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205. </LI>&#xD;&#xA;<LI>Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228. </LI></OL></div><div id=\"graphicVersion\">Graphic 74693 Version 11.0</div></div></div>"},"74694":{"type":"graphic_figure","displayName":"PAPSS2 deficiency","title":"Apparent DHEA sulfotransferase deficiency (PAPSS2 deficiency)","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Apparent DHEA sulfotransferase deficiency (PAPSS2 deficiency)</div><div class=\"cntnt\"><img style=\"width:602px; height:387px;\" src=\"images/ENDO/74694_PAPSS2_deficiency.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74694 Version 1.0</div></div></div>"},"74695":{"type":"graphic_diagnosticimage","displayName":"Molar tooth sign","title":"Molar tooth sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molar tooth sign</div><div class=\"cntnt\"><img style=\"width:276px; height:288px;\" src=\"images/PEDS/74695_Molar_tooth_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain magnetic resonance imaging (MRI) axial image in a patient with Joubert syndrome at the level of the superior cerebellar peduncles showing an abnormally increased depth of the interpeduncular fossa, narrowing of the midbrain tegmentum, and thickening of the superior cerebellar peduncles, all of which contribute to the radiologic feature known as the \"molar tooth sign.\"</div><div id=\"graphicVersion\">Graphic 74695 Version 3.0</div></div></div>"},"74696":{"type":"graphic_diagnosticimage","displayName":"Hashimotos thyroiditis Doppler","title":"Hashimoto's thyroiditis Doppler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hashimoto's thyroiditis Doppler</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/ENDO/74696_Hashimotos_thyr_doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal view of a hypoechoic left lobe from a patient with Hashimoto's thyroiditis. Color Doppler interrogation shows moderate hypervascularity.</div><div id=\"graphicVersion\">Graphic 74696 Version 2.0</div></div></div>"},"74697":{"type":"graphic_table","displayName":"CSF PMNs chronic meningitis","title":"Chronic meningitis with neutrophilic pleocytosis in the cerebrospinal fluid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic meningitis with neutrophilic pleocytosis in the cerebrospinal fluid</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Fungal pathogens</td>\n</tr>\n<tr>\n<td>Aspergillosis</td>\n</tr>\n<tr>\n<td>Zygomycosis</td>\n</tr>\n<tr>\n<td>Dematiaceous fungi</td>\n</tr>\n<tr>\n<td>Candidiasis</td>\n</tr>\n<tr>\n<td>Blastomycosis</td>\n</tr>\n<tr>\n<td>Histoplasmosis</td>\n</tr>\n<tr>\n<td>Coccidioidomycosis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Bacterial pathogens</td>\n</tr>\n<tr>\n<td>Nocardiosis</td>\n</tr>\n<tr>\n<td>Actinomycosis</td>\n</tr>\n<tr>\n<td>Brucellosis</td>\n</tr>\n<tr>\n<td>Tuberculosis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Noninfectious diseases</td>\n</tr>\n<tr>\n<td>Systemic lupus erythematosus</td>\n</tr>\n<tr>\n<td>Chemical meningitis</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74697 Version 1.0</div></div></div>"},"74698":{"type":"graphic_picture","displayName":"Immunofluorescence microscopy showing membranous nephropathy","title":"Immunofluorescence microscopy showing membranous nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy showing membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:294px;\" src=\"images/NEPH/74698_MembranousIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in membranous nephropathy showing diffuse, granular IgG deposition along the capillary walls.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 74698 Version 4.0</div></div></div>"},"74699":{"type":"graphic_table","displayName":"CHD by nuchal thickness","title":"Prevalence of congenital heart disease in chromosomally normal fetuses according to nuchal translucency thickness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of congenital heart disease in chromosomally normal fetuses according to nuchal translucency thickness</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Nuchal translucency thickness, mm</td>\n<td class=\"subtitle1\">Prevalence per 1000 fetuses</td>\n</tr>\n<tr>\n<td>3.5 to 4.4</td>\n<td>28.9</td>\n</tr>\n<tr>\n<td>4.5 to 5.4</td>\n<td>90.9</td>\n</tr>\n<tr>\n<td>&#8805;5.5</td>\n<td>195.1</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Hyett, J, Perdu, M, Sharland, G, et al. BMJ 1999; 318:81.</div><div id=\"graphicVersion\">Graphic 74699 Version 1.0</div></div></div>"},"74701":{"type":"graphic_figure","displayName":"Acetabular index","title":"Acetabular index","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acetabular index</div><div class=\"cntnt\"><img style=\"width:414px; height:256px;\" src=\"images/PEDS/74701_Acetabular_index.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The acetabular index is the angle formed between Hilgenreiner line (a horizontal line through the upper margin of the radiolucent triradiate cartilage) and a tangential line to the lateral ossific margin of the roof of the acetabulum. The acetabular index changes with axial and sagittal plane rotation of the pelvis and is helpful in measuring the development of the osseous roof of the acetabulum. In the newborn, the acetabular index must be over 40° to be significantly abnormal.</div><div class=\"graphic_footnotes\">DDH: developmental dysplasia of the hip.</div><div id=\"graphicVersion\">Graphic 74701 Version 3.0</div></div></div>"},"74702":{"type":"graphic_picture","displayName":"Hunter syndrome","title":"Patient with mucopolysaccharidosis type II (MPS II, Hunter syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with mucopolysaccharidosis type II (MPS II, Hunter syndrome)</div><div class=\"cntnt\"><img style=\"width:211px; height:484px;\" src=\"images/PEDS/74702_Hunter_syndrome_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A six-year-old boy with severe Hunter syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Neufeld, E, Meunzer, J. The Mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver, CR, Beaudet, AL, Valle, D, et al (Eds), McGraw-Hill, New York 2001. Copyright &#169; 2001 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 74702 Version 4.0</div></div></div>"},"74703":{"type":"graphic_picture","displayName":"DLBCL CD20 and T-cell membrane staining","title":"Immunohistochemistry diffuse large B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Immunohistochemistry diffuse large B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:584px; height:223px;\" src=\"images/HEME/74703_DLBCLCD20Tcellmembrane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Distinct membrane staining for CD20, a pan B-cell marker. CD20/peroxidase staining.<br> (B) Membrane staining of incidental non-lymphoma T-cells. CD3/peroxidase staining.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Diffuse large B-cell lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74703 Version 7.0</div></div></div>"},"74704":{"type":"graphic_figure","displayName":"WHI risk of stroke","title":"Women's Health Initiative: Risk of stroke","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Women's Health Initiative: Risk of stroke</div><div class=\"cntnt\"><img style=\"width:537px; height:307px;\" src=\"images/ENDO/74704_HRT_stroke_WHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of cumulative hazard rates of stroke. In the Women's Health Initiative, combined estrogen-progestin therapy was associated with a significant increase in stroke when compared with placebo. The intention-to-treat&nbsp;hazard ratio was 1.31, 95% CI 1.02-1.68.</div><div class=\"graphic_reference\">Data from: Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003; 289:2673.</div><div id=\"graphicVersion\">Graphic 74704 Version 4.0</div></div></div>"},"74705":{"type":"graphic_figure","displayName":"Steroid modifications","title":"Steroid structures","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Steroid structures</div><div class=\"cntnt\"><img style=\"width:491px; height:539px;\" src=\"images/ENDO/74705_Steroid_modifications.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Structures of cortisol, cortisone, and several of the more commonly prescribed synthetic glucocorticoids, and the mineralo-corticoid fludrocortisone. Triamcinolone, a topical glucocorticoid, is identical to dexamethasone except for a 16 alpha hydroxyl group in place of the 16 alpha methyl group.</div><div id=\"graphicVersion\">Graphic 74705 Version 2.0</div></div></div>"},"74708":{"type":"graphic_figure","displayName":"Polyclonal pattern on SPEP","title":"Polyclonal gammopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polyclonal gammopathy</div><div class=\"cntnt\"><img style=\"width:267px; height:335px;\" src=\"images/HEME/74708_Polycl_pattern_SPEP_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Densitometer tracing of these findings reveals a broad-based peak of gamma mobility. This pattern is most often due to the presence of an inflammatory or reactive process, such as chronic liver disease, connective tissue disease, chronic infection, or a lymphoproliferative disorder.<br> (B) A polyclonal pattern is seen on serum protein electrophoresis on agarose gel (anode on left). The band at the right (red asterisk) is broad, and extends throughout the gamma mobility area.</div><div class=\"graphic_reference\">Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &#169; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 74708 Version 4.0</div></div></div>"},"74709":{"type":"graphic_picture","displayName":"Lactating breast abscess treated with needle aspiration","title":"Lactating breast abscess before and after needle aspiration","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Lactating breast abscess before and after needle aspiration</div><div class=\"cntnt\"><img style=\"width:514px; height:266px;\" src=\"images/PC/74709_Lactating_breast_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the overlying skin is normal, aspiration under ultrasound guidance is the preferred method of management.<br> (A) This shows appearance at presentation.<br> (B) This shows appearance following treatment with aspiration and antibiotics.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 74709 Version 4.0</div></div></div>"},"74711":{"type":"graphic_algorithm","displayName":"Neuropathic arthropathy in DM","title":"Possible pathogenesis of diabetic neuropathic arthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possible pathogenesis of diabetic neuropathic arthropathy</div><div class=\"cntnt\"><img style=\"width:290px; height:434px;\" src=\"images/RHEUM/74711_Neuropathic_arthropathy_in.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74711 Version 3.0</div></div></div>"},"74712":{"type":"graphic_picture","displayName":"Vitiligo - elbow","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74712_Vitiligo_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An irregularly shaped hypopigmented patch is present on the elbow.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74712 Version 3.0</div></div></div>"},"74714":{"type":"graphic_figure","displayName":"Aortic stenosis PI","title":"Aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Aortic stenosis</div><div class=\"cntnt\"><img style=\"width:535px; height:536px;\" src=\"images/PI/74714_Aortic_stenosis_PI_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When people have aortic stenosis, the aortic valve does not open fully. This prevents blood from flowing normally from the left ventricle, through the aortic valve, and to the aorta. The direction of blood flow is shown by the black arrow. The aorta is a big blood vessel that carries blood to the rest of the body.</div><div id=\"graphicVersion\">Graphic 74714 Version 2.0</div></div></div>"},"74715":{"type":"graphic_table","displayName":"Correlation HBV serotyp genotyp","title":"Correlation between HBV serotypes and genotypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Correlation between HBV serotypes and genotypes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">HBV genotypes</td>\n<td class=\"subtitle1\">HBV serotypes</td>\n</tr>\n<tr>\n<td>A</td>\n<td>adw2, adw4, ayw1, ayw2</td>\n</tr>\n<tr>\n<td>B</td>\n<td>adw2, ayw1</td>\n</tr>\n<tr>\n<td>C</td>\n<td>adrq+, adrq-, ayr, adw2, ayw2, ayw3</td>\n</tr>\n<tr>\n<td>D</td>\n<td>adw3, ayw2, ayw3, ayw4</td>\n</tr>\n<tr>\n<td>E</td>\n<td>ayw4</td>\n</tr>\n<tr>\n<td>F</td>\n<td>adw2, adw4, ayw4</td>\n</tr>\n<tr>\n<td>G</td>\n<td>adw2</td>\n</tr>\n<tr>\n<td>H</td>\n<td>adw4</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Anna SF Lok, MD and Chi-Jen Chu, MD.</div><div id=\"graphicVersion\">Graphic 74715 Version 1.0</div></div></div>"},"74717":{"type":"graphic_diagnosticimage","displayName":"Brain MRIs ages 20 mo and 9 yrs juvenile Alexander disease","title":"Early and late brain MRIs of a patient with autopsy-confirmed juvenile Alexander disease, obtained at ages 20 months and nine years","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early and late brain MRIs of a patient with autopsy-confirmed juvenile Alexander disease, obtained at ages 20 months and nine years</div><div class=\"cntnt\"><img style=\"width:436px; height:527px;\" src=\"images/NEURO/74717_MRI_juv_20mo_9yr_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early (A) and late (B-D) MR studies of a patient with autopsy-confirmed juvenile Alexander disease, obtained at ages 20 months (A) and 9 years (B-D). The early T2-weighted image (A) shows extensive cerebral white matter abnormalities with partial sparing of the occipital region. There is a thin periventricular rim of low signal intensity (arrows, A). The basal ganglia and thalamus have an increased signal intensity. The putamen and caudate nucleus are mildly swollen (A). On follow-up, the extent of the cerebral white matter abnormalities is more or less the same; the occipital white matter is still partially spared (D). The basal nuclei are dark and atrophic on the T2-weighted images (D). A thin periventricular rim of low signal intensity is visible (arrows, D). The proton density-weighted image (C) shows enormous cysts in the frontoparietal white matter, a large cavum vergae, and enlarged lateral ventricles. A lesion is seen in the posterior part of the medulla (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 74717 Version 4.0</div></div></div>"},"74718":{"type":"graphic_figure","displayName":"Diagram explaining constipation and fecal incontinence","title":"Constipation and bowel retraining","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Constipation and bowel retraining</div><div class=\"cntnt\"><img style=\"width:537px; height:483px;\" src=\"images/PEDS/74718_Encopresis_diagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fecal incontinence in children is when a toilet-trained child has bowel movements in the wrong place. Constipation is the most common cause. This diagram shows how constipation can make bowel movements build up and how treatment works.</div><div id=\"graphicVersion\">Graphic 74718 Version 5.0</div></div></div>"},"74721":{"type":"graphic_diagnosticimage","displayName":"Cervical flexion teardrop fracture","title":"Cervical vertebral body fractures: Flexion tear drop fracture","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Cervical vertebral body fractures: Flexion tear drop fracture</div><div class=\"cntnt\"><img style=\"width:511px; height:352px;\" src=\"images/EM/74721_Cervical_flex_tear_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flexion teardrop fracture results when severe flexion causes a vertebral body to collide with the one below, leading to anterior displacement of a wedge-shaped fragment (resembling a teardrop).</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 74721 Version 2.0</div></div></div>"},"74722":{"type":"graphic_table","displayName":"Review of symptoms in gyn","title":"Review of symptoms in gynecology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Review of symptoms in gynecology</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n\n  <tbody>\n\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle1_single\">Abnormal Vaginal Bleeding</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Significant increase or decrease in menstrual flow</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Intermenstrual or postcoital bleeding</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Change in pattern</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Amenorrhea</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle1_single\">Vulvovaginal symptoms</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"sublist1_start\">Presence of vaginal discharge</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n      <td class=\"sublist1\">Odor, color, itching, burning, relationship to menses or intercourse</td>\n    </tr>\n    <tr>\n\n\n\n      <td>Vaginal dryness</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Vulvar or vaginal pain with intercourse</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Vulvar lesions, pain, infections, itching</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle1_single\">Pelvic pain</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Time of onset: acute or chronic</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Location</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Intensity and degree of debilitation</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Relationship to menstrual cycle</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Relationship to eating, bowel, or bladder function</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Relationship to sexual or physical activity</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Associated symptoms, such as nausea or diarrhea</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Use of analgesics or hormonal therapy and their effectiveness</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle1_single\">Urologic</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"sublist1_start\">History of recurrent urinary tract infections</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"sublist1\">Relationship to sexual activity or diaphragm use</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist1\">Use of suppressive antibiotics</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td>Dysuria, urgency or urinary frequency</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Difficulty voiding</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Urinary incontinence or leakage</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Hematuria</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle1_single\">Pelvic relaxation</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Sense of vaginal pressure or that something is \"falling out\"</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td>Difficulty with penetration during intercourse</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n      <td class=\"sublist1_start\">Difficulty with voiding or defecating</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"sublist1\">Need to \"splint\", or apply vaginal pressure with above activities</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td>Incontinence of urine, stool, flatus</td>\n\n\n\n    </tr>\n\n\n\n  \n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74722 Version 1.0</div></div></div>"},"74723":{"type":"graphic_picture","displayName":"Carpenter bee","title":"Carpenter bee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carpenter bee</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/74723_Carpenter_bee.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 74723 Version 1.0</div></div></div>"},"74724":{"type":"graphic_diagnosticimage","displayName":"Curved planar reformation","title":"Curved planar reformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Curved planar reformation</div><div class=\"cntnt\"><img style=\"width:346px; height:324px;\" src=\"images/PULM/74724_Curved_planar_reformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Curved planar reconstruction of the trachea (T) in a patient with moderate tracheal stenosis below the thoracic inlet, from previous tracheostomy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74724 Version 2.0</div></div></div>"},"74725":{"type":"graphic_picture","displayName":"Pacemaker pocket erosion","title":"Pacemaker pocket erosion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pacemaker pocket erosion</div><div class=\"cntnt\"><img style=\"width:259px; height:392px;\" src=\"images/CARD/74725_Pacemaker_pocket_erosion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pacemaker generator, implanted several years prior to presentation, is clearly visible beneath the skin and is on the verge of complete erosion (arrow). The patient was asymptomatic. The device and leads were easily removed. Although purulent material was present, cultures of the pocket obtained at the time of explant were negative. A new pacing system was placed on the contralateral side.</div><div class=\"graphic_reference\">Courtesy of Margaret Lloyd, MD.</div><div id=\"graphicVersion\">Graphic 74725 Version 3.0</div></div></div>"},"74726":{"type":"graphic_figure","displayName":"Sentinel node biopsy","title":"Sentinel node biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sentinel node biopsy</div><div class=\"cntnt\"><img style=\"width:372px; height:382px;\" src=\"images/SURG/74726_Ident_sent_lymph_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Identification of the sentinel lymph node. Note the blue node with a blue lymphatic channel leading directly to the node.</div><div class=\"graphic_reference\">Reproduced with permission from: Harris, JR, Lippman, ME, Morrow, M, Osborne, CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74726 Version 1.0</div></div></div>"},"74728":{"type":"graphic_picture","displayName":"Laceration from coral","title":"Laceration from coral","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laceration from coral</div><div class=\"cntnt\"><img style=\"width:400px; height:300px;\" src=\"images/EM/74728_Laceration_from_coral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These coral lacerations were sustained while surfing.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor KS, Zoltan TB, Suraj A. Medical illnesses and injuries encountered during surfing. Curr Sports Med Rep 2006; 5:262. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74728 Version 8.0</div></div></div>"},"74730":{"type":"graphic_diagnosticimage","displayName":"Aortic root calcification Lat","title":"Calcification of the aortic root","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcification of the aortic root</div><div class=\"cntnt\"><img style=\"width:260px; height:330px;\" src=\"images/CARD/74730_Aortic_root_calcification_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of chest x-ray shows calcification at the aortic root (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 74730 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"74731":{"type":"graphic_table","displayName":"Secondary retroperitoneal fibrosis","title":"Major causes of secondary retroperitoneal fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of secondary retroperitoneal fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Drugs</td> <td>Methysergide, pergolide, bromocriptine, ergotamine, methyldopa, hydralazine, phenacetin, beta blockers </td> </tr> <tr> <td>Malignant diseases</td> <td>Carcinoid, Hodgkin and non-Hodgkin lymphomas, sarcomas, carcinomas of the colon, prostate, breast, stomach</td> </tr> <tr> <td>Infections</td> <td>Tuberculosis, histoplasmosis, actinomycosis</td> </tr> <tr> <td>Radiotherapy</td> <td>Testicular seminoma, colon carcinoma, pancreatic carcinoma</td> </tr> <tr> <td>Surgery</td> <td>Lymphadenectomy, colectomy, hysterectomy, aortic aneurysmectomy</td> </tr> <tr> <td>Others</td> <td>Histiocytoses, Erdheim-Chester disease, amyloidosis, trauma, barium enema</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from The Lancet, Vol. 367, Vaglio A, Salvarani C, Buzio C, Retroperitoneal Fibrosis, pp. 241-252, Copyright © 2006, with permission from Elsevier.</div><div id=\"graphicVersion\">Graphic 74731 Version 5.0</div></div></div>"},"74733":{"type":"graphic_table","displayName":"Intravenous lipid emulsion formulas pediatric","title":"Comparison of different intravenous lipid emulsion formulations used in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of different intravenous lipid emulsion formulations used in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Intralipid<br /> (Fresenius Kabi)</td> <td class=\"subtitle1\">Nutrilipid<br /> (B. Braun)</td> <td class=\"subtitle1\">Omegaven*<sup>&#182;</sup><br /> (Fresenius Kabi)</td> <td class=\"subtitle1\">Smoflipid<br /> (Fresenius Kabi)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Concentrations (percent)</strong></td> <td>10, 20, 30</td> <td>20</td> <td>10</td> <td>20</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Oil source (percent)</strong></td> <td>Soybean 100</td> <td>Soybean 100</td> <td>Fish 100</td> <td> <p>Soybean 30</p> <p>MCT 30</p> <p>Olive 25</p> Fish 15</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\"><strong>Fatty acids (percent)</strong><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Linoleic (C 18:2 &#969;-6)</td> <td>44 to 62</td> <td>48 to 58</td> <td>1 to 7</td> <td>18.7</td> </tr> <tr> <td class=\"indent1\">Linolenic (C 18:3 &#969;-3)</td> <td>4 to 11</td> <td>4 to 11</td> <td>2</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">Palmitic (C 16:0)</td> <td>7 to 14</td> <td>9 to 13</td> <td>2.5 to 10</td> <td>9.2</td> </tr> <tr> <td class=\"indent1\">Oleic (C 18:1 &#969;-9)</td> <td>19 to 30</td> <td>17 to 30</td> <td>6 to 13</td> <td>27.8</td> </tr> <tr> <td class=\"indent1\">Stearic (C 18:0)</td> <td>1.4 to 5.5</td> <td>2.5 to 5</td> <td>0.5 to 2</td> <td>2.7</td> </tr> <tr> <td class=\"indent1\">EPA (C 20:5 &#969;-3)</td> <td>0</td> <td>0</td> <td>12.5 to 28.2</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">DHA (C 22:6 &#969;-3)</td> <td>0</td> <td>0</td> <td>14.4 to 30.9</td> <td>2.2</td> </tr> <tr> <td class=\"indent1\">Caprylic acid (C 8:0)</td> <td>0</td> <td>0</td> <td>0</td> <td>16.3</td> </tr> <tr> <td class=\"indent1\">Caproic acid (C 10:0)</td> <td>0</td> <td>0</td> <td>0</td> <td>11.4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ratio (&#969;-6:&#969;-3)</td> <td>7:1</td> <td>Not available</td> <td>1:7</td> <td>2.5:1</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Egg yolk phospholipids (percent)</strong></td> <td>1.2</td> <td>1.2</td> <td>1.2</td> <td>1.2</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Glycerin (percent)</strong></td> <td>2.25, 2.25, 1.7</td> <td>2.5</td> <td>2.5</td> <td>2.5</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Energy density (kcal/mL)</strong></td> <td>1.1, 2, 3</td> <td>2</td> <td>1.1</td> <td>2</td> </tr> <tr> <td><strong>Osmolarity (mosm/L)</strong></td> <td>260, 260, 200</td> <td>390<sup>&#9674;</sup></td> <td>308 to 376<sup>&#9674;</sup></td> <td>380<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Approved product labeling in the&nbsp;United States&nbsp;and other countries&nbsp;warns of risks of&nbsp;hyperlipidemia, fat accumulation in lungs, and potential aluminum toxicity with use of intravenous fat emulsions in preterm and very low birth weight infants. Refer&nbsp;to accompanying text and local product information.<br />Smoflipid is not approved by US Food&nbsp;&amp; Drug Administration&nbsp;for use in pediatric patients.&nbsp;</div><div class=\"graphic_footnotes\">PUFA: long-chain n-3 polyunsaturated fatty acids; MCT: medium chain triglycerides; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid.<br />* Omegaven is available in many countries, but is&nbsp;not approved by the US FDA. Omegaven&nbsp;may be&nbsp;available in the US under an expanded access program administered by the FDA. For information on how to obtain Omegaven in the US, refer to FDA's&nbsp;Omegaven <A spellcheck=true href=\"http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm368740.htm\">expanded access&nbsp;</A>website.<br />¶ Omegaven fish oil contains several other n-3 PUFAs and arachidonic acid in addition to those shown in this table. Additional information&nbsp;is available&nbsp;from the <A spellcheck=true href=\"https://oley.site-ym.com/?page=newsonomegaven&amp;terms=%22omegaven%22\" target=_blank>oley.org</A> website.<br />Δ For fatty acids the percentages shown are based on the lipid component of emulsion only. Thus, for a 10 percent lipid emulsion, the final concentration (ie, grams per 100 mL) is obtained by dividing each fatty acid percent shown in the table by 10. The chemical structure is noted as: length of hydrocarbon chain (C atoms): number of double bonds; and position of first double bond (ω).<br /><FONT class=lozenge>◊</FONT> mosm/kg.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition - associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:197.</LI>&#xD;&#xA;<LI>Nordenstrom J, Thorne A. Comparative studies on a new concentrated fat emulsion: intralipid 30 percent vs. 20 percent. Clin Nutr 1993; 12:160.</LI>&#xD;&#xA;<LI>Smoflipid (lipid injectable emulsion) US product information; May, 2016 (available at: <A href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207648lbl.pdf\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207648lbl.pdf</A>) </LI>&#xD;&#xA;<LI>Rayvan M, Devliger H, Jochum F et al. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides and fish oil: A randomized double-blind study in preterm infants. J Parenter Enteral Nutr 2012; 36:81S.</LI></OL></div><div id=\"graphicVersion\">Graphic 74733 Version 11.0</div></div></div>"},"74734":{"type":"graphic_picture","displayName":"Small CMN","title":"Small congenital melanocytic nevus on the palm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small congenital melanocytic nevus on the palm</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/74734_Small_CMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In thiss small (&lt;1.5 cm) palmar congenital nevus, the linear streaks of hyperpigmentation reflect the prominent skin markings.</div><div class=\"graphic_reference\">Courtesy of Kalman Watsky, MD.</div><div id=\"graphicVersion\">Graphic 74734 Version 2.0</div></div></div>"},"74735":{"type":"graphic_picture","displayName":"Trendelenburg gait","title":"Trendelenburg gait in a boy with SCFE","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Trendelenburg gait in a boy with SCFE</div><div class=\"cntnt\"><img style=\"width:531px; height:502px;\" src=\"images/EM/74735_Trendelenburg_gait.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) When stepping on the unaffected side, the pelvis remains level. B) When stepping on the affected side, the pelvis tilts downward toward the unaffected side, and there is a subtle shift of the torso.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 74735 Version 2.0</div></div></div>"},"74737":{"type":"graphic_picture","displayName":"Eosinophilic esophagitis","title":"Eosinophilic esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic esophagitis</div><div class=\"cntnt\"><img style=\"width:380px; height:396px;\" src=\"images/EM/74737_Eosinophilic_esophagitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 14-month-old with failure to thrive and loose stools. Endoscopy demonstrates a thickened furrowed esophagus consistent with eosinophilic esophagitis. These patients commonly have dysphagia with, as well as without, evidence of stricture. Eosinophilic esophagitis is also a common cause of dysphagic in atopic school-aged children. Histology would demonstrate sheets of eosinophils in the lamina propria.</div><div class=\"graphic_reference\">Courtesy of Karen Murray, MD.</div><div id=\"graphicVersion\">Graphic 74737 Version 1.0</div></div></div>"},"74738":{"type":"graphic_picture","displayName":"Jobes test of supraspinatus strength","title":"Jobe's test of supraspinatus strength","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Jobe's test of supraspinatus strength</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/EM/74738_Jobe_strength.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Jobe's test (or the \"empty can\" test) assesses supraspinatus function. The patient places a straight arm in about 90 degrees of abduction and 30 degrees of forward flexion, and then internally rotates the shoulder completely. The clinician then attempts to adduct the arm while the patient resists. Pain without weakness suggests tendinopathy; pain with weakness is consistent with tendon tear.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD.</div><div id=\"graphicVersion\">Graphic 74738 Version 6.0</div></div></div>"},"74740":{"type":"graphic_picture","displayName":"Meat bolus impaction Endosc","title":"Esophageal meat bolus impaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal meat bolus impaction</div><div class=\"cntnt\"><img style=\"width:432px; height:210px;\" src=\"images/GAST/74740_Meat_bolus_impaction_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy of a meat bolus impaction above a preexisting malignant esophageal stricture due to advanced squamous lung cancer. Panel A: Meat bolus completely obliterates the esophageal lumen. Panel B: Endoscopic appearance of the stricture after complete removal of the impaction.</div><div class=\"graphic_reference\">Courtesy of George Triadafilopoulos, MD.</div><div id=\"graphicVersion\">Graphic 74740 Version 1.0</div></div></div>"},"74741":{"type":"graphic_figure","displayName":"Hegar dilators","title":"Hegar cervical dilators (uterine cervix)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hegar cervical dilators (uterine cervix)</div><div class=\"cntnt\"><img style=\"width:423px; height:253px;\" src=\"images/OBGYN/74741_Hegar_dilators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These dilators are double-ended and of progressive sizes.</div><div id=\"graphicVersion\">Graphic 74741 Version 3.0</div></div></div>"},"74742":{"type":"graphic_figure","displayName":"Nerves of the female perineum","title":"Nerves of the female perineum","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Nerves of the female perineum</div><div class=\"cntnt\"><img style=\"width:520px; height:506px;\" src=\"images/OBGYN/74742_Nerves_perineum_female.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74742 Version 3.0</div></div></div>"},"74743":{"type":"graphic_picture","displayName":"Internal external hip rotation","title":"Internal and external rotation of the hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Internal and external rotation of the hip</div><div class=\"cntnt\"><img style=\"width:338px; height:297px;\" src=\"images/EM/74743_Internal_external_hip_rotat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal and external rotation are measured to assess the integrity of the hip joint, measure rotation, and evaluate pain and stiffness. The examiner places one hand at the ankle and one hand at the knee. The lower leg is rotated laterally to test internal rotation, and medially to test external rotation. The patient is instructed to avoid rolling the buttocks during the maneuver. Internal and external rotation can be reduced by the loss of articular cartilage and outgrowth of acetabular osteophytes associated with osteoarthritis and the pain and muscle spasms of acute synovitis. Patients with severe osteoarthritis, acute synovitis, and septic arthritis may have as little as 5 to 10 degrees&nbsp;of rotation.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 74743 Version 3.0</div></div></div>"},"74744":{"type":"graphic_picture","displayName":"Pulmonary aspergillosis","title":"Invasive aspergillosis in lung transplant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive aspergillosis in lung transplant</div><div class=\"cntnt\"><img style=\"width:442px; height:339px;\" src=\"images/ID/74744_Pulmonary_aspergillosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomography (CT) scan of the chest showing fungal ball with pulmonary infiltrates, (B) gross anatomy on autopsy of the same patient showing mottling of the involved lobe, and (C) Grocott stain of the lung tissue of same patient showing multiple acute angle septate hyphae of <EM>Aspergillus</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74744 Version 11.0</div></div></div>"},"74745":{"type":"graphic_diagnosticimage","displayName":"Oblique shaft fracture of second metacarpal ","title":"Oblique shaft fracture of second metacarpal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique shaft fracture of second metacarpal</div><div class=\"cntnt\"><img style=\"width:270px; height:360px;\" src=\"images/EM/74745_Metacarpal_shaft_fx_2nd_MC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a displaced oblique fracture though the proximal shaft of the 2nd metacarpal. This fracture warrants orthopedic referral for reduction.</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 74745 Version 3.0</div></div></div>"},"74746":{"type":"graphic_figure","displayName":"Lymphatic drainage of the breast ","title":"Lymphatic drainage of the breast","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Lymphatic drainage of the breast</div><div class=\"cntnt\"><img style=\"width:526px; height:509px;\" src=\"images/SURG/74746_Axillarynodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymphatic drainage of the breast flows toward the axillary and internal mammary lymph nodes.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, Second Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74746 Version 4.0</div></div></div>"},"74750":{"type":"graphic_figure","displayName":"Tracheal occlusion for CDH","title":"Schematic representation of tracheal occlusion (TO) for severe CDH","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Schematic representation of tracheal occlusion (TO) for severe CDH</div><div class=\"cntnt\"><img style=\"width:478px; height:539px;\" src=\"images/OBGYN/74750_Tracheal_occlusion_for_CDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TO occludes trachea preventing normal egress of lung fluid, resulting in increased lung stretch and accelerated lung growth.</div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 74750 Version 1.0</div></div></div>"},"74751":{"type":"graphic_figure","displayName":"Risser sign","title":"Risser sign for skeletal maturity","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Risser sign for skeletal maturity</div><div class=\"cntnt\"><img style=\"width:544px; height:432px;\" src=\"images/PEDS/74751_Risser_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The iliac apophysis ossifies in a stepwise fashion from anterolateral to posteromedial along the iliac crest. The Risser sign is a visual grading of the degree to which the iliac apophysis has undergone ossification and fusion; it is used to assess skeletal maturity. Risser grade 0 corresponds to no ossification. As depicted above, grade 1 describes up to 25 percent ossification; grade 2 describes 26 to 50 percent ossification; grade 3 describes 51 to 75 percent ossification; grade 4 describes greater than 76 percent ossification; and grade 5 describes full bony fusion of the apophysis.</div><div id=\"graphicVersion\">Graphic 74751 Version 3.0</div></div></div>"},"74752":{"type":"graphic_picture","displayName":"Giant papillae in giant papillary conjunctivitis","title":"Giant papillary conjunctivitis with giant papillae on the palpebral conjunctiva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant papillary conjunctivitis with giant papillae on the palpebral conjunctiva</div><div class=\"cntnt\"><img style=\"width:320px; height:223px;\" src=\"images/PC/74752_Giantpapillaryconjunct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reaction to lid movement over a foreign substance, such as a contact lens.</div><div id=\"graphicVersion\">Graphic 74752 Version 4.0</div></div></div>"},"74753":{"type":"graphic_table","displayName":"Delivered FIO2 using HeO2","title":"Delivered FIO2 during Heliox utilization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Delivered FIO2 during Heliox utilization</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">FIO<sub>2</sub> set</td>\n\n      <td class=\"subtitle1\">Veolar FT</td>\n\n      <td class=\"subtitle1\">Galileo </td>\n\n      <td class=\"subtitle1\">Evita 2</td>\n\n      <td class=\"subtitle1\">Evita 4</td>\n\n      <td class=\"subtitle1\">Servo 900C</td>\n\n      <td class=\"subtitle1\">Servo 300</td>\n\n      <td class=\"subtitle1\">7200 series</td>\n\n    </tr>\n\n    <tr>\n\n      <td>0.21</td>\n\n      <td>0.22</td>\n\n      <td>0.22</td>\n\n      <td>0.22</td>\n\n      <td>0.22</td>\n\n      <td>0.22</td>\n\n      <td>0.22</td>\n\n      <td>0.22</td>\n\n    </tr>\n\n    <tr>\n\n      <td>0.25</td>\n\n      <td>0.25</td>\n\n      <td>0.25</td>\n\n      <td>0.24</td>\n\n      <td>0.24</td>\n\n      <td>0.25</td>\n\n      <td>0.26</td>\n\n      <td>0.56</td>\n\n    </tr>\n\n    <tr>\n\n      <td>0.3</td>\n\n      <td>0.31</td>\n\n      <td>0.31</td>\n\n      <td>0.28</td>\n\n      <td>0.27</td>\n\n      <td>0.33</td>\n\n      <td>0.33</td>\n\n      <td>0.73</td>\n\n    </tr>\n\n    <tr>\n\n      <td>0.35</td>\n\n      <td>0.37</td>\n\n      <td>0.35</td>\n\n      <td>0.31</td>\n\n      <td>0.3</td>\n\n      <td>0.35</td>\n\n      <td>0.38</td>\n\n      <td>0.83</td>\n\n    </tr>\n\n    <tr>\n\n      <td>04</td>\n\n      <td>0.4</td>\n\n      <td>0.41</td>\n\n      <td>0.35</td>\n\n      <td>0.34</td>\n\n      <td>0.46</td>\n\n      <td>0.43</td>\n\n      <td>0.88</td>\n\n    </tr>\n\n    <tr>\n\n      <td>0.5</td>\n\n      <td>0.51</td>\n\n      <td>0.5</td>\n\n      <td>0.42</td>\n\n      <td>0.41</td>\n\n      <td>0.51</td>\n\n      <td>0.52</td>\n\n      <td>0.95</td>\n\n    </tr>\n\n    <tr>\n\n      <td>0.6</td>\n\n      <td>0.61</td>\n\n      <td>0.6</td>\n\n      <td>0.52</td>\n\n      <td>0.5</td>\n\n      <td>0.62</td>\n\n      <td>0.63</td>\n\n      <td>0.99</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1.0</td>\n\n      <td>0.98</td>\n\n      <td>1.0</td>\n\n      <td>0.98</td>\n\n      <td>0.97</td>\n\n      <td>0.99</td>\n\n      <td>0.99</td>\n\n      <td>1.0</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Tassaux D, Jolliet P, Thouret J, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22. Copyright &#169;1999 American Lung Association.</div><div id=\"graphicVersion\">Graphic 74753 Version 2.0</div></div></div>"},"74755":{"type":"graphic_picture","displayName":"Orientation adjuster","title":"Orientation adjuster","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Orientation adjuster</div><div class=\"cntnt\"><img style=\"width:540px; height:395px;\" src=\"images/GAST/74755_Orientation_adjuster.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture showing the orientation adjuster (insert showing its effect on the trucut needle).</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 74755 Version 1.0</div></div></div>"},"74756":{"type":"graphic_figure","displayName":"Probability of pregnancy by day of intercourse","title":"Possibility of pregnancy from intercourse on days relative to ovulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possibility of pregnancy from intercourse on days relative to ovulation</div><div class=\"cntnt\"><img style=\"width:426px; height:255px;\" src=\"images/OBGYN/74756_Probability_of_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Wilcox A, et al. Post-ovulatory aging of the human oocyte and embryo failure. Hum Reprod 1998; 12:394. Reproduced with permission from the Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 74756 Version 2.0</div></div></div>"},"74757":{"type":"graphic_table","displayName":"Pleural fluid characteristics","title":"Observations of pleural fluid helpful in diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Observations of pleural fluid helpful in diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Suggested diagnosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Color of fluid</td> </tr> <tr> <td class=\"indent1\">Pale yellow (straw)</td> <td>Transudate, some exudates</td> </tr> <tr> <td class=\"indent1\">Red (bloody)</td> <td>Malignancy, benign asbestos pleural effusion, postcardiac injury syndrome, or pulmonary infarction in absence of trauma</td> </tr> <tr> <td class=\"indent1\">White (milky)</td> <td>Chylothorax or cholesterol effusion</td> </tr> <tr> <td class=\"indent1\">Brown</td> <td>Long-standing bloody effusion; rupture of amebic liver abscess</td> </tr> <tr> <td class=\"indent1\">Black<sup>[1-4]</sup></td> <td>Aspergillus niger, Rhizomes oryzae, metastatic melanoma, pancreaticopleural fistula, crack cocaine use, bronchogenic adenocarcinoma, esophageal perforation during treatment with activated charcoal, chronic hemothorax</td> </tr> <tr> <td class=\"indent1\">Yellow-green </td> <td>Rheumatoid pleurisy </td> </tr> <tr> <td class=\"indent1\">Dark green</td> <td>Biliothorax</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Color of:</td> </tr> <tr> <td class=\"sublist2\">Enteral tube feeding</td> <td class=\"sublist_other\">Feeding tube has entered pleural space</td> </tr> <tr> <td class=\"sublist2\">Central venous catheter infusate</td> <td class=\"sublist_other\">Extravascular catheter migration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Character of fluid</td> </tr> <tr> <td class=\"indent1\">Pus</td> <td>Empyema</td> </tr> <tr> <td class=\"indent1\">Viscous</td> <td>Mesothelioma</td> </tr> <tr> <td class=\"indent1\">Debris</td> <td>Rheumatoid pleurisy</td> </tr> <tr> <td class=\"indent1\">Turbid</td> <td>Inflammatory exudate or lipid effusion</td> </tr> <tr> <td class=\"indent1\">Anchovy paste</td> <td>Amebic liver abscess</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Odor of fluid</td> </tr> <tr> <td class=\"indent1\">Putrid</td> <td>Anaerobic empyema</td> </tr> <tr> <td class=\"indent1\">Ammonia</td> <td>Urinothorax</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Chhabra A, Mukherjee V, Chowdhary M, et al. Black Pleural Effusion: A Unique Presentation of Metastatic Melanoma. Case Rep Oncol 2015; 8:222. </LI>&#xD;&#xA;<LI>Huang TY, Tsai MJ. Education and imaging. Gastrointestinal: black pleural effusion induced by pancreaticopleural fistula. J Gastroenterol Hepatol 2013; 28:1798. </LI>&#xD;&#xA;<LI>Jayakrishnan B, Dildar B, Rizavi DM, et al. Black pleural effusion. Lancet 2015; 386:e7. </LI>&#xD;&#xA;<LI>Saraya T, Light RW, Takizawa H, Goto H. Black Pleural Effusion. Am J Med 2013; 126:641.e1.</LI></OL></div><div id=\"graphicVersion\">Graphic 74757 Version 2.0</div></div></div>"},"74759":{"type":"graphic_figure","displayName":"Sutures PI","title":"Stitches","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Stitches</div><div class=\"cntnt\"><img style=\"width:518px; height:626px;\" src=\"images/PI/74759_Sutures-PI-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stitches (also called &quot;sutures&quot;) help a cut heal faster. Doctors use a special type of needle and thread to bring the ends of the skin together (as shown in A). Picture B shows a cut that has been closed with stitches.</div><div id=\"graphicVersion\">Graphic 74759 Version 4.0</div></div></div>"},"74760":{"type":"graphic_picture","displayName":"Neonatal chlamydia conjunctivitis","title":"Neonatal chlamydia conjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Neonatal chlamydia conjunctivitis</div><div class=\"cntnt\"><img style=\"width:540px; height:371px;\" src=\"images/PEDS/74760_Neonatal_chlamydia_conjunct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twelve-day-old with five-day history of progressive lid swelling and discharge typical of chlamydial conjunctivitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd Edition. Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74760 Version 2.0</div></div></div>"},"74761":{"type":"graphic_picture","displayName":"Esophageal coin erosion 1","title":"Upper esophageal injury from ingested coin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper esophageal injury from ingested coin</div><div class=\"cntnt\"><img style=\"width:355px; height:359px;\" src=\"images/EM/74761_Coin_erosion_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 3-year-old female with upper esophageal injury from coin ingestion five days prior to evaluation. Endoscopy reveals deep ulceration and exudate at area of coin removal.</div><div class=\"graphic_reference\">Courtesy of Karen Murray, MD.</div><div id=\"graphicVersion\">Graphic 74761 Version 2.0</div></div></div>"},"74762":{"type":"graphic_table","displayName":"Determining BMI B","title":"Determining body mass index using kilograms and centimeters*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determining body mass index using kilograms and centimeters*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">BMI, kg/m<sup>2</sup></td> <td class=\"subtitle1\">19</td> <td class=\"subtitle1\">20</td> <td class=\"subtitle1\">21</td> <td class=\"subtitle1\">22</td> <td class=\"subtitle1\">23</td> <td class=\"subtitle1\">24</td> <td class=\"subtitle1\">25</td> <td class=\"subtitle1\">26</td> <td class=\"subtitle1\">27</td> <td class=\"subtitle1\">28</td> <td class=\"subtitle1\">29</td> <td class=\"subtitle1\">30</td> <td class=\"subtitle1\">35</td> <td class=\"subtitle1\">40</td> </tr> <tr> <td class=\"subtitle2\">Height, cm*</td> <td class=\"subtitle2\" colspan=\"14\">Weight, kg*</td> </tr> <tr> <td class=\"subtitle2_left\">147</td> <td>41</td> <td>43</td> <td>45</td> <td>48</td> <td>50</td> <td>52</td> <td>54</td> <td>56</td> <td>58</td> <td>61</td> <td>63</td> <td>65</td> <td>76</td> <td>86</td> </tr> <tr> <td class=\"subtitle2_left\">150</td> <td>43</td> <td>35</td> <td>47</td> <td>50</td> <td>52</td> <td>54</td> <td>56</td> <td>59</td> <td>61</td> <td>63</td> <td>65</td> <td>68</td> <td>79</td> <td>90</td> </tr> <tr> <td class=\"subtitle2_left\">152</td> <td>44</td> <td>46</td> <td>49</td> <td>51</td> <td>53</td> <td>55</td> <td>58</td> <td>60</td> <td>62</td> <td>65</td> <td>67</td> <td>69</td> <td>81</td> <td>92</td> </tr> <tr> <td class=\"subtitle2_left\">155</td> <td>46</td> <td>48</td> <td>50</td> <td>53</td> <td>55</td> <td>58</td> <td>60</td> <td>62</td> <td>65</td> <td>67</td> <td>70</td> <td>72</td> <td>84</td> <td>96</td> </tr> <tr> <td class=\"subtitle2_left\">158</td> <td>47</td> <td>50</td> <td>52</td> <td>55</td> <td>57</td> <td>60</td> <td>62</td> <td>65</td> <td>67</td> <td>70</td> <td>72</td> <td>75</td> <td>87</td> <td>100</td> </tr> <tr> <td class=\"subtitle2_left\">160</td> <td>49</td> <td>51</td> <td>54</td> <td>56</td> <td>59</td> <td>61</td> <td>64</td> <td>67</td> <td>69</td> <td>72</td> <td>74</td> <td>77</td> <td>90</td> <td>102</td> </tr> <tr> <td class=\"subtitle2_left\">162</td> <td>50</td> <td>52</td> <td>55</td> <td>58</td> <td>60</td> <td>63</td> <td>66</td> <td>68</td> <td>71</td> <td>73</td> <td>76</td> <td>79</td> <td>92</td> <td>105</td> </tr> <tr> <td class=\"subtitle2_left\">165</td> <td>52</td> <td>54</td> <td>57</td> <td>60</td> <td>63</td> <td>65</td> <td>68</td> <td>71</td> <td>74</td> <td>76</td> <td>79</td> <td>82</td> <td>95</td> <td>109</td> </tr> <tr> <td class=\"subtitle2_left\">168</td> <td>54</td> <td>56</td> <td>59</td> <td>62</td> <td>65</td> <td>68</td> <td>71</td> <td>73</td> <td>76</td> <td>79</td> <td>82</td> <td>85</td> <td>99</td> <td>113</td> </tr> <tr> <td class=\"subtitle2_left\">170</td> <td>55</td> <td>58</td> <td>61</td> <td>64</td> <td>66</td> <td>69</td> <td>72</td> <td>75</td> <td>78</td> <td>81</td> <td>84</td> <td>87</td> <td>101</td> <td>116</td> </tr> <tr> <td class=\"subtitle2_left\">173</td> <td>57</td> <td>60</td> <td>63</td> <td>66</td> <td>69</td> <td>72</td> <td>75</td> <td>78</td> <td>81</td> <td>84</td> <td>87</td> <td>90</td> <td>105</td> <td>120</td> </tr> <tr> <td class=\"subtitle2_left\">175</td> <td>58</td> <td>61</td> <td>64</td> <td>67</td> <td>70</td> <td>74</td> <td>77</td> <td>80</td> <td>83</td> <td>86</td> <td>89</td> <td>92</td> <td>107</td> <td>123</td> </tr> <tr> <td class=\"subtitle2_left\">178</td> <td>60</td> <td>63</td> <td>67</td> <td>70</td> <td>73</td> <td>76</td> <td>79</td> <td>82</td> <td>86</td> <td>89</td> <td>92</td> <td>95</td> <td>111</td> <td>127</td> </tr> <tr> <td class=\"subtitle2_left\">180</td> <td>62</td> <td>65</td> <td>68</td> <td>71</td> <td>75</td> <td>78</td> <td>81</td> <td>84</td> <td>87</td> <td>91</td> <td>94</td> <td>97</td> <td>113</td> <td>134</td> </tr> <tr> <td class=\"subtitle2_left\">183&nbsp;</td> <td>64</td> <td>67</td> <td>70</td> <td>74</td> <td>77</td> <td>80</td> <td>84</td> <td>87</td> <td>90</td> <td>94</td> <td>97</td> <td>100</td> <td>117</td> <td>134</td> </tr> <tr> <td class=\"subtitle2_left\">185&nbsp;</td> <td>65</td> <td>68</td> <td>72</td> <td>75</td> <td>79</td> <td>82</td> <td>86</td> <td>89</td> <td>92</td> <td>96</td> <td>99</td> <td>103</td> <td>120</td> <td>137</td> </tr> <tr> <td class=\"subtitle2_left\">188</td> <td>67</td> <td>71</td> <td>74</td> <td>78</td> <td>81</td> <td>85</td> <td>88</td> <td>92</td> <td>95</td> <td>99</td> <td>102</td> <td>106</td> <td>124</td> <td>141</td> </tr> <tr> <td class=\"subtitle2_left\">190</td> <td>69</td> <td>72</td> <td>76</td> <td>79</td> <td>83</td> <td>87</td> <td>90</td> <td>94</td> <td>97</td> <td>101</td> <td>105</td> <td>108</td> <td>126</td> <td>144</td> </tr> <tr> <td class=\"subtitle2_left\">193</td> <td>71</td> <td>74</td> <td>78</td> <td>82</td> <td>86</td> <td>89</td> <td>93</td> <td>97</td> <td>101</td> <td>104</td> <td>108</td> <td>112</td> <td>130</td> <td>149</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.<br />* The health risk from any level of BMI is increased if the patient has gained more than 5 kg (11 pounds) since age 25 years, or if the waist circumference is above 100 cm (40 in) due to central fatness.</div><div id=\"graphicVersion\">Graphic 74762 Version 3.0</div></div></div>"},"74763":{"type":"graphic_diagnosticimage","displayName":"AS AR continuous wave Doppler","title":"Aortic stenosis/aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic stenosis/aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:315px; height:210px;\" src=\"images/CARD/74763_AS_AR_continuous_wave_Doppl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous wave Doppler shows a peak systolic velocity across the aortic valve of 3 m/sec or a gradient of 36 mmHg. Aortic regurgitation is also present and is of moderate degree based on the slope of diastolic deceleration which is intermediate in value.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 74763 Version 3.0</div></div></div>"},"74764":{"type":"graphic_table","displayName":"Infections with urticaria","title":"Infectious agents and illnesses associated with urticaria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious agents and illnesses associated with urticaria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Illness</td> </tr> <tr> <td>Bedbugs, kissing bugs, ants, fleas, flies, and mosquitoes </td> <td>Bites and stings</td> </tr> <tr> <td><em>Coxiella burnetii</em> </td> <td>Q Fever</td> </tr> <tr> <td>Coxsackieviruses A9, A16, B4, B5</td> <td>Rash</td> </tr> <tr> <td><em>Echinococcus</em> sp</td> <td>Echinococcosis</td> </tr> <tr> <td>Echovirus 11</td> <td>Rash</td> </tr> <tr> <td>Epstein-Barr virus</td> <td>Infectious mononucleosis</td> </tr> <tr> <td><em>Entamoeba histolytica</em></td> <td>Amebiasis</td> </tr> <tr> <td><em>Enterobius vermicularis</em></td> <td>Pinworm infestation</td> </tr> <tr> <td><em>Giardia lambdia</em></td> <td>Giardiasis</td> </tr> <tr> <td>Hepatitis B virus</td> <td>Hepatitis B</td> </tr> <tr> <td>Mites</td> <td>Bites</td> </tr> <tr> <td>Mumps virus </td> <td>Mumps</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> <td>Atypical pneumonia</td> </tr> <tr> <td><em>Necator americanus</em></td> <td>Hookworm disease</td> </tr> <tr> <td><em>Neisseria meningitidis</em></td> <td>Meningococcemia</td> </tr> <tr> <td><em>Plasmodium</em> spp</td> <td>Malaria</td> </tr> <tr> <td><em>Pediculus humanus</em></td> <td>Pediculosis</td> </tr> <tr> <td><em>Sarcoptes scabiei</em></td> <td>Scabies</td> </tr> <tr> <td><em>Schistosoma</em> spp</td> <td>Schistosomiasis</td> </tr> <tr> <td><em>Shigella sonnei</em></td> <td>Shigellosis</td> </tr> <tr> <td><em>Trichinella spiralis</em></td> <td>Trichinosis</td> </tr> <tr> <td><em>Trichobilharzia</em> spp</td> <td>Swimmer's itch; collector's itch</td> </tr> <tr> <td><em>Trichomonas vaginalis</em></td> <td>Vulvovaginitis</td> </tr> <tr> <td><em>Trombicula irritans</em></td> <td>Chigger bites</td> </tr> <tr> <td><em>Wuchereria bancrofti</em></td> <td>Filariasis</td> </tr> <tr> <td><em>Yersinia enterocolitica</em></td> <td>Yersiniosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permissiom from Sanders CV, Diagnosis of the Patient with Fever and Rash. In: The Skin and Infection: A Color Atlas and Text. Sanders CV,&nbsp;Nesbitt LT (Eds), Baltimore, Maryland: Williams &amp; Wilkins, 1995. Originally modified from Textbook of Pediatric Infectious Diseases, 3rd ed,&nbsp;Vol 1, Feigin RD and Cherry JD (Eds), Philadelphia, WB Saunders, Philadelphia 1992, p. 771.</div><div id=\"graphicVersion\">Graphic 74764 Version 3.0</div></div></div>"},"74765":{"type":"graphic_movie","displayName":"Pericardial effusion with tamponade subcostal echocardiogram","title":"Tamponade","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tamponade</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/74765_subtampoconv.mp4\" style=\"width:326px;height:236px\"></div><img style=\"width:239px; height:366px;\" src=\"images/CARD/74765_subtampo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The subcostal view of a 2-D echocardiogram shows a large pericardial effusion encircling the heart which shows a &quot;swinging&quot; motion during the cardiac cycle. There is also diastolic collapse of the right atrium and ventricle, a result of tamponade.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 74765 Version 2.0</div></div></div>"},"74768":{"type":"graphic_picture","displayName":"Ulcerated hemangioma perineum","title":"Ulcerated hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerated hemangioma</div><div class=\"cntnt\"><img style=\"width:394px; height:260px;\" src=\"images/PEDS/74768_Ulcerated_hemangioma_perine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulceration is the most common complication of hemangiomas. Large segmental lesions, especially in trauma-prone locations, as the one of the perineum depicted above, are at increased risk for ulceration.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD.</div><div id=\"graphicVersion\">Graphic 74768 Version 1.0</div></div></div>"},"74769":{"type":"graphic_diagnosticimage","displayName":"Wide mortise associated with tibiofibular syndesmosis tear","title":"Wide mortise associated with tibiofibular syndesmosis tear","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Wide mortise associated with tibiofibular syndesmosis tear</div><div class=\"cntnt\"><img style=\"width:500px; height:523px;\" src=\"images/RHEUM/74769_Wd_mrts_assc_tbfblr_sndsms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph of the ankle shows widening of the ankle mortise. Note the increased space between the medial malleolus and the adjacent talus. This appearance strongly suggests a tear of the distal tibiofibular syndesmosis, an injury that is referred to as a syndesmotic sprain or, in layman's terms, as a high ankle sprain.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 74769 Version 6.0</div></div></div>"},"74771":{"type":"graphic_figure","displayName":"Ear wax impaction PI","title":"Ear wax impaction","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Ear wax impaction</div><div class=\"cntnt\"><img style=\"width:525px; height:410px;\" src=\"images/PI/74771_Ear-wax-impaction-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows where ear wax can build up (become impacted) in the ear canal.</div><div id=\"graphicVersion\">Graphic 74771 Version 2.0</div></div></div>"},"74772":{"type":"graphic_figure","displayName":"Dist phalanx fracture types","title":"Distal phalanx fracture types","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal phalanx fracture types</div><div class=\"cntnt\"><img style=\"width:390px; height:532px;\" src=\"images/EM/74772_Dist_phalanx_fx_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fracture patterns seen in the distal phalanx are (A) longitudinal, (B) transverse, (C) tuft, (D) dorsal base, (E) volar base, and (F) complete articular.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, MD and Heckman JD, MD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott, Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74772 Version 2.0</div></div></div>"},"74774":{"type":"graphic_figure","displayName":"Urinary IgG fragment immunofix","title":"Urinary immunoglobulin fragment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urinary immunoglobulin fragment</div><div class=\"cntnt\"><img style=\"width:338px; height:162px;\" src=\"images/HEME/74774_Urinary_IgG_fragment_immuno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates immunofixation of a single urine specimen with antisera to IgG and lambda light chain determinants. There are two lambda bands. A discrete IgG band corresponds to one of the lambda bands (red asterisk). The findings indicate a monoclonal lambda protein plus an IgG lambda fragment.</div><div id=\"graphicVersion\">Graphic 74774 Version 1.0</div></div></div>"},"74776":{"type":"graphic_picture","displayName":"Telangiectatic matting following sclerotherapy","title":"Telangiectatic matting following sclerotherapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectatic matting following sclerotherapy</div><div class=\"cntnt\"><img style=\"width:360px; height:332px;\" src=\"images/PC/74776_Sclerotherapy_matting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Telangiectatic matting consists of multiple, fine dilated vessels in the area of the injection site. Repeat sclerotherapy to feeding reticular veins can be attempted; otherwise, the area can be treated with laser therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Zimmet, SE. Complications of Sclerotherapy. Available at: http://www.veindirectory.org/news/pdf/18.pdf.</div><div id=\"graphicVersion\">Graphic 74776 Version 4.0</div></div></div>"},"74778":{"type":"graphic_table","displayName":"Drug and toxin related skin findings","title":"Drug- and toxin-induced skin abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced skin abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Red and flushed</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergic agents</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1\">Atropine</td> </tr> <tr> <td class=\"sublist1\">Scopolamine</td> </tr> <tr> <td class=\"sublist1\">Belladonna alkaloids</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td>Boric acid</td> </tr> <tr> <td class=\"sublist1_start\">Disulfiram reaction</td> </tr> <tr> <td class=\"sublist1\">Disulfiram/ethanol</td> </tr> <tr> <td class=\"sublist1\">Cephalosporins/ethanol</td> </tr> <tr> <td class=\"sublist1\">Solvents/ethanol</td> </tr> <tr> <td class=\"sublist1\">Coprinus mushrooms/ethanol</td> </tr> <tr> <td>Monosodium glutamate</td> </tr> <tr> <td>Scombroid fish poisoning</td> </tr> <tr> <td>Rifampin</td> </tr> <tr> <td>Carbon monoxide (rare)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pale and diaphoretic</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Ephedrine</td> </tr> <tr> <td class=\"sublist1\">Phenylpropanolamine</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergic agents</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td class=\"sublist1\">Nerve agents</td> </tr> <tr> <td class=\"sublist1_start\">Central hallucinogens</td> </tr> <tr> <td class=\"sublist1\">Lysergic acid diethylamide (LSD)</td> </tr> <tr> <td class=\"sublist1\">Phencyclidine</td> </tr> <tr> <td class=\"sublist1\">Mescaline</td> </tr> <tr> <td class=\"sublist1\">Psilocybin</td> </tr> <tr> <td class=\"sublist1\">Designer amphetamines</td> </tr> <tr> <td class=\"sublist1\">Synthetic cannabinoids</td> </tr> <tr> <td>Arsenic</td> </tr> <tr> <td>Salicylates</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cyanotic</td> </tr> <tr> <td>Methemoglobinemia</td> </tr> <tr> <td>Sulfhemoglobinemia</td> </tr> <tr> <td>Hypoxemia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Desquamation</td> </tr> <tr> <td>Stevens-Johnson syndrome</td> </tr> <tr> <td>Toxic epidermal necrolysis</td> </tr> <tr> <td>Boric acid</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals</td> </tr> <tr> <td class=\"sublist1\">Arsenic</td> </tr> <tr> <td class=\"sublist1\">Mercury</td> </tr> <tr> <td class=\"sublist1\">Thallium</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74778 Version 6.0</div></div></div>"},"74779":{"type":"graphic_table","displayName":"Disorders that may exacerbate and/or contribute to CRS","title":"Disorders that may exacerbate and/or contribute to CRS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders that may exacerbate and/or contribute to CRS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Allergic rhinitis</td> </tr> <tr> <td>Chronic exposure to environmental irritants or ciliostatic substances (eg, tobacco smoke)</td> </tr> <tr> <td>Immunodeficiency states (especially defects in antibody production or function)</td> </tr> <tr> <td>Defects in mucociliary clearance (eg, cystic fibrosis and primary ciliary dyskinesia)</td> </tr> <tr> <td>Recurrent viral upper respiratory tract infections</td> </tr> <tr> <td>Systemic disorders (eg, granulomatosis with polyangiitis [Wegener's], eosinophilic granulomatosis with polyangiitis [Churg-Strauss], sarcoidosis)</td> </tr> <tr> <td>Anatomic abnormalities predisposing to sinus obstruction</td> </tr> <tr> <td>Iatrogenic (due to complications of repeated sinus surgery)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRS: chronic rhinosinusitis.</div><div id=\"graphicVersion\">Graphic 74779 Version 6.0</div></div></div>"},"74780":{"type":"graphic_figure","displayName":"Modified Seldinger tech","title":"Modified seldinger technique for central venous access","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Modified seldinger technique for central venous access</div><div class=\"cntnt\"><img style=\"width:523px; height:379px;\" src=\"images/PULM/74780_Modified_Seldinger_tech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The needle is inserted into the selected vein. (B) The flexible end of the guidewire is passed through the needle and advanced into the vessel. (C) The needle is removed, leaving the guidewire in place. (D) The catheter is advanced over the guidewire with a twisting motion into the vessel. A vascular dilator should be passed over the wire prior to placement of a large catheter. (E) The guidewire is removed while the catheter is held in place.</div><div class=\"graphic_reference\">Reproduced with permission from Ruddy RM (Ed). Illustrated technique of pediatric emergency medicine procedures. In: Textbook of Pediatric Emergency Medicine, 3rd ed, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Baltimore 1993. Copyright © 1993 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74780 Version 11.0</div></div></div>"},"74786":{"type":"graphic_picture","displayName":"Laryngeal cleft type 1","title":"Endoscopic palpation of type 1 laryngeal cleft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic palpation of type 1 laryngeal cleft</div><div class=\"cntnt\"><img style=\"width:370px; height:370px;\" src=\"images/PEDS/74786_Laryngeal_cleft_type_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type 1 clefts are limited to the supraglottic, interarytenoid area.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 74786 Version 1.0</div></div></div>"},"74787":{"type":"graphic_figure","displayName":"Normal SPEP","title":"Normal pattern on serum protein electrophoresis","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Normal pattern on serum protein electrophoresis</div><div class=\"cntnt\"><img style=\"width:510px; height:556px;\" src=\"images/HEME/74787_Normal_SPEP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Looking from left to right on the serum protein electrophoresis, a normal pattern has a large peak representing albumin followed by significantly smaller peaks for alpha-1, alpha-2, beta, and gamma.</div><div id=\"graphicVersion\">Graphic 74787 Version 4.0</div></div></div>"},"74790":{"type":"graphic_picture","displayName":"Head lice nits","title":"Pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:246px; height:414px;\" src=\"images/PC/74790_Head_lice_nits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous nits on hair.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 74790 Version 4.0</div></div></div>"},"74792":{"type":"graphic_table","displayName":"Causes diaphragmatic paralysis","title":"Causes of diaphragmatic paralysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of diaphragmatic paralysis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Neurologic causes</td></tr>\n\t\t\t\t\t\t<tr><td>Spinal cord transection</td></tr>\n\t\t\t\t\t\t<tr><td>Multiple sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td>Amyotrophic lateral sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td>Cervical spondylosis</td></tr>\n\t\t\t\t\t\t<tr><td>Poliomyelitis </td></tr>\n\t\t\t\t\t\t<tr><td> Guillain-Barre syndrome</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Phrenic nerve dysfunction</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Compression by tumor</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Cardiac surgery cold injury</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\"> Blunt trauma</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Idiopathic phrenic neuropathy</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Postviral phrenic neuropathy</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Radiation therapy</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Cervical chiropractic manipulation</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Myopathic causes</td></tr>\n\t\t\t\t\t\t<tr><td>Limb-girdle dystrophy</td></tr>\n\t\t\t\t\t\t<tr><td>Hyperthyroidism or hypothyroidism</td></tr>\n\t\t\t\t\t\t<tr><td>Malnutrition</td></tr>\n\t\t\t\t\t\t<tr><td>Acid maltase deficiency</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Connective tissue diseases</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Systemic lupus erythematosus&nbsp;</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Dermatomyositis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Mixed connective tissue disease</td></tr>\n\t\t\t\t\t\t<tr><td>Amyloidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Idiopathic myopathy</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74792 Version 1.0</div></div></div>"},"74795":{"type":"graphic_table","displayName":"Hepatocyte transplantation","title":"Potential indications for hepatocyte transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications for hepatocyte transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inherited metabolic disorders</td> </tr> <tr> <td>Allogeneic (with immunosuppression or tolerization)</td> </tr> <tr> <td>Autologous with ex-vivo gene transfer</td> </tr> <tr> <td class=\"subtitle1_single\">Acute liver failure</td> </tr> <tr> <td>As a \"bridge\" while awaiting liver transplantation</td> </tr> <tr> <td>As definitive therapy in selected cases</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic liver failure</td> </tr> <tr> <td>For improving metabolic function and encephalopathy</td> </tr> <tr> <td>To \"buy time\" while awaiting liver transplantation</td> </tr> <tr> <td class=\"subtitle1_single\">Rescuing patients who require curative doses of hepatic irradiation</td> </tr> <tr> <td>As a part of treatment</td> </tr> <tr> <td class=\"subtitle1_single\">Generating animal models</td> </tr> <tr> <td>For human hepatocyte-specific infections by transplanting human hepatocytes into immunodeficient animals</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74795 Version 2.0</div></div></div>"},"74796":{"type":"graphic_table","displayName":"Hypovolemia in diarrhea","title":"Assessment of severity of volume depletion among patients with acute diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of severity of volume depletion among patients with acute diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination</td> <td class=\"subtitle1\">Mild hypovolemia</td> <td class=\"subtitle1\">Moderate hypovolemia</td> <td class=\"subtitle1\">Severe hypovolemia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Look at:</td> </tr> <tr> <td class=\"indent1\">Mental status</td> <td>Alert</td> <td>Restless, irritable</td> <td>Lethargic or unconscious</td> </tr> <tr> <td class=\"indent1\">Eyes</td> <td>Normal</td> <td>Sunken</td> <td>Very sunken and dry</td> </tr> <tr> <td class=\"indent1\">Tears</td> <td>Present</td> <td>Absent</td> <td>Absent</td> </tr> <tr> <td class=\"indent1\">Mouth/tongue</td> <td>Moist, slightly dry</td> <td>Dry</td> <td>Very dry</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thirst</td> <td>Increased thirst</td> <td>Thirsty, drinks eagerly</td> <td>Drinks poorly or not able to drink</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Feel:</td> </tr> <tr> <td class=\"indent1\">Skin pinch</td> <td>Goes back rapidly</td> <td>Goes back slowly</td> <td>Goes back very slowly (tenting)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pulse</td> <td>Normal</td> <td>Rapid, weak</td> <td>Very fast, weak or nonpalpable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Extent of volume loss</strong></td> <td>&#60;5 percent of body weight</td> <td>From 5 to 10 percent of body weight</td> <td>&#62;10 percent of body weight</td> </tr> <tr> <td><strong>Estimated fluid deficit</strong></td> <td>&#60;50 mL/kg</td> <td>50-100 mL/kg</td> <td>&#62;100 mL/kg</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Swerdlow DL, Ries AA. JAMA 1992; 267:1495 and World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers, 4th revision. WHO/FCH/CAH/05.1. World Health Organization, Geneva 2005. (Available at <a href=\"http://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">http://whqlibdoc.who.int/publications/2005/9241593180.pdf</a>).</div><div id=\"graphicVersion\">Graphic 74796 Version 4.0</div></div></div>"},"74799":{"type":"graphic_picture","displayName":"Skin in disseminated histo","title":"Disseminated histoplasmosis in a patient with AIDS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated histoplasmosis in a patient with AIDS</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/ID/74799_Skin_in_disseminated_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized maculopapular eruption and vesiculopustules resemble varicella zoster virus infection.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 74799 Version 6.0</div></div></div>"},"74801":{"type":"graphic_figure","displayName":"Anatomy of the subclavian and internal jugular veins","title":"Anatomy of the subclavian and internal jugular veins","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the subclavian and internal jugular veins</div><div class=\"cntnt\"><img style=\"width:542px; height:436px;\" src=\"images/EM/74801_Anatomy_SC_IJ_central_line.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74801 Version 3.0</div></div></div>"},"74802":{"type":"graphic_table","displayName":"Circadian rhythm disorders PI","title":"Circadian rhythm disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Circadian rhythm disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Circadian rhythms are changes in body functions, such as temperature regulation and sleep cycles, which occur during a 24-hour period. People with circadian rhythm disorders may experience insomnia and daytime sleepiness because their circadian rhythms follow an abnormal pattern.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Shift work sleep disorder</strong> - People who work late night shifts can have difficulty sleeping during the daytime. This is especially true for people who work rotating or permanent night shifts, who often revert to sleeping at night on days off to maintain contact with their family. Treatment often includes adopting a consistent daily sleep routine seven days per week.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Delayed sleep phase syndrome</strong> - Some people have a sleep-wake rhythm that is longer than 24 hours. These people want to go to bed at a later time and sleep later every morning. However, this is usually not practical because of school or work requirements. Treatment usually includes trying to wake at an earlier, consistent time each day.</td> </tr> <tr> <td><strong>Advanced sleep phase syndrome</strong> - This is the opposite of delayed sleep phase syndrome, and is more common in middle age and older adults. A person with this disorder may go to sleep in the early evening and wake much earlier than they wish. Attempts to stay up later do not always allow the person to wake later in the morning. Sleep can be normal if the person is willing to accept the early bedtime and wake time.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74802 Version 6.0</div></div></div>"},"74803":{"type":"graphic_waveform","displayName":"M mode mitral valve","title":"M mode echocardiogam of mitral valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M mode echocardiogam of mitral valve</div><div class=\"cntnt\"><img style=\"width:335px; height:269px;\" src=\"images/CARD/74803_M_mode_mitral_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior leaflet of the mitral valve opens widely at the beginning of diastole (D), reaching a peak at the end of rapid left ventricular filling (E). During diastasis, the valve leaflet floats back towards a closed position (F) and it opens again with atrial systole (A). At the end of diastole and the initiation of systole, the mitral leaflets are closed (C). The posterior leaflet is a mirror image of the anterior leaflet except that its amplitude of motion is less.</div><div id=\"graphicVersion\">Graphic 74803 Version 4.0</div></div></div>"},"74804":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CXR I","title":"Mediastinal subcarinal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal subcarinal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:378px;\" src=\"images/PULM/74804_Med_bronchogen_cyst_CXR_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a subtle subcarinal mass.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74804 Version 2.0</div></div></div>"},"74805":{"type":"graphic_figure","displayName":"Post MI survival in patients with VT or VF","title":"Sustained ventricular arrhythmias after myocardial infarction (MI) decrease survival","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Sustained ventricular arrhythmias after myocardial infarction (MI) decrease survival</div><div class=\"cntnt\"><img style=\"width:470px; height:293px;\" src=\"images/CARD/74805_Post_MI_survival_VT_VF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the GUSTO-1 trial of 40,825 patients, the in-hospital and one year mortality rates were higher in those who had sustained ventricular tachcardia (VT) or ventricular fibrillation (VF) compared to those without either arrhythmia. The group with both VT and VF had highest mortality rates.</div><div class=\"graphic_reference\">Redrawn from Newby, KH, Thompson, T, Stebbins, A, et al, Circulation 1998; 98:2567.</div><div id=\"graphicVersion\">Graphic 74805 Version 2.0</div></div></div>"},"74807":{"type":"graphic_movie","displayName":"Bartholin gland excision","title":"Bartholin gland excision video","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Bartholin gland excision video</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/74807_Barthglandexcisionmovie.mp4\" style=\"width:480px;height:352px\"></div><img style=\"width:265px; height:320px;\" src=\"images/OBGYN/74807_Barthglandexcisionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gerald Harkins, MD and Kristin Riley, MD.</div><div id=\"graphicVersion\">Graphic 74807 Version 1.0</div></div></div>"},"74808":{"type":"graphic_table","displayName":"Classification unstable angina","title":"Original Braunwald classification of unstable angina","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Original Braunwald classification of unstable angina</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Severity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Class I - New onset, severe, or accelerated</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Class II - Angina at rest and subacute (no anginal episodes within the preceding 48 hours)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Class III - Angina at rest and acute (angina within the preceding 48 hours)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Clinical circumstances</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Class A - Secondary unstable angina (in the setting of anemia, infection, fever, etc)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Class B - Primary unstable angina</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Class C - Post-MI angina</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Intensity of treatment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>No or minimal treatment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Symptoms occurring in the setting of standard medical therapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Symptoms occurring despite maximally tolerated doses of beta blockers, nitrates, and calcium channel blockers</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Braunwald E. Circulation 1989; 80:410.</div><div id=\"graphicVersion\">Graphic 74808 Version 2.0</div></div></div>"},"74811":{"type":"graphic_figure","displayName":"Common pathoanatomical conditions of the lumbar spine","title":"Common pathoanatomical conditions of the lumbar spine","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Common pathoanatomical conditions of the lumbar spine</div><div class=\"cntnt\"><img style=\"width:542px; height:623px;\" src=\"images/PC/74811_Pathoanatomical_conditions_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A superior view of a normal lumbar vertebra with cauda equina, nerve roots, intervertebral disc and ligamentum flavum.<br />(B) A superior view demonstrating abnormalities including a thickened ligamentum flavum, a hypertrophied facet and a herniated disc. These pathologic structures cause the canal to narrow and can impinge on the cauda equina and nerve roots.<br />(C) A lateral view of the lumbosacral spine demonstrating spondylolysis and spondylolisthesis. Spondylolysis is a fracture in the pars interarticularis of the vertebra. Spondylolisthesis occurs when this fracture widens and the vertebral body slides forward on the one below it.</div><div id=\"graphicVersion\">Graphic 74811 Version 5.0</div></div></div>"},"74817":{"type":"graphic_movie","displayName":"Bilateral Babinski signs in ALS","title":"Bilateral Babinski signs in a patient with amyotrophic lateral sclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral Babinski signs in a patient with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/74817_alsbbnsconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:238px;\" src=\"images/NEURO/74817_alsbbns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral Babinski signs consistent with upper motor neuron involvement are noted.</div><div class=\"graphic_reference\">Courtesy of Nestor Galvez-Jimenez, MD, FACP.</div><div id=\"graphicVersion\">Graphic 74817 Version 3.0</div></div></div>"},"74819":{"type":"graphic_table","displayName":"Nutritional comparison of milk with alternative sources","title":"Nutritional comparison of cow's milk with alternative sources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional comparison of cow's milk with alternative sources</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Milk alternatives, per 8 ounce</td> <td class=\"subtitle1\">Kcal*</td> <td class=\"subtitle1\">Protein, grams*</td> <td class=\"subtitle1\">Fat, grams*</td> <td class=\"subtitle1\">Calcium, mg*</td> <td class=\"subtitle1\">Vitamin D, international units*</td> </tr> <tr> <td>Cow's milk, whole; 2%; skim</td> <td>150; 130; 85</td> <td>8</td> <td>8; 5; &#60;1</td> <td>300</td> <td>100</td> </tr> <tr> <td>Toddler formula (Nutramigen with Enflora LGG Toddler) </td> <td>160</td> <td>4</td> <td>6</td> <td>208</td> <td>96</td> </tr> <tr> <td>Toddler formula (Neocate Junior Unflavored)</td> <td>240</td> <td>7.9</td> <td>12</td> <td>283</td> <td>190.8</td> </tr> <tr> <td>Enriched soy milk</td> <td>110</td> <td>8</td> <td>4.5</td> <td>350</td> <td>100</td> </tr> <tr> <td>Enriched rice milk</td> <td>120</td> <td>1</td> <td>2.5</td> <td>300</td> <td>100</td> </tr> <tr> <td>Enriched oat milk</td> <td>130</td> <td>4</td> <td>2.5</td> <td>300</td> <td>100</td> </tr> <tr> <td>Enriched almond milk</td> <td>60</td> <td>1</td> <td>2.5</td> <td>300</td> <td>100</td> </tr> <tr> <td>Enriched&nbsp;coconut milk</td> <td>70</td> <td>0</td> <td>4.5</td> <td>100 to 450</td> <td>100</td> </tr> <tr> <td>Enriched hemp milk</td> <td>140</td> <td>3</td> <td>5</td> <td>300 to 500</td> <td>100</td> </tr> <tr> <td>Enriched quinoa milk</td> <td>70</td> <td>2</td> <td>1</td> <td>300</td> <td>100</td> </tr> <tr> <td>Mare's milk<sup>[1]</sup></td> <td>120</td> <td>5&nbsp;</td> <td>4</td> <td>238&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Dromedary camel's milk<sup>[1]</sup>&nbsp;</td> <td>140&nbsp;</td> <td>7.8&nbsp;</td> <td>8&nbsp;</td> <td>285&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Bactrian camel's milk<sup>[1]</sup>&nbsp;</td> <td>190&nbsp;</td> <td>9.8&nbsp;</td> <td>12.5&nbsp;</td> <td>384&nbsp;</td> <td>160&nbsp;</td> </tr> <tr> <td>Juice - 10% (30%) calcium fortified</td> <td>120</td> <td>0</td> <td>0</td> <td>100 (300)</td> <td>Varies</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Blank spaces indicate that no data were available.</div><div class=\"graphic_footnotes\"><FONT color=black>* May vary based upon brand.</FONT></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Medhammar E, Wijesinha-Bettoni R, Stadlmayr B, et al. Composition of milk from minor dairy animals and buffalo breeds from a biodiversity perspective. J&nbsp; Sci Foood Agr 2011; 92:445.</LI></OL></div><div id=\"graphicVersion\">Graphic 74819 Version 9.0</div></div></div>"},"74823":{"type":"graphic_figure","displayName":"24h plasma amylin","title":"Twenty-four-hour plasma amylin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Twenty-four-hour plasma amylin</div><div class=\"cntnt\"><img style=\"width:424px; height:548px;\" src=\"images/ENDO/74823_24h_plasma_amylin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Twenty-four-hour plasma insulin and amylin profiles in healthy subjects.<br />(B) Mean amylin&nbsp;±standard deviation versus time after a meal. Amylin response is absent in patients with type 1 diabetes and impaired in insulin-requiring patients with type 2 diabetes.</div><div class=\"graphic_reference\">Modified with permission from: Buse J, Weyer C, Maggs D. Amylin replacement with pramlintide in type 2 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright © 2002 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 74823 Version 3.0</div></div></div>"},"74826":{"type":"graphic_algorithm","displayName":"Respiratory assessment of potential divers","title":"Algorithm assessing respiratory fitness for diving","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Algorithm assessing respiratory fitness for diving</div><div class=\"cntnt\"><img style=\"width:494px; height:515px;\" src=\"images/EM/74826_Assessment_of_potential_div.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; PEFR: peak expiratory flow rate.</div><div class=\"graphic_reference\">Reproduced from Thorax, British Thoracic Society guidelines on respiratory aspects of fitness for diving, volume 58, pages 3-13, Copyright © 2003, BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 74826 Version 13.0</div></div></div>"},"74827":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT VIII","title":"Bronchogenic carcinoma with speckled calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchogenic carcinoma with speckled calcification</div><div class=\"cntnt\"><img style=\"width:260px; height:238px;\" src=\"images/PULM/74827_Bronchogenic_carcinoma_CT5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malignant speckled calcification in a solitary pulmonary nodule, proven to represent a bronchogenic carcinoma by biopsy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74827 Version 3.0</div></div></div>"},"74830":{"type":"graphic_table","displayName":"IHC staining Paget breast","title":"IHC staining of ductal cells, Paget cells, and epidermal cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">IHC staining of ductal cells, Paget cells, and epidermal cells</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Monoclonal antibody\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Keratin specificity\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Mammary ductal cells\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Paget cells\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Nipple epidermal basal cells\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LE41</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>TROMA1</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>CAM5.2</td>\r\n  \r\n   <td>8, 18</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LE61</td>\r\n  \r\n   <td>19</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>MO8</td>\r\n  \r\n   <td>18</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LP2K</td>\r\n  \r\n   <td>18</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>BA16</td>\r\n  \r\n   <td>19</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>BA17</td>\r\n  \r\n   <td>19</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LP34</td>\r\n  \r\n   <td>All epithelia</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>LPK</td>\r\n  \r\n   <td>Type II keratins</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>PAb421</td>\r\n  \r\n   <td>Basal keratinocytes</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>HMFG1</td>\r\n  \r\n   <td>Membrane proteins</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>HMFG2</td>\r\n  \r\n   <td>Membrane proteins</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46512&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>IHC_staining_Paget_breast.htm</title></head></div><div class=\"graphic_footnotes\">IHC: immunohistochemical.</div><div class=\"graphic_reference\">Data from Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat 1986; 8:139.</div><div id=\"graphicVersion\">Graphic 74830 Version 3.0</div></div></div>"},"74834":{"type":"graphic_table","displayName":"Poisons causing nystagmus","title":"Common poisonings that can cause nystagmus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common poisonings that can cause nystagmus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t  <tr>\n\t    <td>Anticonvulsants: carbamazepine, phenytoin</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Barbiturates</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Dextromethorphan</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Ethanol</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Ketamine</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Lithium</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Phencyclidine</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Scorpion sting</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Serotonin syndrome</td>\n\t  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74834 Version 1.0</div></div></div>"},"74836":{"type":"graphic_table","displayName":"Success single dose MTX","title":"Success of single dose methotrexate  for ectopic pregnancy according to hCG concentration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Success of single dose methotrexate  for ectopic pregnancy according to hCG concentration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">hCG concentration (IU/L) </td> <td class=\"subtitle1\">Number of women successfully treated (%) </td> <td class=\"subtitle1\">Number of women failing treatment (%) </td> </tr> <tr> <td>&#60;1000</td> <td>133 (99)</td> <td>2 (1)</td> </tr> <tr> <td>1000 to 1999</td> <td>51 (94)</td> <td>3 (6)</td> </tr> <tr> <td>2000 to 4999</td> <td>106 (96)</td> <td>4 (4)</td> </tr> <tr> <td>5000 to 9999</td> <td>42 (86)</td> <td>7 (14)</td> </tr> <tr> <td>10,000 to 150,000</td> <td>18 (82)</td> <td>4 (18)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; IU: international units.</div><div class=\"graphic_reference\">Adapted from: Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy:&nbsp;A systematic review. Fertil Steril 2007; 87:481.</div><div id=\"graphicVersion\">Graphic 74836 Version 3.0</div></div></div>"},"74837":{"type":"graphic_picture","displayName":"Follicular small cleaved NHL","title":"Follicular lymphoma grade 1 (follicular small cleaved cell lymphoma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma grade 1 (follicular small cleaved cell lymphoma)</div><div class=\"cntnt\"><img style=\"width:324px; height:276px;\" src=\"images/HEME/74837_Follicular_small_cleaved_NH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This neoplastic lymph node follicle is composed almost entirely of small cleaved cells with indented, angulated nuclear membranes and very little cytoplasm (centrocytes). A small population of large, noncleaved cells (centroblasts, red arrow) can also be seen.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 74837 Version 2.0</div></div></div>"},"74838":{"type":"graphic_picture","displayName":"Eczema herpeticum hand","title":"Eczema herpeticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczema herpeticum</div><div class=\"cntnt\"><img style=\"width:425px; height:350px;\" src=\"images/PC/74838_Eczema_herpeticum_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic crusts and vesicles due to herpes simplex virus infection are present on the hand of this infant with underlying atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74838 Version 3.0</div></div></div>"},"74840":{"type":"graphic_figure","displayName":"LVRS survival curves","title":"LVRS survival curves","html":"<div class=\"graphic\"><div style=\"width: 1025px\" class=\"figure\"><div class=\"ttl\">LVRS survival curves</div><div class=\"cntnt\"><img style=\"width:1005px; height:1081px;\" src=\"images/PULM/74840_LVRSsurvivalcurvesed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of the cumulative probability of death as a function of years after randomization to LVRS (red line) or medical treatment (blue line) for (A) all patients in the National Emphysema Treatment Trial and (B-D) non-high-risk and upper-lobe-predominant emphysema subgroups of patients:<br />(A) All patients (n = 1218).<br />(B) Non-high-risk patients (n = 1078).<br />(C) Upper-lobe-predominant and low baseline exercise capacity (n = 290).<br />(D) Upper-lobe-predominant and high exercise capacity (n = 419).<br />The p value is from the Fisher exact test for difference in the proportions of patients who died during the 4.3 years (median) of follow-up.</div><div class=\"graphic_footnotes\">LVRS: lung volume reduction surgery; RR: relative risk.</div><div class=\"graphic_reference\">Reproduced with permission from: Naunheim, KS, Wood, DE, Mohsenifar, Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82:431. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74840 Version 2.0</div></div></div>"},"74841":{"type":"graphic_movie","displayName":"Subvalvar aortic stenosis","title":"Echocardiogram in the parasternal long axis view of subvalvar aortic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram in the parasternal long axis view of subvalvar aortic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/74841_Subvalvaraorticstenosis.mp4\" style=\"width:432px;height:336px\"></div><img style=\"width:480px; height:408px;\" src=\"images/PEDS/74841_Subvalvaraorticsten.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram in the parasternal long axis view demonstrates a thick, circumferential subaortic membrane about 5 mm below the aortic valve (AoV). Note the attachment to the anterior leaflet of the mitral valve (AML).</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; %: percent.</div><div id=\"graphicVersion\">Graphic 74841 Version 4.0</div></div></div>"},"74842":{"type":"graphic_picture","displayName":"Pemphigus vulgaris extensive lesions","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74842_Pemph_vulgaris_exten_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread erosions are present on the skin in this patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74842 Version 3.0</div></div></div>"},"74843":{"type":"graphic_picture","displayName":"Improper twisting carrying load","title":"IMPROPER mechanics: Twisting at the waist while carrying a load","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IMPROPER mechanics: Twisting at the waist while carrying a load</div><div class=\"cntnt\"><img style=\"width:268px; height:369px;\" src=\"images/RHEUM/74843_Improp_Twist_Carry.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 74843 Version 1.0</div></div></div>"},"74844":{"type":"graphic_figure","displayName":"HDV HBV reinfxn in liver TPL","title":"Hepatitis D virus and hepatitis B virus reinfection after liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Hepatitis D virus and hepatitis B virus reinfection after liver transplantation</div><div class=\"cntnt\"><img style=\"width:521px; height:431px;\" src=\"images/GAST/74844_HDV_HBV_reinfxn_in_liver_TP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patient who underwent transplantation for HDV cirrhosis developed HBV recurrence at eight months. Acute hepatitis (AH) occurred two months later with expression of HDAg in the liver. Serum HDV-RNA became detectable at 13 months. The patient progressed to chronic active hepatitis (CAH) with persistence of detectable HBV and HDV replication seven years after grafting. ALT, alanine aminotransferases; hatched area, upper limit of normal for ALT.</div><div class=\"graphic_reference\">Adapted from Samuel, D, Zignego, AL, Reynes, M, et al, Hepatology 1995; 21:334.</div><div id=\"graphicVersion\">Graphic 74844 Version 2.0</div></div></div>"},"74846":{"type":"graphic_diagnosticimage","displayName":"Adult TB case 1 PA view","title":"Classic adult tuberculosis posterior-anterior view case I","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Classic adult tuberculosis posterior-anterior view case I</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/74846_ClassicadultTBPAview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph,&nbsp;posterior-anterior view, of an 18-year-old high school student exposed four years earlier to an infectious pulmonary tuberculosis patient. She was noncompliant with isoniazid prophylaxis. She now presents with cough for one month, fever, and night sweats. Posterior-anterior radiograph shows right upper lobe apical and posterior segment infiltrate with cavitation. This radiograph is \"classic\" for adult-type reactivation tuberculosis.</div><div class=\"graphic_reference\">Courtesy of John Bernardo, MD.</div><div id=\"graphicVersion\">Graphic 74846 Version 4.0</div></div></div>"},"74847":{"type":"graphic_picture","displayName":"Echinococcal liver cyst gross  ","title":"Macroscopic appearance of echinococcal cysts in liver tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macroscopic appearance of echinococcal cysts in liver tissue</div><div class=\"cntnt\"><img style=\"width:360px; height:271px;\" src=\"images/ID/74847_Macroscopic_cyst_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Craig PS, McManus DP, Lightlowlers MW, et al. Prevention and control of cystic echinococcosis. Lancet Infect Dis 2007; 7:385. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 74847 Version 3.0</div></div></div>"},"74850":{"type":"graphic_figure","displayName":"Urethral prolapse","title":"Urethral prolapse in a 6-year-old girl","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Urethral prolapse in a 6-year-old girl</div><div class=\"cntnt\"><img style=\"width:513px; height:224px;\" src=\"images/EM/74850_Urethralprolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Urethral prolapse in a 6-year-old girl with &quot;vaginal&quot; bleeding. The vaginal orifice cannot be seen.<br> (B) The smooth doughnut shape and central lumen are characteristic features of a urethral prolapse, which, if large or swollen, often conceals the vagina below it.</div><div class=\"graphic_reference\">Reproduced with permission from: Hettler J. Pediatric and adolescent gynecology. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74850 Version 11.0</div></div></div>"},"74851":{"type":"graphic_waveform","displayName":"Variable AV block tutorial","title":"Variable atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variable atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:439px; height:134px;\" src=\"images/CARD/74851_Variable_AV_block_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial flutter is commonly associated with variable AV block. The AV conduction ratio varies between 2:1 and 3:1 in this case.</div><div id=\"graphicVersion\">Graphic 74851 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"74854":{"type":"graphic_table","displayName":"DMD pre-anesthesia","title":"Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the evaluation and management of patients with Duchenne muscular dystrophy (DMD) before general anesthesia or procedural sedation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the evaluation and management of patients with Duchenne muscular dystrophy (DMD) before general anesthesia or procedural sedation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Obtain anesthesiology and pulmonology consultations before procedures involving general anesthesia or procedural sedation</td> </tr> <tr> <td class=\"sublist1_start\">Perform a pulmonary evaluation that includes measurement of forced vital capacity (FVC), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), peak cough flow (PCF), and oxyhemoglobin saturation measured by pulse oximetry (SpO2) in room air</td> </tr> <tr> <td class=\"sublist1\">&#8226; Measure the blood and/or end-tidal carbon dioxide level if SpO2 is &#60;95% in room air</td> </tr> <tr> <td class=\"sublist1\">&#8226; For patients with DMD who are at increased risk of respiratory complications, defined by an FVC &#60;50% of predicted, and especially for patients at high risk for complications, defined by an FVC &#60;30% of predicted, consider preoperative training in the use of noninvasive positive pressure ventilation (NPPV)</td> </tr> <tr> <td class=\"sublist1\">&#8226; For patients at high risk of ineffective cough, defined in adults by PCF &#60;270 L/min or MEP &#60;60 cmH2O, consider preoperative training in manual and mechanically assisted cough, emphasizing use of mechanical insufflation-exsufflation with a bronchial secretion clearance device (eg, CoughAssist)</td> </tr> <tr> <td class=\"sublist1_start\">Refer the patient to a cardiologist for clinical evaluation and optimization of cardiac therapies</td> </tr> <tr> <td class=\"sublist1_start\">Obtain a nutritional assessment, optimize nutritional status, and consider strategies to manage dysphagia</td> </tr> <tr> <td class=\"sublist1_start\">Discuss the risks and benefits of general anesthesia or procedural sedation with the patient and guardians, and help them to decide on and implement their decisions regarding resuscitation parameters and, if applicable, advance directives</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Birnkrant, DJ, Panitch, HB, Benditt, JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132:1977.</div><div id=\"graphicVersion\">Graphic 74854 Version 2.0</div></div></div>"},"74855":{"type":"graphic_table","displayName":"Burn center referral criteria","title":"Burn center referral criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Burn center referral criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Partial-thickness burns greater than 10% of TBSA</td> </tr> <tr> <td>Burns that involve the face, hands, feet, genitalia, perineum, or major joints</td> </tr> <tr> <td>Third-degree burns in any age group</td> </tr> <tr> <td>Electrical burns, including lightning injury</td> </tr> <tr> <td>Chemical burns</td> </tr> <tr> <td>Inhalation injury</td> </tr> <tr> <td>Burn injury in patients with preexisting medical disorders that could complicate management, prolong recovery, or affect mortality</td> </tr> <tr> <td>Any patient with burns and concomitant trauma (such as fractures) in which the burn injury poses the greatest risk for morbidity or mortality. In such cases, if the trauma poses the greater immediate risk, the patient may be stabilized initially in a trauma center before being transferred to a burn unit. Physician judgment will be necessary in such situations and should be in concert with the regional medical control plan and triage protocols. </td> </tr> <tr> <td>Burned children in hospitals without qualified personnel or equipment for the care of children</td> </tr> <tr> <td>Burn injury in patients who will require special social, emotional, or rehabilitative intervention</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TBSA: total body surface area.<br />* A burn center may treat adults, children, or both. Burn injuries that should be referred to a burn center include any of the criteria listed.</div><div class=\"graphic_reference\">Copyright © American Burn Association. Advanced Burn Life Support Provider Manual. Chicago. 2011. 25-27. Print.</div><div id=\"graphicVersion\">Graphic 74855 Version 5.0</div></div></div>"},"74856":{"type":"graphic_waveform","displayName":"Low voltage limb leads tutorial","title":"Low voltage in the limb leads","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Low voltage in the limb leads</div><div class=\"cntnt\"><img style=\"width:499px; height:111px;\" src=\"images/CARD/74856_Low_voltage_limb_leads_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low voltage of the limb leads is present when the amplitude of the QRS complex in each of the three standard limb leads (1, 2, and 3) is &lt;5 mm. Each large box represents 5 mm (calibration: 1 mV = 10 mm).</div><div id=\"graphicVersion\">Graphic 74856 Version 2.0</div></div></div>"},"74857":{"type":"graphic_diagnosticimage","displayName":"Rheumatoid pleural disease chest x-ray","title":"Rheumatoid pleural disease chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid pleural disease chest x-ray</div><div class=\"cntnt\"><img style=\"width:313px; height:326px;\" src=\"images/PULM/74857_Rheumatic_pleural_dz_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loculated right pleural effusion in a patient with rheumatoid arthritis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74857 Version 4.0</div></div></div>"},"74858":{"type":"graphic_table","displayName":"Use of SCOOP system II","title":"Patient management tips for the SCOOP transtracheal oxygen system - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient management tips for the SCOOP transtracheal oxygen system - II</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phase</td> <td class=\"subtitle1\">Goal</td> <td class=\"subtitle1\">Management strategy</td> </tr> <tr> <td class=\"centered\" rowspan=\"4\">II</td> <td>Prevent infection</td> <td>Instruct the patient in the importance of taking antibiotics for the time prescribed. This prevents infection and may reduce the risk of chondritis. Teach the patient to clean the site daily with 1/2 strength hydrogen peroxide; evaluate for warmth, redness, swelling, or drainage; and report these symptoms.</td> </tr> <tr> <td>Minimize cough</td> <td>Encourage the patient to use guaifenesin for mild cough. Oral narcotics (eg, dextromethorphan, codeine) may be prescribed for moderate cough. Severe, uncontrolled cough can be relieved by instructing the patient to inject 0.5 to 1 mL 1 percent lidocaine into the stent every 4 to 6 hours as needed for 24 hours.</td> </tr> <tr> <td rowspan=\"2\">Anticipate air leaks</td> <td>MST procedure patients: Alert the patient to expect some air loss and secretions through the stent for 1 to 2 days until it becomes blocked by secretions.</td> </tr> <tr> <td>Fast Tract patients will have some air loss and secretions from the stoma while it is healing and may have difficulty speaking for the first few days. The patient can apply gentle pressure to the SCOOP flange to make speaking easier.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCOOP: Spofford Christopher Oxygen Optimizing Program; MST: modified Seldinger technique.</div><div class=\"graphic_reference\">Adapted from: Hoffman LA, Wesmiller SW.Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.</div><div id=\"graphicVersion\">Graphic 74858 Version 4.0</div></div></div>"},"74859":{"type":"graphic_form","displayName":"Immunotherapy prescription form, blank","title":"Immunotherapy prescription form, blank","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Immunotherapy prescription form, blank</div><div class=\"cntnt\"><img style=\"width:638px; height:801px;\" src=\"images/ALLRG/74859_SCIT_prescription_form_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maintenance concentration and subsequent dilutions reported as volume/volume (v/v) dilutions with maintenance concentration 1:1 v/v.</div><div class=\"graphic_footnotes\">AU: allergy unit; BAU: bioequivalent allergy unit; w/v: weight per volume ratio; PNU: protein nitrogen unit; 50% G: 50% glycerinated; Aq: aqueous; Ly: lyophilized; AP: alum-precipitated; AcP: acetone-precipitated.<br />* Volume to add = (maintenance concentration/concentration of manufacturer's extract) × total volume.<br />¶ Target maintenance dose volume is 0.5 mL per injection.</div><div class=\"graphic_reference\">Reproduced from: Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74859 Version 5.0</div></div></div>"},"74862":{"type":"graphic_table","displayName":"Clinical features of Dent-1 disease","title":"Clinical features of patients with documented mutations in <em>CLCN5</em> (Dent-1 disease)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of patients with documented mutations in <em>CLCN5</em> (Dent-1 disease)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Prevalence (percent)</td> </tr> <tr> <td>LMW proteinuria</td> <td class=\"centered\">100</td> </tr> <tr> <td>Hypercalciuria*</td> <td class=\"centered\">92 to 95</td> </tr> <tr> <td>Hematuria</td> <td class=\"centered\">94</td> </tr> <tr> <td>Nephrocalcinosis</td> <td class=\"centered\">42 to 74</td> </tr> <tr> <td>Nephrolithiasis</td> <td class=\"centered\">32 to 49</td> </tr> <tr> <td>Renal failure</td> <td class=\"centered\">64</td> </tr> <tr> <td>Rickets or osteomalacia</td> <td class=\"centered\">19 to 30</td> </tr> <tr> <td>Concentrating defect</td> <td class=\"centered\">81</td> </tr> <tr> <td>Amino aciduria</td> <td class=\"centered\">50 to 76</td> </tr> <tr> <td>Glycosuria</td> <td class=\"centered\">45 to 54</td> </tr> <tr> <td>Hypophosphatemia</td> <td class=\"centered\">50</td> </tr> <tr> <td>Hypokalemia</td> <td class=\"centered\">35 to 44</td> </tr> <tr> <td>Acidification defect</td> <td class=\"centered\">17</td> </tr> <tr> <td>Incomplete Fanconi syndrome</td> <td class=\"centered\">73</td> </tr> <tr> <td>Complete Fanconi syndrome</td> <td class=\"centered\">11</td> </tr> <tr> <td>Renal hypouricemia</td> <td class=\"centered\">63</td> </tr> <tr> <td>Failure to thrive</td> <td class=\"centered\">30</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LMW: low molecular weight.<br />* Excludes patients with reduced kidney function.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Scheinman SJ. Nephrolithiasis. Semin Nephrol 1999; 19:381.</li>&#xD;&#xA;    <li>Blanchard A, Curis E, Guyon-Roger T, et al. Observations of a large Dent disease cohort. Kidney Int 2016; 90:430.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 74862 Version 4.0</div></div></div>"},"74863":{"type":"graphic_figure","displayName":"Reverse breech extraction","title":"Reverse breech extraction","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Reverse breech extraction</div><div class=\"cntnt\"><img style=\"width:521px; height:401px;\" src=\"images/OBGYN/74863_Reverse_breech_method.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74863 Version 3.0</div></div></div>"},"74865":{"type":"graphic_algorithm","displayName":"Management of suspected meningitis in children","title":"Management algorithm for infants (≥1 month) and children with suspected bacterial meningitis","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Management algorithm for infants (&ge;1 month) and children with suspected bacterial meningitis</div><div class=\"cntnt\"><img style=\"width:488px; height:635px;\" src=\"images/PEDS/74865_Managementsuspectedmening.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">STAT: intervention should be performed emergently; CBC: complete blood count; PT: prothrombin time; PTT: partial thromboplastin time; BUN: blood urea nitrogen; CSF: cerebrospinal fluid; CNS: central nervous system.<br />* Antimicrobial therapy should not be delayed if lumbar puncture cannot be performed or is unsuccessful.<br />¶ Decisions regarding the administration of dexamethasone should be individualized depending on careful analysis of the risks and benefits as discussed in the text. Refer to UpToDate topic on the treatment and prognosis of acute bacterial meningitis in children.<br />Δ Empiric antibiotic therapy and dexamethasone (if warranted) should be administered immediately after cerebrospinal fluid is obtained; if dexamethasone is to be administered, it should be given before, or immediately after, the first dose of antimicrobial therapy.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</LI>&#xD;&#xA;<LI>Fleisher GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.792.</LI></OL></div><div id=\"graphicVersion\">Graphic 74865 Version 9.0</div></div></div>"},"74866":{"type":"graphic_figure","displayName":"BPH combination therapy","title":"Combination therapy for benign prostatic hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Combination therapy for benign prostatic hyperplasia</div><div class=\"cntnt\"><img style=\"width:566px; height:441px;\" src=\"images/PC/74866_BPH_combination_therapy_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean adjusted change in International Prostate Symptom Score (IPSS) from baseline by visit and treatment group.</div><div class=\"graphic_footnotes\">* p&lt;0.001 for combination versus dutasteride.<br> &#167; p&lt;0.001 for combination versus tamsulosin.</div><div class=\"graphic_reference\">Reproduced from: Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 74866 Version 2.0</div></div></div>"},"74867":{"type":"graphic_diagnosticimage","displayName":"Type III endoleak after endovascular aortic repair","title":"Type III endoleak after endovascular aortic repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type III endoleak after endovascular aortic repair</div><div class=\"cntnt\"><img style=\"width:260px; height:359px;\" src=\"images/CARD/74867_Type_III_endoleak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistence of blood flow into the aneurysm sac is seen (arrow). Angiography confirmed the presence of modular dissociation (type III endoleak).</div><div id=\"graphicVersion\">Graphic 74867 Version 3.0</div></div></div>"},"74868":{"type":"graphic_table","displayName":"CVS support resources","title":"Family support and informational resources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Family support and informational resources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Cyclic Vomiting Syndrome Association (CVSA)</td> </tr> <tr> <td class=\"indent1\"> <p>2819 W Highland Blvd, Milwaukee, WI 53208</p> <p>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">414-342-7880<a href=\"#\" title=\"Call: 414-342-7880\"><img alt=\"\" title=\"Call: 414-342-7880\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAABcklEQVR4XpXTPUvDUBTH4aR2c2hBQXGpTiIORhBcBOvgYKf0Awi+4Ggr1MVPIIrYdnEpShddHIyLi6AVXVxsRRDRwbi4KNgu4lCIv8i/i6QRDzycy+09555LqOl5nhEUptPoJe1iDHU8oYlrlDw79m4QEbSLPexzsIc8hDRm8YBjLpj4q8EgxQdab+MNd4ghhQ2adIc1+ORAFEnWWfTDRp7GDfImlsIavKALLuqoqMGUCs4wHtagiQ5uc8kDyCOBKlP1k78QNTOZnMXCQRxWsbjl6iuskV41SQG2Gj9rikvcR1WcgKFDBa1LOEUK56hqv8BUFV3SGWkVS9JQ6Dsv4wQ1DKMPORUvkm78BhdQMI1CTa5I0yrcwSFqFD+SZ7DQesIkCG5S/JpkHYERQRmuNsrZ7Grc+Ef8/Bcoslkfae8Wc7CUHZ++TuAEBj86pHntjaDKXllPy6PW/gkKFaThwp/K87N8hDcQTTKKFTioSxqB8Q2BNX5JtAljwgAAAABJRU5ErkJggg==\" /></a></span></p> <p>Fax: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">414-342-8980<a href=\"#\" title=\"Call: 414-342-8980\"><img alt=\"\" title=\"Call: 414-342-8980\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></p> <p>cvsa&#64;cvsaonline.org, www.cvsaonline.org</p> </td> </tr> <tr> <td class=\"subtitle2_left\">International Foundation for Functional Gastrointestinal Disorders (IFFGD)</td> </tr> <tr> <td class=\"indent1\"> <p>PO Box 170864, Milwaukee, WI 53217</p> <p>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">414-964-1799<a href=\"#\" title=\"Call: 414-964-1799\"><img alt=\"\" title=\"Call: 414-964-1799\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></p> <p>Children: http://www.aboutkidsgi.org</p> <p>Adults: http://www.iffgd.org</p> </td> </tr> <tr> <td class=\"subtitle2_left\">Migraine Awareness Group (MAGNUM)</td> </tr> <tr> <td class=\"indent1\"> <p>100 N Union St, Suite B, Alexandria,&nbsp;VA 22314</p> <p>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">703-349-1929<a href=\"#\" title=\"Call: 703-739-9384\"><img alt=\"\" title=\"Call: 703-739-9384\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></p> <p>www.migraines.org</p> </td> </tr> <tr> <td class=\"subtitle2_left\">National Organization for Rare Disorders</td> </tr> <tr> <td class=\"indent1\"> <p>55 Kenosia Ave, PO Box 1968, Danbury, CT 06810</p> <p>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">203-744-0100<a href=\"#\" title=\"Call: 203-744-0100\"><img alt=\"\" title=\"Call: 203-744-0100\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-999-6673<a href=\"#\" title=\"Call: 800-999-6673\"><img alt=\"\" title=\"Call: 800-999-6673\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></p> <p>TDD number: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">203-797-9590<a href=\"#\" title=\"Call: 203-797-9590\"><img alt=\"\" title=\"Call: 203-797-9590\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></p> <p>Fax: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">203-263-9938<a href=\"#\" title=\"Call: 203-798-2291\"><img alt=\"\" title=\"Call: 203-798-2291\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></p> <p>www.nord-rdb.com</p> </td> </tr> <tr> <td class=\"subtitle2_left\">United Mitochondrial Disease Foundation</td> </tr> <tr> <td class=\"indent1\"> <p>8085 Saltsburg Road, Suite 201, Pittsburgh,&nbsp;PA 15239</p> <p>Phone: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">412-793-8077<a href=\"#\" title=\"Call: 412-793-8077\"><img alt=\"\" title=\"Call: 412-793-8077\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAABcklEQVR4XpXTPUvDUBTH4aR2c2hBQXGpTiIORhBcBOvgYKf0Awi+4Ggr1MVPIIrYdnEpShddHIyLi6AVXVxsRRDRwbi4KNgu4lCIv8i/i6QRDzycy+09555LqOl5nhEUptPoJe1iDHU8oYlrlDw79m4QEbSLPexzsIc8hDRm8YBjLpj4q8EgxQdab+MNd4ghhQ2adIc1+ORAFEnWWfTDRp7GDfImlsIavKALLuqoqMGUCs4wHtagiQ5uc8kDyCOBKlP1k78QNTOZnMXCQRxWsbjl6iuskV41SQG2Gj9rikvcR1WcgKFDBa1LOEUK56hqv8BUFV3SGWkVS9JQ6Dsv4wQ1DKMPORUvkm78BhdQMI1CTa5I0yrcwSFqFD+SZ7DQesIkCG5S/JpkHYERQRmuNsrZ7Grc+Ef8/Bcoslkfae8Wc7CUHZ++TuAEBj86pHntjaDKXllPy6PW/gkKFaThwp/K87N8hDcQTTKKFTioSxqB8Q2BNX5JtAljwgAAAABJRU5ErkJggg==\" /></a></span></p> <p>www.umdf.org</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright © 2008 Lippincott Williams &amp; Wilkins. Contact information current as of February 2018.</div><div id=\"graphicVersion\">Graphic 74868 Version 10.0</div></div></div>"},"74870":{"type":"graphic_figure","displayName":"Stretching exercises PI","title":"Stretching exercises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stretching exercises</div><div class=\"cntnt\"><img style=\"width:276px; height:412px;\" src=\"images/PI/74870_Stretching_exercises_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Back stretch.<br />(B) Shoulder shrug.<br />(C) Neck stretch.<br />(D) Arm circles.<br />(E) Standing groin stretch.<br />(F) Calf stretch.<br />(G) Modified sit-up.<br />(H) Hamstring stretch.<br />(I) Sitting groin stretch.<br />(J) Side stretch.<br />(K) Quadricep stretch.</div><div id=\"graphicVersion\">Graphic 74870 Version 3.0</div></div></div>"},"74872":{"type":"graphic_table","displayName":"Vasopressors in septic shock","title":"Vasoactive agents in septic shock","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vasoactive agents in septic shock</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Effect on heart rate</td> <td class=\"subtitle1\">Effect on contractility</td> <td class=\"subtitle1\">Arterial constriction effects</td> </tr> <tr> <td>Dobutamine</td> <td>+</td> <td>+++</td> <td>- (dilates)</td> </tr> <tr> <td>Dopamine</td> <td>++</td> <td>++</td> <td>++</td> </tr> <tr> <td>Epinephrine</td> <td>+++</td> <td>+++</td> <td>++</td> </tr> <tr> <td>Norepinephrine</td> <td>++</td> <td>++</td> <td>+++</td> </tr> <tr> <td>Phenylephrine</td> <td>0</td> <td>0</td> <td>+++</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74872 Version 2.0</div></div></div>"},"74874":{"type":"graphic_picture","displayName":"Cutaneous anthrax with lymphangitis","title":"Cutaneous anthrax with lymphangitis","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Cutaneous anthrax with lymphangitis</div><div class=\"cntnt\"><img style=\"width:599px; height:396px;\" src=\"images/ID/74874_Cute_anthrax_lymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Necrotic wound with associated erythema and edema of the right forearm of a patient with cutaneous anthrax.<br> (B) Lymphangitis with an associated bulla and serous discharge of the medial right arm of the same patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Cinquetti G, Banal F, Dupuy A-L, et al. Three related cases of cutaneous anthrax in France. Medicine 2009; 88:371. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74874 Version 6.0</div></div></div>"},"74875":{"type":"graphic_table","displayName":"Time at which PCI loses survival superiority over fibrinolysis","title":"Time at which PCI loses superiority in survival over fibrinolysis varies depending upon patient risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Time at which PCI loses superiority in survival over fibrinolysis varies depending upon patient risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Pre-hospital delay (minutes)</td> <td class=\"subtitle1\" colspan=\"2\">Age &#60;65 years</td> <td class=\"subtitle1\" colspan=\"2\">Age &#8805;65 years</td> </tr> <tr> <td class=\"subtitle2\">Anterior infarction</td> <td class=\"subtitle2\">Non-anterior infarction</td> <td class=\"subtitle2\">Anterior infarction</td> <td class=\"subtitle2\">Non-anterior infarction</td> </tr> <tr> <td>0-120</td> <td>40&nbsp;minutes</td> <td>58 minutes</td> <td>107 minutes</td> <td>168 minutes</td> </tr> <tr> <td>121+</td> <td>43&nbsp;minutes</td> <td>103 minutes</td> <td>148 minutes</td> <td>179 minutes</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114:2019. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74875 Version 10.0</div></div></div>"},"74877":{"type":"graphic_table","displayName":"Causes of obstruction","title":"Causes and locations of urinary tract obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and locations of urinary tract obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Location</td>\n\t\t\t\t\t<td class=\"subtitle1\">Causes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" rowspan=\"3\">Kidney</td>\n\t\t\t\t\t<td>Stones</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Transitional call carcinoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sloughed papilla</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" rowspan=\"10\">Ureter</td>\n\t\t\t\t\t<td>Stones</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Transitional call carcinoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sloughed papilla</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Extrinsic tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Retroperitoneal fibrosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Infection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Obstructed stent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Blood clot</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Trauma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ectopia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" rowspan=\"5\">Bladder</td>\n\t\t\t\t\t<td>Transitional call carcinoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Blood clot</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Edema/inflammation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bladder dysfunction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Posterior urethral valves</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" rowspan=\"3\">Urethra</td>\n\t\t\t\t\t<td>Prostatic enlargement</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Stones</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Stricture</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 74877 Version 1.0</div></div></div>"},"74881":{"type":"graphic_table","displayName":"Arterial needle catheter size","title":"Arterial needle and catheter sizes by site and body weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Arterial needle and catheter sizes by site and body weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Artery</td> <td class=\"subtitle1\" colspan=\"2\">&#60;10 kg</td> <td class=\"subtitle1\" colspan=\"2\">10-40 kg</td> <td class=\"subtitle1\" colspan=\"2\">&#62;40 kg</td> </tr> <tr> <td class=\"subtitle2\">Needle/catheter size*</td> <td class=\"subtitle2\">French size</td> <td class=\"subtitle2\">Needle/catheter size*</td> <td class=\"subtitle2\">French size</td> <td class=\"subtitle2\">Needle/catheter size*</td> <td class=\"subtitle2\">French size</td> </tr> <tr> <td>Radial, posterior tibial, dorsalis pedis, or brachial</td> <td>25 or 23 / 24 or 22</td> <td>&nbsp;</td> <td>23 / 22</td> <td>&nbsp;</td> <td>23 or 21 / 22 or 20</td> <td>&nbsp;</td> </tr> <tr> <td>Femoral or axillary</td> <td>23 / 20 or 18</td> <td>3.0-4.0</td> <td>23 or 21 / 18 or 16</td> <td>4.0-5.0</td> <td>21 &nbsp;/ 18, 16, or 14</td> <td>5.0-6.0</td> </tr> <tr> <td>Umbilical</td> <td>&nbsp;</td> <td>3.5-5.0</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Needle and catheter sizes refer to gauge.</div><div class=\"graphic_reference\">Adapted from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.715.</div><div id=\"graphicVersion\">Graphic 74881 Version 3.0</div></div></div>"},"74882":{"type":"graphic_figure","displayName":"Dorsalis pedis arterial puncture site","title":"Dorsalis pedis arterial puncture site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsalis pedis arterial puncture site</div><div class=\"cntnt\"><img style=\"width:306px; height:590px;\" src=\"images/EM/74882_DorspedisartpuncsitePR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The site for arterial puncture of the dorsalis pedis artery is shown.</div><div class=\"graphic_reference\">Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74882 Version 6.0</div></div></div>"},"74883":{"type":"graphic_table","displayName":"Cardiac alterations in obesity","title":"Comparison of cardiac structural and hemodynamic alterations in patients with morbid obesity and hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of cardiac structural and hemodynamic alterations in patients with morbid obesity and hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Obesity alone</td> <td class=\"subtitle1\">Hypertension alone</td> <td class=\"subtitle1\">Obesity&nbsp;and hypertension</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Variable</td> </tr> <tr> <td class=\"indent1\">Heart rate </td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td class=\"indent1\">Blood pressure</td> <td>Normal</td> <td>Increased</td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">Stroke volume</td> <td>Increased</td> <td>Normal</td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">Cardiac output</td> <td>Increased</td> <td>Normal</td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">Systemic vascular resistance&nbsp;</td> <td>Decreased</td> <td>Increased</td> <td>Normal or increased</td> </tr> <tr> <td class=\"indent1\">LV volume</td> <td>Increased</td> <td>Normal</td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">LV wall stress</td> <td>Normal or increased</td> <td>Normal or increased</td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">LV hypertrophy</td> <td>Eccentric</td> <td>Concentric</td> <td>Hybrid</td> </tr> <tr> <td class=\"indent1\">LV diastolic dysfunction</td> <td>Usually present</td> <td>Usually present</td> <td>Usually present</td> </tr> <tr> <td class=\"indent1\">LV systolic dysfunction</td> <td>Occasionally present</td> <td>Usually absent</td> <td>Occasionally present</td> </tr> <tr> <td class=\"indent1\">LV failure</td> <td>Occasionally present</td> <td>Occasionally present</td> <td>Commonly present</td> </tr> <tr> <td class=\"indent1\">RV hypertrophy</td> <td>Occasionally present</td> <td>Usually absent</td> <td>Occasionally present</td> </tr> <tr> <td class=\"indent1\">RV enlargement</td> <td>Occasionally present</td> <td>Usually absent</td> <td>Occasionally present</td> </tr> <tr> <td class=\"indent1\">RV failure</td> <td>Occasionally present</td> <td>Usually absent</td> <td>Occasionally present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LV: left ventricular; RV: right ventricular.</div><div class=\"graphic_reference\">Adapted from: Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993; 306:117.</div><div id=\"graphicVersion\">Graphic 74883 Version 3.0</div></div></div>"},"74885":{"type":"graphic_waveform","displayName":"Advanced case 11 with answer","title":"Atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Atrial septal defect</div><div class=\"cntnt\"><img style=\"width:540px; height:244px;\" src=\"images/CARD/74885_Advancedcase11withanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with a large atrial septal defect (3:1 left-to-right shunt). There is a right ventricular conduction delay with right axis deviation due to right ventricular hypertrophy. (qR complexes are sometimes seen in leads V1 and V2 with right-sided chamber enlargement). The tall P waves in V2 and V3 are due to right atrial enlargement. In comparison, mitral stenosis is associated with right ventricular hypertrophy plus left (not right) atrial enlargement.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 74885 Version 3.0</div></div></div>"},"74886":{"type":"graphic_figure","displayName":"Megakaryocyte development","title":"Origin and development of megakaryocytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Origin and development of megakaryocytes</div><div class=\"cntnt\"><img style=\"width:398px; height:392px;\" src=\"images/HEME/74886_Megakaryocyte_development.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the origin and development of megakaryocytes. The multipotent stem cell produces a progenitor cell committed to megakaryocyte differentiation (Meg-CFC) which undergoes mitosis. The Meg-CFC eventually stops mitosis and enters endomitosis, during which neither cytoplasm nor nucleus divides but DNA replication proceeds and gives rise to polyploid immature precursor cells. Upon completion of endomitosis, the immature progenitor cells become large, morphologically identifiable mature megakaryocytes that shed platelets.</div><div class=\"graphic_reference\">Courtesy of David J Kuter, MD, PhD.</div><div id=\"graphicVersion\">Graphic 74886 Version 2.0</div></div></div>"},"74888":{"type":"graphic_table","displayName":"Promotion of language literacy","title":"Suggestions for enhancing a child's language and literacy skills before kindergarten entry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggestions for enhancing a child's language and literacy skills before kindergarten entry</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Parents are encouraged to provide repeated experiences in development of the following areas:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Expressive and receptive language readiness skills:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle3_single\">\r\n  \r\n   Understand and express the following linguistic concepts:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Quality: Show me the one that is the same. Show me the one that is different.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Quantity: Which coat has more/fewer/the most buttons?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3_start\">\r\n  \r\n   Position words:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3\">\r\n  \r\n   Put the book on the lower shelf.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3\">\r\n  \r\n   Show me the boy farthest from the tree.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3\">\r\n  \r\n   Show me the boy nearest to the tree.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3\">\r\n  \r\n   (Other positions are in front of, behind, ahead of, first, last, etc.)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Direction words: Take the doll up the ladder. Take the doll down the ladder.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Time words: Before I clap my hands, stand up.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Verb tense, passive: Show me: The truck was hit by the car.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle3_single\">\r\n  \r\n   Identify the sound patterns of words\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Rhyming words\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Rhyming sentences\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Nursery rhymes\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3_start\">\r\n  \r\n   Alliteration: Sister Suzie is sitting by the seashore sifting sand...\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist3\">\r\n  \r\n   What is the common sound?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle3_single\">\r\n  \r\n   Understand and re-tell narrative stories\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Reading readiness skills\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Recognize the meaning of common signs and symbols in the environment\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Sing the ABC song\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Develop an awareness of print\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Show me the title.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Show me where I should begin reading.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   What story do the pictures tell?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Show me where the story ends.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Show me how to turn the pages.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Writing readiness skills\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Hold a pencil or crayon with an appropriate grasp\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Assemble multi-piece wooden and cardboard puzzles of people, animals, forms, numbers, or letters\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Create models of airplanes, prehistoric animals, cars, etc.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Use crayons or a pencil to draw, follow the dots, or solve maze tasks\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Copy patterns using beads on a string, a pegboard, or parquetry blocks\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Use wooden or plastic blocks to match geometric shapes and build copies of models\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Find shapes or designs in a picture\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Copy geometric configurations with rubber bands stretched between rows of nails on a board\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 74888 Version 1.0</div></div></div>"},"74889":{"type":"graphic_diagnosticimage","displayName":"ETT overinflation CT","title":"Computed tomographic scans of the chest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomographic scans of the chest</div><div class=\"cntnt\"><img style=\"width:376px; height:524px;\" src=\"images/PULM/74889_ETT_overinflation_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper image shows an endotracheal tube (ETT) at the level of the mid-trachea; the wide ring of air surrounding the tube suggests ETT cuff over-inflation, a risk factor for iatrogenic tracheal injury. The lower image demonstrates a focal injury to the posterior tracheal wall and herniation of the cuff into the posterior mediastinum.</div><div id=\"graphicVersion\">Graphic 74889 Version 3.0</div></div></div>"},"74891":{"type":"graphic_figure","displayName":"Activation TPO receptor","title":"Activation of the TPO receptor","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Activation of the TPO receptor</div><div class=\"cntnt\"><img style=\"width:516px; height:453px;\" src=\"images/HEME/74891_Activation_TPO_receptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TPO receptor has been proposed to exist as an inactive preformed dimer (left) with a proximal (HRD-1) and distal (HRD-2) hematopoietic receptor domain (HRD). Upon binding of thrombopoietin to the distal HRD-2, the receptor (right) conformation changes and a number of signal transduction pathways are activated that increase platelet production.</div><div class=\"graphic_reference\">Illustration by Paulette Dennis. This research was originally published in Blood. Kuter, DJ. New thrombopoietic growth factors. Blood 2007; 109:4607. Copyright &#169; 2007 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 74891 Version 1.0</div></div></div>"},"74892":{"type":"graphic_picture","displayName":"Infantile psoriasis","title":"Infantile psoriasis of the diaper area","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile psoriasis of the diaper area</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/74892_Infantile_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply defined plaques with silvery scales in an infant with psoriasis of the diaper area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74892 Version 4.0</div></div></div>"},"74893":{"type":"graphic_picture","displayName":"Polyarteritis nodosa - light micrograph","title":"Polyarteritis nodosa","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/74893_Polyarteritis_nodosa_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a small muscular renal artery in polyarteritis nodosa. There is diffuse inflammation of the adventitia and marked thickening of the inner layers by loose connective tissue (arrows). The lumen (L) is significantly narrowed. Involvement of a vessel this large would be unusual in microscopic polyarteritis or granulomatosis with polyangiitis (Wegener's).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 74893 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"74894":{"type":"graphic_table","displayName":"EORTC progn groups mesothelioma","title":"Prognostic indices of survival for advanced mesothelioma in EORTC studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic indices of survival for advanced mesothelioma in EORTC studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">EORTC studies</td> </tr> <tr> <td class=\"subtitle2\">Study</td> <td class=\"subtitle2\">Response (percent)</td> <td class=\"subtitle2\" colspan=\"3\">MST (months)</td> </tr> <tr> <td class=\"indent1\">Mitoxantrone</td> <td>2.4 </td> <td colspan=\"3\">7.5</td> </tr> <tr> <td class=\"indent1\">Epidoxorubicin</td> <td>13.5</td> <td colspan=\"3\">8.9</td> </tr> <tr> <td class=\"indent1\">Etoposide (IV)</td> <td>4.2</td> <td colspan=\"3\">6.7</td> </tr> <tr> <td class=\"indent1\">Etoposide (PO)</td> <td>7.3</td> <td colspan=\"3\">8.7</td> </tr> <tr> <td class=\"indent1\">Paclitaxel</td> <td>0</td> <td colspan=\"3\">9.3</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Poor prognostic factors in multivariate analysis</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;<br /> </td> <td class=\"subtitle2\">Variable</td> <td class=\"subtitle2\" colspan=\"3\">MST (months)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Performance status (PS)</td> <td>Good (0)</td> <td colspan=\"3\">10.7</td> </tr> <tr> <td>Poor (1-2)</td> <td colspan=\"3\">7.2</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">WBC count</td> <td>High (&#62;8.3)</td> <td colspan=\"3\">6</td> </tr> <tr> <td>Low (&#60;8.3)</td> <td colspan=\"3\">10.4</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hemoglobin difference*</td> <td>High (&#62;1 g/dL)</td> <td colspan=\"3\">7.3</td> </tr> <tr> <td>Low (&#60;1 g/dL)</td> <td colspan=\"3\">9.6</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Histologic diagnosis</td> <td>Definite</td> <td colspan=\"3\">9.8</td> </tr> <tr> <td>Possible</td> <td colspan=\"3\">6</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Sarcomatous subtype</td> <td>Present</td> <td colspan=\"3\">5</td> </tr> <tr> <td>Other subtype</td> <td colspan=\"3\">8.4-9.1</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"5\">EORTC prognostic groups</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Group characteristics</td> <td class=\"subtitle2\">MST (months)</td> <td class=\"subtitle2\">1 yr OS</td> <td class=\"subtitle2\">2 yr OS</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><strong>Low risk</strong> (prognostic score &#60;1.27)</td> <td class=\"sublist_other_start\" rowspan=\"2\">10.8</td> <td class=\"sublist_other_start\" rowspan=\"2\">40 percent</td> <td class=\"sublist_other_start\" rowspan=\"2\">14 percent</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Equivalent to having 0-2 poor prognostic factors</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><strong>High risk </strong>(prognostic score &#62;1.27)</td> <td class=\"sublist_other_start\" rowspan=\"2\">5.5</td> <td class=\"sublist_other_start\" rowspan=\"2\">12 percent</td> <td class=\"sublist_other_start\" rowspan=\"2\">0 percent</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Equivalent to having three or more poor prognostic factors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EORTC: European Organization for Research and Treatment of Cancer; MST: median survival time; WBC: white blood cell count, X 1000/microL.<br />*&nbsp;The difference relative to 16 g/dL in males and 14 g/dL in females.</div><div id=\"graphicVersion\">Graphic 74894 Version 2.0</div></div></div>"},"74895":{"type":"graphic_figure","displayName":"Blood pressure algorithm","title":"Blood pressure algorithm","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Blood pressure algorithm</div><div class=\"cntnt\"><img style=\"width:499px; height:142px;\" src=\"images/PEDS/74895_Blood_pressure_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arterial blood pressure is the product of cardiac output and systemic vascular resistance. Cardiac output is the volume of blood ejected by the heart each minute; it is the product of heart rate and stroke volume. The stroke volume is the volume of blood ejected by the ventricles with each contraction; it is affected by myocardial contractility, preload, and afterload.</div><div id=\"graphicVersion\">Graphic 74895 Version 1.0</div></div></div>"},"74896":{"type":"graphic_table","displayName":"Diagnostic criteria ADEM in children","title":"Diagnostic criteria of acute disseminated encephalomyelitis (ADEM) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria of acute disseminated encephalomyelitis (ADEM) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features (all are required)</td> </tr> <tr> <td class=\"indent1\">A first polyfocal, clinical central nervous system event with presumed inflammatory demyelinating cause</td> </tr> <tr> <td class=\"indent1\">Encephalopathy that cannot be explained by fever, systemic illness, or postictal symptoms</td> </tr> <tr> <td class=\"indent1\">No new clinical and MRI findings emerge three months or more after the onset</td> </tr> <tr> <td class=\"indent1\">Brain MRI is abnormal during the acute (three-month) phase</td> </tr> <tr> <td class=\"subtitle1_single\">Lesion characteristics on brain MRI</td> </tr> <tr> <td class=\"indent1\">Diffuse, poorly demarcated, large (&#62;1 to 2 cm) lesions involving predominantly the cerebral white matter</td> </tr> <tr> <td class=\"indent1\">Deep gray matter lesions (eg, involving the basal ganglia or thalamus) can be present</td> </tr> <tr> <td class=\"indent1\">T1 hypointense lesions in the white matter are rare</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The clinical features of ADEM typically follow a monophasic disease course, although they can fluctuate in severity and evolve in the first three months following disease onset. <STRONG>Multiphasic ADEM</STRONG> is defined as two episodes consistent with ADEM separated by three months but not followed by any further events. The second ADEM event can involve either new or a re-emergence of prior neurologic symptoms, signs and MRI findings.</div><div class=\"graphic_reference\">Adapted from: Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19:1261.</div><div id=\"graphicVersion\">Graphic 74896 Version 4.0</div></div></div>"},"74897":{"type":"graphic_figure","displayName":"Pathogenesis of NEC","title":"Contributing mechanisms to the pathogenesis of necrotizing enterocolitis in neonates","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Contributing mechanisms to the pathogenesis of necrotizing enterocolitis in neonates</div><div class=\"cntnt\"><img style=\"width:554px; height:633px;\" src=\"images/PEDS/74897_Pathogenesis_of_NEC.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Kliegman RM, Pediatr Res 1993; 34:701.</div><div id=\"graphicVersion\">Graphic 74897 Version 3.0</div></div></div>"},"74899":{"type":"graphic_figure","displayName":"Superior mesenteric artery syndrome","title":"Superior mesenteric artery syndrome","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Superior mesenteric artery syndrome</div><div class=\"cntnt\"><img style=\"width:531px; height:635px;\" src=\"images/SURG/74899_Normal-SMA-AP-view_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superior mesenteric artery arises from the anterior aspect of the aorta at the level of the L1 vertebral body. It is enveloped in fatty and lymphatic tissue and extends in a caudal direction at an acute angle into the mesentery. In the majority of patients, the normal angle between the superior mesenteric artery and the aorta is between 38 and 65 degrees.&nbsp;Superior mesenteric artery syndrome is characterized by compression of the third portion of the duodenum due to narrowing of the space between the superior mesenteric artery and aorta and is primarily attributed to loss of the intervening mesenteric fat pad.&nbsp;With superior mesenteric artery syndrome, the angle between the superior mesenteric artery and the aorta can be narrowed to as little as 6 degrees.</div><div id=\"graphicVersion\">Graphic 74899 Version 4.0</div></div></div>"},"74901":{"type":"graphic_picture","displayName":"Macro-ovalocytes","title":"Macro-ovalocytes in vitamin B12 deficiency","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macro-ovalocytes in vitamin B12 deficiency</div><div class=\"cntnt\"><img style=\"width:394px; height:256px;\" src=\"images/HEME/74901_Macroovalocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear shows marked macro-ovalocytosis in a patient with vitamin B12 deficiency. In this case, teardrop cells are an advanced form of macro-ovalocytes.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 74901 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"74903":{"type":"graphic_figure","displayName":"Radial artery catheterization techniques","title":"Radial artery catheterization techniques","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Radial artery catheterization techniques</div><div class=\"cntnt\"><img style=\"width:501px; height:703px;\" src=\"images/SURG/74903_Radial_artery_catheterization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Separate-guidewire approach*:</STRONG> The nondominant hand palpates the artery while the dominant hand manipulates the catheter, which is inserted and advanced slowly until pulsatile blood return is observed. The catheter is advanced slightly, ensuring the outer catheter has also entered the lumen. Care must be taken to avoid puncturing the posterior wall of the vessel when advancing the catheter. The nondominant hand then stabilizes the catheter while the dominant hand removes the needle from the intravascular catheter. If pulsatile blood return is observed after the needle is removed, the guidewire is advanced until its tip is beyond the distal end of the catheter. Finally, the catheter is advanced into the artery over the guidewire and the guidewire is removed.<BR><STRONG>Integral-guidewire approach*:</STRONG> The guidewire of this specialized device is integrated with the needle and catheter. The nondominant hand palpates the artery, while the dominant hand manipulates the needle-guidewire-catheter unit, which is inserted and advanced slowly until pulsatile blood return is observed. The nondominant hand then stabilizes the needle-guidewire-catheter unit, while the dominant hand advances the guidewire tab to push the wire into and through the needle and catheter. The outer catheter is advanced over the needle and wire into the artery. Finally, the needle-guidewire unit is removed.</div><div class=\"graphic_footnotes\">* For illustration purposes, full barrier precautions are not pictured.</div><div id=\"graphicVersion\">Graphic 74903 Version 6.0</div></div></div>"},"74904":{"type":"graphic_picture","displayName":"Thumb spica cast 1","title":"Thumb spica cast: Step 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 1</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/EM/74904_Thumb_spica_cast_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First, place a piece of stockinette or similar material over the thumb.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 74904 Version 4.0</div></div></div>"},"74905":{"type":"graphic_picture","displayName":"Morgan lens insertion","title":"Insertion of Morgan® lens","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Insertion of Morgan&#174; lens</div><div class=\"cntnt\"><img style=\"width:552px; height:308px;\" src=\"images/EM/74905_Morgan_lens_insert.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Solution acts as a cushion, suspending the Lens above the cornea and protecting injured surfaces from the eyelids.</div><div class=\"graphic_reference\">Reproduced with permission from: MorTan, Inc. Copyright &#169; 2009.</div><div id=\"graphicVersion\">Graphic 74905 Version 4.0</div></div></div>"},"74906":{"type":"graphic_picture","displayName":"AIP phlebitis Light LP","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/74906_AIP_phlebitis_Light_LP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a pancreas biopsy in a patient with autoimmune pancreatitis. Obliterative phlebitis is present focally (arrow).</div><div class=\"graphic_reference\">Courtesy of Russell Dorer, MD.</div><div id=\"graphicVersion\">Graphic 74906 Version 1.0</div></div></div>"},"74909":{"type":"graphic_figure","displayName":"Protamine reversal in HD","title":"Schematic diagram showing protamine reversal regimen for regional anticoagulation in hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Schematic diagram showing protamine reversal regimen for regional anticoagulation in hemodialysis</div><div class=\"cntnt\"><img style=\"width:530px; height:427px;\" src=\"images/NEPH/74909_Protamine_reversal_in_HD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of protamine reversal regimen for regional anticoagulation during hemodialysis. Protamine is infused into the venous return line to lower the ACT to its predialysis baseline level.</div><div class=\"graphic_footnotes\">ACT: activated clotting time.</div><div id=\"graphicVersion\">Graphic 74909 Version 5.0</div></div></div>"},"74910":{"type":"graphic_figure","displayName":"McRoberts maneuver and suprapubic pressure","title":"McRoberts maneuver and suprapubic pressure","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">McRoberts maneuver and suprapubic pressure</div><div class=\"cntnt\"><img style=\"width:540px; height:406px;\" src=\"images/OBGYN/74910_McRoberts_maneuv_and_supr_p.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An assistant applies pressure suprapubically with the palm or fist, directing the pressure on the anterior shoulder both downward (to below the pubic bone) and laterally (toward the baby's face or sternum), and in conjunction with the McRoberts maneuver. Suprapubic pressure is supposed to adduct the shoulders or bring them into an oblique plane, since the oblique diameter is the widest diameter of the maternal pelvis. It is most useful in mild cases and those caused by an impacted anterior shoulder.</div><div id=\"graphicVersion\">Graphic 74910 Version 5.0</div></div></div>"},"74913":{"type":"graphic_diagnosticimage","displayName":"Sequestration CT II","title":"Intralobar sequestration right lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration right lower lobe</div><div class=\"cntnt\"><img style=\"width:396px; height:332px;\" src=\"images/PULM/74913_Sequestration_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a right basal multicystic mass with systemic arterial supply.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 74913 Version 4.0</div></div></div>"},"74914":{"type":"graphic_table","displayName":"Classification of iodine status","title":"Classification of iodine status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of iodine status</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Median urinary iodine concentration (mcg/L)</td> <td class=\"subtitle1\">Corresponding approximate iodine intake (mcg/day)</td> <td class=\"subtitle1\">Iodine nutrition</td> </tr> <tr> <td>&#60;20</td> <td>&#60;30</td> <td>Severe deficiency</td> </tr> <tr> <td>20-49</td> <td>30-74</td> <td>Moderate deficiency</td> </tr> <tr> <td>50-99</td> <td>75-149</td> <td>Mild deficiency</td> </tr> <tr> <td>100-199*</td> <td>150-299</td> <td>Optimal</td> </tr> <tr> <td>200-299</td> <td>300-449</td> <td>More than adequate</td> </tr> <tr> <td>&#62;299</td> <td>&#62;449</td> <td>Possible excess</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For pregnant women, urinary iodine concentrations of 150 to 249 mcg/L are considered adequate.</div><div class=\"graphic_reference\">Reproduced with permission from: ICCIDD.</div><div id=\"graphicVersion\">Graphic 74914 Version 4.0</div></div></div>"},"74915":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis AGA","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:329px; height:338px;\" src=\"images/PEDS/74915_Derm_herp_AGA_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A skin blister on the elbow of a subject with dermatitis herpetiformis.</div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association. Ciclitira PJ. Gastroenterology 2001; 120:1526.</div><div id=\"graphicVersion\">Graphic 74915 Version 5.0</div></div></div>"},"74916":{"type":"graphic_figure","displayName":"Peptide hormone binding","title":"Peptide hormone binding","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Peptide hormone binding</div><div class=\"cntnt\"><img style=\"width:473px; height:265px;\" src=\"images/GAST/74916_Peptide_hormone_binding.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A peptide hormone in the extracellular space binds to a cell-surface specific receptor, causing stimulation of the cell. As an example, the signal produced by secretin, a peptide hormone, would be transduced to the inside of the cell by binding to specific secretin receptors on the cell surface.</div><div class=\"graphic_reference\">Courtesy of Michael A Shetzline, MD, PhD and Rodger A Liddle, MD.</div><div id=\"graphicVersion\">Graphic 74916 Version 3.0</div></div></div>"},"74918":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of breast cancer recurrence","title":"Breast MRI of breast cancer recurrence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast MRI of breast cancer recurrence</div><div class=\"cntnt\"><img style=\"width:366px; height:658px;\" src=\"images/SURG/74918_Breast_MRI_br_cx_recurrence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be used to differentiate postoperative scarring from breast cancer recurrence. This series depicts a patient with a prior history of right lumpectomy for invasive carcinoma who presented for annual mammography.<br />(A) The mammogram shows a new irregular mass posterior to the lumpectomy bed in the posterior central right breast (arrow).<br />(B) Sagital MRI images demonstrate a low signal mass in the posterior inferior right breast on the T2-weighted MRI image and on the pre-gadolinium enhanced T1-weighted image.<br />(C) Subtraction of the pre and post contrast sagittal T1-weighted images of the right breast shows an enhancing mass in the posterior central right breast confirming suspicion for recurrence. Biopsy revealed recurrent invasive ductal carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 74918 Version 4.0</div></div></div>"},"74919":{"type":"graphic_figure","displayName":"Amsler grid PI","title":"Amsler grid","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Amsler grid</div><div class=\"cntnt\"><img style=\"width:505px; height:573px;\" src=\"images/PI/74919_Amsler_grid_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When people with wet age-related macular degeneration (AMD) look at straight lines, the lines actually look bent or wavy. Doctors often test people's vision by asking them to look at a grid of straight lines like this one.</div><div class=\"graphic_reference\">Reproduced from: Age-Related Macular Degeneration: What You Should Know. U.S. Department of Health and Human Services. Available at: http://www.nei.nih.gov/health/maculardegen/nei_wysk_amd.PDF.</div><div id=\"graphicVersion\">Graphic 74919 Version 2.0</div></div></div>"},"74920":{"type":"graphic_diagnosticimage","displayName":"Bamboo spine in ankylosing spondylitis","title":"Bamboo spine in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bamboo spine in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:319px; height:525px;\" src=\"images/RHEUM/74920_Bamboo_spine_ankyl_spondyl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph shows continuous fusion of the lumbar spine and lateral fusion of the sacroiliac joints.</div><div class=\"graphic_reference\">Courtesy of Sheng Guang Li, PLA Hospital, China.</div><div id=\"graphicVersion\">Graphic 74920 Version 4.0</div></div></div>"},"74921":{"type":"graphic_table","displayName":"Thallium 201 protocols","title":"Thallium-201 protocols for viability detection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thallium-201 protocols for viability detection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>1. Stress - 4 hour redistribution</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Stress - 4 hour redistribution, late-delayed imaging</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Stress - 4 hour redistribution, rest reinjection and immediate imaging</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Rest - 4 hour redistribution</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 74921 Version 1.0</div></div></div>"},"74922":{"type":"graphic_picture","displayName":"Hyperpigmentation in Addison's disease","title":"Hyperpigmentation in Addison's disease","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Hyperpigmentation in Addison's disease</div><div class=\"cntnt\"><img style=\"width:584px; height:414px;\" src=\"images/ENDO/74922_Hyperpigment_Addisons_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 57-year-old woman presented with symptoms of primary adrenal insufficiency secondary to autoimmune Addison's disease. Diffuse skin hyperpigmentation had developed during the last year, as illustrated by her facial appearance.<br />(B) The hands demonstrate increased pigmentation of the palmar creases and wrists compared to a normal female control (far right).<br />(C) With long-term glucocorticoid and mineralocorticoid therapy, her hyperpigmentation resolved, as shown by the normal palmar skin pigmentation in the patient at age 83.<br />Of note, she wears a medical bracelet indicating her requirement for glucocorticoids in case of severe illness.</div><div class=\"graphic_reference\">Courtesy of André Lacroix, MD.</div><div id=\"graphicVersion\">Graphic 74922 Version 3.0</div></div></div>"},"74923":{"type":"graphic_table","displayName":"Side effects of drugs for diabetic neuropathy","title":"Side effects of drugs used for diabetic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects of drugs used for diabetic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Side effect</td> <td class=\"subtitle1\">Amitriptyline</td> <td class=\"subtitle1\">Desipramine</td> <td class=\"subtitle1\">Fluoxetine</td> <td class=\"subtitle1\">Placebo</td> </tr> <tr> <td>Dry mouth</td> <td class=\"centered\">63</td> <td class=\"centered\">32</td> <td class=\"centered\">11</td> <td class=\"centered\">35</td> </tr> <tr> <td>Fatigue</td> <td class=\"centered\">34</td> <td class=\"centered\">34</td> <td class=\"centered\">13</td> <td class=\"centered\">17</td> </tr> <tr> <td>Headache</td> <td class=\"centered\">21</td> <td class=\"centered\">11</td> <td class=\"centered\">24</td> <td class=\"centered\">9</td> </tr> <tr> <td>Constipation</td> <td class=\"centered\">8</td> <td class=\"centered\">21</td> <td class=\"centered\">2</td> <td class=\"centered\">7</td> </tr> <tr> <td>Palpitations</td> <td class=\"centered\">13</td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> </tr> <tr> <td>Any symptoms</td> <td class=\"centered\">81</td> <td class=\"centered\">76</td> <td class=\"centered\">63</td> <td class=\"centered\">68</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Percentage of patients reporting side effects during treatment with amitripyline, desipramine, fluoxetine, or placebo.</div><div id=\"graphicVersion\">Graphic 74923 Version 3.0</div></div></div>"},"74924":{"type":"graphic_diagnosticimage","displayName":"Gastric pseudomass","title":"Fetal gastric pseudomass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal gastric pseudomass</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/74924_Gastric_pseudomass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of fetal abdomen at gestational age of 19 weeks shows echogenic debris (arrow) within the stomach.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 74924 Version 2.0</div></div></div>"},"74926":{"type":"graphic_figure","displayName":"Thoracic dermatomes PI","title":"Thoracic dermatomes","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Thoracic dermatomes</div><div class=\"cntnt\"><img style=\"width:539px; height:447px;\" src=\"images/PI/74926_Thoracic_dermatomes_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the thoracic dermatomes, which are bands of skin that are supplied by the thoracic nerves of the spine.</div><div id=\"graphicVersion\">Graphic 74926 Version 2.0</div></div></div>"},"74927":{"type":"graphic_picture","displayName":"CRPS dystrophic skin","title":"Dystrophic skin changes in complex regional pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dystrophic skin changes in complex regional pain syndrome</div><div class=\"cntnt\"><img style=\"width:396px; height:281px;\" src=\"images/PEDS/74927_CRPS_dystrophic_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: David D Sherry, MD.</div><div id=\"graphicVersion\">Graphic 74927 Version 2.0</div></div></div>"},"74928":{"type":"graphic_figure","displayName":"Posterior drawer test","title":"Posterior drawer test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior drawer test</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/PEDS/74928_Posterior_drawer_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior drawer test is used to assess the integrity of the posterior cruciate ligament. With the knee flexed to 90 degrees&nbsp;and the foot stabilized (often the examiner sits on the patient's foot), the proximal tibia is grasped firmly with both hands and the tibia is forcibly pushed posteriorly, noting any laxity compared with the other side.</div><div id=\"graphicVersion\">Graphic 74928 Version 4.0</div></div></div>"},"74930":{"type":"graphic_figure","displayName":"TR isoform tissue distribution","title":"Distribution of thyroid hormone receptors in different tissues of fetal and adult rats","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distribution of thyroid hormone receptors in different tissues of fetal and adult rats</div><div class=\"cntnt\"><img style=\"width:448px; height:604px;\" src=\"images/ENDO/74930_TR_isoform_tissue_distribu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Total T3-binding capacity in nuclei of different tissues.<br />(B) Distribution of different isoforms of TRs as determined by measurements using isoform-specfic antibodies.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; TR: thyroid hormone receptor.</div><div class=\"graphic_reference\">Data from: Schwartz HL, Lazar MA, Oppenheimer JH. Widespread distribution of immunoreactive thyroid hormone beta 2 receptor (TR beta 2) in the nuclei of extrapituitary rat tissues. J Biol Chem 1994; 269:24777.</div><div id=\"graphicVersion\">Graphic 74930 Version 4.0</div></div></div>"},"74931":{"type":"graphic_figure","displayName":"Area of vulva to be grafted","title":"Skinning vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skinning vulvectomy</div><div class=\"cntnt\"><img style=\"width:284px; height:360px;\" src=\"images/OBGYN/74931_Area_of_vulva_to_be_grafted.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Raw area to be grafted.</div><div id=\"graphicVersion\">Graphic 74931 Version 1.0</div></div></div>"},"74932":{"type":"graphic_figure","displayName":"Deep femoral lymph nodes","title":"Anatomic view of the deep inguinal lymph nodes with deep fascia removed","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Anatomic view of the deep inguinal lymph nodes with deep fascia removed</div><div class=\"cntnt\"><img style=\"width:517px; height:417px;\" src=\"images/OBGYN/74932_Deep_femoral_lymph_nodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mann WJ, Stovall TG. Gynecologic Surgery. Churchill Livingstone, New York 1996. Copyright © 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 74932 Version 2.0</div></div></div>"},"74933":{"type":"graphic_table","displayName":"Contributory factors vaso-occlusion","title":"Possible contributory factors in sickle cell vaso-occlusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible contributory factors in sickle cell vaso-occlusion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>HbS polymer formation</td> </tr> <tr> <td>Sickle cell deformability</td> </tr> <tr> <td>Sickle cell whole blood viscosity</td> </tr> <tr> <td>Fraction of dense irreversibly sickled cells</td> </tr> <tr> <td>Red cell function</td> </tr> <tr> <td>Sickle cell adherence to vascular endothelium</td> </tr> <tr> <td>Endothelial cell activation</td> </tr> <tr> <td>Mast cell activation</td> </tr> <tr> <td>Hemostatic activation</td> </tr> <tr> <td>Platelet activation</td> </tr> <tr> <td>White blood cell numbers and activity</td> </tr> <tr> <td>Vasoregulatory factors</td> </tr> <tr> <td>Vascular architecture</td> </tr> <tr> <td>Environmental factors</td> </tr> <tr> <td>Psychosocial adaptation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74933 Version 3.0</div></div></div>"},"74935":{"type":"graphic_picture","displayName":"Cutis marmorata telangiectatica congenita - leg","title":"Cutis marmorata telangiectatica congenita","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutis marmorata telangiectatica congenita</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/74935_Cutis_marm_telang_cong_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticular, red patches with areas of atrophy and ulceration are present on the leg of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74935 Version 3.0</div></div></div>"},"74936":{"type":"graphic_picture","displayName":"Lightwand placement","title":"Lightwand placement","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lightwand placement</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/74936_Lightwand_placement_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transillumination of the lighted stylet appears as a focused glow in the thyroid cartilage, indicating that the lightwand assembly is in the trachea.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphy MF, Hung OR. Lighted stylet intubation. In: Walls RM, Murphy MF (eds). Manual of Emergency Airway Management, 3rd edition. Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74936 Version 5.0</div></div></div>"},"74938":{"type":"graphic_diagnosticimage","displayName":"Sesamoid under fifth metatarsophalangeal joint - Oblique","title":"Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)</div><div class=\"cntnt\"><img style=\"width:360px; height:405px;\" src=\"images/EM/74938_Sesamoid_under_5th_mcp_obli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique view also shows the medial and lateral sesamoids below the metatarsophalangeal joint of the great toe (arrowhead), and a nondisplaced, transverse fracture of the proximal phalanx of the little toe (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 74938 Version 4.0</div></div></div>"},"74939":{"type":"graphic_figure","displayName":"Secretion and metabolism PTH","title":"Secretion and metabolism of PTH","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Secretion and metabolism of PTH</div><div class=\"cntnt\"><img style=\"width:544px; height:332px;\" src=\"images/ENDO/74939_Secretion_and_metabolism_PT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Secretion of intact PTH by the parathyroid glands is accompanied by release of a family of CPTH fragments (stippled shading), the amount of which, relative to intact PTH, increases at higher serum calcium concentrations. Intact PTH acts directly on PTH1Rs via its amino-terminal sequence (black shading) in target tissues (ie, bone) or is directly cleared by liver or kidney. Hepatic clearance of PTH involves rapid proteolysis by Kupffer cells to amino-terminal fragments (degraded in situ) and a series of carboxyl-terminal fragments, some of which reappear in the circulation (refer to UpToDate topic on parathyroid hormone secretion and action). CPTH fragments produced by the parathyroids and the liver are chemically similar or identical and include minimally amino-truncated, long forms and some midregion fragments truncated at both ends. Like intact PTH, CPTH fragments can exert direct effects on bone cells via a novel class of CPTH receptors. CPTH fragments normally circulate at fivefold higher concentrations than intact PTH but are cleared predominantly by the kidney and, thus, accumulate disproportionately during renal failure.</div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; Ca<SUP>++</SUP>: serum calcium; PTH1Rs: PTH1 receptors; CPTHRs: PTH receptors with specificity for the carboxyl-terminal region of PTH.</div><div class=\"graphic_reference\">Reproduced with permission from: Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocrine Reviews 2005; 26:78. http://edrv.endojournals.org/. Copyright © 2005 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 74939 Version 8.0</div></div></div>"},"74940":{"type":"graphic_figure","displayName":"Time course of diuretic action","title":"Steady state after initiation of a thiazide diuretic","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Steady state after initiation of a thiazide diuretic</div><div class=\"cntnt\"><img style=\"width:361px; height:280px;\" src=\"images/NEPH/74940_Timecoursediureticaction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sodium and potassium balance (intake minus excretion) after the administration of 100 mg of hydrochlorothiazide to three normal subjects. Negative balance persisted for only three days for sodium and six days for potassium before a steady state was reestablished, in which intake and excretion were roughly equal.</div><div class=\"graphic_reference\">Data from Maronde RF, Milgrom M, Vlachakis ND, Chan L. Response of thiazide-induced hypokalemia to amiloride. JAMA 1983; 249:237.</div><div id=\"graphicVersion\">Graphic 74940 Version 8.0</div></div></div>"},"74942":{"type":"graphic_figure","displayName":"Glycine deficit serum Na","title":"Association between the maximal difference between preoperative and postoperative serum sodium (S-Na) and glycine deficit (volume of retained fluid) assessed by simple linear regression","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Association between the maximal difference between preoperative and postoperative serum sodium (S-Na) and glycine deficit (volume of retained fluid) assessed by simple linear regression</div><div class=\"cntnt\"><img style=\"width:332px; height:586px;\" src=\"images/NEPH/74942_Glycine_deficit_serum_Na.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">R: Pearson correlation coefficient. Each symbol may represent more than one subject; NS: not significant.</div><div class=\"graphic_reference\">Reproduced with permission from: Istre O, Skajaa K, Schjoensby AP, Forman A. Changes in serum electrolytes after transcervical resection of endometrium and submucous fibroids with use of glycine 1.5 percent for uterine irrigation. Obstet Gynecol 1992; 80:218. Copyright © 1992 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 74942 Version 9.0</div></div></div>"},"74944":{"type":"graphic_figure","displayName":"CV response hypovolemia","title":"Model for cardiovascular response to hypovolemia from hemorrhage (based on normative data)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Model for cardiovascular response to hypovolemia from hemorrhage (based on normative data)</div><div class=\"cntnt\"><img style=\"width:292px; height:276px;\" src=\"images/PEDS/74944_CV_response_hypovolemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood pressure in hypovolemic children is maintained by increases in vascular resistance until hypovolemia exceeds 30 percent.</div><div class=\"graphic_reference\">Data from Schwaitzberg, SD, Bergman, KS, Harris, BH, A Peditric trauma model of continuous hemorrhage. J Pediatr Surg 1988; 23:606.</div><div id=\"graphicVersion\">Graphic 74944 Version 1.0</div></div></div>"},"74945":{"type":"graphic_table","displayName":"RF in nonrheumatic diseases","title":"The major nonrheumatic diseases associated with rheumatoid factor (RF)-positivity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The major nonrheumatic diseases associated with rheumatoid factor (RF)-positivity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Frequency of RF, percent</td> </tr> <tr> <td class=\"subtitle2_left\">Aging (&#62;age 60)</td> <td>5 to 25</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infection</td> </tr> <tr> <td class=\"indent1\">Bacterial endocarditis*</td> <td>25 to 50</td> </tr> <tr> <td class=\"indent1\">Hepatitis B or hepatitis C*</td> <td>20 to 75</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> <td>8</td> </tr> <tr> <td class=\"indent1\">Syphilis*</td> <td>Up to 13</td> </tr> <tr> <td class=\"indent1\">Parasitic diseases</td> <td>20 to 90</td> </tr> <tr> <td class=\"indent1\">Leprosy*</td> <td>5 to 58</td> </tr> <tr> <td class=\"indent1\">Other viral infection*</td> <td>15 to 65</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis*</td> <td>3 to 33</td> </tr> <tr> <td class=\"indent1\">Interstitial pulmonary fibrosis</td> <td>10 to 50</td> </tr> <tr> <td class=\"indent1\">Silicosis</td> <td>30 to 50</td> </tr> <tr> <td class=\"indent1\">Asbestosis</td> <td>30</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous diseases</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis*</td> <td>45 to 70</td> </tr> <tr> <td class=\"indent1\">Malignancy*</td> <td>5 to 25</td> </tr> <tr> <td class=\"indent1\">After multiple immunizations</td> <td>10 to 15</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refers to disorders that may cause symptoms suggestive of rheumatoid arthritis. The best-documented examples of viral infection (in addition to hepatitis B and C)&nbsp;are rubella, mumps, influenza, and HIV. Chagas' disease, Leishmaniasis, onchocerciasis, and schistosomiasis are major parasitic diseases. B cell neoplasms are the most common malignancies.</div><div class=\"graphic_reference\">Reprinted by permission from the publisher from: Shmerling RH, Delbanco TL. The rheumatoid factor: An analysis of clinical utility, Am J Med 1991; 91:528. Copyright © 1991 by Excerpta Medica Inc.</div><div id=\"graphicVersion\">Graphic 74945 Version 8.0</div></div></div>"},"74947":{"type":"graphic_diagnosticimage","displayName":"EUS insulinoma","title":"Endosonographic image of an insulinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endosonographic image of an insulinoma</div><div class=\"cntnt\"><img style=\"width:370px; height:273px;\" src=\"images/GAST/74947_EUS_insulinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic image of an insulinoma detected in a woman with recurrent episodes of hypoglycemia showing a well demarcated, homogenous hypoechoic mass lesion in the head of the pancreas adjacent to the common bile duct (CBD, above) and portal vein (PV, below) without invasion of these structures. The lesion had not been detected with other imaging modalities.</div><div class=\"graphic_reference\">Courtesy of Maryam Moini, MD, and Seyed Alireza Taghavi, MD.</div><div id=\"graphicVersion\">Graphic 74947 Version 2.0</div></div></div>"},"74948":{"type":"graphic_diagnosticimage","displayName":"Leak after gastric bypass","title":"Leak after gastric bypass on upper gastrointestinal series","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leak after gastric bypass on upper gastrointestinal series</div><div class=\"cntnt\"><img style=\"width:360px; height:343px;\" src=\"images/GAST/74948_Leak_after_gastric_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early clinical symptoms of a leak after bariatric surgery are subtle and require clinical vigilance for signs such as low-grade fevers, respiratory compromise, or unexplained tachycardia. A leak (arrow) may be radiographically confirmed by an upper gastrointestinal series (as shown here) or contrast computed tomography (CT). If a leak is suspected clinically, emergent surgical exploration should be performed even if the imaging is negative, given the rapid progression to sepsis in the severely obese patient with comorbidities.</div><div class=\"graphic_reference\">Courtesy of Vivian Sanchez, MD and Edward Mun, MD.</div><div id=\"graphicVersion\">Graphic 74948 Version 6.0</div></div></div>"},"74949":{"type":"graphic_diagnosticimage","displayName":"UGI-SMA syndrome I","title":"Upper gastrointestinal contrast study","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper gastrointestinal contrast study</div><div class=\"cntnt\"><img style=\"width:242px; height:242px;\" src=\"images/GAST/74949_UGI-SMA_syndrome_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This upper gastrointestinal contrast study (UGI) in an oblique projection demonstrates filling of the stomach and proximal duodenum with contrast (left side of photograph). Distal to this (dark arrowhead), there is compression of the third portion of the duodenum with only a scant amount of contrast in this region. This patient had repair of his scoliosis as evidenced by the hardware (right side of photograph).</div><div class=\"graphic_reference\">Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.</div><div id=\"graphicVersion\">Graphic 74949 Version 2.0</div></div></div>"},"74951":{"type":"graphic_picture","displayName":"Swollen hands early scleroderma","title":"Swollen hands in early systemic sclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Swollen hands in early systemic sclerosis</div><div class=\"cntnt\"><img style=\"width:426px; height:278px;\" src=\"images/RHEUM/74951_Swollen_hands_early_sclerod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swollen hands, which may mimic juvenile idiopathic arthritis, in a patient with early generalized scleroderma. These symptoms generally persist for a few weeks.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 74951 Version 3.0</div></div></div>"},"74953":{"type":"graphic_picture","displayName":"Concentric hamstring strength testing","title":"Concentric hamstring strength testing","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Concentric hamstring strength testing</div><div class=\"cntnt\"><img style=\"width:548px; height:264px;\" src=\"images/EM/74953_Concen_hamstr_strength_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both concentric and eccentric strength should be part of the hamstring examination. Concentric strength testing begins with the knee bent at 90 degrees.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 74953 Version 2.0</div></div></div>"},"74954":{"type":"graphic_table","displayName":"Thromboelastography definitions","title":"Thromboelastography definitions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thromboelastography definitions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clot phase</td> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Measurement</td> <td class=\"subtitle1\">TEG<sup>&#174;</sup> abbreviation</td> <td class=\"subtitle1\">ROTEM<sup>&#174;</sup> abbreviation</td> <td class=\"subtitle1\">Enzymatic stage</td> <td class=\"subtitle1\">Abnormalities</td> </tr> <tr> <td><strong>Clot initiation</strong></td> <td>Clotting time</td> <td>Time from start of sample to 2 mm clot amplitude</td> <td>Reaction time (R) </td> <td>Clot time (CT)</td> <td>Early activation of clotting cascade resulting in initial thrombin burst</td> <td>Prolonged by clotting factor deficiencies, anticoagulants, and hypofibrinogenemia. Shortened in hypercoagulable states.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Clot kinetics</strong></td> <td>Clot formation time</td> <td>Time from 2 mm to 20 mm clot amplitude</td> <td>Clot formation time (K)</td> <td>Clot formation time (CFT)</td> <td rowspan=\"2\">Clot potentiation by activation of platelets and thrombin-mediated cleavage of soluble fibrinogen</td> <td>Prolonged by clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction.</td> </tr> <tr> <td>Angle</td> <td>Angle of tangent line from 2 mm to 20 mm clot formation</td> <td>Alpha angle</td> <td>Alpha angle</td> <td>Abnormally low in clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Clot strength</strong></td> <td>Maximal clot strength</td> <td>Amplitude measured at peak clot strength</td> <td>Maximal amplitude (MA)</td> <td>Maximal clot firmness (MCF)</td> <td rowspan=\"2\">Maximal clot strength achieved via GP IIb/IIIa-mediated platelet-fibrin interactions</td> <td>Abnormally low in hypofibrinogenemia, thromboyctopenia, or platelet dysfunction.</td> </tr> <tr> <td>Clot viscoelasticity</td> <td>Calculated from maximal amplitude</td> <td>G</td> <td>Maximal clot elasticity (MCE)</td> <td>Abnormally high in platelet hypercoagulability.</td> </tr> <tr class=\"divider_top\"> <td><strong>Clot lysis</strong></td> <td>Clot lysis</td> <td>Percentage of loss of amplitude at fixed time after maximal amplitude</td> <td>Lysis at 30 min (LY30), estimated percentage of lysis (EPL)</td> <td>Lysis index at 30 min (LI30), maximal lysis (ML)</td> <td>Activation of fibrinolytic system</td> <td>Abnormally high in enzymatic or mechanical hyperfibrinolysis.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74954 Version 4.0</div></div></div>"},"74955":{"type":"graphic_figure","displayName":"Arterial supply of the femoral head and neck","title":"Arterial supply of the femoral head and neck","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Arterial supply of the femoral head and neck</div><div class=\"cntnt\"><img style=\"width:579px; height:312px;\" src=\"images/EM/74955_Proxfemurvasc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral ascending cervical arteries provide the blood supply to the majority of the femoral head. Foveal vessels may supply a varying area directly adjacent to the insertion of the ligamentum. There is little to no direct contribution to the head from the anterior vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 74955 Version 13.0</div></div></div>"},"74956":{"type":"graphic_picture","displayName":"AEN GE junction Endosc","title":"Acute esophageal necrosis","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Acute esophageal necrosis</div><div class=\"cntnt\"><img style=\"width:463px; height:238px;\" src=\"images/GAST/74956_AEN_GE_junction_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharp demarcation at the gastroesophageal junction is visible in these endoscopic images of acute esophageal necrosis.</div><div class=\"graphic_reference\">Courtesy of Daniel Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 74956 Version 1.0</div></div></div>"},"74957":{"type":"graphic_algorithm","displayName":"DILI hepatotoxins","title":"Mechanisms of drug-induced liver injury","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Mechanisms of drug-induced liver injury</div><div class=\"cntnt\"><img style=\"width:515px; height:395px;\" src=\"images/GAST/74957_DILI_hepatotoxins.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 74957 Version 3.0</div></div></div>"},"74958":{"type":"graphic_diagnosticimage","displayName":"AIDS patient with PML","title":"AIDS patient with progressive multifocal leukoencephalopathy (PML)","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">AIDS patient with progressive multifocal leukoencephalopathy (PML)</div><div class=\"cntnt\"><img style=\"width:491px; height:339px;\" src=\"images/ID/74958_AIDS_and_PML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a focal area of low density on CT scan (A) which involves the right periventricular white matter and extends peripherally to involve the subcortical white matter. MRI of same patient shows the lesion to be hyperintense on T2-weighted (B) and FLAIR (C) images, without contrast enhancement on post-contrast T1-weighted image (D). Diffusion-weighted image (E) shows increased signal intensity with a more hyperintense ring along the periphery, or advancing edge of the lesion. MR Spectroscopy of this lesion (F) shows that this lesion has characteristic decreased NAA, increased MI, increased choline, and elevated lactate/lipid peaks. (Refer to Izano et al).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; mI: myoinositol; Ch: choline; Cr: creatine; NAA: N-acetyl-aspartate; Lac/Lip: lactate/lipids.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 74958 Version 4.0</div></div></div>"},"74959":{"type":"graphic_picture","displayName":"IF for apoE kid LPG","title":"Immunofluorescence study for apolipoprotein E (apoE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence study for apolipoprotein E (apoE)</div><div class=\"cntnt\"><img style=\"width:396px; height:293px;\" src=\"images/NEPH/74959_IF_for_apoE_kid_LPG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apo E is present mainly in the lumen of glomerular capillary. Frozen section.</div><div class=\"graphic_reference\">Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 74959 Version 2.0</div></div></div>"},"74960":{"type":"graphic_picture","displayName":"Laminated intervillous thrombus","title":"Laminated intervillous thrombus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laminated intervillous thrombus</div><div class=\"cntnt\"><img style=\"width:450px; height:320px;\" src=\"images/OBGYN/74960_Laminated_intervillous_thro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A laminated intervillous thrombus filling slide.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 74960 Version 3.0</div></div></div>"},"74962":{"type":"graphic_table","displayName":"CF enteral formulas","title":"Enteral formulas used for individuals with cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enteral formulas used for individuals with cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Formula</td> <td class=\"subtitle1\">Company</td> <td class=\"subtitle1\">MCT:LCT ratio</td> <td class=\"subtitle1\">LCT, g/1000 mL<sup>&#182;</sup>&nbsp;</td> <td class=\"subtitle1\">kCal/mL</td> <td class=\"subtitle1\">Protein source</td> <td class=\"subtitle1\">Osmolarity, mOsm/kg water</td> </tr> <tr> <td>Pregestimil</td> <td>Mead-Johnson</td> <td>55:45</td> <td>16.9&nbsp;</td> <td>0.67</td> <td>Hydrolyzed casein</td> <td>320</td> </tr> <tr> <td>Peptamen Junior</td> <td>Nestle</td> <td>60:40</td> <td>14.4</td> <td>1.0</td> <td>Hydrolyzed whey</td> <td>260 (unflavored)</td> </tr> <tr> <td>Peptamen Junior 1.5&nbsp;</td> <td>Nestle&nbsp;</td> <td>60:40&nbsp;</td> <td>27.2&nbsp;</td> <td>1.5&nbsp;</td> <td>Hydrolyzed whey&nbsp;</td> <td>450&nbsp;</td> </tr> <tr> <td>Peptamen*</td> <td>Nestle</td> <td>70:30</td> <td>11.4&nbsp;</td> <td>1.0</td> <td>Hydrolyzed whey</td> <td>270 (unflavored)</td> </tr> <tr> <td> <table cellspacing=\"0\"> <tbody> </tbody> </table> Pediasure Peptide&nbsp;&nbsp;</td> <td>Abbott&nbsp;&nbsp;</td> <td>50:50&nbsp;</td> <td>20.2&nbsp;</td> <td>1.0&nbsp;</td> <td>Hydrolyzed whey&nbsp;</td> <td>250 (unflavored)&nbsp;&nbsp;</td> </tr> <tr> <td>Pediasure Peptide 1.5&nbsp;&nbsp;</td> <td>Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>50:50&nbsp;</td> <td>30.3&nbsp;</td> <td>1.5&nbsp;</td> <td>Hydrolyzed whey, hydrolyzed casein&nbsp;</td> <td>450&nbsp;</td> </tr> <tr> <td>Two Cal HN*&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>19:81&nbsp;</td> <td>73&nbsp;</td> <td>2.0&nbsp;</td> <td>Caseinate&nbsp;</td> <td>730 (flavored)&nbsp;</td> </tr> <tr> <td>Nutren 1.5*</td> <td>Nestle</td> <td>50:50</td> <td>34&nbsp;</td> <td>1.5</td> <td>Caseinate</td> <td>430 (unflavored)</td> </tr> <tr> <td>Nutren 2.0*</td> <td>Nestle</td> <td>75:25</td> <td>26&nbsp;</td> <td>2.0</td> <td>Caseinate</td> <td>745</td> </tr> <tr> <td>Elecare Infant</td> <td>Abbott</td> <td>33:67</td> <td>21&nbsp;</td> <td>0.67</td> <td>Free amino acids</td> <td>350</td> </tr> <tr> <td> <p>Elecare Junior&nbsp;</p> <p>(unflavored/vanilla)&nbsp;&nbsp;&nbsp;</p> </td> <td>Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>33:67&nbsp;</td> <td>33&nbsp;</td> <td>1.0&nbsp;</td> <td>Free amino acids&nbsp;</td> <td>590</td> </tr> <tr> <td>Neocate Infant</td> <td>Nutricia</td> <td>33:67</td> <td>23&nbsp;</td> <td>0.67</td> <td>Free amino acids</td> <td>375</td> </tr> <tr> <td> <p>Neocate Junior </p> <p>(unflavored/vanilla)</p> </td> <td>Nutricia</td> <td>35:65</td> <td>32.5&nbsp;</td> <td>1.0</td> <td>Free amino acids</td> <td>590</td> </tr> <tr> <td>Vivonex Pediatric</td> <td>Nestle</td> <td>70:30</td> <td>7.2&nbsp;</td> <td>0.8</td> <td>Free amino acids</td> <td>360</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCT: medium-chain triglycerides; LCT: long-chain triglycerides; kcal: kilocalories.<br />* Appropriate&nbsp;selections for adolescents and adults.<br />¶ Long-chain triglyceride (LCT) is the main determinant of the lipase requirement for patients requiring pancreatic enzyme replacement. Pancrelipase should be dosed as 1600 to 2000 lipase units per gram LCT. </div><div class=\"graphic_reference\">Modified with permission from: Pediatric Nutrition for Patients with Cystic Fibrosis. Consensus Conference: Concepts in CF Care 2001; 10:31. Copyright © 2001 Cystic Fibrosis Foundation.</div><div id=\"graphicVersion\">Graphic 74962 Version 9.0</div></div></div>"},"74965":{"type":"graphic_figure","displayName":"BMI symptomatic gallstones AGA","title":"Relationship between body mass index (BMI) and gallstones","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Relationship between body mass index (BMI) and gallstones</div><div class=\"cntnt\"><img style=\"width:455px; height:297px;\" src=\"images/GAST/74965_BMI_symptomatic_gallstones.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between the incidence of symptomatic gallstones (defined as cholecystectomy or newly diagnosed symptomatic unremoved gallstones) and BMI in the Nurse's Health Study.</div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123:882.</div><div id=\"graphicVersion\">Graphic 74965 Version 3.0</div></div></div>"},"74967":{"type":"graphic_picture","displayName":"Embryology penis","title":"Embryology of the penis","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Embryology of the penis</div><div class=\"cntnt\"><img style=\"width:495px; height:492px;\" src=\"images/PEDS/74967_Embryology_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Embryologic development of the penis at different gestational ages. Note the penile curvature resolves at the end of normal development.</div><div class=\"graphic_footnotes\">UF: urethral folds; VC: ventral curvature; MS: midline seam.</div><div class=\"graphic_reference\">Courtesy of Dr. Laurence Baskin.</div><div id=\"graphicVersion\">Graphic 74967 Version 2.0</div></div></div>"},"74971":{"type":"graphic_table","displayName":"Causes of secondary constipation","title":"Causes of secondary constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Example</td> </tr> <tr> <td>Organic</td> <td>Colorectal cancer, extraintestinal mass, postinflammatory, ischemic, or surgical stenosis</td> </tr> <tr> <td>Endocrine or metabolic</td> <td>Diabetes mellitus, hypothyroidism, hypercalcemia, porphyria, chronic renal insufficiency, panhypopituitarism, pregnancy</td> </tr> <tr> <td>Neurological</td> <td>Spinal cord injury, Parkinson's disease, paraplegia, multiple sclerosis, autonomic neuropathy, Hirschsprung disease, chronic intestinal pseudo-obstruction</td> </tr> <tr> <td>Myogenic</td> <td>Myotonic dystrophy, dermatomyositis, scleroderma, amyloidosis, chronic intestinal pseudo-obstruction</td> </tr> <tr> <td>Anorectal</td> <td>Anal fissure, anal strictures, inflammatory bowel disease, proctitis</td> </tr> <tr> <td>Drugs</td> <td>Opiates, antihypertensive agents, tricyclic antidepressants, iron preparations, antiepileptic drugs, anti-Parkinsonian agents (anticholinergic or dopaminergic), barium</td> </tr> <tr> <td>Diet or lifestyle</td> <td>Low fiber diet, dehydration, inactive lifestyle</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74971 Version 2.0</div></div></div>"},"74972":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis 2","title":"Lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/74972_Lymphomatoid_papulosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lymphomatoid papulosis nodule showing initial central necrosis (whitish area).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 74972 Version 3.0</div></div></div>"},"74974":{"type":"graphic_diagnosticimage","displayName":"Severe pulmonary paracocci","title":"Severe pulmonary paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Severe pulmonary paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:480px; height:252px;\" src=\"images/ID/74974_Severe_pulmonary_paracocci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph at diagnosis showing severe mixed-type infiltrative lesions in a 65-year-old patient with paracoccidioidomycosis. (B) Radiograph for the same patient at the end of the post-therapy follow-up period (12 months) showing extensive fibrosis and basal bullae.</div><div class=\"graphic_reference\">Reproduced with permission from: Tobon AM, Agudelo CA, Osorio ML, et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003; 37:898. Copyright ©2003 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 74974 Version 3.0</div></div></div>"},"74975":{"type":"graphic_table","displayName":"Circumcision info sheet B","title":"Circumcision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Circumcision</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Care of the uncircumcised penis.</td> </tr> <tr> <td>If your child has not been circumcised, his foreskin will usually separate from the glans in about three to five years. Once this has occurred, the foreskin should be pulled back and washed with soap and water. Dry the foreskin before pulling it forward. The foreskin should never be forcibly pulled back when there is resistance.</td> </tr> <tr> <td class=\"subtitle1_single\">Care of the circumcised penis.</td> </tr> <tr> <td>After your son's circumcision is done, a Vaseline gauze dressing is usually applied. Remove this gauze after 24 hours. To do this, apply Vaseline to the gauze with a diaper change, then at the next diaper change take the gauze off. Clean the circumcision site with warm water and a cotton ball once or twice a day. Apply Vaseline for several days. This helps keep the area clean and keeps the wound site from adhering to the diaper. At first, the penis will appear red. In a few days, you may notice a soft yellow scab. This is normal and will go away in a few days. During this process, you will need to watch for redness, swelling, bleeding or drainage that does not go away. If you notice any of these, notify your baby's doctor. Usually, the circumcision needs no further care once it has healed. Sometimes a small portion of foreskin remains attached to the glans. It should be pulled back gently and cleaned during bath time.</td> </tr> <tr> <td class=\"subtitle1_single\">Special situations that influence circumcisions.</td> </tr> <tr> <td>There are a few situations that may cause a circumcision to be delayed. Babies that are born too soon need to wait until they grow before they can have a circumcision. Sometimes a baby is born with a birth defect of the penis. In this circumstance, a urologist may be consulted before the circumcision can be performed. If there is a history of bleeding disorders, your baby's doctor may ask you to wait until the risk of bleeding can be determined.</td> </tr> <tr> <td class=\"subtitle1_single\">When do I need to make a decision?</td> </tr> <tr> <td>This decision is best made before your baby is born. The procedure can be performed at the hospital or as an outpatient procedure with local anesthesia up to 12 months of age. Many pediatricians' offices, however, are not equipped for this procedure. Thereafter, this procedure usually requires general anesthesia. As a parent, it is strongly recommended that you discuss this topic with your baby's doctor before making the final decision.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 74975 Version 4.0</div></div></div>"},"74976":{"type":"graphic_picture","displayName":"Mogan clamp","title":"Mogan clamp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mogan clamp</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/74976_Mogan_clamp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 74976 Version 1.0</div></div></div>"},"74977":{"type":"graphic_waveform","displayName":"ECG polymorphic VPBs","title":"ECG of polymorphic ventricular premature beats","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">ECG of polymorphic ventricular premature beats</div><div class=\"cntnt\"><img style=\"width:540px; height:203px;\" src=\"images/CARD/74977_ECG_polymorphic_VPBs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ambulatory monitoring tracing demonstrates ventricular premature beats with three different morphologies, know as polymorphic ventricular premature beats; one ventricular couplet (two successive preamture beats) is also seen (arrow). The blocked P waves after the first and second premature beats (*) are due to concealed retrograde AV nodal conduction from the premature beat.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 74977 Version 3.0</div></div></div>"},"74979":{"type":"graphic_diagnosticimage","displayName":"Fetal schizencephaly","title":"Fetal schizencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal schizencephaly</div><div class=\"cntnt\"><img style=\"width:326px; height:360px;\" src=\"images/PEDS/74979_Fetal_schizencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetus at 31 weeks with schizencephaly. Note the cleft in the brain.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 74979 Version 1.0</div></div></div>"},"74980":{"type":"graphic_figure","displayName":"Cystic fibrosis PI","title":"Organs most affected by cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Organs most affected by cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:479px; height:522px;\" src=\"images/PI/74980_Cystic-fibrosis-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystic fibrosis is a disease that some children are born with. It causes thick mucus and other fluids to build up and clog different parts of the body, including the lungs, pancreas, liver, and intestine.</div><div id=\"graphicVersion\">Graphic 74980 Version 1.0</div></div></div>"},"74981":{"type":"graphic_picture","displayName":"Hashimotos thyroiditis FNA I","title":"Hashimoto's thyroiditis: Findings on fine-needle aspirate of the thyroid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hashimoto's thyroiditis: Findings on fine-needle aspirate of the thyroid</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/ENDO/74981_Hashimotos_thyroiditis_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FNA of the thyroid in Hashimoto's thyroiditis. Lymphocytes are predominant, sometimes surrounding rare follicular cells. No formed follicles are seen. Some colloid is present in the background.</div><div class=\"graphic_footnotes\">FNA: fine-needle aspirate.</div><div id=\"graphicVersion\">Graphic 74981 Version 3.0</div></div></div>"},"74982":{"type":"graphic_figure","displayName":"Modified Martius fat pad graft2","title":"Modified Martius fat pad graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Martius fat pad graft</div><div class=\"cntnt\"><img style=\"width:410px; height:395px;\" src=\"images/OBGYN/74982_Modified_Martius_fat_pad_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graft is sharply mobilized with care taken to preserve the inferior blood supply.</div><div id=\"graphicVersion\">Graphic 74982 Version 1.0</div></div></div>"},"74983":{"type":"graphic_figure","displayName":"IVUS artery remodeling","title":"Remodeling of a coronary artery assessed with intracoronary ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Remodeling of a coronary artery assessed with intracoronary ultrasound</div><div class=\"cntnt\"><img style=\"width:316px; height:291px;\" src=\"images/CARD/74983_IVUS_artery_remodeling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Remodeling is a physiologic way of maintaining blood flow as plaque builds up inside an artery. The wall of the artery expands as the plaque accumulates, keeping the lumen open as long as possible. The reverse of this process, negative remodeling, can happen after angioplasty, as contraction of the treated segment leads to accelerated renarrowing or &quot;restenosis.&quot;</div><div class=\"graphic_reference\">By permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.</div><div id=\"graphicVersion\">Graphic 74983 Version 2.0</div></div></div>"},"74986":{"type":"graphic_diagnosticimage","displayName":"MRI sacroiliitis","title":"Magnetic resonance imaging of a patient with active sacroiliitis","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of a patient with active sacroiliitis</div><div class=\"cntnt\"><img style=\"width:501px; height:181px;\" src=\"images/RHEUM/74986_MRI_sacroiliitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows the T1 sequence. Panel B shows the STIR sequence. The bright white areas in STIR, which are not seen in the T1, are the areas of bone edema (arrows).</div><div class=\"graphic_footnotes\">STIR: short tau inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 74986 Version 6.0</div></div></div>"},"74987":{"type":"graphic_figure","displayName":"Cutaneous innervation from cervical plexus","title":"Cutaneous innervation from cervical plexus","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Cutaneous innervation from cervical plexus</div><div class=\"cntnt\"><img style=\"width:524px; height:622px;\" src=\"images/SURG/74987_Cut_innerv_cervical_plexus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cervical plexus supplies the skin of the anterior and lateral neck, and scalp, as well as the muscles of the neck including the scalenes and strap muscles. It also innervates the diaphragm via the phrenic nerve.</div><div id=\"graphicVersion\">Graphic 74987 Version 3.0</div></div></div>"},"74988":{"type":"graphic_picture","displayName":"Hemolok clip","title":"Hem-o-lok clip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hem-o-lok clip</div><div class=\"cntnt\"><img style=\"width:432px; height:352px;\" src=\"images/SURG/74988_Hemolok_clip.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Teleflex Medical Incorporated. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 74988 Version 1.0</div></div></div>"},"74991":{"type":"graphic_table","displayName":"Painful neuropathies","title":"Primary types of painful sensory neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary types of painful sensory neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Usual clinical setting</td> </tr> <tr> <td>Idiopathic small fiber neuropathy</td> <td> <p>Prevalence increases with age</p> <p>Normal strength and deep tendon reflexes</p> <p>Normal position and vibration sensation</p> <p>Diminished pin sensation in lower extremities</p> <p>Normal electrodiagnostic testing</p> <p>Diminished sudomotor function</p> <p>Abnormal skin biopsy</p> </td> </tr> <tr class=\"divider_top\"> <td>Diabetic peripheral neuropathy</td> <td> <p>History or family history of diabetes</p> <p>Obesity, hypertension</p> <p>Diminished deep tendon reflexes</p> <p>Diminished distal sensation</p> <p>Usually abnormal electrodiagnostic testing</p> <p>Impaired glucose tolerance, impaired fasting glucose, elevated hemoglobin A1C</p> </td> </tr> <tr class=\"divider_top\"> <td>Hereditary neuropathies</td> <td> <p>Family history</p> <p>Pes cavus or hammer toe</p> <p>Usually diminished deep tendon reflexes</p> <p>Diminished distal sensation</p> <p>Abnormal electrodiagnostic testing</p> </td> </tr> <tr class=\"divider_top\"> <td>Neuropathy related to connective tissue disease</td> <td> <p>History of rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, Sj&#246;gren syndrome</p> <p>Diminished deep tendon reflexes</p> <p>Diminished distal sensation</p> <p>Abnormal electrodiagnostic testing</p> <p>Positive for autoimmune antibodies</p> </td> </tr> <tr class=\"divider_top\"> <td>Vasculitic neuropathy</td> <td> <p>Known systemic vasculitis (but vasculitic neuropathy may occur in isolation)</p> <p>Multifocal examination findings</p> <p>Abnormal electrodiagnostic testing</p> <p>Positive for autoimmune antibodies, hepatitis B or C, cryoglobulins</p> <p>Abnormal nerve biopsy</p> </td> </tr> <tr class=\"divider_top\"> <td>Neuropathy associated with monoclonal gammopathy</td> <td> <p>Prevalence increases with age</p> <p>Variable examination findings depending upon mode of presentation (mononeuritis multiplex, distal polyneuropathy, radiculopathy, or plexopathy)</p> <p>Abnormal electrodiagnostic testing</p> <p>Monoclonal gammopathy (often IgM)</p> </td> </tr> <tr class=\"divider_top\"> <td>Paraneoplastic sensory neuropathy</td> <td> <p>Tobacco smoking, family history, asbestos exposure</p> <p>Solid tumor cancer (mainly lung)</p> <p>Diminished deep tendon reflexes</p> <p>Diminished distal sensation</p> <p>Abnormal electrodiagnostic testing</p> <p>Anti-Hu antibodies</p> </td> </tr> <tr class=\"divider_top\"> <td>Familial or acquired amyloid polyneuropathy</td> <td> <p>Family history or known plasma cell dyscrasia (acquired form)</p> <p>Diminished deep tendon reflexes</p> <p>Sensory loss</p> <p>Autonomic dysfunction (eg, postural hypotension, impotence, bladder dysfunction)</p> <p>Compressive mononeuropathy (mainly carpal tunnel syndrome)</p> <p>Abnormal electrodiagnostic testing</p> <p>Monoclonal gammopathy (acquired form)</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NCS: nerve conduction study.</div><div class=\"graphic_reference\">Data from: Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. N Engl J Med 2003; 348:1243.</div><div id=\"graphicVersion\">Graphic 74991 Version 7.0</div></div></div>"},"74994":{"type":"graphic_table","displayName":"Imaging ACS","title":"Strengths and weaknesses of available noninvasive imaging modalities for patients presenting with suspected ACS in an ED setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strengths and weaknesses of available noninvasive imaging modalities for patients presenting with suspected ACS in an ED setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Strengths</td> <td class=\"subtitle1\">Weaknesses</td> </tr> <tr class=\"divider_bottom\"> <td>Myocardial perfusion scintigraphy</td> <td> <ul> <li>Widely available </li> <li>Standard interpretive approaches, can be quantitated </li> <li>Images the process responsible for symptoms </li> <li>Multiple RCTs and observational data support use </li> </ul> </td> <td> <ul> <li>Usually not available 24/7 </li> <li>Rest imaging not as useful &#62;~2 to 3 hours after symptoms but stress imaging is useful </li> <li>Entails radiation exposure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Echocardiography</td> <td> <ul> <li>Widely available </li> <li>Standard interpretive approaches </li> <li>Images a process associated with symptoms </li> <li>RCT and observational data support use </li> <li>Relatively low cost </li> </ul> </td> <td> <ul> <li>May not be available 24/7 </li> <li>Rest imaging not as useful after symptom cessation but stress imaging is useful </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Coronary CTA</td> <td> <ul> <li>Widely available </li> <li>Standard qualitative interpretive approaches </li> <li>Images anatomy indirectly associated with symptoms </li> <li>Multiple RCTs and observational data support use </li> </ul> </td> <td> <ul> <li>May not be available 24/7 </li> <li>Coronary calcium may interfere with interpretation </li> <li>Implications of \"moderate\" stenoses or non-obstructive plaque not clear, patients would need further testing </li> <li>Some patients not eligible due to renal dysfunction. Fast heart rate, arrhythmias such as atrial fibrillation may be problematic with slower temporal resolution scanners. Entails radiation exposure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Echocardiography with contrast for perfusion imaging</td> <td> <ul> <li>Images the process responsible for symptoms </li> <li>Large observational data suggests incremental diagnostic information </li> </ul> </td> <td> <ul> <li>Not available for general use - contrast agents for perfusion not FDA approved </li> <li>Interpretive approaches not standardized </li> <li>Most data come from specialized centers </li> </ul> </td> </tr> <tr> <td>Cardiovascular MR</td> <td> <ul> <li>Comprehensively images anatomy and physiology associated with symptoms (including&nbsp;myocardial perfusion, infarction, ventricular function) </li> <li>Small amount of observational data support use </li> </ul> </td> <td> <ul> <li>Expertise for comprehensive imaging not widely available </li> <li>Interpretive approaches not standardized </li> <li>Data come from specialized centers </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTA: computed tomographic angiography; MR: magnetic resonance; RCT: randomized controlled trial.</div><div class=\"graphic_reference\">Courtesy of Drs. Prem Soman and James Udelson.</div><div id=\"graphicVersion\">Graphic 74994 Version 6.0</div></div></div>"},"74995":{"type":"graphic_table","displayName":"Causes of fecal incontinence","title":"Causes of fecal incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of fecal incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Structural abnormalities</td> </tr> <tr> <td class=\"indent1\">Anal sphincter muscles</td> <td>Obstetrical injury, hemorrhoidectomy, anal dilation, radiation, inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Rectum</td> <td>Prolapse, hypersensitivity/hyposensitivity, neoplasms, congenital abnormalities, excessive perineal descent</td> </tr> <tr> <td class=\"indent1\">Puborectalis muscle</td> <td>Trauma, obstetrical injury</td> </tr> <tr> <td class=\"indent1\">Pudendal nerve</td> <td>Surgical injury, excessive perineal descent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Central nervous system, spinal cord, autonomic nervous system</td> <td>Spinal cord injury, head injury, stroke, back surgery, diabetes mellitus, multiple sclerosis, tabes dorsalis, cauda equina injury or tumor</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Functional abnormalities</td> </tr> <tr> <td class=\"indent1\">Anorectal sensation</td> <td>Obstetrical injury, central nervous system/autonomic nervous system injury, diabetes mellitus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fecal impaction</td> <td>Dyssynergic defecation</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Stool characteristics</td> </tr> <tr> <td class=\"indent1\">Volume and consistency</td> <td>Inflammatory bowel disease, irritable bowel syndrome, medications, infections</td> </tr> <tr> <td class=\"indent1\">Irritants</td> <td>Bile salt malabsorption, laxatives</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hard stools and retention</td> <td>Dyssynergic defecation, fecal impaction, medications</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Physical mobility and cognitive function</td> <td>Aging, disability, dementia, sedation</td> </tr> <tr> <td class=\"indent1\">Psychosis</td> <td>Willful soiling</td> </tr> <tr> <td class=\"indent1\">Medications</td> <td>Laxatives, anticholinergics, antidepressants, caffeine, muscle relaxants</td> </tr> <tr> <td class=\"indent1\">Food intolerance</td> <td>Lactose, fructose, sorbitol</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Lazarescu A, Turnbull GK, Vanner S. Investigating and treating fecal incontinence: When and how. Can J Gastroenterol 2009; 23:301. Copyright &copy; 2009 Pulsus Group Inc.</div><div id=\"graphicVersion\">Graphic 74995 Version 7.0</div></div></div>"},"74997":{"type":"graphic_picture","displayName":"Red macular high grade squamous intraepithelial lesion of vulva","title":"Red macular high-grade squamous intraepithelial lesion (HSIL) of vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Red macular high-grade squamous intraepithelial lesion (HSIL) of vulva</div><div class=\"cntnt\"><img style=\"width:302px; height:339px;\" src=\"images/OBGYN/74997_Red_macular_lesion_of_VIN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red macular lesion as a manifestation of a high-grade squamous intraepithelial lesion (HSIL) of the vulva.</div><div class=\"graphic_reference\">Courtesy of Christine Holschneider, MD.</div><div id=\"graphicVersion\">Graphic 74997 Version 3.0</div></div></div>"},"74998":{"type":"graphic_figure","displayName":"Deep neck space anatomy","title":"Deep neck spaces and fascial layers","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Deep neck spaces and fascial layers</div><div class=\"cntnt\"><img style=\"width:466px; height:538px;\" src=\"images/PEDS/74998_Retropharynspaceanatedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"danger\" space lies behind the anatomic retropharyngeal space. It&nbsp;is a potential space that provides a path for retropharyngeal infections to extend into the mediastinum. </div><div id=\"graphicVersion\">Graphic 74998 Version 11.0</div></div></div>"}};